GUTS UK CHARITY

England & Wales · Charity number 1137029

Details

Other names	CORE - THE DIGESTIVE DISORDERS FOUNDATION, DIGESTIVE DISORDERS FOUNDATION, CORE
Status	Registered
Legal form	Charitable company
Company number	07274105
Registered	2010-07-22
Register	View on the Charity Commission register

Contact

Address	2 St Andrews Place London NW1 4LB
Phone	020 7486 0341
Email	info@gutscharity.org.uk
Website	www.gutscharity.org.uk

Activities

Objects: THE ADVANCEMENT OF THE SCIENCE AND PRACTICE OF MEDICINE AND SURGERY FOR THE BENEFIT OF THE PUBLIC WITH PARTICULAR REFERENCE TO THE FIELD OF GASTROENTEROLOGY WHICH INCLUDES THE STUDY OF THE PHYSIOLOGY AND PATHOLOGY OF THE DIGESTIVE SYSTEM AND TO PROMOTE THE STUDY OF AND RESEARCH INTO MEDICINE AND SURGERY WITH PARTICULAR REFERENCE TO THE PHYSIOLOGY AND PATHOLOGY OF THE DIGESTIVE SYSTEM AND TO ENSURE DISSEMINATION WHERE APPROPRIATE OF THE RESULTS OF SUCH STUDY AND RESEARCH; ANDTO PROVIDE EDUCATIONAL MATERIAL, INFORMATION AND ADVICE TO THE GENERAL PUBLIC ON GASTROINTESTINAL DISEASES

Activities: Guts UK is the national charity for the digestive system. We provide support and information via our Helpline and publications. We raise awareness and understanding including campaigns to recognise the impact of digestive conditions, for better care and treatment. We fund innovative research to find the breakthroughs that will change how we understand, diagnose, and treat digestive conditions.

Downloaded from opencharities.uk/ew/1137029

Classification

- **How:** Makes Grants To Organisations, Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** Other Charities Or Voluntary Bodies, Other Defined Groups, The General Public/mankind

Geography

- **Area of benefit:** UNDEFINED. IN PRACTICE, NATIONAL
- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£1,180,140	£1,256,519	£5,946,444	12
2023-12-31	£1,448,468	£1,086,582	£5,795,777	9
2022-12-31	£1,180,044	£1,661,217	£5,286,325	9
2021-12-31	£1,078,130	£920,771	£6,389,416	8
2020-12-31	£550,019	£583,135	£5,645,054	8

Downloaded from opencharities.uk/ew/1137029

Trustees

Name	Role	Appointed
Dr Victoria Ann King	Chair	2023-03-13
Angharad Rose Widlake		2025-07-01
Conor McCann		2023-06-30
Dr Linda Dugdale-Bradley		2020-04-29
Jon Carter		2026-04-29
Melissa Davey		2021-12-09
Professor Christine Norton		2022-03-14
Professor Christopher Simon John Probert		2022-06-10
Professor Debbie Shawcross		2024-09-04
Ravinder Chahil		2023-06-07

Linked charities

- DEREK BUTLER FELLOWSHIP (1137029-1)

Downloaded from opencharities.uk/ew/1137029

GUTS UK CHARITY

England & Wales - Charity number 1137029

Accounts

ANNUAL REPORT AND FINANCIAL STATEMENTS 2024

Guts UK

Charity Registration No. 1137029

CONTENTS

Welcome from our Chair	3
Welcome from our CEO	4
2024 report	5
Our new strategy	10
Plans for 2025	11
Financial performance review	13
Governance, policies and standards	16
Reference and administrative information	20
Report of the Independent Auditors	24
Statement of Financial Activities	28
Statement of Financial Position	29
Cash Flow Statement	31
Notes to the Cash Flow Statement	32
Notes to the Financial Statements	33
Detailed Statement of Financial Activities	49

The report of trustees is a combined annual report incorporating both the directors report and the trustees report for the charity as required by company law.

WELCOME FROM VICTORIA KING, OUR CHAIR OF TRUSTEES

2024 was a pivotal year of change and development for Guts UK. With rising demand for our information and support, and in the context of continued challenges across the health and charity sectors, we recognised the need to prepare for the future. In response, we committed to developing a new strategy focused on enabling sustainable growth in the years ahead.

Early in the year, our CEO Julie Harrington decided to step down to pursue new challenges and we commenced recruitment for our new CEO. Katie Noon, our COO, agreed to step in as interim CEO to support the smooth running of the charity. On behalf of my fellow Trustees, we wish to thank Julie, Katie and the team for their work, energy, and dedication. In September, we welcomed our new CEO Suzanne Hudson. As an experienced charity CEO, Suzanne led the final phases of developing the new strategy, and the development of the three-year budget and operational plans to support strategy delivery.

What we hadn't fully appreciated 12 months ago was the phenomenal level of interest, insight, and support from our community in shaping the new strategy. This collective effort has been truly inspiring. By working together, we created a strategy that brings us even closer to our vision: a future where digestive conditions are better understood, better treated, and where everyone gets the support they need.

The following pages highlight some of the amazing work we achieved over the past year. Importantly, we also laid the foundations for the future by developing key plans, processes, and infrastructure to ensure we were ready to deliver our new strategy in 2025. If the early months of this year are anything to go by, we hit the ground running. It is an exciting time for everyone involved with Guts UK as we embark on a new phase of our development and growth for the benefit of the millions affected by digestive conditions in the UK.

Finally, I want to extend a heartfelt thanks to everyone who has supported and engaged with our work over the last year. Many thousands of you joined us to make a real difference. Whether you responded to our strategy survey, took part in our awareness campaigns, contributed to research priority setting partnerships, supported our initiatives, or fundraised in countless creative ways – thank you. Your involvement is what powers our progress.

Victoria King
Chair of the Board of Trustees

WELCOME FROM SUZANNE HUDSON, OUR CHIEF EXECUTIVE

I joined Guts UK as chief executive in September with only a few months left of this review period, but it's already been one of the most busy and enjoyable times of my professional career. It's a massive privilege – thrilling, exciting, and a huge challenge – to lead the national charity for the digestive system at this critical time for health services across the UK.

Far too many people across the UK are struggling with the daily impact of living with digestive conditions and symptoms. Far too many are unable to get the support they need. Far too many feel isolated, worried, and alone.

We are the national charity for the digestive system and demand for our services, support, and work is at record highs. We have no option but to develop and grow. In developing our new five-year strategy, it was essential we discussed and listened to our community, donors, partners, and key stakeholders. To support engagement and reach, we publicly consulted with a strategy survey and received an incredible 850 responses from people across our community. Every response helped us make important decisions about our strategy, including a new mission statement and our priorities for the next five years. As requested by our community, our 2025 priorities include the development of a new pilot Helpline service, expanding specific condition information including webinars, further developing our research programme and patient and public involvement, and continuing to fight for improved funding, treatments and support for individuals affected by digestive conditions.

The new strategy, launched in January 2025, is highlighted in pages 10-12 and is fully supported by a new three-year budget and comprehensive operational plans, all of which were approved by our Board in December 2024.

Guts UK is a very special charity. Collaboration and connection are our heart and soul, and we best support individuals affected by digestive conditions when we work together. I look forward to working with and for you in the years ahead. Together, we can create a brighter future for everyone affected by digestive conditions and symptoms. Thank you.

Suzanne Hudson
Chief Executive

WHAT WE ACHIEVED IN 2024

Guts UK is the national charity for the digestive system. Indeed, we are the only charity that covers all – yes, the entire 25ft length - of our digestive system. We provide a range of services and support including Information Support services, Communications & Public Education, and Research & Patient and Public Involvement and Engagement (PPIE).

Digestive conditions and symptoms affect millions of individuals and families across the UK every day. Collectively, digestive conditions are a factor in 1 in 8 deaths. The demand for support across health services and charities is immense. No organisation should work in isolation, and at Guts UK we work collaboratively and in partnership with charities, healthcare professionals, support organisations, the research community, and those affected by digestive conditions. Together, we work to raise awareness and improve understanding, treatment, and support.

2024 was a transformational year for the charity. With the amazing support of our community, donors, partners, volunteers, and our staff team, we continued to deliver our information support, communications and awareness, and research work, whilst taking the opportunity to evaluate what we do and why, reflect on our history, hear from our community, the organisations we work with and our valued supporters, and develop a new strategy providing the framework for all we do in the next five years. The following pages highlight a few of our many successes.

Information Support Services

We supported just under 2,400 individuals affected by digestive conditions and symptoms who contacted the charity by phone or online with queries on over 40 digestive conditions or symptoms. With the continued acceleration in individuals contacting us for support, the Board of Trustees approved the development of a pilot Helpline project in 2024 and following the development of a comprehensive service framework, the new pilot Helpline service soft-launched in April 2025.

"Thank you for forwarding the information. I am so glad I have found you. I so needed to read the advice on the website, and it is so handy and easy to read."

With the support of the British Society of Gastroenterology (BSG), we reviewed five specialist condition leaflets and introduced two new leaflets for cholangiocarcinoma (bile duct cancer) and understanding endoscopic surveillance for gastric atrophy and intestinal metaplasia. We are accredited by the Patient Information Forum (PIF) for our medical/health information. During the year, just under 163,000 of our printed condition leaflets were requested from hospitals and health care settings. More than 23,000 condition leaflets were downloaded from our website. We also distributed over 2,300 Can't Wait Cards to individuals requesting from across the UK, helping to improve urgent access to public toilet facilities.

In October, we hosted our first condition specific webinar on gastroparesis with expert panellists Gastroenterologist, Dr Ray Shidrawi and Specialist Dietitian, Bethany Hallam. Two experts by experience shared their personal stories, from their journey to diagnosis and treatment options, to how the condition impacts their daily lives and advice on what family, friends and others can do to better support their loves ones who are affected.

We joined three professional and healthcare events and facilitated eight Health at Work talks/presentations, raising awareness of digestive conditions, symptoms and Guts UK's work and support. In total we estimate we engaged with more than 3,000 medical and healthcare professionals in person during the year.

Due to limited UK supply of pancreatic exocrine replacement therapy (PERT) in 2024, a medication that replaces digestive enzymes for people with pancreas disease, Guts UK supported patients with information to help them navigate this difficult situation (the website information alone received over 24,000 views in the year). We also worked closely with other charities and health professionals to develop an information video for GPs and pharmacists, to help their understanding and support for their patients. We and the other organisations involved also worked with the Department of Health and Social Care to raise awareness of the impact for patients and campaign for a resolution. We attended the parliamentary medicines shortages enquiry of the All Party Parliamentary Group (APPG) on Pharmacy and the organisations group wrote to the Secretary of State to highlight the problem. Guts UK continues to work to support patients experiencing difficulties in supply of PERT.

"After looking online for advice about the shortage of PERT medication, I came across your updates. Having had pancreatitis last year, I was really worried about what would happen to me without the medication. I feel reassured now. Thank you."

Communications and Public Education

Nearly 2 million people visited our website, and our social media content was seen more than 3.3 million times in 2024. Subscribers to our monthly e-newsletter rose by 13% during the year.

We hosted our Science of Digestion event in Hull and supported a Disability Awareness Day event, where more than 300 members of the public had the opportunity to learn about the digestive system, take an interactive tour through our inflatable colon, Colin, and hear the latest information and developments in gut health from leading experts.

We supported more than 30 people to share their personal experiences of digestive conditions in 2024 through story-based case studies on our website and user generated video content on social media. These, in turn, helped inspire hundreds more to share their experiences online. These powerful stories both support and empower others including breaking down stigma and reducing the isolation that many feel when struggling with their symptoms.

We receive positive feedback from those who share their stories with us, highlighting the impact that sharing their experiences has, both personally and for others who are affected by digestive conditions.

"Thank you for giving me the platform to be able to spread the word. I wanted to be the person that I needed back then. I felt that nobody understood what I was going through. I had nobody to talk to about it. I've had people reach out to me personally who've read my story, and I am so humbled to have made a difference. I always said if I could make a difference to just one person, that would be enough for me."

"Thank you for making me feel seen and heard whilst living with something so invisible. I am so proud to share a day in the life with my condition because it sheds light on the daily struggles and challenges that I face. It was an absolute honour to help you raise awareness of achalasia during the awareness month. Here's to making changes and breaking stigmas!"

Our annual #GUTSelfie campaign in June provided an opportunity for hundreds of people affected by all types of digestive conditions to share their personal experiences and raise awareness and understanding of the common myths, misunderstandings and misconceptions they so often face.

"I am excited to participate in the #GUTSelfie campaign to raise awareness for digestive conditions and specifically ulcerative colitis, which I was diagnosed with in 2022. This year's theme is deeply important to me as it addresses common myths and misconceptions that looking well equates to feeling well. Ulcerative colitis is an invisible illness with no cure, often misunderstood due to its hidden nature. By participating in the campaign, I hope to create a better understanding and awareness for those living with digestive conditions."

Many more shared their personal experiences during our Kranky Panky campaign in November, with comments from people across the UK and beyond highlighting the impact of pancreatitis for them and their loved ones.

"My stepmum's journey with pancreatitis underpins the need for better awareness, research and funding for pancreatitis. If sharing her story can do one thing, I hope it brings about greater awareness. Pancreatitis can bring devastation to the people it impacts, and I hope her legacy drives change, so that others have better chances and more options in the future."

Our partnership and collaborative working with national alliances and groups continued to develop. Guts UK was one of the founding members of the Less Survivable Cancers Taskforce and during the year we worked together on a highly successful awareness week campaign, responded to the Lord Darzi review, and developed a report highlighting that more than half (58%) of people in England diagnosed with a cancer of the stomach, oesophagus, pancreas, lung, liver, or brain will die from their disease within one year. This new analysis of existing cancer registry data shows that the average one-year survival for a patient diagnosed with a less survivable cancer in England is just 42%. This contrasts sharply with the overall one-year survival rate for all cancers, which is over 70%.

We worked in partnership with Imodium for the second year, helping people to better understand and manage their gut health whilst tackling the stigma that surrounds our poo. In May, we were thrilled to win the Consumer Goods Award at the Third Sector Business Charity Awards in recognition of our collaborative campaign.

Research & PPIE

We invested over half a million pounds in **research funding & PPIE support** in the year. Supporting early career researchers through our PhD studentship, fellowship and trainee funding and providing funding for research into specific conditions such as acute pancreatitis and inflammatory bowel disease.

"This is the first award I've received, so this really does mean a great deal to me as a (relatively) young researcher."
Dr Conley, University of Liverpool

A number of grant projects came to a close during the year, including an Early Career Researcher Development grant to Dr Merianne Mohamad to support her research into antimicrobial resistance.

"I recognise the significance of this award at my career stage. It has served as a steppingstone, providing credibility and confidence to apply for larger, more competitive grants in the future. This experience has been instrumental in shaping my research trajectory and advancing my academic aspirations."
Dr Merianne Mohamad, King's College London

Guts UK Trustee and Chair of Research Strategy Committee, Dr Conor McCann, and Professor Matthew Brookes, Founder of the Guts UK/BSG Trainee Awards presented 'The Future of Research in Gastroenterology' symposium at the BSG conference showcasing four Guts UK/BSG Trainee and Early Career Research funded projects emphasising the important role that the charity plays in developing the future leaders in digestive disease research

We had another very busy year bringing patients, carers and health care professionals together in our research Priority Setting Partnerships (PSPs) work. With the support of the BSG we completed the Pancreatitis PSP, identifying the top 10 priorities for pancreatitis research and ran a sandpit workshop in November leading to the development of four new research projects. We also started the Diverticular Disease PSP with Bowel Research UK, receiving 1,612 responses which have now been used to identify the top 10 priorities for research into this common but still unknown condition.

Together with our patient/carer advocates we also attended, supported and presented to National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium, the NHS and government committees and reviews.

"Thank you for allowing my voice to be heard in decision making."
Steve

"I feel that I'm giving something back to the NHS and people that are in the position I was in three years ago. Thank you."
Ceri

Our fantastic 'Experts by Experience' (EBE) panel continued to meet monthly supporting key activities and developments across the charity including research grants/awards, strategy development, communications and awareness work, and early thinking to the new pilot Helpline service, ensuring patient, carer and loved ones' involvement.

"Since my husband Steve died five years ago, I have been involved with Guts UK as an EBE. It means everything to me to keep his memory alive, learn from his experience, and to ensure that others living with and are affected by digestive conditions and symptoms are always at the heart of Guts UK and the incredible work they do."
David

"As a member of the EBE team, Guts UK provide the important and most valuable opportunities to have my voice not only heard but genuinely valued and respected by the influential medical professionals and policymakers that can actually act on and implement the changes and improvements I and other members suggest. Rather than being a token participant my involvement makes a difference and results in real impact."

Rachel

Working with other charities and organisations

We are proud to work closely with colleagues in other digestive condition charities, in the NHS, and in other organisations to ensure the voices of people affected by digestive conditions are heard and supported. Our CEO and other managers also represent Guts UK and our community in national and condition focused alliances and taskforces. Collaborative and partnership working is key in ensuring that together we can make a difference for individuals affected by digestive conditions. We look forward to further strengthening and establishing new working relationships.

OUR NEW STRATEGY

The development of our **five-year strategy** provided the opportunity to evaluate our work, reflect on our history, hear from our community, partners and donors, and identify our priorities for the future. Our mission and values have changed, reflecting the development and growth of our charity and priorities for those we support.

Our vision

A world where digestive conditions are better understood, better treated and everyone who lives with one gets the support they need.

Our mission

To improve the lives of the millions of people affected by digestive conditions.

Our values and behaviour

At Guts UK, we live by our three values:

- **Bold**
- **Brave**
- **United**

Our values, alongside our foundations of being **inclusive**, **collaborative** and **engaging** underpin everything we do and reflect those we support who are affected by digestive conditions every day.

Our social ambition for the next five years is to be **known as the trusted organisation for digestive conditions**, backed by evidenced information. We will do this by:

- Providing accurate **information** and excellent **support** to people affected by digestive symptoms and conditions.
- Raising public **awareness** of digestive conditions to reach more people and drive engagement.
- Driving a programme of **research** that will improve quality of life, treatment and survival.

Our business ambition for the next five years is **to increase income generation, develop and optimise our capacity to deliver the social objectives**. We will do this by:

- Developing and growing **operational capacity.**
- Increasing **income generation** to support the social objectives.
- Providing the best **leadership** to steer Guts UK.

Guts UK will:

- Provide **information** and excellent **support** services to people affected by digestive symptoms and conditions.
- Raise public **awareness** of digestive conditions to reach more people and drive engagement.
- Drive a programme of **research** that will improve quality of life, treatment and survival.
- Develop and grow **operational capacity.**
- Increase **income generation** to support the social objectives.
- Provide the best **leadership** to steer Guts UK.

OUR PLANS FOR 2025

Our new strategy provides the framework for everything we do and with the phenomenal response to our strategy survey, clear priorities were identified for 2025 including:

Information Services

- We will develop and implement a **pilot Helpline service**, a dedicated information and support service for people experiencing digestive symptoms and for those living with and affected by digestive conditions. The pilot will allow us to better understand public demand for this type of dedicated support to inform the development of a new permanent service. The pilot Helpline service launched in April 2025.
- We will further develop our **patient information leaflets** and information in line with regular reviews and feedback with the aim that more patients are able to access evidence-based information about their symptoms and conditions.
- With the success of our gastroparesis webinar, we will develop other **condition webinars** to raise awareness and understanding.
- We will develop **Health at Work** talks/presentations with the aim of raising awareness of digestive symptoms, conditions and the available support to employees and supporting employers to better understand the impact of digestive conditions in the workplace, and raise awareness of digestive symptoms, conditions and support to employees.
- We will continue to work with other organisations in raising awareness of the impact of ongoing PERT supply issues and campaign for resolution with decision makers.

Research & PPIE

- We will continue to fund our **core programme of research awards** and grants including the Guts UK/Dr Falk awards, the Guts UK/BSG trainee awards and our Early Career Researcher development grants.
- We will continue to work on the outputs of our hugely successful **Priority Setting Partnerships (PSPs)** in Pancreatitis, IBS, Diverticular Disease, and survey public interest in a potential Endoscopy PSP.
- We will complete an impact survey with our past grant recipients to better understand the impact of our research grant funding.
- We will review and develop a new Research & PPIE Strategy working closely with key stakeholders.
- Across all our research and other charitable activities, we will continue to develop and support our panel of **Experts by Experience** to ensure the patient and carer voice is core to our work.

Communications & Public Education

- We will develop and implement **website** enhancements to improve information accessibility and user experience.
- We will continue to **build our social media presence and engagement** including more personal stories and Guts community involvement.
- We will review and develop **a new Communications and Campaigns Strategy** to support future develop work to meet new charity strategy aims and within is the identified priorities from the public consultation survey.
- We will review and plan for more public events with Colin the colon, our team, and organisations we partner and collaborate with, to raise public awareness and understanding of digestive conditions and break down the taboo of talking about digestive health.

Operational Capacity & Resources

- Our new strategy, budget, and operational plans provide a comprehensive framework for developing and growing our operations.
- Our small staff team are dedicated, hardworking, high performing and focused. Our work requires skill and experience as well as energy and resilience, and we are committed to attracting and retaining the right people to help deliver our strategic aims.
- We will continue to invest, develop, train, and support our valued team members including plans to implement new HR platform, and review and develop our resources including policies, procedures and the annual appraisal and review processes.
- We will develop our collaborative and partnership working for the benefit of individuals affected by digestive conditions.

Develop and grow income generation to support our charitable activities

- Supporting our new strategy, budget and plans we reviewed and developed a new fundraising strategy in 2024 for implementation in 2025 and the years ahead.
- Importantly, we will broaden our funding base to support our growth, including further developing community and events, individual giving, and legacies, developing a new philanthropy support framework for corporates, major donors, and trusts/foundations.

Governance

- We will complete a comprehensive governance review including trustee recruitment, induction and support, a trustee skills/experiences audit, and review of our delegated Committees structure.

FINANCIAL PERFORMANCE REVIEW

Overview

Total income for the year was £1.2M compared with £1.4M in 2023. Lower income was entirely explained by the timing of Guts UK research grant awards programme with income received in 2023 ahead of 2024 grant awards. At £1.3M, total expenditure was higher (from £1.1M in 2023), explained by planned investment during the year and research grants awards. Incorporating net gains on investments, we achieved a surplus of £150k in the year.

INCOME



EXPENDITURE



Income

Owing to the timing of Guts UK research grant awards, research income was significantly lower (£181k from £483k in 2023) resulting in lower total income. Non-research income, however, rose during the year including a 10% rise in donations to £387k, a 10% rise in income from charitable activities to £75.5k, and a 3% rise in investment income to £287k. Legacies were a little lower at £248k from £268k in 2023.

The income chart above explains how our income streams supported the charity.

Fundraising income

Fundraising income rose in the year (£635k from £619k). As noted above, although legacy income was lower, donations including individual giving, events, community, in-memory, and corporates all rose (by 10% to £387k).

2024 was an important year for the charity's fundraising development. Our fundraising lead joined mid-year. A key focus was to review, refine, and develop with the aim of broadening our funding base delivering sustainable income. As part of this, alongside the new charity strategy, a three-year fundraising strategy was developed and implemented. Over the next five years we will expand our fundraising programme, supported by a professional proactive approach. We are already seeing the benefits in the first half of 2025, and it is anticipated that we will generate a strong return in fundraising investment from 2026.

We are supported by and exceptionally grateful to our wonderful community. To fully appreciate the opportunities with our current audience and explore potential ways to engage new supporters, we undertook a data insight project, which has and will inform our plans.

We will continue to be supporter led and as part of this, we enhanced all touchpoints and ways of interacting with our fundraisers. During the year, we embarked on some new activities such as a legacy marketing programme, as future legacy income is increasingly important for charities. Examples of our legacy development included partnering with the National Free Wills Service, providing an additional offering to our supporters in addition to producing a legacy guide to aid potential legacy pledgers. We have already seen a positive response to these, and it is envisaged this will increase further in 2025/26.

During the second half of the year, we developed and diversified our sporting challenges programme, offering a variety of ways for supporters to get involved, which continues to perform well.

We have maintained fundraising momentum and have started to see the benefits of the work initiated in 2024 in the early months of the current year. We look forward to highlighting the developments in next year's report.

Other charitable activities income

Income from charitable activities role 10% to £76k from £69k the previous year, largely led by continued rising demand for our digestive condition leaflets to hospitals and health centres and corporate support for education and awareness programmes. We received donations from three pharmaceutical companies to support important awareness campaigns; Dr Falk with our continued awareness work on Microscopic Colitis; Kenvue to support the third year of our Imodium and Guts UK awareness campaign which reached even wider audiences this year; Enterra to support a new educational webinar as part of Gastroparesis awareness month. A further two pharmaceutical companies (Cyted and Astellas) made donations in recognition of Guts UK's work to coordinate patient engagement activities allowing them to truly understand the patient voice and perspective.

Research grants

Research partner income includes collaborations with pharmaceutical companies and other professional bodies such as the British Society of Gastroenterology (BSG), the Pancreatic Society of Great Britain and Ireland, and The British Society of Paediatric Gastroenterology, Hepatology and Nutrition. As explained previously, with grant award timings research income was as budgeted significantly lower in the year.

We also received the third, and final year funding from the Government's COVID Medical Research Charity Support Fund to support our Early Career Researchers and gastroenterology trainee grants. The grant was £67k from £171,606 in 2023.

Expenditure

Total expenditure rose during the year to £1.3M from £1.1M, reflecting planned development and investment in charitable activities and fundraising. Expenditure on Information Support Services and Communications & Public Education were £246k and £247k respectively including additional resourcing (staff and infrastructure) to support rising demand from across the UK. With the planned development of our charitable activities, the 2024 accounts separately identify Information Support Services and Communications & Public Education. The combined £493k expenditure represents a 55% increase compared with the previous year. With the timing of research grants programme, research expenditure was slightly lower at £514k from £541k.

Fundraising expenditure rose 10% to £250k.

The planned increase in expenditure included new staff roles to the operational team enabling us to better manage demands across our charitable activities, and fundraising. Staff costs rose to £454k in the year.

Balance Sheet

At 31 December 2024, Guts UK had net assets of £5.9M, an increase of £0.1M from 2023. Over half of the charity's net assets are restricted including restricted endowment funds.

Unrestricted funds which can be spent at the discretion of the trustees were £2.6M from £2.7M the previous year, reflecting planned expenditure. From unrestricted funds, the Board each year allocates expenditure to specific research grants. In 2024, the Board also approved allocated expenditure for the development of a new pilot Helpline service and to support website development.

More details of the disposition of Guts UK net assets can be found in the financial statements on page 29.

Reserves policy

As at 31st December 2024, total funds of the charity stood at £5,946,444 (2023: £5,795,777) of which;

- Unrestricted funds stood at £2,569,722 (2023: £2,658,089)
- Restricted funds stood at £578,630 (2023: £441,986)
- Endowment funds stood at £2,798,092 (2023: £2,695,702)

Guts UK has reviewed the amount of reserves it regards as a minimum prudent requirement and in 2024 The Board agreed to reduce the policy from twelve months of operational expenditure down to six months. The twelve month policy was put in place during covid to be more prudent considering the market environment, but in line with a number of other charities and auditor guidance, it was deemed sensible to now reduce the reserve required. A six month reserve still provides ample time to manage cost reductions and/or fund appeals as required whilst minimising the impact on service provision. Based on the approved budget for 2025, the reserves level is approximately £650k.

Note that the general reserve does not consider research grants or research administration costs as these are covered by unrestricted designated funds allocated by the Board and are deemed sufficient to cover research commitments for the next 24 months.

2025 Budget

In December 2025, the Board approved a three-year budget to support the new Strategy. Recognising the rising demands across the charity, the Board approved a deficit budget in the first two years to support necessary operational development and growth. The planned investment prioritises charitable activities and fundraising resourcing and capacity, with the aim of sustainably growing the charity and income generation.

Investment policy and performance

The charity's listed investments are managed by Cazenove. The investment strategy is set by the trustees and takes into account income requirements, the risk profile and the investment manager's advice on the market prospects in the medium term. Investments are held in a Responsible Multi-Asset Fund which adopts a total returns approach and provides even distribution payment alongside being an ethically responsible investment policy. The performance of the portfolio is monitored by Audit, Risk & Compliance Committee (ARC) and the Board. A regular update on the investment portfolio is reviewed by ARC.

Going concern

As required by the Charities Statement of Recommended Practice (FRS 102), we assess whether there are any uncertainties that may cast doubt over our ability to continue as a going concern. For this purpose, we focus on at least 12 months following the signing of these financial statements, which is to end-September 2026 at a minimum.

In approving the five-year strategy, budget, and operational plans in December 2024, the Board recognised the need to invest in our development and resourcing in the early years and therefore approved an operational deficit budget for 2025 and 2026 supported by the charity's unrestricted reserves. Taking into account our current position and our principal risks, trustees believe there are no material uncertainties that call into doubt the charity's ability to continue operating as a going concern. Trustees therefore continue to adopt the going concern basis of accounting in preparing the financial statements.

GOVERNANCE, POLICIES & STANDARDS

Guts UK is a charitable company limited by guarantee. Its governing document is its Memorandum and Articles of Association. The trustees have overall responsibility for setting the strategic direction of the charitable company. The Trustees confirm that they have complied with the duty in section 17 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Commission in determining the activities undertaken by the charity. The Trustees' Report sets out how the charity addresses the public benefit requirement. The work of the Board is supported by four delegated committees:

a) **Audit, Risk and Compliance Committee** (ARC) whose purpose is to oversee the operational activities of the charity covering finance, investment, audit, legal compliance, HR and risk management;
b) **Funding, Communications and Industry Committee** (FUNCI) whose purpose is to deliver on Guts UK's fund-raising programmes, ensuring engagement with patients, public, the medical profession and industry;
c) **Information Support Committee** (ISC) whose purpose is to recommend the strategic direction for information service provision; and to facilitate peer review and quality control of written and web-based information, plus any other public sources of information such as webinars provided by Guts UK.

d) **Research Strategy Committee** (RSC) whose purpose is to recommend areas of focus for Guts UK's research priorities.

Committees made up of volunteers external to the Board of Trustees:

a) **Research Awards Committee** ("RAC") whose purpose is to ensure the integrity of Guts UK's research awards and that they align with the charity's stated objectives. The RAC is responsible for assessing, approving and monitoring applications for research funding. The RAC's processes are governed by the Terms of Reference and committee members (including those co-opted for specific awards) are required to sign a declaration of conflicts of interests form. Membership is open to members of the gastroenterology research profession and is assigned on a three-year term. The Chair of the RAC must be from outside of the gastroenterology field and is also a three-year term.

The policies of the charity are determined by its Board of Trustees. The research policy of the charity is decided by the Trustees in consultation with the Research Committee of the BSG. Guts UK is a member of the Association of Medical Research Charities.

All Trustee roles are openly advertised. Shortlisted candidates are interviewed by panel including the Chair, CEO and Trustees. Following interviews, successful candidates are then invited to observe a delegated committee and Board meeting providing the opportunity to meet other trustees, managers, and gain an insight to how we work. Formal appointment requires a majority vote of the Board. The usual term of office is three years, renewable on approval by the board up to a maximum of nine years.

Trustees receive a comprehensive induction which covers both the responsibilities of the role and the specifics of the charity. All new Trustees are required to review and understand the Essential Trustee information on the Charity Commission website and other accompanying documents. They also have access to the latest governance training provided by charity sector bodies, such as NCVO. In getting to know the charity, the Trustees have a series of briefing meetings with the Chair, CEO, and COO. Through these meetings, they are introduced to the Charity's Articles of Association and other governance documents including the Strategy, Operation Plan, Budget, management accounts, and Risk Register.

Related parties and relationships with other organisations - there are no related party relationships with any other organisations.

Guts UK continues to work closely with the BSG in providing strong links with the professional community and support its ability to disseminate research and patient information. The Chair of the BSG's Research Committee is a member of the Board.

Senior Leadership Team

The day-to-day operation of Guts UK is delegated to the Chief Executive who is supported by the Chief Operating Officer. Toward the close of the year, we recruited a Head of Research, a member of the Senior Leadership Team, who joined in February 2025.

Staff pay, including Senior Leadership Team, is monitored and reviewed by ARC and annually by the Board as part of budget approval process. Senior Leadership Team remuneration details are provided in Note 13 to the financial statements.

Risk management

Guts UK has a risk register identifying the likelihood, impact and mitigating actions of the major risks to which the charity is exposed. The risks incorporate governance and compliance, operational, financial, fundraising, investment, and reputational. The risk register is reviewed regularly by ARC and discussed in Board meetings. The Trustees identified the following principal risks facing the charity in 2024:

Staffing

We have a small staff team at Guts UK and as highlighted demands across all our work and charitable activities is sharply accelerating. During the year we reviewed our HR practices and support. We will continue to invest in HR practices valued by staff including investment in learning and development. This is managed by the Chief Executive and COO. As also noted elsewhere, the Board of Trustees approved a deficit budget for 2025 and 2026 to support investment in and expansion of our operational team.

Cyber and systems security

Cyber security is a major concern across the charity sector. With our external IT support provider, we implemented a number of additional measures during the year and continuously monitor and upgrade our system defences as needed. We also actively maintain staff awareness and training.

Fundraising and income generation

The continuing uncertainty in long term income planning continues to impact the charity sector and in developing and approving our new strategy we were and continue to be aware of the risks particularly as we look to significantly increase our fundraising income across the new strategy planning period. Mitigations include appointment of our fundraising lead and new CEO both of whom have significant fundraising experience, the fundraising strategy and plans including our small-scale testing and agile switching to successful approaches.

Information Standards at Guts UK

We are proud of the quality of the information we provide and work to a comprehensive process including:

- All information leaflets including are signed off by our Information Support Committee.
- All information is subject to the PIF Tick[1] quality standards and assurance including an annual audit which must be passed to maintain PIF accreditation.
- All information leaflets are written by a healthcare professional and reviewed by BSG Committee member and/or a specialist to ensure factual accuracy and the inclusion of current evidence-based developments and research. Leaflets are then reviewed by a lay reviewer to ensure readability and understanding.
- All information leaflets are cobranded with the BSG as trusted information that has been developed with the help of multidisciplinary expert clinicians in medical and surgical gastroenterology, hepatology and pancreatology and people with lived experience.
- All information is subject to a strict, published Code of Practise which is governed by the Information Committee and is reviewed as part of the PIF annual audit.
- Health condition information published on social media and other communication channels is signed off by Guts UK Information Manager to ensure compliance with our standards.
- We record all complaints and adhere to the Guts UK Complaints Policy. Complaints (and compliments) inform our approach to information provision and our wider work.

[1] The PIF TICK is an independently-assessed quality mark for trusted health information recognised by the NHS. Further information can be found here: The PIF TICK | Patient Information Forum (pifonline.org.uk)

Grant Making Policy at Guts UK

We know that better treatments and support and earlier or quicker diagnosis are a priority for our community and we want to ensure we fund the best research and researchers.

- Guts UK is a member of the Association of Medical Research Charities (AMRC) and complies with their policies including those on animal research, patient and public engagement, conflicts of interest, and funding.
- The charity will consider all applications that fall within our charitable purposes and meet our eligibility criteria and, for which, the due diligence process has not identified any unacceptable issues
- Applicants' data will be held in accordance with data protection legislation. It will be held securely, disclosed if subject to an access request, treated as confidential, only used for the purpose for which it has been provided and destroyed, once no longer needed.
- Research grant applications are reviewed by our independent Research Awards Committee (which includes representation from our Experts by Experience patient panel) with recommendations to Research Strategy Committee and then Board.
- All grantees are required to report on progress of their project, financial costs, and impact of the project/work. The charity reviews and monitors the reports liaising with grantees as appropriate.
- Full terms and conditions are available to all applicants and their associated trusts/universities on our website. These are reviewed annually and ratified by the Research Strategy Committee.

The Annual Report of the trustees is a combined annual report incorporating both the directors report and the trustees report for the charity as required by company law

This Annual Report of the trustees was approved by order of the board of trustees, as the company directors, on 10th September 2025 and signed on the board's behalf by:



.....

Dr Victoria King, Chair of the Board of Trustees

Royal Patron	HRH Princess Alexandra
Trustees	• Dr Victoria King PhD, Chair • Dr Linda Dugdale-Bradley, Vice Chair and FUNCI Chair • Mrs Melissa Davey • Miss Natalie Bridge (resigned 4-Sep-24) • Prof Sebastian Shaji* (resigned 4-Sep-24) • Dr Miranda Lomer MBE PhD • Professor Christine Norton, ISC Chair • Professor Chirs Probert MD FRCP • Dr Connor McCann PhD, RSC Chair • Ms Charlotte Leonard, Treasurer and ARC Chair • Mr Ravinder Chahil • Professor Debbie Shawcross* BSc MBBS PhD FRCP (appointed 4-Sep-24) • Ms Rose Widlake (appointed 4-June-25) * nominee of the British Society of Gastroenterology (BSG)
Chief Executive	Suzanne Hudson (from 2-Sep-24) Katie Noon COO acting as Interim CEO (16-Apr-24 to 1-Sep-24) Julie Harrington (to 15-Apr-24)
Principal office	2 St Andrews Place Regent's Park London. NW1 4LB
Telephone	0207 486 0341
Website	www.gutscharity.org.uk
E-mail	info@gutscharity.org.uk
Company registration number	07274105 (England and Wales)
Charity registration number	1137029
Auditor	Harris, Lacey and Swain Suite 1, The Riverside Building Livingstone Road Hessle, HU13 0DZ
Bankers	National Westminster Bank plc 1 Cavendish Square London, W1A 4NU
Investment managers	Cazenove Capital Management 12 Moorgate London, EC2R 6DA
Solicitors	Hempsons 40 Villiers Street London, WC2N 6NJ

REGISTERED COMPANY NUMBER: 07274105 (England and Wales)
REGISTERED CHARITY NUMBER: 1137029

Financial Statements for the Year Ended 31 December 2024

for

Guts UK Charity

Harris Lacey and Swain
Chartered Accountants and Statutory Auditors
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees (who are also the directors of Guts UK Charity for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charity SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditors are unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

Report of the trustees, incorporating a strategic report, approved by order of the board of trustees, as the company directors, on 10th September 2025 and signed on the board's behalf by:



.....
Dr Victoria King – Chair of Board of Trustees

Opinion
We have audited the financial statements of Guts UK Charity (the 'charitable company') for the year ended 31 December 2024 which comprise the Statement of Financial Activities, the Statement of Financial Position, the Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
- give a true and fair view of the state of the charitable company's affairs as at 31 December 2024 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information
The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Matters on which we are required to report by exception
We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:
- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- the charitable company has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements
We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion.

Identifying and assessing potential risks related to irregularities
In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

Audit response to risks identified
- the nature of the industry and sector, control environment and business performance including key drivers for directors' remuneration, bonus levels and performance targets
- results of our enquiries of management and their own identification and assessment of the risks of irregularities;
- any matters we identified having obtained and reviewed the companies' documentation of their policies and procedures relating to:
- identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of noncompliance;
- detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;
- the internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;
- the matters discussed among the audit engagement team including regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in relation to revenue deferrals. In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override.

We also obtained an understanding of the legal and regulatory frameworks that the company operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. The key laws and regulations we considered in this context included the UK Companies Act, UK Corporate Governance Code and local tax legislation.

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which may be fundamental to the company's ability to operate or to avoid a material penalty.

Audit response to risks identified

Our procedures to respond to risks identified included the following:
- reviewing the financial statement disclosures and testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
- enquiring of management concerning actual and potential litigation and claims;
- performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
- reading minutes of meetings of those charged with governance

- obtained an understanding of provisions and held discussions with management to understand the basis of recognition or non-recognition of tax provisions; and
- in addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members, and remained alert to any indications of fraud or noncompliance with laws and regulations throughout the audit.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report
This report is made solely to the charitable company's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable company's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.


Laura J Drew BFP ACA FCCA (Sep 15, 2025 13:51:49 GMT+1)

Harris Lacey and Swain
Chartered Accountants and Statutory Auditors
Eligible to act as an auditor in terms of Section 1212 of the Companies Act 2006
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Date: 11th September 2025

Guts UK Charity

Statement of Financial Activities
for the Year Ended 31 December 2024

	Notes	Unrestricted funds £	Restricted fund £	Endowment fund £	2024 Total funds £	2023 Total funds £
INCOME AND ENDOWMENTS FROM						
Donations and legacies	2	621,471	13,390	-	634,861	618,566
Charitable activities	5					
Gastro-enterology research		-	180,968	-	180,968	482,839
Information services	3	75,500	-	-	75,500	68,687
Investment income	4	145,528	143,283	-	288,811	278,376
Total		842,499	337,641	-	1,180,140	1,448,468
EXPENDITURE ON						
Charitable activities	6					
Cost of raising funds		235,658	2,859	-	238,517	213,257
Gastro-enterology research		171,926	341,657	-	513,583	540,826
Education and awareness		247,481	-	-	247,481	318,332
Information services		245,651	-	-	245,651	-
Investment manager fees		5,418	-	5,869	11,287	14,168
Total		906,134	344,516	5,869	1,256,519	1,086,583
Net gains on investments		227,046	-	-	227,046	147,566
NET INCOME/(EXPENDITURE)		163,411	(6,875)	(5,869)	150,667	509,451
Transfers between funds	18	(251,778)	143,519	108,259	-	-
Net movement in funds		(88,367)	136,644	102,390	150,667	509,451
RECONCILIATION OF FUNDS						
Total funds brought forward		2,658,089	441,986	2,695,702	5,795,777	5,286,326
TOTAL FUNDS CARRIED FORWARD		2,569,722	578,630	2,798,092	5,946,444	5,795,777

The notes form part of these financial statements

Guts UK Charity

Statement of Financial Position
31 December 2024

	Notes	Unrestricted funds £	Restricted fund £	Endowment fund £	2024 Total funds £	2023 Total funds £
FIXED ASSETS						
Tangible assets	12	9,565	-	-	9,565	6,316
Investments	13	3,678,364	-	2,818,906	6,497,270	6,107,174
		3,687,929	-	2,818,906	6,506,835	6,113,490
CURRENT ASSETS						
Stocks	14	12,713	-	-	12,713	18,679
Debtors	15	342,844	-	-	342,844	447,941
Cash at bank and in hand		(154,095)	578,630	(20,814)	403,721	756,488
		201,462	578,630	(20,814)	759,278	1,223,108
CREDITORS						
Amounts falling due within one year	16	(916,568)	-	-	(916,568)	(658,136)
NET CURRENT ASSETS		(715,106)	578,630	(20,814)	(157,290)	564,972
TOTAL ASSETS LESS CURRENT LIABILITIES		2,972,823	578,630	2,798,092	6,349,545	6,678,462
CREDITORS						
Amounts falling due after more than one year	17	(403,101)	-	-	(403,101)	(882,685)
NET ASSETS		2,569,722	578,630	2,798,092	5,946,444	5,795,777
FUNDS	18					
Unrestricted funds:						
General fund					1,015,978	1,092,510
Designated funds					1,553,744	1,565,579
					2,569,722	2,658,089
Restricted funds					578,630	441,986
Endowment funds					2,798,092	2,695,702
TOTAL FUNDS					5,946,444	5,795,777

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not deposited notice, pursuant to Section 476 of the Companies Act 2006 requiring an audit of these financial statements.

The notes form part of these financial statements

continued...

The trustees acknowledge their responsibilities for

(a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and

(b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been audited under the requirements of Section 145 of the Charities Act 2011.

The financial statements were approved by the Board of Trustees and authorised for issue on 10th September 2025 and were signed on its behalf by:



.....
Dr Victoria King – Chair of Board of Trustees

Guts UK Charity

Statement of Cash Flows
for the Year Ended 31 December 2024

	Notes	2024 £	2023 £
Cash flows from operating activities			
Cash generated from operations	1	(473,803)	(396,887)
Net cash used in operating activities		(473,803)	(396,887)
Cash flows from investing activities			
Purchase of tangible fixed assets		(7,465)	(5,338)
Movement in cash within investments		(171,965)	(10,183)
Proceeds from disposal of investments		11,655	8,196
Interest received		288,811	278,376
Net cash provided by investing activities		121,036	271,051
Change in cash and cash equivalents in the reporting period		(352,767)	(125,836)
Cash and cash equivalents at the beginning of the reporting period		756,488	882,324
Cash and cash equivalents at the end of the reporting period		403,721	756,488

The notes form part of these financial statements

1. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2024 £	2023 £
Net income for the reporting period (as per the Statement of Financial Activities)	150,667	509,451
Adjustments for:		
Depreciation charges	4,216	2,444
Gain on investments	(227,046)	(147,566)
Interest received	(288,811)	(278,376)
Decrease/(increase) in stocks	5,966	(18,679)
Decrease/(increase) in debtors	105,097	(27,282)
Decrease in creditors	(223,892)	(436,879)
Net cash used in operations	(473,803)	(396,887)

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.1.24 £	Cash flow £	At 31.12.24 £
Net cash			
Cash at bank and in hand	756,488	(352,767)	403,721
	756,488	(352,767)	403,721
Total	756,488	(352,767)	403,721

The notes form part of these financial statements

1. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

Assessment of going concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements and have made this assessment in respect to a period of one year from the date of approval of these financial statements.

The trustees have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the charity to continue as a going concern. The trustees are confident that the charity has sufficient funds to cover its existing liabilities.

With regard to the next accounting period, the year ending 31 December 2022, the most significant areas that affect the carrying value of the assets held by the charity are the level of investment return and the performance of the investment markets (see the investment policy and the risk management sections of the trustees' report for more information).

Monetary amounts in these financial statements are rounded to the nearest whole £1. The financial statements are presented in sterling which is also the functional currency of the company.

Income
Income is recognised in the period in which the charity has entitlement to the income, the amount of income can be measured reliably and it is probable that the income will be received.

Donations are recognised when the charity has confirmation of both the amount and settlement date. In the event of donations pledged but not received, the amount is accrued for where the receipt is probable.

Legacies are included in the statement of financial activities when the charity is entitled to the legacy, the executors have established that there are sufficient surplus assets in the estate to pay the legacy, and any conditions attached to the legacy are within the control of the charity. Entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor to the charity that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity or the charity is aware of the granting of probate, but the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material. In the event that the gift is in the form of an asset other than cash or a financial asset traded on a recognised stock exchange, recognition is subject to the value of the gift being reliably measurable with a degree of reasonable accuracy and the title of the asset having being transferred to the charity.

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

continued...

1. ACCOUNTING POLICIES - continued

Income
Research funding income is recognised in the period in which the charity receives a written commitment from the funder. Research funding is deferred only when the charity has to fulfil conditions before becoming entitled to it or the donor has specified that the income has to be spent in a future period.

Debtors
Debtors include amounts owed to the charity for the provision of services or amounts the charity has paid in advance for the goods and services it will receive. Debtors also include amounts receivable on grant funding to which the charity is entitled.

Debtors are measured at their recoverable amounts.

Expenditure
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to make a payment to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis and is stated inclusive of irrecoverable VAT. Expenditure comprises direct costs and support costs. All expenses, including support costs, are allocated or apportioned to the applicable expenditure headings. The classification between activities is as follows:

a) Cost of raising funds which includes direct fundraising costs and investment manager's fees.

b) Expenditure on charitable activities comprises expenditure on the charity's primary charitable purposes as described in the trustees' report. Such costs include grants payable, other direct costs and support costs, which are apportioned based on the level of activity in each area.

Research grants payable are included in the statement of financial activities when approved and when the intended recipient has either received the funds or been informed of the decision to make the grant, and has satisfied all relevant conditions. Grants approved but not paid at the end of the financial year are accrued for. Grants where the beneficiary has not been informed or has to meet certain conditions before the grant is payable are not accrued for but are noted as financial commitments in the notes to the financial statements.

The provision of a multi-year grant is recognised at its present value where settlement is due over more than one year from the date of the award, there are no unfulfilled performance conditions under the control of the charity that would permit the charity to avoid making the future payments, settlement is probable and the effect of the discounting is material. The discount rate used is the average rate of investment yield in the year in which the grant is made. This discount rate is regarded by the trustees as providing the most current available estimate of the opportunity cost of money reflecting the time value of money to the charity.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Creditors
A liability is recognised for the amount that the charity anticipates it will pay to settle the debt or the amount it has received as an advance payment for services it must provide. Liabilities are measured at their settlement amount.

Allocation and apportionment of costs
Support costs represent indirect charitable expenditure. In order to carry out the primary purposes of the charity it is necessary to provide support in the form of financial procedures, provision of office services and equipment and a suitable working environment.

continued...

1. ACCOUNTING POLICIES - continued

Allocation and apportionment of costs
Governance costs comprise the costs directly attributable to the governance of the charity, including audit costs and the necessary legal procedures for compliance with statutory requirements. Support costs and governance costs are allocated between activities with the allocation based on staff time.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment	-	33% on cost

Stock
Stock is valued at the lower of cost and net realisable value. Cost is based on the cost of purchase on a first in first out basis. Net realisable value is the estimated selling price. Included within the stock value is a provision of 50% of the stock which will be gifted free of charge, this stock has been valued at £nil in the accounts.

Taxation
The charity is exempt from corporation tax on its charitable activities.

Fund accounting
The charity has various types of funds for which it is responsible, and which require separate disclosure. These are as follows:

General funds
Funds which are expendable at the discretion of the trustees in furtherance of the objects of the charity.

Designated funds
Funds which are set aside as part of the charity's unrestricted funds for particular purposes in the future as determined by the trustees from time to time.

Restricted funds
Funds raised for, and their use restricted to, a specific purpose, or donations subject to donor imposed conditions.

Endowment funds
Funds which must be held indefinitely as capital. Income therefore is credited to general funds and applied for general purposes unless under the terms of the endowments such income must be used for specific purposes in which cases it is credited to restricted funds.

Financial Instruments
The charity only holds basic financial instruments as defined in FRS 102. The financial assets and financial liabilities of the charity and their measurement basis are as follows:

Financial assets - other debtors are basic financial instruments and are debt instruments measured at amortised cost. Listed investments are a basic financial instrument as detailed above. Prepayments are not financial instruments.

Cash at bank - classified as a basic financial instrument and is measured at face value.

Financial liabilities - accruals and other creditors are financial instruments, and are measured at amortised cost.

continued...

1. ACCOUNTING POLICIES - continued

Investments
Fixed asset investments are measured initially at cost and subsequently at fair value at the reporting date. Changes in fair value are recognised as income or expenditure in the Statement of Financial Activities.

Redundancy and termination benefits
Redundancy and termination benefits are recognised as expenditure. Amounts provided are in respect of settlement of employment agreements made between the entity and employed individual.

Critical accounting judgements and key sources of estimation uncertainty
Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Although these estimates are based on the Trustees' best knowledge of the amount, events or actions, actual results ultimately differ from these estimates. The Trustees do not consider there to be any material estimates and judgements.

Cash and cash equivalents
As at the year end, the Charity held a portion of its cash reserves within high interest, fixed rate bonds. Due to their highly liquid nature, these have been included within Cash at bank and in hand.

2. DONATIONS AND LEGACIES

	Unrestricted funds £	Restricted funds £	Endowment funds £	2024 Total funds £	2023 Total funds £
Donations	376,293	10,438	-	386,731	350,850
Legacies	245,178	2,952	-	248,130	267,716
	621,471	13,390	-	634,861	618,566

3. INFORMATION SERVICES

	Unrestricted funds £	Restricted funds £	Endowment funds £	2024 Total funds £	2023 Total funds £
Public education/info services	75,500	-	-	75,500	68,687

4. INVESTMENT INCOME

	Unrestricted funds £	Restricted funds £	**2024 Total funds £**	2023 Total funds £
Interest - fixed interest securities	1,730	1,229	**2,959**	6,285
Multi-asset funds	132,605	142,054	**274,658**	258,824
Interest on cash deposits	5,101	-	**5,101**	12,367
Other interest income	4,864	-	**4,864**	900
2024 Total funds	144,299	143,283	**287,582**	278,376

continued...

5. INCOME FROM CHARITABLE ACTIVITIES

	2024 Gastro-enterology research	2023 Total activities
	£	£
Grants	180,968	482,839

Grants received, included in the above, are as follows:

	2024	2023
	£	£
Other grants for research	113,878	311,233
Government grants received	67,090	171,606
	180,968	482,839

continued...

6. CHARITABLE ACTIVITIES COSTS

	Direct staff costs £	Direct other costs £	Research grants awarded (below) £	Charitable Support costs (note 7) £	**2024 Total funds £**
Gastroenterology research	96,617	-	316,926	47,771	**461,314**
Information Services	101,566	48,994	-	47,771	**198,331**
Education & Awareness	106,462	42,957	-	49,682	**199,101**
2024 Total funds	304,645	91,951	316,926	145,224	**858,746**

	Direct costs £	Research grants awarded £	Support costs £	2023 Total funds £
Gastroenterology research	2,570	379,899	158,357	540,826
Public education	77,864	-	240,468	318,332
2023 Total funds	80,434	379,899	398,825	859,158

COST OF RAISING FUNDS

	Unrestricted funds £	Restricted funds £	**2024 Total funds £**
Fundraising costs	46,868	2,859	**49,727**
Investment manager's fees	5,418	5,869	**11,287**
Staff costs	121,668	-	**121,668**
Support costs (note 7)	45,859	-	**45,859**
2024 Total funds	219,813	8,728	**228,541**

	Unrestricted funds £	Restricted funds £	2023 Total funds £
Fundraising costs	25,574	-	25,574
Investment manager's fees	7,388	6,780	14,168
Support costs	187,682	-	187,682
2023 Total funds	220,644	6,780	227,424

continued...

6. CHARITABLE ACTIVITIES COSTS - continued

Research Grants Awarded

	2024 Total funds £	2023 Total funds £
New research grants	**341,657**	436,153
Less; grants no longer required - research commitments	**(24,731)**	(56,254)
Research grants awarded	**316,926**	379,899

Research grants awarded represent commitments made for research.

7. SUPPORT COSTS

	Cost of raising funds £	Charitable activities (Note 6) £	Admin/ Support costs £	**2024 Totals £**	2023 Totals £
Staff costs	-	-	80,636	**80,636**	335,612
Premises and donated facilities	-	-	55,912	**55,912**	46,541
Printing, postage, marketing and telephone	4,172	13,212	-	**17,384**	15,239
Insurance	-	-	6,124	**6,124**	3,408
Bank charges	397	1,255	-	**1,652**	6,741
Meeting costs	5,310	16,814	-	**22,124**	21,193
Subscriptions and publications	4,948	15,667	-	**20,615**	12,288
Equipment/ maintenance and website development	20,488	64,880	-	**85,368**	58,409
Depreciation	1,012	3,204	-	**4,216**	2,444
Training and recruitment	8,936	28,302	-	**37,238**	26,904
Consultancy fees	-	-	-	**-**	13,332
Governance costs					
- Accountancy & bookkeeping	-	-	12,589	**12,589**	18,490
- Auditors remuneration	-	-	9,420	**9,420**	13,728
- Professional fees	-	-	4,299	**4,299**	-
- Trustees expenses	-	-	254	**254**	2,237
Brand development	596	1,890	-	**2,486**	9,941
Totals	45,859	145,224	169,234	**360,317**	586,507

continued...

8. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2024	2023
	£	£
Depreciation - owned assets	4,216	2,444

9. AUDITORS' REMUNERATION

	2024	2023
	£	£
Fees payable to the charity's auditors and their associates for the audit of the charity's financial statements	9,420	12,736

10. TRUSTEES' REMUNERATION AND BENEFITS

A total of £nil remuneration (2023: £nil) was paid or payable, directly or indirectly, out of the funds of the charity for the period to any trustee, or to any person or persons known to be connected with any of them.

Trustees' expenses

A total of 0 trustees were reimbursed for expenses in the year. However, advertising expenses of £254 were incurred for the recruitment of a new trustee (2023: 3 trustees: £536 for travel expenses).

11. STAFF COSTS

	2024 Total funds	2023 Total funds
	£	£
Salaries and wages (including temporary staff)	**461,297**	302,402
Social security	**36,272**	24,944
Pension costs	**9,380**	8,266
	506,948	335,612

The average monthly number of employees during the year was as follows:

	2024	2023
General	12	9

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2024	2023
£60,001 - £70,000	2	1

The key management personnel of the charity in charge of directing and controlling, running and operating the charity on a day to day basis comprises the Chief Executive and the COO. The total remuneration (including taxable benefits and employer's pension contributions) of the key management personnel for the year was £144,032 (2023: £108,613).

continued...

11. STAFF COSTS - continued

Included in the above figure is a termination cost of £16,890.

Employee benefit obligations

	2024	2023
	£	£
Pension commitments under defined contribution schemes:		
Within one year	**9,380**	8,266
	9,380	8,266

12. TANGIBLE FIXED ASSETS

	Computer equipment
	£
COST	
At 1 January 2024	17,131
Additions	7,465
Disposals	(5,202)
At 31 December 2024	19,394
DEPRECIATION	
At 1 January 2024	10,815
Charge for year	4,216
Eliminated on disposal	(5,202)
At 31 December 2024	9,829
NET BOOK VALUE	
At 31 December 2024	9,565
At 31 December 2023	6,316

13. FIXED ASSET INVESTMENTS

	Listed investments
	£
MARKET VALUE	
At 1 January 2024	6,107,174
Revaluations	390,096
At 31 December 2024	6,497,270
NET BOOK VALUE	
At 31 December 2024	6,497,270
At 31 December 2023	6,107,174

continued...

13. FIXED ASSET INVESTMENTS - continued

Cost or valuation at 31 December 2024 is represented by:

	Listed investments £
Valuation in 2024	390,096
Valuation in 2023	149,554
Valuation in 2022	(478,009)
Valuation in 2021	443,269
Valuation in 2020	239,836
Valuation in 2019	481,689
Valuation in 2018	(512,324)
Valuation in 2017	1,526,071
Valuation in 2016	341,197
Valuation in 2015	3,915,891
	6,497,270

14. STOCKS

	2024 £	2023 £
Stocks	12,713	18,679

15. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024 £	2023 £
Trade debtors	42,628	44,037
Other debtors	229,999	351,851
Prepayments and accrued income	54,901	37,620
Prepayments	15,316	14,433
	342,844	447,941

Included within debtors under commitments due is £162,628 (2023: £149,921) which is due within one year.

continued...

16. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024	2023
	£	£
Trade creditors	6,304	11,610
Social security and other taxes	16,424	8,294
Other creditors	863,950	621,716
Accrued expenses	29,890	16,516
	916,568	658,136

17. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

	2024	2023
	£	£
Other creditors	403,101	882,685

18. MOVEMENT IN FUNDS

See note 20 onwards for the movements in funds.

19. RELATED PARTY DISCLOSURES

During the year the charity received donations of £625 from trustees (2023: £925). Included in trustee expenses during the period is £254 reimbursed to 1 trustee for recruitment expenses (2023: 3 trustees £536 for travel expenses).

Transactions with the British Society of Gastroenterology are detailed in note 24.

20. RESTRICTED FUNDS

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust to be applied for specific purposes:

	At 1 January 2024	Income	Expenditure	Transfers	**At 31 December 2024**
	£	£	£	£	**£**
Research awards - Dr Falk Pharma	-	19,000	(20,000)	1,000	**-**
Restricted research grants	-	4,878	(118,657)	113,779	**-**
Medical Research Charity support fund	-	67,090	-	(67,090)	**-**
Partner funding for Priority Setting Partnerships (PSP)					
- Diverticular Disease PSP	-	20,000	(20,000)	-	-
- Endoscopy PSP	-	30,000	(30,000)	-	-
Pancreatitis					
- General	12,214	2,995	-	-	**15,209**
- Research	6,895	3,970	-	(10,865)	**-**
Viatris	5,337	-	(2,859)	-	**2,478**
Stomach Cancer	5,133	-	-	-	**5,133**
LSCT	5,229	1,374	-	-	**6,603**

continued...

20. RESTRICTED FUNDS - continued

Restricted - Hirschprungs Disease	-	4,100	-	(4,100)	-
Research into adhesions	548	-	-	-	**548**
Diverticular	500	-	-	-	**500**
Oesophageal	2,204	950	-	(2,204)	**950**
Microbiome	625	-	-	-	**625**
Barrett's Oesophagus	28,633	-	-	-	**28,633**
Trust donation - Pancreatitis Research	-	40,000	-	(40,000)	**-**
Company donations - restricted	15,896	-	-	-	**15,896**
Derek Butler Endowment Income fund	358,772	143,283	-	-	**502,055**
	441,986	337,640	(191,516)	(9,480)	**578,630**

	At 1 January 2023 £	Income £	Expenditure £	Transfers £	At 31 December 2023 £
Guts UK/Dr Falk Awards	-	19,000	(25,862)	6,862	-
Restricted research grants	-	292,233	(410,291)	118,058	-
Medical Research Charity support fund	-	171,606	-	(171,606)	-
Pancreatitis					-
- Liverpool research	-	9,626	-	(9,626)	-
- Research	-	5,472	-	1,423	6,895
- General	10,457	3,180	-	(1,423)	12,214
Stomach Cancer	8,094	-	-	(2,961)	5,133
LSCT	-	2,704	-	2,525	5,229
Viatris	-	12,300	(6,963)	-	5,337
Research into adhesions	548	-	-	-	548
Diverticular	500	-	-	-	500
Oesophageal	2,204	810	-	(810)	2,204
Microbiome	625	-	-	-	625
Barrett's Oesophagus	28,633	-	-	-	28,633
Trust funding	-	-	-	-	-
Company donations - restricted	15,896	-	-	-	15,896
Derek Butler Endowment Income fund	224,315	133,647	-	810	358,772
	291,272	650,578	(443,116)	(56,748)	441,986

The transfer represents the contribution from general funds towards the research grants or from restricted funds to general or designated funds for previously committed research as specified by the donor.

continued...

21. DESIGNATED FUNDS

Amelie Waring

	At 1 January 2024 £	Income £	Expenditure £	Transfers £	Investment (losses) £	**At 31 December 2024 £**
Investments	796,878	34,592	(1,971)	-	31,753	**861,252**
Cash held in current account	56,401	-	-	(109,434)	-	**(53,033)**
Transfer to unrestricted	(37,657)	-	-	37,657	-	-
Research Commitments	(87,507)	-	(153,000)	122,642	-	**(117,865)**
Total Amelie Waring Fund	728,115	34,592	(154,972)	50,865	31,753	**690,354**

	At 1 January 2023 £	Income £	Expenditure £	Transfers £	Investment (losses) £	At 31 December 2023 £
Investments	822,660	35,621	(1,999)	(80,000)	20,596	796,878
Cash held in current account	46,775	-	-	9,626	-	56,401
Research Commitments	(199,589)	-	-	112,084	-	(87,505)
Total Amelie Waring Fund	669,846	35,621	(1,999)	41,710	20,596	765,774

GI Research

	At 1 January 2024 £	Income £	Expenditure £	Transfers £	Investment (losses) £	**At 31 December 2024 £**
Investments	907,508	38,630	(2,196)	(28,958)	27,047	**942,031**
Cash held in current account	670,116	-	-	(78,853)	-	**591,263**
Transfer to unrestricted	50,400	-	-	(50,400)	-	-
Research Commitments	(777,817)	-	(162,309)	270,222	-	**(669,904)**

continued...

Total GI Research Fund	850,207	38,630	(164,505)	112,011	27,047	**863,390**

	At 1 January 2023 £	Income £	Expenditure £	Transfer s £	Investment (losses) £	At 31 December 2023 £
Investments	885,235	38,220	(2,134)	(37,684)	23,870	907,507
Cash held in current account	-	-	-	280,146	-	280,146
Research Commitments	(260,092)	-	-	(127,756)	-	(387,848)
Total GI Research Fund	625,143	38,220	(2,134)	114,706	23,870	799,805

Total Designated Funds

Total Designated Funds 2024	**1,578,322**	73,222	(319,476)	162,876	58,800	1,553,744
Total Designated Funds 2023	1,294,989	86,584	(4,133)	156,416	44,466	1,578,322

The Amelie Waring fund was initially established in memory of Amelie Waring to fund pancreatitis research, although the original bequest has been fully expended the trustees continue to designate funds to pancreatitis research in recognition of their ongoing commitment to funding research in this area.

The GI Research Fund is designated to general gastrointestinal research.

continued...

22. ENDOWMENT FUND

	At 1 January 2024 £	Income £	Expenditure/ transfers £	Investment losses £	**At 31 December 2024 £**
Derek Butler Endowment	2,695,702	-	(7,502)	109,892	**2,798,092**

	At 1 January 2023 £	Income £	Expenditure/ transfers £	Investment losses £	At 31 December 2023 £
Derek Butler Endowment	2,631,036	-	(6,780)	71,446	2,695,702

Income from the Derek Butler Endowment fund is credited to restricted funds and is to be spent on research into diseases of the upper gastrointestinal tract.

23. BRITISH SOCIETY OF GASTROENTEROLOGY

Guts UK works closely with the British Society of Gastroenterology (BSG) (Charity Registration No. 1149074 and Company Registration No. 08124892 (England and Wales)) to provide strong links with the main professional community and to improve its ability to disseminate research and patient information. The Chair of the Research Committee of BSG is a member of Guts UK's Board of Trustees. The Chair of Guts UK is an ex-officio member of BSG's Council.

Transactions between the two charities during the period were as follows:

- The BSG provided a grant of £4,878 (2023: £12,312) to support trainee research grants and a payment of £20,000 to co-fund the JLA Priority Setting Partnership on Endoscopy.

24. CONTINGENT ASSET AND LIABILITY

In 2018 the charity secured provisional funding amounting to £1,250,000 for the colorectal research grant of which £1,020,000 has been received to date (2023: £880,000). Future receivables are contingent on a satisfactory annual report being approved by the funding partner and Guts UK has agreed to distribute and monitor use of the funding as a sub-grant. As at 31 December 2024, £451,281 (2023: £488,325) is outstanding in receivables of which £243,460 is due within one year.

continued...

25. LIABILITY OF MEMBERS

The charity is constituted as a company limited by guarantee. In the event of the charity being wound up, members are required to contribute an amount not exceeding £1.

26. COMMITMENTS UNDER OPERATING LEASES

At 31 December 2024 the charity had future minimum commitments under non-cancellable operating leases as set out below:

Payments which fall due:	**2024** **£**	2023 £
Within one year	1,420	768
Within 2 to 5 years	1,420	3,072
	2,840	3,840

These operating leases are for printers held under hire purchase.

Detailed Statement of Financial Activities for the Year Ended 31 December 2024

	2024 £	2023 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	386,731	350,850
Legacies	248,130	267,716
	634,861	618,566
Information services		
Public education/info services	75,500	68,687
Investment income		
Curr asset inv income	288,811	278,376
Charitable activities		
Grants	180,968	482,839
Total incoming resources	1,180,140	1,448,468
EXPENDITURE		
Charitable activities		
Wages	506,949	335,612
Fundraising	61,014	48,059
Grants payable	315,309	379,899
Research administration	1,617	2,570
Public education/info services	91,951	69,547
	976,840	835,687
Support costs		
Administration		
Premises & donated facilities	55,912	46,542
Insurance	6,124	3,408
Printing, P&S and marketing	17,384	15,239
Bank charges	1,652	6,742
	81,072	71,931
Other costs		
Meeting costs	22,124	21,193
Subscriptions	20,615	12,288
	42,739	33,481
Brand development & IT costs		
Brand development	2,484	9,941
Carried forward	2,484	9,941

	2024 £	2023 £
Brand development & IT costs		
Brought forward	2,484	9,941
Equipment/maintenance & web- site development	85,368	71,741
Training and recruitment	37,238	26,905
Computer equipment	4,216	2,444
	129,306	111,031
Governance costs		
Auditors' remuneration	9,420	12,736
Accountancy fees	12,589	19,480
Legal fees	4,299	-
Trustees expenses	254	2,237
	26,562	34,453
Total resources expended	1,256,519	1,086,583
Net (expenditure)/income before gains and losses	(76,379)	361,885
Realised recognised gains and losses		
Realised gains/(losses) on fixed asset investments	227,046	147,566
Net income	150,667	509,451

We’re getting to grips with guts

Guts UK Trustee Report & Financial Accounts to 31 Dec 2024

Final Audit Report 2025-09-15

Created:	2025-09-15
By:	Guts UK (info@gutscharity.org.uk)
Status:	Signed
Transaction ID:	CBJCHBCAABAAlizJDA6sITXj1eU13-yVMsZR0fBOkeL4

"Guts UK Trustee Report & Financial Accounts to 31 Dec 2024" History

Document created by Guts UK (info@gutscharity.org.uk)
2025-09-15 - 9:26:32 AM GMT

Document emailed to ld@hlas.co.uk for signature
2025-09-15 - 9:27:52 AM GMT

Email viewed by ld@hlas.co.uk
2025-09-15 - 12:49:53 PM GMT

Signer ld@hlas.co.uk entered name at signing as Laura J Drew BFP ACA FCCA
2025-09-15 - 12:51:47 PM GMT

Document e-signed by Laura J Drew BFP ACA FCCA (ld@hlas.co.uk)
Signature Date: 2025-09-15 - 12:51:49 PM GMT - Time Source: server

Agreement completed.
2025-09-15 - 12:51:49 PM GMT

Adobe Acrobat Sign

GUTS UK CHARITY

England & Wales - Charity number 1137029

Accounts

ANNUAL REPORT AND FINANCIAL STATEMENTS 2023

Guts UK Charity

Charity Registration No. 1137029

Annual Report and Financial Statements for the Year End 31 December 2023

CONTENTS

Welcome	3
Who we are	5
2023: our most impactful year yet	6
Plans for 2024	8
Financial performance review	10
Governance, policies and standards	15
Report of the Independent Auditors	22
Statement of Financial Activities	25
Balance sheet	26
Cash Flow Statement	28
Notes to the Cash Flow Statement	29
Notes to the Financial Statements	30
Detailed Statement of Financial Activities	50
Reference and administrative information	52
Appendix 1 – Detail of research grants payable	53

The report of trustees is a combined annual report incorporating both the directors report and the trustees report for the charity as required by company law

A WELCOME FROM OUR CHAIR AND INTERIM CEO

Despite a **year of transition for Guts UK** including the appointment of a new Chair, trustees and staff members, we continued to develop, enabling us to expand our reach and impact. During the year everyone at the charity worked tirelessly to support the record high numbers of individuals and families contacting us for support, working with health professionals and researchers, and successfully delivering against our objectives.

In early 2024, Julie Harrington, our chief executive for over seven years decided to step down to pursue new challenges. On behalf of everyone involved with Guts UK, we thank Julie for all her work and wish her the very best for the future.

Despite rising public awareness to Gastroenterology (partly owing to our own fantastic communications and engagement), and therefore unprecedented demand for support and information, research is still woefully underfunded with diagnosis and treatments taking too long. Too many people are suffering alone because they initially don't know where to turn for information and support or are too embarrassed to speak up and seek the help they need.

Guts UK champions their cause, supports those contacting us in need, and funds research to improve medical, health and other support. This year, we are enormously proud to have reached more people, shouted more loudly, funded more research and helped change the focus for the future in digestive health. While we are unable to list everything our small team achieved in the year, we would like to highlight a few amazing successes…

We finalised and published two **Priority Setting Partnerships** (PSPs) in IBS and Pancreatitis. These PSPs are a phenomenal example of collaboration across healthcare professionals, patients, carers and healthcare professionals and have helped determine the top 10 research questions that need to be answered to really get to grips with these two debilitating conditions.

Our fun and unique **digital awareness campaigns** have gone from strength to strength and demonstrate so clearly the power and passion of our community for raising awareness and breaking down taboos; 270 of you were brave enough to join us in our #GutSelfie campaign; our microscopic colitis campaign trended all day on the BBC and we shared 30 heartfelt stories of your experience with pancreatitis during our Kranky Panky month in November.

Our website reached 1.7m web views with people finding our information and tools like the poo-torial quickly and easily, while on **social media** we've been seen 4m times (and that's all organic!)

Our creative **community fundraisers** have run, jumped, baked, knitted and swam more than ever before. Joining our committed fundraising family, 95 new community fundraisers joined sponsored events and challenges in 2023. Each and every one of you is incredible and we cannot thank you enough for spreading the word and supporting our cause.

There's so much more that has been delivered this year, and we hope this report gives you a taste of what we can achieve together. Thank you for your continued passion, support, and dedication. Guts UK charity exists for and because of individuals and families affected by gut conditions. We look forward to the next year of continued growth where we can continue to develop and support more people in need.

Victoria King
Chair of the Board of Trustees

Katie Noon
Interim Chief Executive Officer

WHO WE ARE

Guts UK is the charity for the digestive system
People are suffering. People are dying.
All because of a lack of knowledge about our guts.



Guts UK is *the only charity* that covers all of the digestive system, from 'top to tail' covering the gut, the liver and the pancreas. Guts UK works actively and collaboratively with other charities. However, with our own limited resources, we choose to focus particularly on the conditions that have no other specific charity or voice - those illnesses that really are underserved such as pancreatitis, diverticular disease, irritable bowel syndrome (IBS), childhood gut and liver disease and digestive cancers.

.

Our Vision

A world where digestive disorders are better understood, better treated and everyone who lives with one gets the support they need.

Our mission is to end the pain and suffering for the millions affected by digestive diseases. Guts UK's research leads to earlier diagnoses, kinder treatments and ultimately, a cure.

We deliver this through **three objectives**:

Providing expert information – when armed with the right information, patients can take control of their health and make informed decisions. We provide evidence based information and guidance to patients, carers and health care professionals

Raising public awareness – research shows that 58% of people are embarrassed to talk about their digestive conditions or symptoms. We run campaigns and events to spread awareness and education to empower people to speak up and seek help

Funding and driving research – we fund awards, grants, prizes and fellowships into the entire digestive system. We involve our patient panel in all of our research decisions and in our work on policy, pathways and treatments and we run PSPs to ensure research is focused in the areas that will drive the most difference



Together we will get to grips with guts

2023: our most impactful year yet

It's a joy to share our 2023 achievements. None of which would be possible without your kindness.

We helped 2,446 people with their digestive symptoms or conditions in 2023.
We've answered more phone calls, emails and letters than ever before, helping people during their greatest times of need. Digestive symptoms and conditions can feel really isolating. You can feel like you're the only person in the world struggling. Until you find Guts UK.

Colin the Inflatable Colon met over 10,000 people!
Colin the Inflatable Colon had his busiest year to date, meeting people across the country. He also had a refresh, and now showcases more digestive conditions than ever before (poor Colin!)

By the end of 2023, we had invested over £16,500,000 into medical research to date.
In 2023, we continued to fund research that we feel will have the greatest impact for those with digestive conditions now and in the future. It's all about earlier diagnoses, kinder treatments and ultimately, a cure.

Nearly 2,000,000 people visited our website, and we were seen 4,000,000 times on social media.
We are reaching those who need us most.

We appeared in over 60 news pieces, being seen over 100,000,000 times in the press.
Our name has also been seen more times than ever before.

We sent over 150,000 patient information leaflets to hospitals.

Never underestimate the power of an information leaflet. Whether you're having a procedure, receiving a life-changing diagnosis or undergoing investigations, knowledge is everything. We're proud to provide evidence-based information, backed by science and built around a sense of comfort and community.

Our powerful partnership with Imodium® raised over £30,000.

We were seen nation-wide in service stations, shops such as Boots, and magazines .

We helped over 50 people and their families tell their experiences of digestive conditions.

And in turn, helped people feel heard, understood and less alone. Giving people like you the platform to help others is the most rewarding part of our work.

None of this would have been possible without the phenomenal support of all of our fundraisers, donors and supporters.

Almost 400 of you generously donated to us on a regular basis, 95 of you took place in events, held fundraisers or ran community events to raise money for us, and so many more of you have donated what you can, when you can meaning we have been able to raise

over £450,000

from public donations alone.

OUR PLANS FOR 2024

Over the past few years, Guts UK has been working hard to build a profile, a presence and an engaged community of supporters, all focused on the same vision of **ending the pain and suffering of those living with digestive conditions and symptoms**. The ever-increasing demand for information, awareness and developments in the field is not going away so 2024 is the year in which we plan and further strengthen the foundations for charity growth and development in the years ahead.

We want to be able to educate more people, remove the stigma attached to talking about digestive conditions, support more people directly who are trying to find the best way of living with their condition, we want to invest more into kinder treatments and faster diagnosis and we want to drive more focus and attention at a national level on all things gut related

Refining our strategy, vision and delivery plans

- 2024 will bring together some key changes in both our Board and staff team to allow us to regroup on our goals and strategy for the next five years.
- The Guts UK family – Board, team, volunteers and community – will develop a new strategic plan providing the framework to sustainably develop and grow our engagement and reach, our support, our research, and our community. Whilst we do not envisage the broad vision will change, we want to ensure how we deliver that vision will be re-visited and re-energised to drive real change for those living with digestive conditions and symptoms.

Research Plans for 2024

- We will continue to fund our **core programme of research awards** and grants including the Guts UK / Dr Falk awards, the Guts UK / BSG trainee awards and our Early Career Researcher awards.
- We will continue to work on the outputs of our hugely successful **Priority Setting Partnerships (PSPs)** in IBS and Pancreatitis and ensure we invest in research that will directly answer the questions identified in those pieces of work. Alongside this we will be launching two new PSPs into diverticular disease (in partnership with our colleagues at Bowel Research UK) and into endoscopy (in partnership with the BSG and Crohn's & Colitis UK).
- Across all our research efforts we will continue to consult our panel **of Experts by Experience** to ensure the patient and carer voice is represented clearly and is helping drive our strategic decision making. We will continue to work with our community and panel of Experts by Experience to provide

patient voice input into product and drug development, pathway developments, and relevant think tanks.

Information Services

- We will continue to promote our **patient information leaflets** to gastroenterology clinics and hospitals across the UK in order that more patients are able to access evidence-based information about their symptoms and conditions.
- We will help more people who need us through **our phone and e-mail support** ensuring people understand their conditions, understand where to go for support and understand fact from fiction when it comes to treatments and living well.
- We will drive **collaborations and partnerships** to allow our information services to reach more people and expand our coverage in terms of new information, conditions and symptoms in partnership with other charities and experts.

Public Education and awareness

- We will continue to **build our presence and engagement** via digital platforms such as Facebook, Instagram, Twitter and TikTok that enable us to reach new audiences in a format they favour. We will expand our hugely successful campaigns like #GutSelfie to reach more people and we will develop new campaigns to shed light on other conditions and symptoms.
- We will attend and run more **events to raise public awareness of guts conditions** including Colin the Colon out on the road to meet more people and support breaking down the taboo of talking about digestive health.

Staff, resources and capacity building

- Our plan for 2024 is to strengthen the foundations that support future growth and development. This will involve expanding the team with critical roles in research, support, communications, and fundraising. By investing in our team and resources, we will be able to plan and develop for a new, ambitious growth strategy.
- 2024 will also see us recruit a new Chief Executive Officer to lead the charity on the next leg of this journey. At the time of finalising this report, we are delighted to announce Suzanne Hudson is joining as our new CEO in September 2024.

FINANCIAL PERFORMANCE REVIEW

Overview

This year the charity recorded income of £1.4m (a higher than budgeted rise of 22% in the year) and expenditure of £1.1m (lower than 2022 explained by timing of research awards, explained further below). Income was boosted by a rise in donations and legacies including a significant legacy donation illustrating continued and new support from our supporters and donors. Lower expenditure was entirely related to the award timing of our two three-year research fellowships (both the Derek Butler fellowship for £250k and the Amelie Waring fellowship for £180k were awarded in 2022 and will not be awarded again until 2025).

Total Income 2023: £1.4m



Total Expenditure 2023: £1.1m



Income

Fundraising income

Fundraising income increased significantly on the previous year, contributing £619k or 42% of total income (compared with £455k (38%) in 202). As mentioned, this was explained by a rise in donations (including community fundraising) and legacies. Within legacies we also received a significant, unexpected legacy of over £150k which we now understand was bequeathed following an individual reaching out to us for support including information leaflets.

Excluding legacies, total fundraising income was 16% lower than in 2022 with the variance explained by lower charitable trust and corporate donations. In memory giving, regular giving, and one-off donations all saw steady increases (both in terms of values and individuals supporting us). Regular giving rose 4% partly supported by the launch of our e-newsletter, in-memoriam continued the rising trend of recent years (4% in the year), and donations rose 38%. These rises are remarkable given many of our donors continued to be impacted by the cost-of-living crisis. It also demonstrates our team's work in continuing to build relationships with individuals and families affected by guts conditions.

Other income including leaflets and merchandise

Other trading activities rose to £69k (a rise of 36% compared with 2022). This was driven by sales of our information leaflets to professional organisations and corporate contributions for education and awareness programmes. We received donations from two pharmaceutical companies to support important awareness campaigns; Dr Falk donated £15k to support our Microscopic Colitis Awareness campaign which reached new heights this year and Viatris donated £12.3k to support our information campaign on Pancreatitis in which we have launched three new pancreatitis leaflets which will be distributed to hospitals for free (this forms part of the work following the Pancreatitis PSP).

Overall income was bolstered in 2023 by positive gains from the investment portfolio with investment income up 16% on 2022 contributing £278k to overall income (2022: £240k).



Research grants

Research partner income includes collaborations with pharmaceutical companies and other professional bodies such as the British Society of Gastroenterology, the Pancreatic Society of Great Britain and Ireland,

and The British Society of Paediatric Gastroenterology, Hepatology and Nutrition. 2023 saw a very marginal drop in research partner income (£311k vs £326k in 2022) as a result of slightly lower grant values being awarded this year.

We also successfully applied to the UK Government's COVID Medical Research Charity Support Fund to support our Early Career Researchers and gastroenterology trainee grants. The total grant received was £171,606 towards active research projects.

Expenditure

Whilst overall expenditure was lower when compared to 2022, this is explained by the award timings of our two large research fellowships (both awarded in 2022). Whilst total expenditure at £1.1m is lower than 2022 (£1.6m), excluding research grants other expenditure was £707k (compared with £659k the previous year) illustrating the continued growth and development of the charity.



Support costs were marginally higher than in 2022 (6% increase from £551k in 2022 to £587k in 2023) driven by strategic investment initiatives to help set Guts UK up for the future. These included spending on a user experience and improvement project for the website, the development of an e-commerce platform and investment to scope out the feasibility of a dedicated Guts UK helpline to enable us better support people contacting us and manage rising demand.

Staff costs remained relatively stable year-on-year despite a few changes in the team including the appointment of a Chief Operating Officer. An increase can be seen, however, in recruitment costs including staff and trustee members. Accountancy and bookkeeping costs were also higher as with changing staff team we included outsourced support.

Balance Sheet

As at 31 December 2023, Guts UK had net assets of £5.8m, an increase of £0.5m (9%) compared with 2022, with 91% of assets held in listed investments. These include the Derek Butler endowment fund for research into upper gastrointestinal conditions of £2,695,702. The income from this fund is restricted for funding the Derek Butler fellowship every three years.

With financial markets more stable in 2023, the investment portfolios delivered unrealised gains of £148k. Of this amount, total realised and unrealised gains of £71k related to the endowment fund.

Unrestricted funds which can be spent at the discretion of the trustees were £2.7m of which £1.6m has been designated to contribute to specific research grants awarded by the charity. £766k of that is designated to the Amelie Waring Fellowship which is awarded every three years into research of the pancreas and the other £800k is designated to general gastrointestinal research and covers the annual and bi-annual grants, awards and prizes which Guts UK funds. General funds (un-designated) amounted to £1.1m for 2023. Restricted funds stood at £441k which is primarily made up of funds held for the Derek Butler Fellowship alongside some smaller restricted individual donations, details of which can be found on page 44.

More details of the disposition of Guts UK net assets can be found in the financial statements on page 48.

Reserves policy

As at 31st December 2023, total funds of the charity stood at £5,795,777 (2022: £5,286,325) of which;

- Unrestricted funds stood at £2,658,089 (2022: £2,364,017).
- Restricted funds stood at £441,986 (2022: £291,272)
- Endowment funds stood at £2,695,702 (2022: £2,631,036)

Guts UK has reviewed the amount of reserves it regards as a minimum prudent requirement and in 2023 maintained the policy that twelve months of administration, public education and fundraising costs is a sufficient reserve. This provides time to manage cost reductions and/or fund appeals as required whilst minimising the impact on service provision. Based on our financial forecasts for 2024, the reserves level is approximately £1m. As at 31 December 2023, free reserves less amounts held as fixed assets stands at £1.1m.

Note that the general reserve does not consider research grants or research admin costs as these are covered by funds that have been designated by the Board and are deemed sufficient to cover commitments for the next 24 months.

Investment policy and performance

The charity's listed investments are managed by Cazenove. The investment strategy is set by the trustees and takes into account income requirements, the risk profile and the investment manager's advice on the market prospects in the medium term. Investments are held in a Responsible Multi-Asset Fund which adopts a total returns approach and provides even distribution payment alongside being an ethically responsible investment policy. The performance of the portfolio is monitored by the trustees and on joining the charity in June 2023, the new Treasurer met with the portfolio management team as a priority to understand the portfolio and review our management approach. No immediate changes to approach were deemed necessary and it was agreed that a regular update on the investment portfolio will be included in the Audit, Risk and Compliance committee.

Going concern

There is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. The trustees believe that there are no material uncertainties that call into doubt the charity's ability to continue operating as a going concern. Consequently, the financial statements have therefore been prepared on the basis that the charity remains a going concern.

GOVERNANCE, POLICIES & STANDARDS

Guts UK is a charitable company limited by guarantee. Its governing document is its Memorandum and Articles of Association. The trustees have overall responsibility for setting the strategic direction of the charitable company. The trustees of the charity have had regard to CC / CCNIs guidance in relation to public benefit. The trustees delegate specific responsibility to several committees as follows:

Committees where membership and voting rights are restricted to Trustees:

a) **Audit, Risk and Compliance Committee** ("ARC") whose purpose is to oversee the operational activities of the charity covering finance, investment, audit, legal compliance, HR and risk management;
b) **Funding, Communications and Industry Committee** ("FUNCI") whose purpose is to deliver on Guts UK's fund-raising programmes, ensuring engagement with patients, public, the medical profession and industry alike;
c) **Information Committee** whose purpose is to recommend the strategic direction for information service provision; and to facilitate peer review and quality control of written and web-based information, plus any other public sources of information such as webinars provided by Guts UK.
d) **Research Strategy Committee** (RSC) whose purpose is to recommend areas of focus for Guts UK's research priorities.

Committees made up of volunteers external to the Board of Trustees:

a) **Research Awards Committee** ("RAC") whose purpose is to ensure the integrity of Guts UK's research awards and that they align with the charity's stated objectives. The RAC is responsible for assessing, approving and monitoring applications for research funding. The RAC's processes are governed by the Terms of Reference and committee members (including those co-opted for specific awards) are required to sign a declaration of conflicts of interests form. Membership is open to members of the gastroenterology research profession and is assigned on a 3 year term. The Chair of the RAC must be from outside of the gastroenterology field and is also a 3 year term.

The policies of the charity are determined by its board of trustees. The research policy of the charity is decided by the trustees in consultation with the Research Committee of the BSG. Guts UK is a member of the Association of Medical Research Charities.

Guts UK advertises for new trustees as required. All roles are advertised openly and transparently and prospective trustees are interviewed fairly by the Chair, CEO and fellow trustees. Candidates must be approved by a majority of trustees and the usual term of office is three years, renewable on approval by the board up to a maximum of 9 years.

New trustees receive a full induction to the charity and ongoing training. In 2023, a number of new trustees joined the Board including a new Chair, Treasurer and Legal Trustee. The Chair had a formal handover from the outgoing Interim Chair including attending a Board meeting as an observer before taking over the active role of Chair.

Guts UK continues to work closely with the BSG to provide strong links with the professional community and support its ability to disseminate research and patient information. The Chair of the BSG's Research Committee is a member of the board.

Key management personnel

The day-to-day operation of Guts UK is delegated to the Chief Executive who is supported by our Chief Operating Officer and the wider staff team.

The pay of all staff members, including members of key management, is reviewed annually by the trustees. Remuneration details in relation to key management personnel are provided in Note 13 to the financial statements.

Risk management

Guts UK maintain a risk register covering the major risks to which the charity is exposed. This covers governance and compliance, operational and administration, financial and investment and reputational risks. Guts UK rates potential risks by likelihood and impact. The risk register is reviewed regularly by the trustees and the key risks together with the policies to mitigate them have been identified as:

Key Person risk

We have a small staff team at Guts UK and each role within the team is unique in terms of delivery, knowledge and skills. Similar to charities of our size, there is a heightened risk of loss of knowledge and working relationships particularly with senior and team managers. This is managed closely by the Chief Executive and the Board.

Systems access and authorisations

For the first half of 2023, the Chief Executive Officer was the only senior leadership team member with access and authorisation rights to core systems including payments, banking, databases and website hosting. This was due to the unexpected loss of a team member in late 2022. Temporary agreements and arrangements were made with the Board to ensure all financial transactions had secondary approvals and appropriate authorities in terms of signatories. These were all duly documented through governance. Additional measures were put in place to ensure alternative access was available to databases and critical systems with alternative access provided to trusted team members and board

members where required. This was rectified in June 2023 with the appointment of the COO who now has dual control and access with the CEO to all core systems and platforms.

Failure to meet fundraising and income targets

Management accounts are prepared and regularly reviewed by the ARC Committee to monitor fundraising performance. The fundraising strategy has been reviewed by the Chief Executive and trustees with a view to increasing the number of individual supporters and donors alongside developing different income sources to include approaching former funded researchers and gastroenterologists and industry/pharma for support. The trustees review finances and fundraising performance at each Board meeting.

Failure to comply with GDPR

Policies and procedures have been developed and staff receive regularly training. Data protection is a standing item on the ARC Committee and trustee meeting agendas to ensure trustees are kept up to date with actions taken to ensure compliance with the regulations. There will be ongoing monitoring of compliance with regulations.

Fundraising Standards at Guts UK

Our donors are important to us and we seek to deliver the highest standards of donor care and support at all times and in all activities.

- Open and accountable fundraising - we regularly tell our supporters how they can easily change their preferences
- Communicating with our supporters - we update our supporters through our twice yearly newsletter for those who prefer a print option and regular e-newsletters.
- Complying with laws, regulation and standards - we are a member of the Chartered Institute of Fundraising and are committed to working to a best practice and actively ,complying with the Fundraising Code of Practice. We are registered with the Fundraising Regulator and signed up to The Fundraising Promise.
- Protecting vulnerable people - we do everything possible to meet the needs of potential supporters and protect vulnerable people. In particular, the charity confirms that it complies with all relevant data protection laws. No instances of non-compliance have been identified during the year and no suppression requests were received in 2023 in relation to fundraising activities
- Complaints and negative feedback - we treat all complaints seriously and aim to respond in a timely and fair manner. All complaints inform and influence the charity's approach to fundraising. We use the feedback that we get from our supporters to improve the way we do things.
- Working with partner agencies - we may engage professional third parties to act on our behalf, for example, to produce and distribute direct mailings. To ensure that fundraising activities of third parties

are compliant with regulation and the charity's own internal standards, the charity approves all third-party communications prior to distribution and sets out clear guidelines in formal agreements made with such parties. We also work with commercial participators, such as Amazon Smile, Everyclick., Give as you Live and Easy Fundraising to raise funds. Agreements with commercial partners are checked and actively monitored to ensure compliance with the Fundraising Code of Practice

- We never swap, sell or share any data
- We work hard to ensure we deliver value for money in all of our charitable activities.

Information Standards at Guts UK

We are very proud of the quality of the trusted information we provide to the general public and in ensuring all information we produce is factually correct and based on recognised, published evidence.

- All information leaflets including those housed on-line are signed off through our Information Committee whose members are health care professionals and trustees on our Board
- All information is subject to the PIF tick[1] quality standards and assurance including an annual audit which must be passed to maintain PIF tick accreditation
- All information leaflets are written by a healthcare professional and are reviewed by a specialist in the appropriate field to ensure both factual accuracy and the inclusion of the most up to date evidence based developments in the field. They are then also reviewed by a lay-reviewer to ensure readability and understanding.
- All information leaflets are cobranded with the British Society of Gastroenterology as trusted information that has been developed with the help of multidisciplinary expert clinicians in medical and surgical gastroenterology, hepatology and pancreatology and people with lived experience.
- All information is subject to a strict, published Code of Practise which is governed by the Information Committee and is reviewed as part of the PIF tick annual audit
- Any information published on social media or other channels is signed off by the Guts UK Information Manager to ensure it is factually correct and based only on evidence based information
- Any partnerships or collaborations are reviewed and signed off by the Information Committee, prior to which a thorough check is made to ensure they withhold the same standards of evidence based information as we do at Guts UK Charity
- We record all complaints and treat all of them seriously. We aim to respond in a timely and fair manner. All complaints inform and influence the charity's approach to information provision. We use the feedback that we get from our supporters to improve the way we do things.

[1] The PIF TICK is an independently-assessed quality mark for trusted health information recognised by the NHS. Further information can be found here: The PIF TICK | Patient Information Forum (pifonline.org.uk)

Grant Making Policy at Guts UK

We know that better treatments and quicker diagnosis are a priority for our community and so we want to be sure we can fund the best research and the best researchers.

- Guts UK is a member of the Association of Medical Research Charities and is therefore governed by and abides with their policies including those on animal research, patient and public engagement, conflicts of interest and funding.
- The charity will consider all applications that fall within our charitable purposes and meet our eligibility criteria and, for which, the due diligence process has not identified any unacceptable issues
- Applicants' data will be held in accordance with data protection legislation. It will be held securely, disclosed if subject to an access request, treated as confidential, only used for the purpose for which it has been provided and destroyed, once no longer needed.
- Applications will be considered by our independent Research Awards Committee (which includes representation from our Experts by Experience patient panel) and then recommended to and ratified by our Board of Trustees.
- All grantees will be required to provide a report on how their grant was used and the impact this has had. The content and nature of information to be reported will be appropriate for the size and type of grant awarded. The charity will monitor such reports to not only ensure that grants are being use for the purposes intended, but also to assess the impact grants have made.
- Full terms and conditions are available to all applicants and their associated trusts/universities on our website. These T&Cs are reviewed annually and ratified by the Research Strategy Committee.

The Annual Report of the trustees is a combined annual report incorporating both the directors report and the trustees report for the charity as required by company law

This Annual Report of the trustees was approved by order of the board of trustees, as the company directors, on **19th September 2024** and signed on the board's behalf by:

.....

Dr Victoria King, Chair of the Board of Trustees

Financial Statements for the Year Ended 31 December 2023

for

Guts UK Charity

Audited by: Harris Lacey and Swain

Chartered Accountants and Statutory Auditors

Suite 1

The Riverside Building

Hessle

East Yorkshire

HU13 0DZ

Statement of Trustees' Responsibility for the Year Ended 31 December 2023

The trustees (who are also the directors of Guts UK Charity for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charity SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditors are unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

AUDITORS

The auditors, Harris Lacey and Swain, will be proposed for re-appointment at the next Board of Trustees meeting

Report of the trustees, incorporating a strategic report, approved by order of the board of trustees, as the company directors, on **19th September 2024** and signed on the board's behalf by:

Charlotte Leonard

.....

Charlotte Leonard, Treasurer

Opinion
We have audited the financial statements of Guts UK Charity (the 'charitable company') for the year ended 31 December 2023 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
- give a true and fair view of the state of the charitable company's affairs as at 31 December 2023 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice;
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information
The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Trustees has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception
We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- the charitable company has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees
As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements
We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion.

Identifying and assessing potential risks related to irregularities
In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

Audit response to risks identified

- the nature of the industry and sector, control environment and business performance including key drivers for directors' remuneration, bonus levels and performance targets
- results of our enquiries of management and their own identification and assessment of the risks of irregularities;
- any matters we identified having obtained and reviewed the companies' documentation of their policies and procedures relating to:
- identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of noncompliance;
- detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;
- the internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;
- the matters discussed among the audit engagement team including regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in relation to revenue deferrals. In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override.

We also obtained an understanding of the legal and regulatory frameworks that the company operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. The key laws and regulations we considered in this context included the UK Companies Act, UK Corporate Governance Code and local tax legislation.

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which may be fundamental to the company's ability to operate or to avoid a material penalty.

Audit response to risks identified

Our procedures to respond to risks identified included the following:

- reviewing the financial statement disclosures and testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
- enquiring of management concerning actual and potential litigation and claims;
- performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
- reading minutes of meetings of those charged with governance
- obtained an understanding of provisions and held discussions with management to understand the basis of recognition or non-recognition of tax provisions; and
- in addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members, and remained alert to any indications of fraud or noncompliance with laws and regulations throughout the audit.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report

This report is made solely to the charitable company's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable company's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Laura Jennifer Drew BFP ACA FCCA (Senior Statutory Auditor)
for and on behalf of Harris Lacey and Swain
Chartered Accountants and Statutory Auditors
Suite 1, The Riverside Building
Hessle, East Yorkshire
HU13 0DZ

Signed.....Laura Drew (Sep 19, 2024 22:10 GMT+1) 19-Sep-2024

Guts UK Charity

Statement of Financial Activities
for the Year Ended 31 December 2023

	Notes	Unrestricted fund £	Restricted fund £	Endowment fund £	2023 Total Funds £	2022 Total Funds £
INCOME AND ENDOWMENTS FROM						
Donations and legacies	2	596,774	21,792	-	618,566	454,657
Gastro* research	5	-	482,839	-	482,839	434,630
Other trading activities	3	56,387	12,300	-	68,687	50,404
Investment income	4	144,729	133,647	-	278,376	240,353
Total Income		**797,890**	**650,578**	**-**	**1,448,468**	**1,180,044**
EXPENDITURE ON						
Cost of raising funds	7	220,644	-	6,780	227,424	216,023
Charitable activities	6	-	-	-	-	-
Gastro* research		104,673	436,153	-	540,826	1,131,842
Public education		311,369	6,963	-	318,332	313,352
Total expenditure	**9**	**636,686**	**443,116**	**6,780**	**1,086,582**	**1,661,217**
Net income/(expenditure) before transfers		161,204	207,462	(6,780)	361,886	(481,173)
Transfers between funds		56,748	(56,748)	-	-	-
Net income/(expenditure) after transfers		**217,952**	**150,714**	**(6,780)**	**361,886**	**(481,173)**
Net gains/ (losses) on investments						
- Realised		18	-	22	40	(460)
- Unrealised		76,102	-	71,424	147,526	(621,458)
Net movement in funds		294,072	150,714	64,666	509,452	(1,103,091)
RECONCILIATION OF FUNDS						
Funds balances brought forward		2,364,017	291,272	2,631,036	5,286,325	6,389,416
TOTAL FUNDS CARRIED FORWARD		**2,658,089**	**441,986**	**2,695,702**	**5,795,777**	**5,286,325**

Guts UK Charity

Balance Sheet

31 December 2023

	Notes	Unrestricted fund £	Restricted fund £	Endowment fund £	2023 Total Funds £	2022 Total Funds £
FIXED ASSETS						
Tangible fixed assets	14	6,316	-		6,316	3,422
Investments	15	3,411,472	-	2,695,702	6,107,174	5,957,620
		3,417,788	-	2,695,702	6,113,490	5,961,042
CURRENT ASSETS						
Stock	16	18,679	-	-	18,679	
Debtors	**17**	447,941	-	-	447,941	420,659
Short term cash deposits						
Cash at bank and in hand		314,502	441,986	-	756,488	882,324
		781,122	441,986	-	1,223,108	1,302,983
LIABILITIES						
Creditors: amounts falling due within one year	18	(658,136)	-	-	(658,136)	(1,420,150)
NET CURRENT ASSETS		122,986	441,986	-	564,972	(117,167)
TOTAL ASSETS LESS CURRENT LIABILITIES		3,540,774	441,986	-	6,678,462	5,843,875
LIABILITIES						
Creditors: amounts falling due after one year	19	(882,685)	-	-	(882,685)	(557,550)
TOTAL NET ASSETS		2,658,089	441,986	2,695,702	**5,795,777**	**5,286,325**
FUNDS OF THE CHARITY						
Unrestricted income funds						
- General					1,092,510	1,069,028
- Designated funds	21				1,565,579	1,294,989
Restricted funds	20				441,986	291,272
Endowment fund	22				2,695,702	2,631,036
TOTAL FUNDS					**5,795,777**	**5,286,325**

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not deposited notice, pursuant to Section 476 of the Companies Act 2006 requiring an audit of these financial statements.

The trustees acknowledge their responsibilities for

a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006
b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been audited under the requirements of Section 145 of the Charities Act 2011.

The financial statements were approved by the Board of Trustees and authorised for issue on **19th September 2024** and were signed on its behalf by:

.....
Charlotte Leonard, Treasurer

Guts UK Charity

Cash Flow Statement
for the Year Ended 31 December 2023

	Notes	2023 £	2022 £
Cash inflow used in operating activities:			
Net cash used in operating activities	A	(396,886)	(157,850)
Cash inflow from investing activities:			
Dividends and interest from investments		278,376	240,353
Purchase of tangible fixed assets		(5,338)	(2,074)
Proceeds from the disposal of investments		8,195	97,655
Purchase of investments		-	(100,000)
Net cash provided by investing activities		281,234	235,934
Change in cash and cash equivalents in the year		(115,653)	78,084
Cash and cash equivalents at 1 January	B	1,374,331	1,296,247
Cash and cash equivalents at 31 December	B	**1,258,678**	**1,374,331**

These notes form part of these financial statements

A. RECONCILIATION OF NET (EXPENDITURE)/INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2023 £	2022 £
Net movement in funds (as per the statement of financial activities)	509,452	(1,103,091)
Adjustments for:		
Depreciation charge	2,444	2,015
(Gains) / losses on investments	(147,566)	621,918
Dividends and interest from investments	(278,376)	(240,353)
Increase in stock	(18,679)	-
Decrease (increase) in debtors	(27,282)	(76,897)
(Decrease) Increase in creditors	(436,879)	638,558
Net cash used in operating activities	(396,886)	(157,850)

B. ANALYSIS OF CHANGES IN NET FUNDS

	At 01-Jan-23 £	Cash flow £	At 31-Dec-23 £
Net cash			
Cash at bank and in hand	86,937	33,713	120,650
Short term cash deposits	795,388	(159,550)	635,838
Cash held by investment managers	492,006	10,184	502,190
Total cash and cash equivalents	1,374,331	(115,653)	1,258,678

No separate reconciliation of net debt has been prepared as there is no difference between the net cash (debt) of the Charity and the cash and cash equivalents.

COMPANY INFORMATION & PRINCIPAL ACTIVITIES

Guts UK Charity is a charitable company limited by guarantee and is incorporated in England and Wales. The address of its registered office is 2 St. Andrews Place, London, NW1 4LB. The company's registered number is 07274105 and Charity Registration number is 1137029.

The principal activity of the company in the year under review is the advancement of the science and practice of medicine and surgery for the benefit of the public with reference to gastroenterology; to promote study and research into medicine and surgery with reference to the physiology and pathology of the digestive system, ensuring dissemination of the results; to provide educational material and information to the general public on gastrointestinal diseases.

1. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value.

Monetary amounts in these financial statements are rounded to the nearest whole £1. The financial statements are presented in pounds sterling which is also the functional currency of the charity.

Assessment of going concern
The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements and have made this assessment in respect to a period of one year from the date of approval of these financial statements.

The trustees have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the charity to continue as a going concern. The trustees are confident that the charity has sufficient funds to cover its existing liabilities.

With regard to the next accounting period, the year ending 31 December 2024, the most significant areas that affect the carrying value of the assets held by the charity are the level of investment return and the performance of the investment markets (see the investment policy and the risk management sections of the trustees' report for more information).

Income
Income is recognised in the period in which the charity has entitlement to the income, the amount of income can be measured reliably and it is probable that the income will be received.

Donations are recognised when the charity has confirmation of both the amount and settlement date. In the event of donations pledged but not received, the amount is accrued for where the receipt is probable.

Legacies are included in the statement of financial activities when the charity is entitled to the legacy, the executors have established that there are sufficient surplus assets in the estate to pay the legacy, and any conditions attached to the legacy are within the control of the charity. Entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor to the charity that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity or the charity is aware of the granting of probate, but the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

1. ACCOUNTING POLICIES - continued

In the event that the gift is in the form of an asset other than cash or a financial asset traded on a recognised stock exchange, recognition is subject to the value of the gift being reliably measurable with a degree of reasonable accuracy and the title of the asset having being transferred to the charity.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

Research partner funding income is recognised in the period in which the charity receives a written commitment from the funder. Government grants for research funding are recognised in the period in which the charity has entitlement to the income. Research funding is deferred only when the charity has to fulfil conditions before becoming entitled to it or the donor has specified that the income has to be spent in a future period.

Expenditure
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to make a payment to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis and is stated inclusive of irrecoverable VAT. Expenditure comprises direct costs and support costs. All expenses, including support costs, are allocated or apportioned to the applicable expenditure headings. The classification between activities is as follows:

a) Cost of raising funds which includes direct fundraising costs and investment manager's fees.
b) Expenditure on charitable activities comprises expenditure on the charity's primary charitable purposes as described in the trustees' report. Such costs include grants payable, other direct costs and support costs, which are apportioned based on the level of activity in each area.

Research grants payable are included in the statement of financial activities when approved and when the intended recipient has either received the funds or been informed of the decision to make the grant, and has satisfied all relevant conditions. Grants approved but not paid at the end of the financial year are accrued for. Grants where the beneficiary has not been informed or has to meet certain conditions before the grant is payable are not accrued for but are noted as financial commitments in the notes to the financial statements.

The provision of a multi-year grant is recognised at its present value where settlement is due over more than one year from the date of the award, there are no unfulfilled performance conditions under the control of the charity that would permit the charity to avoid making the future payments, settlement is probable and the effect of the discounting is material. The discount rate used is the average rate of investment yield in the year in which the grant is made. This discount rate is regarded by the trustees as providing the most current available estimate of the opportunity cost of money reflecting the time value of money to the charity.

Allocation and apportionment of costs
Support costs represent indirect charitable expenditure. In order to carry out the primary purposes of the charity it is necessary to provide support in the form of financial procedures, provision of office services and equipment and a suitable working environment.

Governance costs comprise the costs directly attributable to the governance of the charity, including audit costs and the necessary legal procedures for compliance with statutory requirements. Support costs and governance costs are allocated between activities with the allocation based on staff time.

1. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits
The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate. Pension costs are taken from the unrestricted funds of the charity.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

- Computer equipment: 33% on cost

Stock
Stock is valued at the lower of cost and net realisable value. Cost is based on the cost of purchase on a first in first out basis. Net realisable value is the estimated selling price.

Taxation
The charity is exempt from corporation tax on its charitable activities.

Fund accounting
The charity has various types of funds for which it is responsible, and which require separate disclosure. These are as follows:

- General funds: Funds which are expendable at the discretion of the trustees in furtherance of the objects of the charity.
- Designated funds: Funds which are set aside as part of the charity's unrestricted funds for particular purposes in the future as determined by the trustees from time to time.
- Restricted funds: Funds raised for, and their use restricted to, a specific purpose, or donations subject to donor-imposed conditions.
- Endowment funds: Funds which must be held indefinitely as capital. Income therefore is credited to general funds and applied for general purposes unless under the terms of the endowments such income must be used for specific purposes in which cases it is credited to restricted funds.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight-line basis over the period of the lease.

Financial instruments
The charity only holds basic financial instruments as defined in FRS 102. The financial assets and financial liabilities of the charity and their measurement basis are as follows:

Financial assets - other debtors are basic financial instruments and are debt instruments measured at amortised cost. Listed investments are a basic financial instrument as detailed above. Prepayments are not financial instruments.

Cash at bank - classified as a basic financial instrument and is measured at face value.

Financial liabilities - accruals and other creditors are financial instruments are measured at amortised cost.

Critical accounting judgements and key sources of estimation uncertainty
Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Although these estimates are based on the Trustees' best knowledge of the amount, events or actions, actual results ultimately differ from these estimates. The Trustees do not consider there to be any material estimates and judgements.

Investments
Investments both current and fixed are included at fair value within the accounts.

2. DONATIONS AND LEGACIES

	Unrestricted Funds £	Restricted funds £	**2023 Total funds £**
Donations	339,964	10,886	**350,850**
Legacies & In Memoriam donations	256,810	10,906	**267,716**
2023 Total funds	596,774	21,792	**618,566**

	Unrestricted Funds £	Restricted funds £	2022 Total funds £
Donations	295,325	(2,581)	292,744
Legacies & In Memoriam donations	151,393	10,520	161,913
2022 Total funds	446,718	7,939	454,657

Individual donations greater than £25,000: Included in Legacies & In Memoriam donations during the reporting period is a donation of £157,438 from the estate of Howard Samuel Fernie.

3. OTHER TRADING ACTIVITIES

	Unrestricted Funds £	Restricted funds £	**2023 Total funds £**
Public education	41,387	12,300	**53,687**
Microscopic Colitis Awareness Week	15,000	-	**15,000**
2023 Total funds	56,387	12,300	**68,687**

	Unrestricted Funds £	Restricted funds £	2022 Total funds £
Public education	41,544	-	41,544
Science of Digestion	1,360	-	1,360
Microscopic Colitis Awareness Week	7,500	-	7,500
2022 Total funds	50,404	-	50,404

4. INVESTMENT INCOME

	Unrestricted Funds £	Restricted funds £	**2023 Total funds £**
Interest – fixed interest securities	3,665	2,620	**6,285**
Multi asset funds	127,797	131,027	**258,824**
Charities property fund	-	-	**-**
Interest on cash deposits	12,367	-	**12,367**
Other interest income	900	-	**900**
2023 Total funds	144,729	133,647	**278,376**

	Unrestricted Funds £	Restricted funds £	2022 Total funds £
Interest – fixed interest securities	2,553	4,185	6,738
Multi asset funds	119,020	110,777	229,797
Charities property fund	-	892	892
Interest on cash deposits	2,926	-	2,926
2022 Total funds	124,499	115,854	240,353

5. INCOME FROM CHARITABLE ACTIVITIES

	Unrestricted Funds £	Restricted funds £	**2023 Total funds £**
Government grants received	-	171,606	**171,606**
Other grants for research	-	311,233	**311,233**
2023 Total funds	-	482,839	**482,839**

	Unrestricted Funds £	Restricted funds £	2022 Total funds £
Government grants received	-	108,540	108,540
Other grants for research	-	326,090	326,090
2022 Total funds	-	434,630	434,630

6. EXPENDITURE ON CHARITABLE ACTIVITIES

	Direct costs	Research grants awarded (note 8)	Support costs (note 9)	**2023 Total funds**
	£	£	£	**£**
Gastroenterology research	2,570	379,899	158,357	**540,826**
Public Education	77,864	-	240,468	**318,332**
2023 Total funds	80,434	379,899	398,825	**859,158**

	Direct costs	Research grants awarded (note 8)	Support costs (note 9)	**2022 Total funds**
	£	£	£	**£**
Gastroenterology research	2,636	1,001,807	127,399	1,131,842
Public Education	69,258	-	244,094	313,352
2022 Total funds	71,894	1,001,807	371,493	1,445,194

7. COST OF RAISING FUNDS

	Unrestricted Funds	Restricted funds	**2023 Total funds**
	£	£	**£**
Fundraising costs	25,574	-	**25,574**
Investment manager's fees	7,388	6,780	**14,168**
Support costs (note 9)	187,682	-	**187,682**
2023 Total funds	220,644	6,780	**227,424**

	Unrestricted Funds	Restricted funds	2022 Total funds
	£	£	£
Fundraising costs	38,392	-	38,392
Investment manager's fees	6,917	6,909	13,826
Support costs (note 9)	163,805	-	163,805
2022 Total funds	209,114	6,909	216,023

8. RESEARCH GRANTS AWARDED

	2023 Total funds £	2022 Total funds £
New research grants	**436,153**	1,004,180
Less grants no longer required – research commitments	**(56,254)**	(2,373)
Research grants awarded	**379,899**	1,001,807

Research grants awarded represent commitments made for research, and are set out in detail in the appendix from page 53.

9. SUPPORT COSTS

		Charitable activities		
	Cost of raising funds	Gastro-Enterology research	Public education	**2023 Total funds**
	£	£	£	**£**
Directly incurred				
Grants payable (see note 8)	-	379,899	-	**379,899**
Research administration	-	2,570	-	**2,570**
Fundraising costs	25,574	-		**25,574**
Public education	-	-	77,864	**77,864**
Investment management fees	14,168	-	-	**14,168**
	39,742	382,469	77,864	**500,075**
Support costs				
Staff costs (see note 13)	107,396	90,615	137,601	**335,612**
Consultancy fees	4,266	3,600	5,466	**13,332**
Premises and donated facilities	14,893	12,566	19,082	**46,541**
Printing, Postage, design, marketing and telephone	4,876	4,115	6,248	**15,239**
Insurance	1,091	920	1,397	**3,408**
Bank charges	2,157	1,820	2,764	**6,741**
Meeting costs	6,782	5,722	8,689	**21,193**
Subscriptions/publications	3,932	3,318	5,038	**12,288**
Equipment/maintenance and website development	18,691	15,770	23,948	**58,409**
Depreciation	782	660	1,002	**2,444**
Training and recruitment	8,609	7,264	11,031	**26,904**
Governance costs:				
- Audit & Accountancy	4,076	3,439	5,222	**12,737**
- Professional fees	-	-	-	**-**
- Bookkeeping costs	6,234	5,260	7,987	**19,481**
- Trustees expenses	716	604	917	**2,237**
Brand development	3,181	2,684	4,076	**9,941**
	187,682	158,357	240,468	**586,507**
2023 Total funds	227,424	540,826	318,332	**1,086,582**

9. SUPPORT COSTS - continued

		Charitable activities		
	Cost of raising funds	Gastro-Enterology research	Public education & Science of digestion	2022 Total funds
	£	£	£	£
Directly incurred				
Grants payable (see note 8)	-	1,001,807	-	1,001,807
Research administration	-	2,636	-	2,636
Fundraising costs	38,393	-	-	38,393
Public education	-	-	69,258	69,258
Investment management fees	13,826	-	-	13,826
	52,219	1,004,443	69,258	1,125,920
Support costs				
Staff costs (see note 13)	105,379	81,962	157,036	344,377
Premises and donated facilities	13,316	10,357	19,844	43,517
Postage	172	134	256	562
Telephone	1,119	870	1,668	3,657
Stationery, printing, design and marketing	1,568	1,219	2,336	5,123
Insurance	1,344	1,045	2,003	4,392
Bank charges	2,597	2,020	3,869	8,486
Meeting costs	4,067	3,163	6,061	13,291
Subscriptions/publications	5,203	4,046	7,753	17,002
Equipment/maintenance and website development	11,673	9,079	17,395	38,147
Depreciation	617	480	918	2,015
Training and recruitment	2,981	2,318	4,441	9,740
Governance costs:				
. Audit & Accountancy	3,094	2,406	4,611	10,111
. Professional fees	5,706	4,437	8,502	18,645
. Bookkeeping costs	2,170	1,687	3,232	7,089
Brand development	2,798	2,176	4,169	9,143
	163,804	127,399	244,094	535,297
2022 Total funds	216,023	1,131,842	313,352	1,661,217

10. NET INCOME / (EXPENDITURE)

This is stated after charging:	**2023 Total funds £**	2022 Total funds £
Staff costs (note 13)	**335,612**	344,377
Depreciation	**2,444**	2,015
Auditor's remuneration (including VAT)		
- Statutory audit services – current year	**7,938**	9,600
- Other services - prior year	**2,280**	-
- Other services - current year	**3,510**	-

11. AUDITORS REMUNERATION

Auditors remuneration (including VAT) for 2023 is £13,728 (2022: £9,600)

12. TRUSTEES' REMUNERATION AND EXPENSES

A total of Nil (2022:Nil) was paid or payable, directly or indirectly, out of the funds of the charity for the period to any trustee, or to any person or persons known to be connected with any of them

Included in trustee expenses during the period is £536 reimbursed to 3 trustees for travel expenses (2022: 4 trustees £678).

13. STAFF COSTS

	2023 Total funds £	2022 Total funds £
Salaries and wages	**302,402**	311,219
Social security	**24,944**	23,950
Pension costs	**8,266**	9,208
	335,612	344,377

The average number of employees during the period was	**2023**	2022
General	**9**	9

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000

	2023	2022
£60,001 - £70,000	**1**	1

The key management personnel of the charity in charge of directing and controlling, running and operating the charity on a day to day basis comprise the trustees, the CEO and the COO. The total remuneration (including taxable benefits and employer's pension contributions) of the key management personnel for the year was £108,613 (2022: £123,830).

14. TANGIBLE FIXED ASSETS

	Computer equipment £
Cost	
At 1 January 2023	**13,054**
Additions in the year	**5,338**
Disposals	**(1,261)**
At 31 December 2023	**17,131**
Depreciation	
At 1 January 2023	**9,632**
Charge for the year	**2,444**
Eliminated on disposal	**(1,261)**
At 31 December 2023	**10,815**
Net book value	
At 31 December 2023	**6,316**
At 31 December 2022	**3,422**

15. FIXED ASSET INVESTMENTS

	Endowment Portfolio £	Unrestricted portfolio £	**2023 £**	2022 £
At valuation				
Balance brought forward at 1 January	2,646,759	2,818,855	**5,465,614**	6,085,187
Additions				100,000
Disposal proceeds	(4,589)	(3,607)	**(8,196)**	(97,655)
Investment gains				
- Realised gains/(losses) on MV	22	18	**40**	(460)
- Unrealised gains/(losses)	71,424	76,102	**147,526**	(621,458)
Total investment gains/(losses)	71,446	76,120	**147,566**	(621,918)
Balance carried forward at 31 December	2,713,616	2,891,368	**5,604,984**	5,465,614
Cash held by investment managers	485,959	16,231	**502,190**	492,006
Total investments	3,199,575	2,907,599	**6,107,174**	5,957,620
Analysis by Type				
Listed investments at market value				
- Multi-asset funds	2,713,616	2,891,368	**5,604,984**	5,465,614
Total investments	2,713,616	2,891,368	**5,604,984**	5,465,614
Historic cost of listed investments (all are listed in the UK) - excluding cash held by investment managers	2,886,263	2,978,517	**5,864,780**	5,882,604

At 31 December 2023 the charity had the following material investment holdings:

	Endowment Portfolio £	Unrestricted portfolio £	**Market Value £**	Percentage of portfolio %
Listed investments within the portfolio are:				
SUTL Cazenove Charity Responsible	2,713,616	2,891,368	**5,604,984**	100%

15. FIXED ASSET INVESTMENTS - continued

The total unrealised gains as at 31 December constitute movements on revaluation and are as follows:

	2023	2022
	£	£
Unrealised (losses) gains included above:		
On investments	**(259,797)**	(416,984)
Total unrealised (losses) gains at 31 December	**(259,797)**	(416,984)
Reconciliation of movements in unrealised gains:		
Unrealised gains at 1 January	**(416,984)**	231,179
Gains (Losses) in respect to disposals in the year	**9,662**	(26,705)
	(407,322)	204,474
Add: net gains arising on revaluation in the year	**147,525**	(621,458)
Total unrealised gains at 31 December	**(259,797)**	(416,984)

16. STOCK

	2023 £	2022 £
Goods for re-sale	**18,679**	-

Stock includes printed leaflets, branded t-shirts and technical t-shirts. Stock held in 2022 was deemed to be immaterial and so was not included in the accounts calculations.

17. DEBTORS

	2023 £	2022 £
Trade debtors	**44,037**	33,232
Other debtors	**351,851**	231,351
Accrued income	**37,620**	143,540
Prepayments	**14,433**	12,536
	447,941	420,659

Included within debtors are commitments due from funding partners of £149,921 (2022: £244,937) which is due within one year

18. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023 £	2022 £
Social security and other taxes	**8,294**	9,513
Trade & other creditors	**23,741**	88,701
Research grants payable	**609,585**	1,308,984
Accruals	**16,516**	12,952
	658,135	**1,420,150**

19. CREDITORS: AMOUNTS FALLING DUE AFTER ONE YEAR

	2023 £	2022 £
Research grants payable	**882,685**	557,550

A full breakdown of research grants payable for 2023 can be found in the Appendix from page 53.

20. RESTRICTED FUNDS

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust to be applied for specific purposes:

	At 1 January 2023 £	Income £	Expenditure £	Transfers £	**At 31 December 2023 £**
Guts UK / Dr Falk Awards	-	19,000	(25,862)	6,862	**-**
Restricted research grants	-	292,233	(410,291)	118,058	**-**
Medical Research Charity support fund	-	171,606		(171,606)	**-**
Pancreatitis					**-**
- Liverpool Research	-	9,626	-	(9,626)	**-**
- Research	-	5,472	-	1,423	**6,895**
- General	10,457	3,180	-	(1,423)	**12,214**
Stomach Cancer	8,094	-	-	(2,961)	**5,133**
LSCT	-	2,704	-	2,525	**5,229**
Pancreatitis Leaflets	-	12,300	(6,963)		**5,337**
Research into adhesions	548	-	-	-	**548**
Diverticular	500	-	-	-	**500**
Oesophageal	2,204	810		(810)	**2,204**
Microbiome	625	-	-	-	**625**
Barrett's Oesophagus	28,633	-	-	-	**28,633**
Trust funding	-	-	-	-	**-**
Company donations - restricted	15,896	-	-	-	**15,896**
Derek Butler Endowment Income fund	224,315	133,647	-	810	**358,772**
	291,272	650,578	(443,116)	(56,748)	**441,986**

The transfer represents the contribution from general funds towards the research grants or from restricted funds to general or designated funds for previously committed research as specified by the donor.

The purposes of Guts UK's restricted income in 2023 is as follows:

- Restricted research grants: grants for specific research schemes (eg Early Career Research ECR)
- Pancreatitis: Funds donated to be used specifically for pancreatitis research. Liverpool Research was one specific fundraiser who specified the particular research project they wanted to contribute to
- LSCT: Funds donated to support Guts UK in their work under the Less Survivable Cancers Trust
- Pancreatitis leaflets: Corporate donation restricted to the design and distribution of pancreatitis leaflets
- UK Government COVID Medical Research Charity Support Fund: contribution to ECR and Trainee awards
- Derek Butler Endowment Income Fund: this represents the income received from the endowment fund and expenditure on research into the diseases of the upper gastrointestinal tract.

20. RESTRICTED FUNDS - continued

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust to be applied for specific purposes:

	At 1 January 2022 £	Income £	Expenditure £	Transfers £	At 31 December 2022 £
Guts UK / Dr Falk Awards	-	28,319	(32,638)	4,319	-
Restricted research grants	-	297,771	(581,542)	283,771	-
UK Government COVID Medical Research Charity support fund	-	108,540		(108,540)	-
Pancreatitis	2,214	8,243	-	-	10,457
Stomach Cancer	6,031	2,063	-	-	8,094
Research into adhesions	548	-	-	-	548
Diverticular	500	-	-	-	500
Oesophageal	-	2,204	-	-	2,204
Liver					-
Microbiome	625	-	-	-	625
Barrett's Oesophagus	18,633	10,000	-	-	28,633
Trust funding - digital		24,429	(40,000)	15,571	-
Company donations - restricted	14,896	1,000	-	-	15,896
Derek Butler Endowment Income fund	318,461	115,854	(210,000)	-	224,315
	361,908	598,423	(864,180)	195,121	291,272

The transfer represents the contribution from general funds towards the research grants or from restricted funds to general or designated funds for previously committed research as specified by the donor.

21. DESIGNATED FUNDS

Amelie Waring

	At 1 January 2023 £	Income £	Expenditure £	Transfers £	Investment gains (losses) £	**At 31 December 2023 £**
Investments	822,660	35,621	(1,999)	(80,000)	20,596	**796,878**
Cash in current account	46,775	-	-	9,626	-	**56,401**
Research Commitments	(199,589)	-	-	112,084	-	**(87,505)**
Total Amelie Waring Fund	669,846	35,621	(1,999)	41,710	20,596	**765,774**

	At 1 January 2022 £	Income £	Expenditure £	Transfers £	Investment gains (losses) £	At 31 December 2022 £
Investments	874,944	32,639	2,325	-	(87,248)	822,660
Cash in current account	46,775	-	-	-	-	46,775
Research Commitments	(147,300)	-	(180,000)	127,711	-	(199,589)
Total Amelie Waring Fund	774,419	32,639	(177,675)	127,711	(87,248)	669,846

GI Research

	At 1 January 2023 £	Income £	Expenditure £	Transfers £	Investment gains (losses) £	**At 31 December 2023 £**
Investments	885,235	38,220	(2,134)	(37,684)	23,870	**907,507**
Cash in current account	-	-	-	280,146	-	**280,146**
Research Commitments	(260,092)	-	-	(127,756)	-	**(387,848)**
Total GI Research Fund	625,143	38,220	(2,134)	114,706	23,870	**799,805**

	At 1 January 2022 £	Income £	Expenditure £	Transfers £	Investment gains (losses) £	At 31 December 2022 £
Investments	986,455	37,318	(2,239)	(35,090)	(101,209)	885,235
Cash in current account	-	-	-	-	-	-
Research Commitments	(138,846)	-	-	(121,246)	-	(260,092)
Total GI Research Fund	847,609	37,318	(2,239)	(156,336)	(101,209)	625,143

21. DESIGNATED FUNDS - continued

Total Designated Funds

	At 1 January £	Income £	Expenditure £	Transfers £	Investment gains (losses) £	At 31 December £
Total Designated Funds 2023	**1,294,989**	**73,841**	**(4,133)**	156,416	**44,466**	**1,565,579**
Total Designated Funds 2022	1,622,028	69,957	(179,914)	(28,625)	(188,457)	1,294,989

The Amelie Waring fund was initially established in memory of Amelie Waring to fund pancreatitis research, although the original bequest has been fully expended the trustees continue to designate funds to pancreatitis research in recognition of their ongoing commitment to funding research in this area.

The GI Research Fund is designated to general gastrointestinal research.

22. ENDOWMENT FUND

	At 1 January 2023 £	Income £	Expenditure / transfer £	Investment gains (losses) £	**At 31 December 2023 £**
Derek Butler Endowment	2,631,036	-	(6,780)	71,446	**2,695,702**

	At 1 January 2022 £	Income £	Expenditure / transfer £	Investment gains (losses) £	At 31 December 2022 £
Derek Butler Endowment	2,937,073	-	(6,909)	(299,128)	2,631,036

Income from the Derek Butler Endowment fund is credited to restricted funds and is to be spent on research into diseases of the upper gastrointestinal tract.

23. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Fixed assets £	Investments £	Net current (liabilities) / assets £	Long-term liabilities £	**Total 2023 £**
Unrestricted funds					
- General	6,316	1,707,087	218,039	(838,932)	**1,092,510**
- Designated funds: AW	-	796,878	12,649	(43,753)	**765,774**
- Designated funds: GI	-	907,507	(107,702)	-	**799,805**
Restricted funds	-	-	441,986	-	**441,986**
Endowment funds	-	2,695,702	-	-	**2,695,702**
	6,316	6,107,174	564,972	(882,685)	**5,795,777**

	Fixed assets £	Investments £	Net current (liabilities) / assets £	Long-term liabilities £	**Total 2022 £**
Unrestricted funds					
- General	3,422	1,618,689	(90,533)	(462,550)	1,069,028
- Designated funds: AW	-	822,660	(57,814)	(95,000)	669,846
- Designated funds: GI	-	885,235	(260,092)	-	625,143
Restricted funds	-	-	291,272	-	291,272
Endowment funds	-	2,631,036	-	-	2,631,036
	3,422	5,957,620	(117,167)	(557,550)	5,286,325

24. BRITISH SOCIETY OF GASTROENTEROLOGY CONNECTED PARTY TRANSACTIONS

Guts UK works closely with the British Society of Gastroenterology (BSG) (Charity Registration No. 1149074 and Company Registration No. 08124892 England & Wales) to provide strong links with the main professional community and to improve its ability to disseminate research and patient information. The Chair of the Research Committee of the BSG is a member of Guts UK's Board of Trustees. The Chair of Guts UK is an ex-officio member of BSG's Council.

Transactions between the two charities during the period were as follows:

The BSG provided a grant of £12,312 (2022: £16,396) to support trainee research grants.
Guts UK paid the BSG a total of £307 for office rates and broadband provision.

25. CONTINGENT ASSET AND LIABILITY

In 2018 the charity secured provisional funding amounting to £1,250,000 for the colorectal cancer research grant of which £650,000 has been received as at 31 December 2023 (2022: £530,000).

Up to £250,000 is receivable on an annual basis contingent on a satisfactory annual report being approved by the funding partner. Should the next stages of funding be received, Guts UK has agreed to distribute and monitor use of this funding as a sub-grant. As at 31 December 2023, £600,000 remains receivable, of which up to £240,000 is receivable and payable within one year.

26. RELATED PARTY TRANSACTIONS

During the year the charity received donations of £925 from trustees (2022: £1,910). Included in trustee expenses during the period is £536 reimbursed to 3 trustees for travel expenses (2022: 4 trustees £678).

Transactions with the British Society of Gastroenterology are detailed in note 24.

27. LIABILITY OF MEMBERS

The charity is constituted as a company limited by guarantee. In the event of the charity being wound up, members are required to contribute an amount not exceeding £1.

28. COMMITMENTS UNDER OPERATING LEASES

At 31 December 2023 the charity had future minimum commitments under non-cancellable operating leases as set out below:

	2023	2022
	£	£
Payments which fall due:		
Within one year	**768**	772
Within 2 to 5 years	**3,072**	387
	3,840	1,159

Lease payments are expensed to the profit and loss account for the year

INCOME AND ENDOWMENTS	2023 £	2022 £
Donations and legacies		
Donations (including in-memoriam)	461,128	421,935
Legacies	157,438	52,721
	618,566	474,657
Other trading activities		
Public education	67,363	50,404
Merchandise	1,324	-
	68,687	50,404
Investment Income		
Curr asset investment income	278,376	240,353
Charitable activities		
Grants	482,839	434,630
Total incoming resources	**1,448,468**	1,180,044
EXPENDITURE		
Other trading activities		
Grants payable	379,899	1,001,807
Fundraising costs	25,574	38,393
Public education	77,864	69,258
Research administration	2,570	2,636
Investment management fees	14,168	13,826
	500,075	1,125,920

EXPENDITURE CONT'D	2023 £	2022 £
Support Costs		
Management		
Staff costs	335,612	344,377
Consultancy fees	13,332	-
Premises & donated facilities	46,541	43,517
Insurance	3,408	4,392
Printing, postage, telephone & design & marketing	15,239	9,342
Bank charges	6,741	8,486
	420,873	410,114
Finance		
Meeting costs	21,193	13,291
Subscriptions	12,288	17,002
	33,481	30,293
Information Technology		
Equipment/maintenance & web- site development	58,409	38,147
Training and recruitment	26,904	9,740
Computer equipment - depreciation	2,444	2,015
	87,757	49,902
Governance costs		
Accountancy fees	12,737	10,111
Legal fees	-	18,645
Trustees expenses	2,237	-
Bookkeeping costs	19,481	7,089
Brand development	9,941	9,143
	44,396	44,988
Total resources expended	**1,086,582**	1,661,217
Net income (expenditure) before gains and losses	361,886	(481,173)
Realised gains(losses) on fixed asset investments	147,566	(621,918)
Net income (expenditure)	**509,542**	(1,103,091)

Royal Patron	HRH Princess Alexandra
Trustees	• Professor C Hawkey DM FRCP FMedsci – **President** (resigned 06-Jan-23) • Professor J McLaughlin MBChB PhD FRCP (**Interim Chair** 10-Jan-23 – 13-Mar-23, resigned 13-Mar-23) • Dr V King PhD, **Chair** (appointed 13-Mar-23) • Professor D Adams MD FRCP FMedSci (resigned 13-Mar-24) • Mrs M Davey • Dr L Dugdale-Bradley • Miss N Bridge (term ended 4-Sep-24) • Professor M Lomer MBE PhD • Professor S Sebastian* MD FRCP (term ended 4-Sep-24) • Professor C Norton • Professor C Probert MD FRCP • Dr C McCann PhD (appointed 30-Jun-23) • Ms C Leonard, Treasurer (appointed 06-Jul-23) • Mr R Chahil (appointed 06-Jul-23) • Mr C McCann (appointed 06-Jul-23) • Professor D Shawcross* BSc MBBS PhD FRCP (appointed 4-Sep-24) * nominee of the British Society of Gastroenterology (BSG)
Chief Executive	Ms J Harrington (up to 15-Apr-24) Ms K Noon acting as Interim CEO (16-Apr-24 to 1-Sep-24) Ms S Hudson MBE (appointed 2-Sep-24)
Principal office	2 St Andrews Place Regent's Park London. NW1 4LB
Telephone	0207 486 0341
Website	www.gutscharity.org.uk
E-mail	info@gutscharity.org.uk
Company registration number	07274105 (England and Wales)
Charity registration number	1137029
Auditor	Harris, Lacey and Swain Suite 1, The Riverside Building Livingstone Road Hessle, HU13 0DZ
Bankers	National Westminster Bank plc 1 Cavendish Square London, W1A 4NU
Investment managers	Cazenove Capital Management 12 Moorgate London, EC2R 6DA
Solicitors	Hempsons 40 Villiers Street London, WC2N 6NJ

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2023

Research grants payable

	2023 Total funds £	*2022 Total funds £*
At 1 January	**1,866,538**	1,251,335
Research grants awarded in the year	**436,153**	1,004,179
Research grants no longer required	**(56,255)**	(2,371)
Paid during the year	**(754,166)**	(386,605)
At 31 December	**1,492,270**	1,866,538
Research grants at 31 December are payable as follows:		
Within one year (see note 18)	**609,585**	1,308,988
After more than one year (see note 19)	**882,685**	557,550
	1,492,270	1,866,538

Specific details of individual research grants are provided on the following pages.

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2023

			At 1 January 2023 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2023 £**
Ongoing research							
Dr Wadiamu Gashau	Core-BSG Trainee Research Network Award	RISE NoW (Regional IBD Surveillance Endoscopy North West) study: A real world experience of dysplasia and colorectal cancer surveillance in Inflammatory Bowel Disease (IBD)	2,500	-	-	-	**2,500**
Professor Colin Rees	Parabola-Guts UK Colorectal Cancer Research Grant	COLO-COHORT Colorectal Cancer Cohort Study	391,855	250,000	-	(153,530)	**488,325**
Dr Louise China	Guts UK-BSG Trainee Research Award	Exploring Periodontitis in Cirrhosis (EPIC): a single arm feasibility study to explore the relationship between periodontitis and infection in patients with liver cirrhosis.	4,980	-	-	(2,500)	**2,480**
Dr Salvatore Papa	Development Grant	Starving livers of glucose for HCC prevention and treatment	48,572	-	-	(22,982)	**25,590**
Professor Chris Probert[2]	Development Grant	Evaluation of the gut metabolome, micro and myco biome in ulcerative colitis patients undergoing anti-fungal therapy: can we predict response to therapy?	48,099	-	-	(12,367)	**35,732**
Dr James Pritchett	Development Grant	Decoding Yes Associated Protein 1 driven hepatic stellate cell activation	21,942	-	-	(1,274)	**20,668**
Dr Catherine Williamson	Nutrition Development Grant	Impact of cold exposure in conjunction with dietary modification on metabolic regulation in children with non-alcoholic fatty liver disease	48,283	-	-	(11,953)	**36,330**
Professor Graham Lord	For Crohn's Development Grant	Modulation of the effector/regulatory T-cell balance by targeting a causal genetic variant as a novel therapeutic paradigm in Crohn's disease	43,336	-	-	(9,571)	**33,765**
Balance carried forward			**609,567**	**250,000**	**-**	**(214,177)**	**645,390**

[2] Professor Chris Probert was awarded this Grant in 2019 before he was appointed as a Trustee in 2022. As a trustee, he does not sit on the Research Awards Committee.

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2023

…			At 1 January 2023 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2023 £**
Ongoing research cont'd							
Balance brought forward			**609,567**	**250,000**	**-**	**(214,177)**	**645,390**
Dr Rebecca Harris	Guts UK-BSG Trainee Research Award	Non-invasive risk stratification of patients with compensated advanced chronic liver disease : Results from a real world cohort from the Nottingham Scarred Liver pathway	5,000	-	-	-	**5,000**
Dr Tessa Cacciottolo	Guts UK - Dr Falk SpR Trainee Audit/Quality Improvement Award	Using age-appropriate information to support adolescents and young adults with liver disease as they transition from paediatric to adult services	2,325	-	-	-	**2,325**
Dr Nicholas Edward Ilott	Guts UK - BSG Early Career Researcher Grant	DYNAMHIX in PSC : Longitudinal Dynamics of the Hepatic-Intestinal axis in PSC-UC	12,331	-	-	(376)	**11,955**
Dr Nikhil Vergis	Guts UK - BSG Early Career Researcher Grant	Which socioeconomic and healthcare factors determine survival for patients with alcohol related liver disease? A secondary analysis of patient data from the Steroids or Pentoxyfilline for Alcoholic Hepatitis (STOPAH) trial 2011-2015	15,000	-	-	-	**15,000**
Dr Naaventhan Palaniyappan	Guts UK - BSG Early Career Researcher Grant	Risk stratification of patients with cirrhosis undergoing colorectal surgery: pilot feasibility study."	13,350	-	-	-	**13,350**
Dr Paloma Ordonez Moran	Guts UK - BSG Early Career Researcher Grant	MINIGUTS: Development of novel in vitro models of paediatric IBD	14,977	-	-	(10,296)	**4,681**
Dr Zoe Saynor	Guts UK - BSG Early Career Researcher Grant	EnablExercise in Crohn's: A qualitative study to understand the barriers and facilitators to physical activity and exercise in children and adolescents with Crohn's disease - perceptions of patients, caregivers and clinicians	12,225	-	-	(11,725)	**500**
Pancreatitis Priority Setting Partnership (PSP)		Identification and prioritisation of gaps in evidence in the diagnosis, treatment, management and support of patients with pancreatitis	16,366	-	-	(3,496)	**12,870**
Irritable Bowel Syndrome (IBS) Priority Setting Partnership		Identification and prioritisation of the unanswered questions about the diagnosis, treatment and care of people (16 years +) with IBS	33,571	-	-	(14,643)	**18,928**
Balance carried forward			**734,712**	**250,000**	**-**	**(254,713)**	**729,999**

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2023

			At 1 January 2023 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2023 £**
Ongoing research cont'd							
Balance brought forward			**734,712**	**250,000**	**-**	**(254,713)**	**729,999**
Professor Anil Dhawan	Guts UK – BSG trainee grant	Umbilical Cord-Mesenchymal Stromal/stem cell immunotherapy for Biliary Atresia	**38,902**	**-**	-	-	**38,902**
Dr Tassos Grammatikopoulos	Guts UK – BSG trainee grant	Mental health and quality of life in children and young people with acute recurrent and chronic pancreatitis	**4,248**	**-**	-	-	**4,248**
Dr Julian Yeh	Guts UK – BSG trainee grant	Microscopic Colitis: a regional multi-centre audit."	**4,000**	**-**	-	-	**4,000**
Dr Simeng Lin	Guts UK – BSG trainee grant	End of life care provision in patients with advanced liver disease in the south-west: a regional perspective	**765**	**-**	(704)	**-**	**61**
Dr Oliver Tavabie	Guts UK – BSG trainee grant	Does the implementation of the BASL/BSG bundle improve the survival of patients with decompensated chronic liver disease acutely admitted into hospital	**2,000**	**-**	**-**	-	**2,000**
Dr Ayman Bannaga	Guts UK – BSG trainee grant	The Fatty Liver and Liver Cancer Study (Tendency)	**5,000**	**-**	**-**	(2,500)	**2,500**
Mr Arjun Kattakayam	Guts UK/Amelie Waring Research Fellowship	Novel high resolution insights into mitochondrial dysfunction in acute pancreatitis within and beyond the pancreas	**180,000**	**-**	**-**	(92,494)	**87,506**
Dr Katja Christodoulou	Guts UK/ Derek Butler Research Fellowship	Non - invasive testing of Early Oesophageal Cancer and Dysplasia	**210,000**	**-**	**-**	(71,378)	**138,622**
Professor Sheena Cruickshank	For Crohns	Characterising the immune signature of genital Crohn's disease	**19,874**	**-**	**-**	**(2,965)**	**16,909**
Dr Mohamed Albed Alhnan	For Crohns	Enabling the oral delivery of adalimumab via novel 4D printing architectures fro the treatment of Crohn's	**16,019**	**-**	**-**	**-**	**16,019**
Dr Tovah Shaw	For Crohns	Determining the contribution of long-lived Tim4+ gut macrophages to oral tolerance of food, and intestinal microbial community stability	**14,803**	**-**	**-**	**-**	**14,803**
Dr Alice Lapthorn	Guts UK - BSG Early Career Researcher Grants	Repurposing of drugs to prevent intra-abdominal adhesion formation	**15,000**	**-**	**-**	(1,078)	**13,922**
Balance carried forward			**1,245,323**	**250,000**	**(704)**	**(425,128)**	**1,069,491**

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2023

			At 1 January 2023 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2023 £**
Ongoing research cont'd							
Balance brought forward			**1,245,323**	**250,000**	**(704)**	**(425,128)**	**1,069,491**
Dr K Belogianni	Guts UK - BSG Early Career Researcher Grants	Implementing an integrated care pathway for the management of irritable bowel syndrome	**15,000**		-	-	**15,000**
Dr M Mohamed	Guts UK - BSG Early Career Researcher Grants	Development and evaluation of point-of-care diagnostics utilising clinical metagenomic sequencing for rapid pathogen and antimicrobial resistance detection in decompensated cirrhosis and acute-on-chronic liver failure	**14,961**	-	-	(7,176)	**7,785**
Dr Fumi Kamlesh Varyani	Guts UK - BSG Early Career Researcher Grants	Identifying the impact of Specialist Nutrition Support Teams on the outcomes of parenterally fed and gastrostomy patients utilising the Hospital Episode Statistics and National Endoscopy Database"	**15,000**	-	-	(7,498)	**7.502**
Dr Jonathan King	Guts UK-Dr Falk SpR Trainee Audit/Quality Improvement Award	Assessing the impact of using interactive video in the correct languages for the consenting of non-English speaking patients in endoscopy	**8,638**	1,362	-	(5,000)	**5,000**
James Halle-Smith	Guts UK - BSG Trainee Research Award	"The Influence of Pancreatic Exocrine Insufficiency and Pancreatic Enzyme Replacement Therapy on the Intestinal Microbiome of Pancreatic Cancer Patients"	**3,880**	-	-		**3,880**
Amir Saifuddin	Guts UK - BSG Trainee Research Award	"Evaluation of the safety of perioperative advanced anti-inflammatory therapy in patients with inflammatory bowel disease (IBD) undergoing elective surgery"	**5,000**	-	-	-	**5,000**
Nosheen Umar	Guts UK - BSG Trainee Research Award	"Development of a risk prediction tool for inflammatory bowel disease (IBD) in patients presenting in primary care with abdominal symptoms in the Clinical Practice Research Datalink (CPRD Aurum)."	**5,000**	-	-	-	**5,000**
Jonathan Gan	Guts UK - BSG Trainee Research Award	"Monitoring gut permeability in Irritable Bowel Syndrome (IBS) using a novel non invasive optical sensor"	**3,913**	-	-	-	**3,913**
Jonathan Sturgeon	Guts UK - BSG Trainee Research Award	"Spacial profiling of duodenum transcriptomic changes following administration of novel therapeutic agents in children with severe acute malnutrition"	**5,000**	-	-	-	**5,000**
Balance carried forward			**1,321,715**	**251,362**	**(704)**	**(444,802)**	**1,127,571**

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2023

			At 1 January 2023 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2023 £**
Ongoing research cont'd							
Balance brought forward			**1,321,715**	251,362	(704)	(444,802)	**1,127,571**
Joseph Delo	Guts UK - BSG Trainee Research Award	"The role of the TIGIT immune checkpoint axis in susceptibility to infection in decompensated cirrhosis"	**5,000**	-	-	(2,500)	**2,500**
Adeel Harmad	Guts UK - BSG Trainee Research Award	"Exploring the role of the brainstem in human swallowing and post radiotherapy induced dysphagia using functional MRI"	**5,000**	-	-	(2,500)	**2,500**
Marcus Auth	BSPGHAN/GUTS UK/Falk	"Faecal volatile organic compounds in children with eosinophilic oesophagitis potential as non-invasive biomarkers"	**39,995**	-	-	-	**39,995**
Francis Robertson Newcastle	ASGBI	"Micro RNAs in acute pancreatitis"	**7,454**	1,046	-	(5,000)	**3,500**
Hwei Jene Ng	ASGBI	"Micro RNAs in acute pancreatitis"	**1,500**	-	-	-	**1,500**
Diverticular Disease Priority Setting Partnership (PSP)			**20,000**	-	-	-	**20,000**
Dr Maria Alcolea	Worldwide Cancer Research	"Mechanomodulation of mutant clonal competition in oesophageal epithelium : relevance for early tumour formation "	**124,143**	-	-	-	**124,143**
Total ongoing research			**1,524,807**	**252,408**	**(704)**	**(454,802)**	**1,321,709**

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2023

18. Research grants payable (continued)

			At 1 January 2023 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2023 £**
New commitments							
Nadir Abbas	Guts UK-Dr Falk SpR Trainee Audit/Quality Improvement Award	Liver Dojo Website	**-**	10,000	-	(2,185)	**7,815**
Christopher Lewis-Lloyd	Guts UK - BSG Trainee Research Award	Osteoporotic fracture risk in people living with an ileostomy due to nutritional deficiencies.	**-**	5,000	-	-	**5,000**
Theresa Hydes	Guts UK - BSG Trainee Research Award	Can a community-based, patient-centric metabolic liver clinic improve patient outcomes and achieve cost effectiveness?	**-**	4,973	**-**	**-**	**4,973**
Hatem Sadik	Guts UK - BSG Trainee Research Award	Improving liver regeneration by matrix metalloproteinase inhibition using marimastat during normothermic machine perfusion of the liver in a donation after circulatory death porcine model.	**-**	4,963	**-**	**-**	**4,963**
Morven Allan	Guts UK - BSG Trainee Research Award	Exploring the mechanism by which variation at the FUT2 gene imparts elevated risk of colorectal cancer: the contribution of the gut microbiome.	**-**	4,959	**-**	**-**	**4,959**
Mohamed Shiha	Guts UK - BSG Trainee Research Award	Transnasal Endoscopy versus ConvenTional endOscopy for the diagNosIs of Coeliac disease in adults: a comparison of accuracy and tolerability (TECTONIC)	**-**	3,229	**-**	**-**	**3,229**
Victoria Kronsten	Guts UK - BSG Trainee Research Award	Mental health support on the liver transplant waiting list.	**-**	1,500	**-**	**-**	**1,500**
Rachel Barry	Guts UK - BSG Early Career Researcher Grants	Exploring protease activities as a novel diagnostic marker for irritable bowel syndrome.	**-**	11,412	**-**	**-**	**11,412**
Tom Butler	Guts UK - BSG Early Career Researcher Grants	Feeding time: the impact of chrononutrition on microbiome rhythmicity and gut inflammation.	**-**	14,089	**-**	**-**	**14,089**
Daniel Patten	Guts UK - BSG Early Career Researcher Grants	Epigenetic regulation of liver endothelial cells as a novel target to boost immunotherapy efficacy in hepatocellular cancer.	**-**	14,716	**-**	**-**	**14,716**
Balance carried forward			**-**	**74,841**	**-**	**(2,185)**	**72,656**

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2023

18. Research grants payable (continued)

			At 1 January 2023 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2023 £**
New commitments cont'd							
Balance brought forward			**-**	**74,841**	**-**	**(2,185)**	**72,656**
Stephen McSorley			**-**	14,562	-	-	**14,562**
Achalasia Registry	Guts UK commitment	Committed by RSC in 2023 to progress an achalasia registry	**-**	10,000	-	-	**10,000**
Health Inequalities in GI	Guts UK commitment / matched by BSG	Committed by RSC in 2023 to launch a project to measure inequalities in healthcare in GI	**-**	10,000	-	-	**10,000**
Paul Caton	Guts UK/BSPGHAN awards	Investigating the role of eNAMPT as a biomarker of paediatric MASLD/MASH	**-**	20,526	-	-	**20,526**
Jake Mann	Guts UK/BSPGHAN awards	Cellular cross-talk between innate and adaptive immune systems in paediatric biliary fibrosis	**-**	39,317	-	-	**39,317**
Falk Pharma 2023 awards – various			**-**	14,500	-	(11,000)	**3,500**
Total New Commitments				**183,745**		**(13,185)**	**170,651**

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2023

18. Research grants payable (continued)

			At 1 January 2023 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2023 £**
Research completed during the year							
Mr James O'Kelly	Guts UK/Amelie Waring Research Fellowship	Single cell definition of the mechanistic role of kynurenine monooxygenase at the innate immune interface in acute pancreatitis	**19,590**	**-**	(2,138)	(17,452)	**-**
Dr Sara Jamel	Olympus Guts UK Endoscopy Fellowship	Profiling of Dysplastic Changes in Barrett's Oesophagus and Early Oesophageal Cancer Using Non-Invasive Volatile Organic Compound Analysis of Exhaled Breath	**20,747**	**-**	(5,652)	(15,095)	**-**
Dr Marc-Emmanuel Dumas	Guts UK Development Award	Precision medicine through integrative metagenomics and phenomics in a human NAFLD cohort	**49,797**	**-**	-	(49,797)	**-**
Dr Dipesh Vasant	Guts UK-Dr Falk SpR Trainee Audit/Quality Improvement Award	Anorectal dysfunction in ulcerative colitis: a cross sectional survey	**1,300**	**-**	(1,300)	**-**	**-**
Dr Gwo-tzer Ho	Guts UK Development Award	Resolving Inflammation in IBD: Developing a new therapeutic approach by targeting pro-inflammatory mitochondrial formylated peptides on neutrophil FPR1-pathway	**1,892**	**-**	(1,892)	**-**	**-**
Dr Nick Powell	For Crohns	TNFα responsive transcriptional networks in the human intestinal epithelium - the key to predicting therapeutic response to antic-TNFα in Crohn's disease	**3,530**	**-**	(3,530)	**-**	**-**
Dr Samuel Smith	Guts UK-BSG Trainee Research Network Award	Improving key performance measures in inflammatory bowel disease surveillance	**5,000**	**-**	(5,000)	**-**	**-**
Professor Jonathan Fallowfield	Development Grant	A molecular phenomic approach to define the high risk NAFLD population	**13,052**	**-**	(1,545)	(11,507)	**-**
Dr Marnix Jansen	Development Grant	The TARGET study (TArgeted biopsies to Risk Stratify Gastric cancer precursors for tailored Endoscopic surveillance and Treatment)	**46,900**	**-**	(134)	(46,766)	**-**
Professor Christer Hogstrand	Nutrition Development Grant	Targeting “Leaky Gut“ with combined dietary zinc and plant derived Aryl Hydrocarbon Receptor agonists	**50,000**	**-**		(50,000)	**-**
Balance carried forward			**211,808**	**-**	**(21,191)**	**(190,617)**	**-**

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2023

			At 1 January 2023 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2023 £**
Research completed during the year cont'd							
Balance brought forward			**211,808**	**-**	**(21,191)**	**(190,617)**	**-**
Dr Paul Henderson	Guts UK - BSPGHAN Development Grant	The PINPOINT study – The Prospective Incidence of Paediatric – Onset Inflammatory bowel disease in the United Kingdom	**37,540**	**-**	(35)	**-**	
Dr Dimitrios Koutoukidis	Guts UK - BSG Early Career Researcher Grant	A proof-of-concept trial exploring the mechanism of diet-induced weight loss in non-alcoholic steatohepatitis with fibrosis through the gut microbiome and intestinal permeability	**14,996**	**-**	(1)	**-**	
Dr Benjamin P Sharpe	Guts UK - BSG Early Career Researcher Grant	Investigating the cellular microenvironment of lymph node metastasis in oesophageal adenocarcinoma	**14,649**	**-**	(989)	**-**	
Dr Rachael Slater	Guts UK - BSG Early Career Researcher Grant	Investigating the mechanisms of irritable bowel syndrome using shotgun metagenomics sequencing and volatile metabolomics in integrated omics analysis	**10,780**	**-**	(115)	**-**	
Dr Tariq Ahmad	For Crohn's Grant	Impact of biologic and immunomodulatory therapy on SARS-CoV-2 re-infection, chronic carriage and evolution of viral variants	**25,220**	**-**	(25,220)	**-**	
Dr Peter Rimmer	**5,000**	The Microbiome in IBD Inception: An exploratory two year longitudinal analysis of the gastrointestinal microbiome through IBD onset, treatment, and relapse, to guide future microbiome based interventions	**5,000**	**-**	**-**	**-**	
Dr Flora Korkwaro	Guts UK - Dr Falk SpR Trainee Audit/Quality Improvement Award	My Tube Passport - "Mind My Tube" - a hospital e-passport for the patient with an enterostomy device	**8,000**	**-**	(8,000)	**-**	
Dr Robin Dart	Guts UK-BSG Trainee Research Award	The cellular architecture of the human colonic mucosa : a pilot and feasibility study to facilitate longitudinal multi-centre studies	**5,000**	**-**	**-**	**-**	**-**
Dr James Ashton	Guts UK-BSG Trainee Research Award	To establish a UK wide Paediatric IBD Research network (PAIR network) to answer clinical research questions and enable rapid decision making	**3,917**	**-**	**-**	**-**	
Dr John Thomas	Guts UK-BSG Trainee Research Award	Transcriptomic profiling of patient derived colonic epithelial organoids exposed to Ulcerative Colitis-relevant cytokines – a novel approach to uncover IBD pathogenesis and inform precision medicine strategies.	**4,821**	**-**	**-**	**-**	
Total Research completed during the year			**341,731**	**-**	**(55,551)**	**(286,180)**	**-**
Total grants for the year			**1,866,538**	**436,153**	**(56,255)**	**(754,167)**	**1,492,269**

We’re getting to grips with guts

Guts UK Trustee Report and Accounts 2023 - Final

Final Audit Report 2024-09-19

Created:	2024-09-19
By:	Guts UK (info@gutscharity.org.uk)
Status:	Signed
Transaction ID:	CBJCHBCAABAA_AnLy8afKi_1jrqFjEN9RNSjMDoeuxY-

"Guts UK Trustee Report and Accounts 2023 - Final" History

Document created by Guts UK (info@gutscharity.org.uk)
2024-09-19 - 4:38:47 PM GMT

Document emailed to Laura Drew (ld@hlas.co.uk) for signature
2024-09-19 - 4:39:03 PM GMT

Email viewed by Laura Drew (ld@hlas.co.uk)
2024-09-19 - 9:08:33 PM GMT

Document e-signed by Laura Drew (ld@hlas.co.uk)
Signature Date: 2024-09-19 - 9:10:55 PM GMT - Time Source: server

Agreement completed.
2024-09-19 - 9:10:55 PM GMT

Adobe Acrobat Sign

GUTS UK CHARITY

England & Wales - Charity number 1137029

Accounts

ANNUAL REPORT AND FINANCIAL STATEMENTS 2022

Guts UK Charity

Charity Registration No. 1137029

Annual Report and Financial Statements for the Year End 31 December 2022

CONTENTS

Welcome	3
Who we are	4
Our 2022 highlights	6
Plans for 2023	10
Financial performance review	12
Governance, policies and standards	17
Report of the Independent Auditors	21
Statement of Financial Activities	27
Balance sheet	28
Cash Flow Statement	30
Notes to the Cash Flow Statement	31
Notes to the Financial Statements	32
Detailed Statement of Financial Activities	52
Reference and administrative information	54
Appendix 1 – Detail of research grants payable	55

A WELCOME FROM OUR BOARD AND CEO

It's five years since we changed our name to **Guts UK** charity. Despite some of those 5 years being the most challenging we have ever encountered, in this our review of the year 2022 we want to focus on the dynamic, transformational change that is happening.

The name change worked. Many more people can find Guts UK online with our website packed full of helpful, accessible, evidenced-based information about digestive health conditions and symptoms. We hear the heart-lifting tales of people who are empowered by Guts UK information, to manage their symptoms better or finally get to a diagnosis. We have had **Colin the Inflatable Colon** back out on the road (he so doesn't like being in his box, dear reader) to raise awareness of digestive health. And we have the biggest active medical research programme ever with a whopping 70% of our expenditure in 2022 funding yet more new vital research into our gut, liver and pancreas.

We have done this together. You, our beloved Guts UK community of supporters have come on board in droves to support our mantra that **"it's time the UK got to grips with guts"**. You have given vital donations that enable our information services and make the research happen. You have added your powerful voices to our campaigns, being brave and visible when sharing your personal stories, even in the most testing of times imaginable. You volunteer your valuable time to speak at conferences, connect and share on social media on annual #GutSelfieSunday. Our volunteers on the Research Awards Committee lend expertise alongside our lay panel of Experts by Experience, to study, debate and decide on where the charity's precious donations should be invested to further research. Guts UK charity exists for you and because of you. Thank you all. May we continue to grow Guts UK's bold and brave community together, so we can be there for those who do not yet know they will need us.

For the Guts UK staff, we suffered a major blow when we lost our colleague and Finance Manager, Alice Kington, who died in November 2022. Unexpected and utterly untimely; for our small, close-knit team, this loss was huge. As our brilliant Finance Manager for so many years, she watched over every single penny and a better custodian of the charity's finances we could not have wished for. Alice was hugely committed to this charity, its growth and you, the Guts UK community, who we know inspired and motivated her every day.

Alice Kington, 1965-2022

We dedicate these accounts to Alice Kington's memory and resolve to build on her superb contribution and her legacy.

Julie Harrington
CEO



Linda Dugdale-Bradley,
Deputy Chair, Board of Trustees

WHO WE ARE

Guts UK is the charity for the digestive system. Though there are some 150 plus patient groups and charities in the field of digestive health in the UK, many of them are disease specific. Guts UK remains *the only charity* that covers all of the digestive system, from 'top to tail'. Guts UK works actively and collaboratively with other charities. However, with our own limited resources, we choose to focus particularly on the conditions that have no other specific charity or voice - those illnesses that really are underserved such as pancreatitis, diverticular disease, irritable bowel syndrome (IBS), childhood gut and liver disease and digestive cancers. These conditions affect millions of people every day and digestive diseases account for one in eight hospital deaths in the UK each year.

Our Vision

A world where digestive disorders are better understood, better treated and everyone who lives with one gets the support they need.

Objectives and activities
Guts UK's charitable objectives as declared in 1971 remain unchanged and are:

1. The advancement of the science and practice of medicine and surgery for the benefit of the public with particular reference to the field of gastroenterology, which includes the study of the physiology and pathology of the digestive system;
2. To promote the study of and research into medicine and surgery with particular reference to the physiology and pathology of the digestive system and to ensure dissemination where appropriate of the results of such study and research;
3. To provide educational material, information and advice to the general public on gastrointestinal diseases.

To achieve these objectives, Guts UK works across six areas:

- **Providing evidence-based information** to patients and carers that enables people to take proactive decisions and control of their lives;
- **Supporting medical research** that increases our understanding of digestive diseases, leading to better diagnosis and treatment and improved outcomes for patients;
- **Funding research training fellowships** for clinicians and scientists to allow them to pursue academic gastroenterology and to enable the development of future researchers;
- **Hosting scientific research symposia** as part of the British Society of Gastroenterology (BSG) Annual Meeting;
- **Giving general advice** and signposting to other organisations;
- **Raising awareness of digestive health** and the science surrounding it to increase public understanding.

When setting the objectives and planning the work of Guts UK for the year, the trustees gave careful consideration to the Charity Commission's general guidance on public benefit.

The trustees always ensure that the activities undertaken are in line with the charitable objectives and aims of Guts UK. As highlighted in this report, we are continuing to develop our information provision and public education programme thereby helping the general population to better understand digestive diseases. Digestive diseases include diseases and disorders of the oesophagus, stomach and intestines, colon and rectum, liver, gall bladder, bile ducts, and pancreas; including inflammatory, neoplastic and functional disorders.

OUR 2022 HIGHLIGHTS

Research

2022 was a bumper year for research commitments as it included the awarding of our two major fellowships; the Derek Butler Fellowship and the Amelie Waring fellowship. In addition, we committed to awarding 28 new grants and awards in partnership with other professional bodies, pharmaceutical companies and private philanthropists. The value of new awards we committed to in 2022 totaled £734k (£301k in 2021). Further detail on our research grants is available in the Appendix on page 55.

Our Experts by Experience (those with direct or indirect experience of digestive diseases, who we fondly refer to as our EBEs) helped our Research Awards Committee with two research grant rounds in 2022.

Information and awareness

Guts UK and our giant inflatable colon, Colin the Colon, hit the road more than ever in 2022.

We are a proud founding member of the **Less Survivable Cancers Taskforce** (LSCT), campaigning at national level to raise the profile of digestive cancers that have been woefully underfunded for decades. Not all cancers are equal.

LESS SURVIVABLE CANCERS AWARENESS DAY
11 JANUARY

Our first ever Less Survivable Cancers Awareness Day in 2022 reached 25,000,000 people in the press!

We're reaching and helping those who need us most

In 2022:

1,700,000 people visited Guts UK's website.

And we reached **4,000,000** on social media.



In 2022, 159 people joined our #GUTSelfie social media awareness campaign, bravely sharing their digestive diseases story.

We joined together with one key message: it's time the UK got to grips with guts.

Celebrating our 50 year milestone

Our Royal Patron HRH Princess Alexandra who has supported our charity since 1994 invited the Guts UK community to St James's Palace to mark the charity's 50th year. It was a huge honour. Despite the pandemic still hovering over, the train and bus strike, we made it. There were tears and laughter, a lot of laughter. Thank you, Your Royal Highness.

OUR PLANS FOR 2023

Since changing the name to Guts UK in 2018, this small but mighty charity has been building profile, presence and an engaged community of supporters. We have been working tirelessly to ensure the digestive system gets more attention and more funding. 2023 will be a year of investment in our growth as we review our strategy, invest in increasing capacity and expertise and our infrastructure. The ever-increasing demand for evidenced based information about digestive conditions and symptoms is not going away.

Refining our strategy, vision and delivery plans

2023 will see changes to our Board as a number of long serving-trustees finish their tenure; this will include a new Chair of Trustees alongside Treasurer, Legal and Research trustees. These changes will bring new perspectives, energy and ideas to our Board to support and refresh our strategy for the coming years. We will also bring in the support of Pilotlight[1] in 2023 to use external expertise to guide our strategic review and develop growth plans to support the increase in demand from our community and the wider public. The Board have also committed to creating a high performing senior management team to support our Chief Executive Officer; leadership roles that can really drive the finalised strategy that will lead to growth to increase the reach of the charity.

Research Plans for 2023

Proposed grant funding

- Guts UK/Dr Falk awards £24,000 – investing in the gastroenterologists of the future
- Guts UK/BSG trainee awards £50,000 - £5,000 for individual and £10,000 for networks
- Guts UK development grants for early career researchers totalling 6 x £15,000
- Research Priority Setting Partnership – focusing on diverticular disease £20,000
- Guts UK/ASGBI awards – working in collaboration with surgeons £15,000

Following the recruitment in 2021 of our first dedicated Public and Patient Involvement and Engagement (PPIE) Officer, in 2023 we aim to have completed, in partnership with the BSG and James Lind Alliance (JLA), two Priority Setting Partnerships (PSPs) for IBS and Pancreatitis. The publishing of these PSPs will be the culmination of 18 months work between medical professionals, patients and carers and should help drive the direction of future research studies.

[1] Pilotlight is a charity that amplifies the impact charities, business and individuals can bring to make a better world. Guts UK has applied and been accepted to their 360 programme in 2023. Further information can be found on their website here.

Fundraising, patient engagement and raising awareness

Sustainable growth in fundraising for Guts UK will remain focused on building up our supporter base which grows naturally as we serve more people via our information services. We will continue to build our presence via digital platforms such as Facebook, Instagram, Twitter and TikTok that enable us to reach new audiences in a format they favour. Our PPIE Officer will also continue to work with our community and panel of Experts by Experience to ensure the patient voice is represented in medical research, product and drug development and relevant think tanks.

We will continue to promote our patient information leaflets to gastroenterology clinics across all four nations of the UK in order that more patients are able to access evidence-based information about their symptoms and/or condition. In 2023 we also hope to receive a PIF Tick[2] (Patient Information Forum Trusted Information Creator) to validate the quality and reliability of our informational materials.

We will build more relationships with companies to increase corporate support and to find successful partnerships with the industry around digestive health, focusing on our shared objective of helping patients get the information they need, get access to more treatments, kinder treatments and ultimately a cure.

Staff, resources and capacity building

2023 will see the recruitment of two critical leadership roles to help facilitate stability and growth; a Chief Operating Officer and a Head of Fundraising and Communications. These two roles will ensure that by the end of the year that we can focus on proactive, targeted fundraising including investing in corporate partnerships, but we can also look at our operating procedures to make the way we work more efficient and smoother for both our community and for our team. These two new roles will, alongside the CEO, form a holistic leadership team for the charity who can then focus on resource, capacity and succession planning to make sure we are supporting our people as well as we support our community.

[2] The PIF TICK is the UK-wide quality mark for trusted health information. Further information can be found on their website here

FINANCIAL PERFORMANCE REVIEW

Overview

This year the charity has recorded income for the year of £1.2m (12% up on 2021 at £1.1m) and expenditure of £1.6m (up 80% on 2021 at £0.9m). This resulted in a net expenditure, before investment losses, of £456,740 (2021 saw a net income of £157,359). This expenditure reflects a bumper year for research funding including awarding two Guts UK Fellowship Grants of £390,000 in total. This demonstrates the commitment and impact that our small team is making into life changing research and getting out into our community and spreading awareness and education amongst the public.

Total Income 2022: £1.2m



Total Expenditure 2022: £1.6m



Income

Voluntary income

At a total level, voluntary income reduced this year when compared with 2021 (down 16% from £567k to £475k) however, this is primarily driven by a reduction in legacy donations. Public donations (excluding legacies) saw an increase of 3% on 2021 and reached £312k (£302k in 2021). Our team's efforts to expand our presence through social media and our brilliant Guts UK community's fundraising efforts continue to drive donations. We have seen steady increases in both regular donations (12% up on 2021) and donations from fundraising events (7% up on 2021) demonstrating sustainable growth in our income streams.

As a recently renamed charity, Guts UK's growing profile and presence today will result in legacies into the future. Legacy income currently is unpredictable and can have a big effect on the overall total voluntary income levels. We have legacy promotion at the heart of our fundraising to develop this as a sustainable source of income for the future as we build a community of supporters.

Leaflet sales and other income

Other trading activities have increased this year bringing in £50k (31% more than 2021 at £38k). This is primarily driven by growth in leaflet sales (£42k in 2022, 8% up from £36k in 2021) where we continue to see increasing demand from medical institutions as we expand our suite of materials. In addition, we received a specific donation this year (£7.5k) to help fund our first proactive PR campaign; Microscopic Colitis Awareness Week which was a great success reaching an audience of 3.5 million people.

Overall income was bolstered in 2022 by positive gains from the investment portfolio with investment income up 42% on 2021 contributing £240k to overall income (2021: £169k).



Research grants

Research partner income came from collaborations with private philanthropists, pharmaceutical companies such as Dr Falk Pharma (UK) and other professional bodies such as the BSG, the Pancreatic Society of Great Britain and Ireland and The British Society of Paediatric Gastroenterology, Hepatology and Nutrition. 2022 saw a 45% increase in research partner grants (£439k in 2022 against £303k in 2021).

In addition, we made a second successful application to the UK Government's COVID Medical Research Charity Support Fund to support our Early Career Researchers and gastroenterology trainees grants. The total grant received was £108,540 towards active research projects.

Expenditure

Overall expenditure is up 80% this year to £1.6m (against £920k in 2021) and this is primarily driven by a significant increase in the value of awards we have granted for research, a key charitable objective for Guts UK. Our spend on research has increased to £1.1m in 2022 (137% rise from £478k in 2021) and represents 68% of total expenditure for 2022.



Spending on our two other charitable objectives, public education and information services, has also increased significantly in 2022 (92% up from £162k in 2021 to £313k in 2022) which demonstrates the rising demand from our community and investment in reaching the wider public who still do not know Guts UK charity exists. This increase in expenditure manifests in us attending more events, raising more awareness and reaching and recruiting new supporters, helping us to build a sustainable future for the charity.

Expenditure (excluding research) was 20% higher than 2021 (£529k in 2022 against £162k in 2021). Staff costs are comparative with 2021 with only a marginal increase in total payroll costs (£344k in 2022, 5% up on £329k in 2021) which is reflective of inflationary increases in salaries. General overheads rose by 36% this year (£191k in 2022 against £140,000 in 2021) where the sharp cost of living increases can be felt in the office costs plus increases in recruitment, professional fees and travel expenses as we began to get out and about more post pandemic.

Balance Sheet

As at 31 December 2022, Guts UK had net assets of £5.3m, a reduction of £1m (16%) on 2021 levels, (2021: £6.4m) with 99.9% of those assets held in listed investments. These include the Derek Butler endowment fund for research into upper gastrointestinal conditions of £3,266,446. The income from this fund will finance the new three-year fellowship awarded in 2022.

The markets were more volatile in 2022 and therefore the investment portfolios delivered unrealised losses of £621k and realised losses of £0.4k (2021: unrealised gains of £213k and realised gains of £373k). Of this amount, total realised and unrealised losses of £306k related to the endowment fund (2021: £267k total realised and unrealised losses).

Unrestricted funds which can be spent at the discretion of the trustees were £2.4m of which £1.3m has been designated to contribute to the Amelie Waring pancreatitis fellowship and general gastrointestinal research grants awarded by the charity. General funds amounted to £1m for 2022. More details of the disposition of Guts UK net assets can be found in the financial statements on pages 51 and 52.

The principal liability of Guts UK Charity is to complete the research programme it has committed to of £1,251,335 at 31 December 2021 as set out in detail in note 18. Of these commitments, £90,000 is due from funding partners and £1,161,335 is to be funded from Guts UK's general unrestricted funds.

Reserves policy

Guts UK has reviewed the amount of reserves it regards as a minimum prudent requirement and has concluded that provision for twelve months administration, public education and fundraising costs is sufficient. This would allow time to manage cost reductions or fund appeals as required whilst minimising the impact on service provision. Based on the forecast for 2023, the desired minimum reserve is approximately £1m. As at 31 December 2022, free reserves less amounts held as fixed assets stands at £1.1m. Additional funds are to be utilised for research expenditure, building capacity and expanding the public information programme going forward.

Investment policy and performance

The charity's listed investments are managed by Cazenove. The investment strategy is set by the trustees and takes into account income requirements, the risk profile and the investment manager's advice on the market prospects in the medium term. Investments are held in a Responsible Multi-Asset Fund which adopts a total returns approach and provides even distribution payment alongside being an ethically responsible investment policy. The performance of the portfolio is monitored by the trustees.

Brexit

As the charity is operational in the UK the impact of Brexit has not been significant for Guts UK charity to date. Where it has manifested is via researchers Guts UK is funding who are unable to get some supplies for their work. This has resulted in a delay in the timescale for their research project, no one has yet been unable to complete their research to date.

Covid-19

The impact of the pandemic is seen clearly in the number of our Guts UK funded researchers who have had to delay their research projects. Most gastroenterologists were pulled back into general medicine throughout the pandemic and returning to their main gastroenterology job has been difficult. On top of that, trying to regain the protected time to do their research has also been difficult within the strains of the NHS environment. Guts UK has been able to accommodate this with No-Cost Extensions to enable researchers to complete the important research. Having the additional funding support from the MRC again in 2022 has enabled the charity to continue to offer the annual research programme during this difficult phase, particularly through the uncertainty of the economic market and the increased risk in terms of the ability to raise funds from the public.

Going concern

There is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. The trustees believe that there are no material uncertainties that call into doubt the charity's ability to continue operating as a going concern. Consequently, the financial statements have therefore been prepared on the basis that the charity remains a going concern.

GOVERNANCE, POLICIES & STANDARDS

Guts UK is a charitable company limited by guarantee. Its governing document is its Memorandum and Articles of Association. The trustees have overall responsibility for setting the strategic direction of the charitable company. The trustees delegate specific responsibility to several committees as follows:

a) **Audit, Risk and Compliance Committee** ("ARC") whose purpose is to oversee the operational activities of the charity covering finance, investment, audit, legal compliance, HR and risk management;
b) **Research Awards Committee** ("RAC") whose purpose is to ensure the integrity of Guts UK's research awards and that they align with the charity's stated objectives. The RAC is responsible for assessing, approving and monitoring applications for research funding. The RAC's processes are governed by the Terms of Reference and committee members (including those co-opted for specific awards) are required to sign a declaration of conflicts of interests form;
c) **Funding, Communications and Industry Committee** ("FUNCI") whose purpose is to deliver on Guts UK's fund-raising programmes, ensuring engagement with patients, public, the medical profession and industry alike;
d) **Information Committee** whose purpose is to recommend the strategic direction for information service provision; and to facilitate peer review and quality control of written and web-based information, plus any other public sources of information such as webinars provided by Guts UK.
e) **Research Strategy Committee** (RSC) whose purpose is to recommend areas of focus for Guts UK's research priorities.

The policies of the charity are determined by its board of trustees whose membership is listed on page 84. The research policy of the charity is decided by the trustees in consultation with the Research Committee of the BSG. Guts UK is a member of the Association of Medical Research Charities.

Guts UK advertises for new trustees as required. Prospective trustees are interviewed by the Chair and fellow trustees and are asked to submit a CV for review by the trustees. Candidates must be approved by a majority of trustees and the usual term of office is three years, renewable on approval by the board up to a maximum of 9 years total.

New trustees are provided with information concerning the finances, fundraising activities, grant-making and research policies of the charity. Those who are not familiar with the legal obligations and responsibilities of a trustee are provided with information published by organisations such as the Charity Commission. Training opportunities are offered to trustees on an ongoing basis.

Guts UK continues to work closely with the BSG to provide strong links with the main professional community and to improve its ability to disseminate research and patient information. The Chair of the BSG's Research Committee is a member of the board. The day-to-day operation of Guts UK is delegated to the Chief Executive who is supported by a team of staff.

Key management personnel

The key management personnel are those involved in managing the organisation, fundraising, communications, research and finance. These comprise the trustees, the Chief Executive and the Finance Manager.

The pay of all staff members, including members of key management, is reviewed annually by the trustees. Remuneration details in relation to key management personnel are provided in Note 10 to the financial statements.

Risk management

Guts UK maintain a risk register covering the major risks to which the charity is exposed. This covers governance and compliance, operational and administration, financial and investment and reputational risks. Guts UK rates potential risks by likelihood and impact. The risk register is reviewed regularly by the trustees and the key risks together with the policies to mitigate them have been identified as:

Failure to comply with GDPR regulations

Policies and procedures have been developed and communicated to all staff. Ongoing training is provided. Data protection is a standing item on the ARC Committee and trustee meeting agendas to ensure trustees are kept up to date with actions taken to ensure compliance with the regulations. There will be ongoing monitoring of compliance with regulations.

Failure to meet strategy to increase donations

Management accounts are prepared and regularly reviewed by the ARC Committee to monitor fundraising performance. The fundraising strategy has been reviewed by the Chief Executive and trustees with a view to increasing the number of individual supporters and donors alongside developing different income sources to include approaching former funded researchers and gastroenterologists and industry/pharma for support. The trustees review income generation, reserves and strategy at each Board meeting to ensure the strategy is still the right one and that the charity has sufficient funds to meet it.

Key Person risk

Unfortunately circumstances in 2022, and the loss of a critical team member with significant operational knowledge, meant that key-person risk became a concern for the organisation. Steps have now been taken to ensure procedures are available to the whole organisation, there are secondary users set-up for all systems and temporary measures were agreed with the Board to ensure financial activities could still be carried out with appropriate oversight and controls. Recruitment is underway to resolve this permanently and critical procedures will be reviewed to ensure any key person risk is mitigated sustainably going forward.

Impact of COVID-19

The COVID-19 Pandemic continues to pose a level of increased risk and trustees will continue to monitor income and expenditure and adjust expenditure as required. Most staff are now working most days in the office, but all staff have the resources to work from home if required. Whilst we are expecting all events to take place in person in 2023, the possibility of digital public awareness events will be investigated as well. The public awareness programme is important to enable the charity to fulfil its charitable objectives of educating the public about digestive diseases but also impacts on the recruitment of new supporters and fundraisers.

This Annual Report of the trustees was approved by order of the board of trustees, as the company directors, on 6th September 2023 and signed on the board's behalf by:



.....

Dr L A Dugdale-Bradley – Trustee

Fundraising Standards at Guts UK

- Our donors are important to us and we seek to deliver the highest standards of donor care and support
- Open and accountable fundraising – we regularly tell our supporters how they can easily change their preferences.
- Communicating with our supporters – we update our supporters through our twice-yearly newsletter for those who prefer a print option, and regular e-newsletters.
- Complying with laws, regulation and standards – we are a member of the Chartered Institute of Fundraising and are committed to working to a best practice framework actively complying with the Fundraising Code of Practice. We are registered with the Fundraising Regulator and signed up to The Fundraising Promise.
- Protecting vulnerable people – we do everything possible to meet the needs of potential supporters and protect vulnerable people. In particular, the charity confirmsthat it complies with all relevant data protection laws. No instances of non-compliance have been identified during the year and no suppression requests were received in 2021 in relation to the fundraising activities.
- Complaints and negative feedback – we treat all complaints seriously and aim to respond in a timely and fair manner. All complaints inform and influence the charity's approach to fundraising. We use the feedback that we get from our supporters to improve the way we do things.
- Working with partner agencies – we may engage professional third parties to act on our behalf, for example, to produce and distribute direct mailings. To ensure that fundraising activities of third parties are compliant with regulation and the charity's own internal standards, the charity approves all third-party communication prior to distribution and sets out clear guidelines in the agreements made with such parties. We also work with commercial participators, such as Amazon Smile, Everyclick, Give as you Live and Easy Fundraising to raise funds. Agreements with commercial participators are checked and activity monitored to ensure compliance with the Fundraising Code of Practice.
- We never swap, sell or share any data.
- We work hard to ensure we deliver value for money in all of our charitable activities.

Financial Statements for the Year Ended 31 December 2022

for

Guts UK Charity

Audited by: Harris Lacey and Swain

Chartered Accountants and Statutory Auditors

Suite 1

The Riverside Building

Hessle

East Yorkshire

HU13 0DZ

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees (who are also the directors of Guts UK Charity for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charity SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:
- there is no relevant audit information of which the charitable company's auditors are unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

AUDITORS
The auditors, Harris Lacey and Swain, will be proposed for re-appointment at the forthcoming Annual General Meeting.

Report of the trustees, incorporating a strategic report, approved by order of the board of trustees, as the company directors, on **6th September 2023** and signed on the board's behalf by:



.....
Dr L A Dugdale-Bradley – Trustee

Opinion

We have audited the financial statements of Guts UK Charity (the 'charitable company') for the year ended 31 December 2022 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2022 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- the charitable company has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements
We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion.

Identifying and assessing potential risks related to irregularities
In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

Audit response to risks identified
- the nature of the industry and sector, control environment and business performance including key drivers for directors' remuneration, bonus levels and performance targets
- results of our enquiries of management and their own identification and assessment of the risks of irregularities;
- any matters we identified having obtained and reviewed the companies' documentation of their policies and procedures relating to:
- identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of noncompliance;
- detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;
- the internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;
- the matters discussed among the audit engagement team including regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in relation to revenue deferrals. In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override.

We also obtained an understanding of the legal and regulatory frameworks that the company operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. The key laws and regulations we considered in this context included the UK Companies Act, UK Corporate Governance Code and local tax legislation.

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which may be fundamental to the company's ability to operate or to avoid a material penalty.

Audit response to risks identified

Our procedures to respond to risks identified included the following:
- reviewing the financial statement disclosures and testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
- enquiring of management concerning actual and potential litigation and claims;
- performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
- reading minutes of meetings of those charged with governance

- obtained an understanding of provisions and held discussions with management to understand the basis of recognition or non-recognition of tax provisions; and
- in addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members, and remained alert to any indications of fraud or noncompliance with laws and regulations throughout the audit.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report
This report is made solely to the charitable company's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable company's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Laura Jennifer Drew BFP ACA ACCA (Senior Statutory Auditor)
for and on behalf of Harris Lacey and Swain
Chartered Accountants and Statutory Auditors
Eligible to act as an auditor in terms of Section 1212 of the Companies Act 2006
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Date: Sep 25, 2023

Laura Drew (Sep 25, 2023 14:33 GMT+1)

Guts UK Charity

Statement of Financial Activities
for the Year Ended 31 December 2022

	Notes	Unrestricted fund £	Restricted fund £	Endowment fund £	2022 Total funds £	2021 Total funds £
INCOME AND ENDOWMENTS FROM						
Donations and legacies	2	446,718	7,939	-	454,657	567,059
Gastro-enterology research		-	434,630	-	434,630	303,289
Other trading activities	3	50,404	-	-	50,404	38,532
Investment income	4	124,499	115,854	-	240,353	169,250
Total		621,621	558,423	-	1,180,044	1,078,130
EXPENDITURE ON						
Cost of raising funds		209,114	-	6,909	216,023	279,438
Charitable activities	6					
Gastroenterology research		307,662	824,180	-	1,131,842	478,526
Public education and Science of Digestion		313,352	-	-	313,352	162,807
Total		830,128	824,180	6,909	1,661,217	920,771
Net gains/(losses) on investments						
- Realised		-	-	(460)	(460)	373,228
- Unrealised		(322,790)	-	(298,668)	(621,458)	213,775
NET INCOME/(EXPENDITURE)		(531,297)	(265,757)	(306,037)	(1,103,091)	744,362
Transfers between funds		(195,121)	195,121	-	-	-
Net movement in funds		(726,418)	(70,636)	(306,037)	(1,103,091)	744,362
RECONCILIATION OF FUNDS						
Total funds brought forward		3,090,435	361,908	2,937,073	6,389,416	5,645,054
TOTAL FUNDS CARRIED FORWARD		2,364,017	291,272	2,631,036	5,286,325	6,389,416

These notes form part of these financial statements

Guts UK Charity

Balance Sheet
31 December 2022

	Notes	Unrestricted fund £	Restricted fund £	Endowment fund £	2022 Total funds £	2021 Total funds £
FIXED ASSETS						
Tangible assets	12	3,422	-	-	3,422	3,363
Investments	13	5,957,620	-	-	5,957,620	6,435,629
		5,961,042	-	-	5,961,042	6,438,992
CURRENT ASSETS						
Debtors	14	420,659	-	-	420,659	343,764
Cash at bank and in hand		(2,079,984)	331,272	2,631,036	882,324	945,805
		(1,659,321)	331,272	2,631,036	1,302,983	1,289,569
CREDITORS						
Amounts falling due within one year	14	(1,937,700)	(40,000)	-	(1,977,700)	(1,339,142)
NET CURRENT ASSETS		(3,597,021)	291,272	2,631,036	(674,717)	(49,573)
TOTAL ASSETS LESS CURRENT LIABILITIES		2,324,017	291,272	2,631,036	5,286,325	6,389,416
NET ASSETS		2,324,017	291,272	2,631,036	5,286,325	6,389,416
FUNDS						
Unrestricted funds						
- General					1,069,028	1,468,407
- Designated fund					1,294,989	1,622,028
Restricted funds					291,272	361,908
Endowment funds					2,631,036	2,937,073
TOTAL FUNDS					5,286,325	6,389,416

These notes form part of these financial statements

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2022.

The members have not deposited notice, pursuant to Section 476 of the Companies Act 2006 requiring an audit of these financial statements.

The trustees acknowledge their responsibilities for
(a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
(b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been audited under the requirements of Section 145 of the Charities Act 2011.

The financial statements were approved by the Board of Trustees and authorised for issue on **6th September 2023** and were signed on its behalf by:



.....
Dr L A Dugdale-Bradley - Trustee

Guts UK Charity

Cash Flow Statement
for the Year Ended 31 December 2022

	Notes	2022 £	2021 £
Cash flows from operating activities			
Cash generated from operations	1	(157,850)	(225,219)
Net cash used in operating activities		(157,850)	(225,219)
Cash flows from investing activities			
Purchase of tangible fixed assets		(2,074)	(1,417)
Purchase of fixed asset investments		(100,000)	(6,473,053)
Proceeds from disposal of investments		97,655	6,504,709
Interest received		240,353	169,251
Net cash provided by investing activities		235,934	199,490
Change in cash and cash equivalents in the reporting period		78,084	(25,730)
Cash and cash equivalents at the beginning of the reporting period		1,296,247	1,321,977
Cash and cash equivalents at the end of the reporting period		1,374,331	1,296,247

These notes form part of these financial statements

1. RECONCILIATION OF NET (EXPENDITURE)/INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2022 £	2021 £
Net (expenditure)/income for the reporting period (as per the Statement of Financial Activities)	(1,103,091)	744,362
Adjustments for:		
Depreciation charges	2,015	1,574
Losses/(gain) on investments	621,918	(587,003)
Interest received	(240,353)	(169,250)
(Increase)/decrease in debtors	(76,897)	14,718
Increase/(decrease) in creditors	638,553	(229,620)
Net cash used in operations	(157,850)	(225,219)

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.1.22 £	Cash flow £	At 31.12.22 £
Net cash			
Cash at bank and in hand	260,268	(173,331)	86,937
Short term cash deposits	685,537	109,851	795,388
Cash held by investment managers	350,442	141,564	492,006
	1,296,247	78,084	1,374,331
Total	1,296,247	78,084	1,374,331

These notes form part of these financial statements

1. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value.

Assessment of going concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements and have made this assessment in respect to a period of one year from the date of approval of these financial statements.

The trustees have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the charity to continue as a going concern. The trustees are confident that the charity has sufficient funds to cover its existing liabilities.

With regard to the next accounting period, the year ending 31 December 2022, the most significant areas that affect the carrying value of the assets held by the charity are the level of investment return and the performance of the investment markets (see the investment policy and the risk management sections of the trustees' report for more information).

Income
Income is recognised in the period in which the charity has entitlement to the income, the amount of income can be measured reliably and it is probable that the income will be received.

Donations are recognised when the charity has confirmation of both the amount and settlement date. In the event of donations pledged but not received, the amount is accrued for where the receipt is probable.

Legacies are included in the statement of financial activities when the charity is entitled to the legacy, the executors have established that there are sufficient surplus assets in the estate to pay the legacy, and any conditions attached to the legacy are within the control of the charity. Entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor to the charity that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity or the charity is aware of the granting of probate, but the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material. In the event that the gift is in the form of an asset other than cash or a financial asset traded on a recognised stock exchange, recognition is subject to the value of the gift being reliably measurable with a degree of reasonable accuracy and the title of the asset having being transferred to the charity.

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

1. ACCOUNTING POLICIES - continued

Income
Research funding income is recognised in the period in which the charity receives a written commitment from the funder. Research funding is deferred only when the charity has to fulfil conditions before becoming entitled to it or the donor has specified that the income has to be spent in a future period.

Expenditure
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to make a payment to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis and is stated inclusive of irrecoverable VAT. Expenditure comprises direct costs and support costs. All expenses, including support costs, are allocated or apportioned to the applicable expenditure headings. The classification between activities is as follows:

a) Cost of raising funds which includes direct fundraising costs and investment manager's fees.

b) Expenditure on charitable activities comprises expenditure on the charity's primary charitable purposes as described in the trustees' report. Such costs include grants payable, other direct costs and support costs, which are apportioned based on the level of activity in each area.

Research grants payable are included in the statement of financial activities when approved and when the intended recipient has either received the funds or been informed of the decision to make the grant, and has satisfied all relevant conditions. Grants approved but not paid at the end of the financial year are accrued for. Grants where the beneficiary has not been informed or has to meet certain conditions before the grant is payable are not accrued for but are noted as financial commitments in the notes to the financial statements.

The provision of a multi-year grant is recognised at its present value where settlement is due over more than one year from the date of the award, there are no unfulfilled performance conditions under the control of the charity that would permit the charity to avoid making the future payments, settlement is probable and the effect of the discounting is material. The discount rate used is the average rate of investment yield in the year in which the grant is made. This discount rate is regarded by the trustees as providing the most current available estimate of the opportunity cost of money reflecting the time value of money to the charity.

Allocation and apportionment of costs
Support costs represent indirect charitable expenditure. In order to carry out the primary purposes of the charity it is necessary to provide support in the form of financial procedures, provision of office services and equipment and a suitable working environment.

Governance costs comprise the costs directly attributable to the governance of the charity, including audit costs and the necessary legal procedures for compliance with statutory requirements. Support costs and governance costs are allocated between activities with the allocation based on staff time.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment	-	33% on cost

Taxation
The charity is exempt from corporation tax on its charitable activities.

1. ACCOUNTING POLICIES - continued

Fund accounting
The charity has various types of funds for which it is responsible, and which require separate disclosure. These are as follows:

General funds
Funds which are expendable at the discretion of the trustees in furtherance of the objects of the charity.

Designated funds
Funds which are set aside as part of the charity's unrestricted funds for particular purposes in the future as determined by the trustees from time to time.

Restricted funds
Funds raised for, and their use restricted to, a specific purpose, or donations subject to donor-imposed conditions.

Endowment funds
Funds which must be held indefinitely as capital. Income therefore is credited to general funds and applied for general purposes unless under the terms of the endowments such income must be used for specific purposes in which cases it is credited to restricted funds.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight-line basis over the period of the lease.

Financial instruments
The charity only holds basic financial instruments as defined in FRS 102. The financial assets and financial liabilities of the charity and their measurement basis are as follows:

Financial assets - other debtors are basic financial instruments and are debt instruments measured at amortised cost. Listed investments are a basic financial instrument as detailed above. Prepayments are not financial instruments.

Cash at bank - classified as a basic financial instrument and is measured at face value.

Financial liabilities - accruals and other creditors are financial instruments are measured at amortised cost.

Critical accounting judgements and key sources of estimation uncertainty
Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Although these estimates are based on the Trustees' best knowledge of the amount, events or actions, actual results ultimately differ from these estimates. The Trustees do not consider there to be any material estimates and judgements.

Investments
Investments both current and fixed are included at fair value within the accounts.

2. DONATIONS AND LEGACIES

	Unrestricted funds £	Restricted funds £	**2022 Total funds £**
Donations	295,325	(2,581)	**312,744**
Legacies & In Memoriam donations	151,393	10,520	**161,913**
2022 Total funds	446,718	7,939	**454,657**

	Unrestricted funds £	Restricted funds £	2021 Total funds £
Donations	276,420	26,489	302,909
Legacies & In Memoriam donations	231,661	32,489	264,150
2021 Total funds	508,081	58,978	567,059

3. OTHER TRADING ACTIVITIES

	Unrestricted funds £	Restricted funds £	**2022 Total funds £**
Public Education	41,544	-	**41,544**
Science of Digestion	1,360	-	**1,360**
Microscopic Colitis Awareness Week	7,500	-	**7,500**
2022 Total funds	50,404	-	**50,404**

	Unrestricted funds £	Restricted funds £	2021 Total funds £
Public Education	38,532	-	38,532
2021 Total funds	38,532	-	38,532

4. INVESTMENT INCOME

	Unrestricted funds £	Restricted funds £	**2022 Total funds £**
Interest - fixed interest securities	2,553	4,185	**6,738**
Multi-asset funds	119,020	110,777	**229,797**
Charities property fund	-	892	**892**
Interest on cash deposits	2,926	-	**2926**
2022 Total funds	124,499	115,854	**240,353**

	Unrestricted funds £	Restricted funds £	2021 Total funds £
Interest - fixed interest securities	7	18	25
Dividends - UK and international equities	22,206	40,470	62,476
Bonds - UK and international	5,643	6,200	11,843
Multi-asset funds	52,389	26,048	78,437
Charities property fund	5,086	4,886	9,972
Other funds	2,979	3,454	6,433
Interest on cash deposits	64	-	64
2021 Total funds	88,174	81,076	169,250

5. INCOME FROM CHARITABLE ACTIVITIES

	Unrestricted funds £	Restricted funds £	**2022 Total funds £**
New grants for research	-	434,630	**434,630**
2022 Total funds	-	434,630	**434,630**

	Unrestricted funds £	Restricted funds £	2021 Total funds £
New grants for research	-	303,289	303,289
2021 Total funds	-	303,289	303,289

6. CHARITABLE ACTIVITIES COSTS

	Direct costs £	Research grants awarded (note 6) £	Support costs (note 8) £	**2022 Total funds £**
Gastroenterology research	2,636	1,001,807	127,399	**1,131,842**
Public education	69,258	-	244,094	**313,352**
2022 Total funds	71,894	1,001,807	371,493	**1,445,194**

	Direct costs £	Research grants awarded (note 6) £	Support costs (note 8) £	2021 Total funds £
Gastroenterology research	1,059	288,068	189,399	478,526
Public education	58,263	-	104,544	162,807
2021 Total funds	59,322	288,068	293,943	641,333

	Unrestricted funds £	Restricted funds £	**2022 Total funds £**
Fundraising costs	38,392	-	**38,392**
Investment manager's fees	6,917	6,909	**13,826**
Support costs	163,805	-	**163,805**
2022 Total funds	209,114	6,909	**216,023**

	Unrestricted funds £	Restricted funds £	2021 Total funds £
Fundraising costs	81,417	-	81,417
Investment manager's fees	9,679	13,476	23,155
Support costs	174,866	-	174,866
2021 Total funds	265,962	13,476	279,438

7. RESEARCH GRANTS AWARDED

	2022 Total funds £	2021 Total funds £
New research grants	**1,004,180**	301,231
Less grants no longer required - research commitments	**(2,373)**	(13,163)
Research grants awarded	**1,001,807**	288,068

Research grants awarded represent commitments made for research, and are set out in detail in the appendix on page 55.

8. SUPPORT COSTS

		Charitable Activities		
	Cost of raising funds £	Gastro-enterology research £	Public education and Science of Digestion £	**2022 Total funds £**
Directly incurred				
Grants payable	-	1,001,807	-	**1,001,807**
Research administration	-	2,636	-	**2,636**
Fundraising costs	38,393	-	-	**38,393**
Public education	-	-	69,258	**69,258**
Investment management fees	13,826	-	-	**13,826**
	52,219	1,004,443	69,258	**1,125,920**
Support costs				
Staff costs	105,379	81,962	157,036	**344,377**
Premises and donated facilities	13,316	10,357	19,844	**43,517**
Postage	172	134	256	**562**
Telephone	1,119	870	1,668	**3,657**
Stationery, printing, design and marketing	1,568	1,219	2,336	**5,123**
Insurance	1,344	1,045	2,003	**4,392**
Bank charges	2,597	2,020	3,869	**8,486**
Meeting costs	4,067	3,163	6,061	**13,291**
Subscriptions/publications	5,203	4,046	7,753	**17,002**
Equipment/maintenance and website development	11,673	9,079	17,395	**38,147**
Depreciation	617	480	918	**2,015**
Training and recruitment	2,981	2,318	4,441	**9,740**
Governance costs:				
- Audit & Accountancy	3,094	2,406	4,611	**10,111**
- Professional fees	5,706	4,437	8,502	**18,645**
- Bookkeeping costs	2,170	1,687	3,232	**7,089**
Brand development	2,798	2,176	4,169	**9,143**
	163,804	127,399	244,094	**535,297**
2022 Total funds	216,023	1,131,842	313,352	**1,661,217**

8. SUPPORT COSTS - continued

		Charitable Activities		
	Cost of raising funds £	Gastro-enterology research £	Public education and Science of Digestion £	2021 Total funds £
Directly incurred				
Grants payable	-	288,068	-	288,068
Research administration	-	1,059	-	1,059
Fundraising costs	81,417	-	-	81,417
Public education	-	-	58,263	58,263
Investment management fees	23,155	-	-	23,155
	104,572	289,127	58,263	451,962
Support costs				
Staff costs	122,674	132,870	73,342	328,886
Premises and donated facilities	8,685	9,407	5,193	23,285
Postage	495	536	296	1,327
Telephone	1,727	1,871	1,033	4,631
Stationery, printing, design and marketing	2,566	2,780	1,534	6,880
Insurance	1,603	1,735	958	4,296
Bank charges	2,968	3215	1,775	7,958
Meeting costs	1,732	1,874	1,033	4,639
Subscriptions/publications	3,685	3992	2,203	9,880
Equipment/maintenance and website development	16,635	18,018	9,945	44,598
Depreciation	587	636	351	1,574
Training and recruitment	(464)	(504)	(278)	(1,246)
Governance costs:				
- Audit & Accountancy	3,702	4,010	2,213	9,925
- Professional fees	2,863	3,101	1,712	7,676
- Bookkeeping costs	1,697	1,838	1,015	4,550
Brand development	3,711	4,020	2,219	9,950
	174,866	189,399	104,544	468,809
2021 Total funds	279,438	478,526	162,807	920,771

9. NET INCOME/(EXPENDITURE)

This is stated after charging:

	2022 Total funds £	2021 Total funds £
Staff costs	**344,377**	328,886
Depreciation	**2,015**	1,574
Auditor's remuneration (including VAT)		
- Statutory audit services	**9,600**	9,000

10. TRUSTEES' REMUNERATION AND BENEFITS

A total of £nil remuneration (2021: £nil) was paid or payable, directly or indirectly, out of the funds of the charity for the period to any trustee, or to any person or persons known to be connected with any of them.

Trustees' expenses

A total of 4 trustees were reimbursed for travel expenses of £678 during the period (2021: 5 trustees: £308).

11. STAFF COSTS

	2022 Total funds £	2021 Total funds £
Salaries and wages	**311,219**	294,066
Social security	**23,950**	26,352
Pension costs	**9,208**	8,468
	344,377	328,886

The average monthly number of employees during the year was as follows:

	2022	2021
General	9	8

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2022	2021
£60,001 - £70,000	1	1

11. STAFF COSTS - continued

The key management personnel of the charity in charge of directing and controlling, running and operating the charity on a day to day basis comprise the trustees, the CEO, the Finance and Research Managers. The total remuneration (including taxable benefits and employer's pension contributions) of the key management personnel for the year was £123,830 (2021: £164,730).

12. TANGIBLE FIXED ASSETS

	Computer Equipment £
COST	
At 1 January 2022	10,980
Additions	2,074
At 31 December 2022	13,054
DEPRECIATION	
At 1 January 2022	7,617
Charge for year	2,015
At 31 December 2022	9,632
NET BOOK VALUE	
At 31 December 2022	3,422
At 31 December 2021	3,363

13. FIXED ASSET INVESTMENTS

	Endowment portfolio £	Unrestricted portfolio £	**2022 £**	2021 £
At valuation				
Balance brought forward at 1 January	2,943,542	3,141,645	**6,085,187**	5,529,842
Additions	100,000	-	**100,000**	6,473,052
Disposal proceeds	(97,655)	-	**(97,655)**	(6,504,710)
Investment gains				
- Realised (losses) / gains	(460)	-	**(460)**	373,228
- Unrealised (losses) / gains	(298,668)	(322,790)	**(621,458)**	213,775
Total investment (losses) / gains	(299,128)	(322,790)	**(621,918)**	587,003
Balance carried forward at 31 December	2,646,759	2,818,855	**5,465,614**	6,085,187
Cash held by investment managers	429,503	62,503	**492,006**	350,442
Total investments	3,076,262	2,881,358	**5,957,620**	6,435,629
Analysis by Type				
Listed investments at market value				
- Multi-asset funds	2,646,759	2,818,855	**5,465,614**	5,987,072
- Property funds	-	-	**-**	98,115
Total investments	2,646,759	2,818,855	**5,465,614**	6,085,187
Historic cost of listed investments (all are listed in the UK) - excluding cash held by investment managers	2,895,796	2,986,808	**5,882,604**	5,866,753

At 31 December 2022, the charity had the following material investment holdings:

	Endowment £	Unrestricted £	**Market Vale £**	Percentage of portfolio %
Listed investments within the portfolio are:				
SUTL Cazenove Charity Responsible	2,646,759	2,818,855	**5,465,614**	100%

13. FIXED ASSET INVESTMENTS - continued

The total unrealised gains as at 31 December 2022 constitute movements on revaluation and are as follows:

	2022	2021
	£	£
Unrealised (losses) gains included above:		
On investments	**(416,984)**	231,179
Total unrealised gains at 31 December	**(416,984)**	231,179
Reconciliation of movements in unrealised gains:		
Unrealised gains at 1 January	**231,179**	320,696
(Losses) in respect to disposals in the year	**(26,705)**	(303,292)
	204,474	17,404
Add: net (losses)/gains arising on revaluation in the year	**(621,458)**	213,775
Total unrealised (losses)/ gains at 31 December	**(416,984)**	231,179

14. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022	2021
	£	£
Trade debtors	33,232	58,886
Other debtors	231,351	90,000
Prepayments and accrued income	143,540	185,470
Prepayments	12,536	9,410
	420,659	343,766

Included within debtors under commitments due from funding partners is £244,937 (2021: £291,100) which is due within one year.

15. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022	2021
	£	£
Social security and other taxes	9,513	9,800
Trade & other creditors	88,701	-
Research grants payable	1,866,534	1,251,332
Deferred income	-	51,374
Accrued expenses	12,952	26,636
	1,977,700	1,339,142

Included behind Research grants payable is £557,550 (2021: 220,040) which is in relation to research grants falling due after more than one year. A full breakdown of research grants payable for 2022 can be found in the Appendix on page 52.

16. RESTRICTED FUNDS

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust to be applied for specific purposes:

	At 1 January 2022	Income	Expenditure	Transfers	**At 31 December 2022**
	£	£	£	£	**£**
Guts UK/Dr Falk Awards	-	28,319	(32,638)	4,319	**-**
Restricted research grants	-	297,771	(581,542)	283,771	**-**
UK Government COVID Medical Research Charity support fund	-	108,540	-	(108,540)	**-**
Pancreatitis	2,214	8,243	-	-	**10,457**
Stomach Cancer	6,031	2,063	-	-	**8,094**
Research into adhesions	548	-	-	-	**548**
Diverticular	500	-	-	-	**500**
Oesophageal	-	2,204	-	-	**2,204**
Liver	-	-	-	-	**-**
Microbiome	625	-	-	-	**625**
Barrett's Oesophagus	18,633	10,000	-	-	**28,633**
Trust Funding - digital	-	24,429	(40,000)	15,571	-
Trust funding for Amelie Waring Fellow	-	-	-	-	**-**
Company donations - restricted	14,896	1,000	-	-	**15,896**
Derek Butler Endowment Income fund	318,461	115,854	(210,000)	-	**224,315**
	361,908	598,423	(864,180)	195,121	**291,272**

16. RESTRICTED FUNDS - continued

	At 1 January 2021 £	Income £	Expenditure £	Transfers £	At 31 December 2021 £
Guts UK/Dr Falk Awards	-	19,163	(24,325)	5,162	-
Restricted research grants	-	133,028	(242,000)	108,972	-
UK Government COVID Medical Research Charity support fund	-	151,100	-	(151,100)	-
Pancreatitis	8,114	12,100	(18,000)	-	2,214
Stomach Cancer	-	6,031	-	--	6,031
Research into adhesions	-	548	-	-	548
Diverticular	-	500	-	-	500
Oesophageal	-	1,312	(1,312)	-	-
Liver	-	831	-	(831)	-
Microbiome	-	625	-	-	625
Barrett's Oesophagus	-	18,633	-	-	18,633
Trust funding	2,500	-	(2,500)	-	-
Trust funding for Amelie Waring Fellow	-	3,500	-	(3,500)	-
Company donations - restricted	-	14,896	-	-	14,896
Derek Butler Endowment Income fund	244,668	81,076	(7,283)	-	318,461
	255,282	443,343	(295,420)	(41,297)	361,908

The transfer represents the contribution from general funds towards the research grants or from restricted funds to general or designated funds for previously committed research as specified by the donor.

The purposes of Guts UK's restricted funds in are as follows:

- Restricted research grants: grants for specific research schemes.
- Pancreatitis: Funds remain for contributions to the Pancreatitis PSP and new funds received for general pancreatitis research
- Oesophageal: contribution to Dr Benjamin Sharpe's research project into oesophageal cancer (Early Career Researcher Grant 2021)
- UK Government COVID Medical Research Charity Support Fund: contribution to the Amelie Waring Fellow, the Olympus Fellow, Development Grants and Trainee Awards.
- Derek Butler Endowment Income Fund: this represents the income received from the endowment fund and expenditure on research into the diseases of the upper gastrointestinal tract.
- Barrett’s Oesophagus – represents a donation received from the Barrett’s Oesophagus Charity for research into Barrett’s oesophagus
- Trust Funding – digital; represents donations received from a charitable Foundation which was restricted to the development of a digital app for pancreatitis. Despite best efforts, this project has not materialised and on mutual agreement the donation will be returned to the donor in 2023. Given the materiality of the donation being returned, the 2022 accounts have been adjusted and the £40k donation can now be seen on the balance sheet as a creditor.

17. DESIGNATED FUNDS

Amelie Waring

	At 1 January 2022 £	Income £	Expenditure £	Transfers £	Investment (losses) £	At 31 December 2022 £
Investments	874,944	32,639	2,325	-	(87,248)	822,660
Research Commitments	(100,525)	-	(180,000)	127,711	-	(152,814)
Total Amelie Waring Fund	774,419	32,639	(177,675)	127,711	(87,248)	669,846

	At 1 January 2021 £	Income £	Expenditure £	Transfers £	Investment (losses) £	At 31 December 2021 £
Investments	889,217	25,967	(8,604)	(120,000)	88,364	874,944
Research Commitments	(147,300)	-	-	46,775	-	(100,525)
Total Amelie Waring Fund	741,917	25,967	(8,604)	(73,225)	88,364	774,419

GI Research

	At 1 January 2022 £	Income £	Expenditure £	Transfers £	Investment (losses) £	**At 31 December 2022 £**
Investments	986,455	37,318	(37,329)	-	(101,209)	885,235
Research Commitments	(138,846)	-	-	(121,246)	-	(260,092)
Total GI Research Fund	847,609	37,318	(37,329)	(121,246)	(101,209)	625,143

17. DESIGNATED FUNDS - continued

	At 1 January 2021 £	Income £	Expenditure £	Transfers £	Investment (losses) £	At 31 December 2021 £
Investments	887,402	28,486	(26,959)	-	97,526	986,455
Research Commitments	(19,950)	-	-	(118,896)	-	(138,846)
Total GI Research Fund	867,452	28,486	(26,959)	(118,896)	97,526	847,609

Total Designated Funds

Total Designated Funds 2022	**,622,028**	**69,957**	**(215,004)**	**6,465**	**(188,457)**	**1,294,989**
Total Designated Funds 2021	,609,369	54,453	(35,563)	(192,121)	185,890	1,622,028

The Amelie Waring fund was initially established in memory of Amelie Waring to fund pancreatitis research, although the original bequest has been fully expended the trustees continue to designate funds to pancreatitis research in recognition of their ongoing commitment to funding research in this area.

The GI Research Fund is designated to general gastrointestinal research.

18. ENDOWMENT FUND

	At 1 January 2022 £	Income £	Expenditure/ transfers £	Investment losses £	**At 31 December 2022 £**
Derek Butler Endowment	2,937,073	-	(6,909)	(299,128)	**2,631,036**

	At 1 January 2021 £	Income £	Expenditure/ transfers £	Investment losses £	At 31 December 2021 £
Derek Butler Endowment	2,683,415	-	(13,476)	267,134	2,937,073

Income from the Derek Butler Endowment fund is credited to restricted funds and is to be spent on research into diseases of the upper gastrointestinal tract.

19. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Fixed assets £	Investments £	Net current (liabilities/) assets £	Long-term liabilities £	**2022 Total £**
Unrestricted funds					
-General	3,422	-	(90,533)	(462,550)	**1,069,028**
-Designated funds - AW	-	822,660	(57,814)	(95,000)	**669,846**
-Designated funds - GI	-	885,235	(260,092)	-	**625,143**
Restricted funds	-	-	291,272	-	**291,272**
Endowment funds	-	2,631,036	-	-	**2,631,036**
	3,422	5,957,620	(117,167)	(557,550)	**5,286,325**

	Fixed assets £	Investments £	Net current (liabilities/) assets £	Long-term liabilities £	2021 Total £
Unrestricted funds					
-General	3,363	1,307,784	298,362	(141,102)	1,468,407
-Designated funds - AW	-	874,944	(100,525)	-	774,419
-Designated funds - GI	-	986,454	(59,907)	(78,938)	847,609
Restricted funds	-	329,374	32,534	-	361,908
Endowment funds	-	2,937,073	-	-	2,937,073
	3,363	6,435,629	170,464	(220,040)	6,389,416

20. BRITISH SOCIETY OF GASTROENTEROLOGY

Guts UK works closely with the British Society of Gastroenterology (BSG) (Charity Registration No. 1149074 and Company Registration No. 08124892 (England and Wales)) to provide strong links with the main professional community and to improve its ability to disseminate research and patient information. The Chair of the Research Committee of BSG is a member of Guts UK's Board of Trustees. The Chair of Guts UK is an ex-officio member of BSG's Council.

Transactions between the two charities during the period were as follows:

- The BSG provided a grant of £16,396 (2021: £52,000) to support trainee research grants.
- Guts UK paid the BSG a total of £3,053 for office rates and broadband provision.

.

21. CONTINGENT ASSET AND LIABILITY

In 2018 the charity secured provisional funding amounting to £1,250,000 for the colorectal cancer research grant of which £530,000 has been received to date.

Up to £250,000 is receivable on an annual basis contingent on a satisfactory annual report being approved by the funding partner. Should the next stages of funding be received, Guts UK has agreed to distribute and monitor use of this funding as a sub-grant. As at 31 December 2022, £590,000 remains receivable, of which up to £240,000 is receivable and payable within one year.

22. RELATED PARTY TRANSACTIONS

During the year the charity received donations of £1,910 from trustees (2021: £3,200). Transactions with the British Society of Gastroenterology are detailed in note 20.

There were no further related party transactions during the period requiring disclosure (2020: none).

23. LIABILITY OF MEMBERS

The charity is constituted as a company limited by guarantee. In the event of the charity being wound up, members are required to contribute an amount not exceeding £1.

24. COMMITMENTS UNDER OPERATING LEASES

At 31 December 2022 the charity had future minimum commitments under non-cancellable operating leases as set out below:

Payments which fall due:	**2022** **£**	2021 £
Within one year	**772**	772
Within 2 to 5 years	**387**	1,160
	1,159	1,932

Guts UK Charity

Detailed Statement of Financial Activities
for the Year Ended 31 December 2022

	2022 £	2021 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	292,744	302,910
Legacies	161,913	264,150
	474,657	567,060
Other trading activities		
Public education	50,404	38,533
Investment income		
Curr asset inv income	240,353	169,251
Charitable activities		
Grants	434,630	303,289
Total incoming resources	1,180,044	1,078,133
EXPENDITURE		
Other trading activities		
Grants payable	1,001,807	288,069
Fundraising	38,393	81,417
Public education	69,258	58,263
Research administration	2,636	1,059
Investment management fees	13,826	23,155
	1,125,920	451,963
Support costs		
Management		
Staff costs	344,377	328,886
Premises & donated facilities	43,517	23,285
Insurance	4,392	4,296
Postage	562	1,327
Telephone	3,657	4,631
Stationery, printing, design & marketing	5,123	6,880
Bank charges	8,486	7,958
	410,114	377,263

Support costs cont'd

	2022 £	2021 £
Management		
Finance		
Meeting costs	13,291	4,639
Subscriptions	17,002	9,880
	30,293	14,519
Information technology		
Equipment/maintenance & web- site development	38,147	44,598
Training and recruitment	9,740	(1,246)
Computer equipment	2,015	1,574
	49,902	44,926
Governance costs		
Accountancy fees	10,111	9,926
Legal fees	18,645	7,676
Bookkeeping costs	7,089	4,550
Brand development	9,143	9,950
	44,988	32,102
Total resources expended	1,661,217	920,773
Net (expenditure)/income before gains and losses	(481,173)	157,360
Realised recognised gains and losses		
Realised gains/(losses) on fixed asset investments	(621,918)	587,003
Net (expenditure)/income	(1,103,091)	744,363

Guts UK Charity

Reference and Administrative Information
As at 31 December 2022

Royal Patron	HRH Princess Alexandra
Trustees	• Professor C Hawkey DM FRCP FMedsci – **President** • Professor J Rhodes MD FRCP FMedSci – **Chair** (Resigned as Chair 10th June 2022, resigned as Trustee 23rd June 2022) • Professor J McLaughlin MBChB PhD FRCP – **Deputy Chair** (Until 10th June, appointed as **Chair** from 10th June 2022) • Mr S Williams BA ACA **Honorary Treasurer** (Resigned 26th October 2022) • Professor D Adams MD FRCP FMedSci • Mrs M Davey (nee Boland) • Dr L Dugdale-Bradley • Miss N Bridge • Mr G Christian-Lim BSc (Resigned 14th March 2022) • Professor A Ford MBChB, MD, FRCP (Resigned 15th March 2022) • Dr M Lomer MBE PhD • Ms S Murray (Resigned 23rd August 2022) • Professor S Sebastian* MD FRCP • Professor C Norton (Appointed 14th March 2022) • Professor C Probert MD FRCP (Appointed 10th June 2022) * nominee of the British Society of Gastroenterology (BSG)
Chief Executive	Ms J Harrington
Principal office	2 St Andrews Place Regent's Park London. NW1 4LB
Telephone	0207 486 0341
Website	www.gutscharity.org.uk
E-mail	info@gutscharity.org.uk
Company registration number	07274105 (England and Wales)
Charity registration number	1137029
Auditor	Harris, Lacey and Swain Suite 1, The Riverside Building Livingstone Road Hessle, HU13 0DZ
Bankers	National Westminster Bank plc 1 Cavendish Square London, W1A 4NU
Investment managers	Cazenove Capital Management 12 Moorgate London, EC2R 6DA
Solicitors	Hempsons 40 Villiers Street London, WC2N 6NJ

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2022

Research grants payable

	2022 Total funds £	*2021 Total funds £*
At 1 January	**1,251,335**	*1,454,984*
Research grants awarded in the year	**1,004,179**	*301,231*
Research grants no longer required	**(2,371)**	*(13,163)*
Paid during the year	**(386,609)**	*(491,717)*
At 31 December	**1,866,534**	*1,251,335*
Research grants at 31 December are payable as follows:		
Within one year	**1,308,984**	*1,031,295*
After more than one year	**557,550**	*220,040*
	1,866,534	*1,251,335*

Specific detail of individual research grants are provided on the following pages

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2022

			At 1 January 2022 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2022 £**
Ongoing research							
Dr Wadiamu Gashau	Core-BSG Trainee Research Network Award	RISE NoW (Regional IBD Surveillance Endoscopy North West) study: A real world experience of dysplasia and colorectal cancer surveillance in Inflammatory Bowel Disease (IBD)	**2,500**	-	-	-	**2,500**
Mr James O'Kelly	Guts UK/Amelie Waring Research Fellowship	Single cell definition of the mechanistic role of kynurenine monooxygenase at the innate immune interface in acute pancreatitis	**147,301**	-	-	(127,711)	**19,590**
Dr Sara Jamel	Olympus Guts UK Endoscopy Fellowship	Profiling of Dysplastic Changes in Barrett's Oesophagus and Early Oesophageal Cancer Using Non-Invasive Volatile Organic Compound Analysis of Exhaled Breath	**51,079**	-	-	(30,332)	**20,747**
Professor Colin Rees	Parabola-Guts UK Colorectal Cancer Research Grant	COLO-COHORT Colorectal Cancer Cohort Study	**271,505**	250,000	-	(129,652)	**391,853**
Dr Marc-Emmanuel Dumas	Guts UK Development Award	Precision medicine through integrative metagenomics and phenomics in a human NAFLD cohort	**49,797**	-	-	-	**49,797**
Dr Dipesh Vasant	Guts UK-Dr Falk SpR Trainee Audit/Quality Improvement Award	Anorectal dysfunction in ulcerative colitis: a cross sectional survey	**1,300**	-	-	-	**1,300**
Dr Gwo-tzer Ho	Guts UK Development Award	Resolving Inflammation in IBD: Developing a new therapeutic approach by targeting pro-inflammatory mitochondrial formylated peptides on neutrophil FPR1-pathway	**11,659**	-	-	(9,767)	**1,892**
Dr Nick Powell	For Crohns	TNFα responsive transcriptional networks in the human intestinal epithelium - the key to predicting therapeutic response to antic-TNFα in Crohn's disease	**3,531**	-	-		**3,531**
Balance carried forward			**538,672**	**250,000**	**-**	**(297,462)**	**491,210**

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2022

Continued…			At 1 January 2022 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2022 £**
Ongoing research cont'd							
Balance brought forward			**538,672**	**250,000**	**-**	**(297,462)**	**491,210**
Dr Louise China	Guts UK-BSG Trainee Research Award	Exploring Periodontitis in Cirrhosis (EPIC): a single arm feasibility study to explore the relationship between periodontitis and infection in patients with liver cirrhosis.	**4,980**	-	-	-	**4,980**
Dr Srivathsan Ravindran	Guts UK-BSG Trainee Research Award	Developing a patient-reported safety incident tool in endoscopy	**1,887**	-	(121)	(1,766)	**0**
Dr Mike Davies	Guts UK-BSG Trainee Research Network Award	Getting to the bottom of acute Lower Gastrointestinal Bleeding: Improving quality of care for patients with acute lower gastrointestinal bleeding and assessing resource implications of adherence to national guidelines	**1,500**	-	-	(1,500)	**0**
Dr Samuel Smith	Guts UK-BSG Trainee Research Network Award	Improving key performance measures in inflammatory bowel disease surveillance	**5,000**	-	-	-	**5,000**
Professor Jonathan Fallowfield	Development Grant	A molecular phenomic approach to define the high risk NAFLD population	**19,306**	-	-	(6,254)	**13,052**
Dr Salvatore Papa	Development Grant	Starving livers of glucose for HCC prevention and treatment	**48,572**	-	-	-	**48,572**
Professor Chris Probert[3]	Development Grant	Evaluation of the gut metabolome, micro and myco biome in ulcerative colitis patients undergoing anti-fungal therapy: can we predict response to therapy?	**48,099**	-	-	-	**48,099**
Dr James Pritchett	Development Grant	Decoding Yes Associated Protein 1 driven hepatic stellate cell activation	**22,447**	-	-	(505)	**21,942**
Dr Marnix Jenson	Development Grant	The TARGET study (TArgeted biopsies to Risk Stratify Gastric cancer precursors for tailored Endoscopic surveillance and Treatment)	**49,560**	-	-	(2,660)	**46,900**
Balance carried forward			**740,023**	**250,000**	**(121)**	**(310,147)**	**679,755**

[3] Professor Chris Probert was awarded this Grant in 2019 before he was appointed as a Trustee in 2022. As a trustee, he does not sit on the Research Awards Committee or the Research Strategy Committee.

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2022

			At 1 January 2022 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2022 £**
Ongoing research cont'd							
Balance brought forward			**740,023**	**250,000**	**(121)**	**(310,147)**	**679,755**
Dr Catherine Williamson	Nutrition Development Grant	Impact of cold exposure in conjunction with dietary modification on metabolic regulation in children with non-alcoholic fatty liver disease	**48,283**	-	-	-	**48,283**
Professor Christer Hogstrand	Nutrition Development Grant	Targeting "Leaky Gut" with combined dietary zinc and plant derived Aryl Hydrocarbon Receptor agonists	**50,000**	-	-	-	**50,000**
Dr Paul Henderson	Guts UK - BSPGHAN Development Grant	The PINPOINT study – The Prospective Incidence of Paediatric – Onset Inflammatory bowel disease in the United Kingdom	**37,540**	-	-	-	**37,540**
Professor Graham Lord	For Crohn's Development Grant	Modulation of the effector/regulatory T-cell balance by targeting a causal genetic variant as a novel therapeutic paradigm in Crohn's disease	**43,336**	-	-	-	**43,336**
Dr Robin Dart	Guts UK-BSG Trainee Research Award	The cellular architecture of the human colonic mucosa : a pilot and feasibility study to facilitate longitudinal multi-centre studies	**10,000**	-	-	(5,000)	**5,000**
Dr James Ashton	Guts UK-BSG Trainee Research Award	To establish a UK wide Paediatric IBD Research network (PAIR network) to answer clinical research questions and enable rapid decision making	**4,000**	-	(83)	-	**3,917**
Dr John Thomas	Guts UK-BSG Trainee Research Award	Transcriptomic profiling of patient derived colonic epithelial organoids exposed to Ulcerative Colitis-relevant cytokines – a novel approach to uncover IBD pathogenesis and inform precision medicine strategies.	**4,975**	-	(154)	-	**4,821**
Dr Rebecca Harris	Guts UK-BSG Trainee Research Award	Non-invasive risk stratification of patients with compensated advanced chronic liver disease : Results from a real world cohort from the Nottingham Scarred Liver pathway	**5,000**	-	-	-	**5,000**
Dr Flora Korkwaro	Guts UK - Dr Falk SpR Trainee Audit/Quality Improvement Award	My Tube Passport - "Mind My Tube" - a hospital e-passport for the patient with an enterostomy device	**8,000**	-	-	-	**8,000**
Balance carried forward			**951,157**	**250,000**	**(358)**	**(315,147)**	**885,652**

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2022

			At 1 January 2022 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2022 £**
Ongoing research cont'd							
Balance brought forward			**951,157**	**250,000**	**(358)**	**(315,147)**	**885,652**
Dr Tessa Cacciottolo	Guts UK - Dr Falk SpR Trainee Audit/Quality Improvement Award	Using age-appropriate information to support adolescents and young adults with liver disease as they transition from paediatric to adult services	**2,325**	-	-	-	**2,325**
Dr Dimitrios Koutoukidis	Guts UK - BSG Early Career Researcher Grant	A proof-of-concept trial exploring the mechanism of diet-induced weight loss in non-alcoholic steatohepatitis with fibrosis through the gut microbiome and intestinal permeability	**14,996**	-	-	-	**14,996**
Dr Nicholas Edward Ilott	Guts UK - BSG Early Career Researcher Grant	DYNAMHIX in PSC : Longitudinal Dynamics of the Hepatic-Intestinal axis in PSC-UC	**12,642**	-	-	(312)	**12,330**
Dr Benjamin P Sharpe	Guts UK - BSG Early Career Researcher Grant	Investigating the cellular microenvironment of lymph node metastasis in oesophageal adenocarcinoma	**14,649**	-	-	-	**14,649**
Dr Rachael Slater	Guts UK - BSG Early Career Researcher Grant	Investigating the mechanisms of irritable bowel syndrome using shotgun metagenomics sequencing and volatile metabolomics in integrated omics analysis	**11,075**	-	-	(295)	**10,780**
Dr Nikhil Vergis	Guts UK - BSG Early Career Researcher Grant	Which socioeconomic and healthcare factors determine survival for patients with alcohol related liver disease? A secondary analysis of patient data from the Steroids or Pentoxyfilline for Alcoholic Hepatitis (STOPAH) trial 2011-2015	**15,000**	-	-	-	**15,000**
Dr Naaventhan Palaniyappan	Guts UK - BSG Early Career Researcher Grant	Risk stratification of patients with cirrhosis undergoing colorectal surgery: pilot feasibility study."	**13,350**	-	-	-	**13,350**
Dr Paloma Ordonez Moran	Guts UK - BSG Early Career Researcher Grant	MINIGUTS: Development of novel in vitro models of paediatric IBD	**14,977**	-	-	-	**14,977**
Dr Tariq Ahmad	For Crohn's Grant	Impact of biologic and immunomodulatory therapy on SARS-CoV-2 re-infection, chronic carriage and evolution of viral variants	**25,220**	-	-	-	**25,250**
Balance carried forward			**1,075,391**	**250,000**	**(358)**	**(315,754)**	**1,009,279**

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2022

			At 1 January 2022 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2022 £**
Ongoing research cont'd							
Balance brought forward			**1,075,391**	**250,000**	**(358)**	**(315,754)**	**1,009,279**
Dr Zoe Saynor	For Crohn's Grant	EnablExercise in Crohn's: A qualitative study to understand the barriers and facilitators to physical activity and exercise in children and adolescents with Crohn's disease - perceptions of patients, caregivers and clinicians	**21,807**	-	-	(9,582)	**12,225**
Pancreatitis Priority Setting Partnership (PSP)	Guts UK / BSG / PSGBI	Identification and prioritisation of gaps in evidence in the diagnosis, treatment, management and support of patients with pancreatitis	**35,382**	-	-	(19,017)	**16,365**
Irritable Bowel Syndrome (IBS) Priority Setting Partnership	Guts UK / BSG	Identification and prioritisation of the unanswered questions about the diagnosis, treatment and care of people (16 years +) with IBS	**35,382**	-	-	(1,811)	**33,571**
Professor Anil Dhawan	Guts UK - BSPGHAN Joint Development Grant	Umbilical Cord-Mesenchymal Stromal/stem cell immunotherapy for Biliary Atresia	**38,902**	-	-	-	**38,902**
Dr Tassos Grammatikopoulos	Guts UK - BSPGHAN Joint Small Grant	Mental health and quality of life in children and young people with acute recurrent and chronic pancreatitis	**4,248**	-	-	-	**4,248**
Dr Peter Rimmer	Guts UK – BSG trainee grant	The Microbiome in IBD Inception: An exploratory two year longitudinal analysis of the gastrointestinal microbiome through IBD onset, treatment, and relapse, to guide future microbiome based interventions	**5,000**	-	-	-	**5,000**
Dr Julian Yeh	Guts UK – BSG trainee grant	Microscopic Colitis: a regional multi-centre audit."	**4,000**	-	-	-	**4,000**
Dr Simeng Lin	Guts UK – BSG trainee grant	End of life care provision in patients with advanced liver disease in the south-west: a regional perspective	**765**	-	-	-	**765**
Balance carried forward			**1,220,877**	**250,000**	**(358)**	**(346,164)**	**1,124,355**

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2022

			At 1 January 2022 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2022 £**
Ongoing research cont'd							
Balance brought forward			**1,220,877**	**250,000**	**(358)**	**(346,164)**	**1,124,355**
Dr Oliver Tavabie	Guts UK – BSG trainee grant	Does the implementation of the BASL/BSG bundle improve the survival of patients with decompensated chronic liver disease acutely admitted into hospital	**2,000**	-	-	-	**2,000**
Dr Ayman Bannaga	Guts UK – BSG trainee grant	The Fatty Liver and Liver Cancer Study (Tendency)	**5,000**	-	-	-	**5,000**
Total ongoing research			**1,227.877**	**250,000**	**(358)**	**(346,164)**	**1,131,355**
New Commitments							
Falk Pharma 2022 awards – various	Guts UK – 9 x Dr Falk awards 2022		-	14,000	-	(14,000)	**-**
Dr Jonathan King	Guts UK-Dr Falk SpR Trainee Audit/Quality Improvement Award	Assessing the impact of using interactive video in the correct languages for the consenting of non-English speaking patients in endoscopy	**-**	8,638	-	-	**8,638**
Mr Arjun Kattakayam	Guts UK/Amelie Waring Research Fellowship	Novel high resolution insights into mitochondrial dysfunction in acute pancreatitis within and beyond the pancreas	**-**	180,000	-	-	**180,000**
Dr Katja Christodoulou	Guts UK/ Derek Butler Research Fellowship	Non - invasive testing of Early Oesophageal Cancer and Dysplasia	**-**	210,000	-	-	**210,000**
Professor Sheena Cruickshank	For Crohns	Characterising the immune signature of genital Crohn's disease	**-**	19,874	-	-	**19,874**
Balance carried forward			**-**	**432,512**	**-**	**(14,000)**	**418,512**

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2022

18. Research grants payable (continued)

			At 1 January 2022 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2022 £**
New commitments cont'd							
Balance brought forward			**-**	**432,512**	**-**	**(14,000)**	**418,512**
Dr Mohamed Albed Alhnan	For Crohns	Enabling the oral delivery of adalimumab via novel 4D printing architectures fro the treatment of Crohn's	**-**	16,019	-	-	**16,019**
Dr Tovah Shaw	For Crohns	Determining the contribution of long-lived Tim4+ gut macrophages to oral tolerance of food, and intestinal microbial community stability	**-**	14,803	-	-	**14,803**
Dr Alice Lapthorn	Guts UK - BSG Early Career Researcher Grants	Repurposing of drugs to prevent intra-abdominal adhesion formation	**-**	15,000	-	-	**15,000**
Dr K Belogianni	Guts UK - BSG Early Career Researcher Grants	Implementing an integrated care pathway for the management of irritable bowel syndrome	**-**	15,000	-	-	**15,000**
Dr M Mohamed	Guts UK - BSG Early Career Researcher Grants	Development and evaluation of point-of-care diagnostics utilising clinical metagenomic sequencing for rapid pathogen and antimicrobial resistance detection in decompensated cirrhosis and acute-on-chronic liver failure	**-**	14,961	-	-	**14,961**
Dr Fumi Kamlesh Varyani	Guts UK - BSG Early Career Researcher Grants	Identifying the impact of Specialist Nutrition Support Teams on the outcomes of parenterally fed and gastrostomy patients utilising the Hospital Episode Statistics and National Endoscopy Database"	**-**	14,999	-	-	**14,999**
James Halle-Smith	Guts UK - BSG Trainee Research Award	"The Influence of Pancreatic Exocrine Insufficiency and Pancreatic Enzyme Replacement Therapy on the Intestinal Microbiome of Pancreatic Cancer Patients"	**-**	3,880	-	-	**3,880**
Amir Saifuddin	Guts UK - BSG Trainee Research Award	"Evaluation of the safety of perioperative advanced anti-inflammatory therapy in patients with inflammatory bowel disease (IBD) undergoing elective surgery"	**-**	5,000	-	-	**5,000**
Nosheen Umar	Guts UK - BSG Trainee Research Award	"Development of a risk prediction tool for inflammatory bowel disease (IBD) in patients presenting in primary care with abdominal symptoms in the Clinical Practice Research Datalink (CPRD Aurum)."	**-**	5,000	-	-	**5,000**
Balance carried forward			**-**	**537,174**	**-**	**(14,000)**	**523,174**

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2022

18. Research grants payable (continued)

			At 1 January 2022 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2022 £**
New commitments cont'd							
Balance brought forward			**-**	**537,174**	**-**	**(14,000)**	**523,174**
Jonathan Gan	Guts UK - BSG Trainee Research Award	"Monitoring gut permeability in Irritable Bowel Syndrome (IBS) using a novel non invasive optical sensor"	**-**	3,917	-	-	**3,917**
Jonathan Sturgeon	Guts UK - BSG Trainee Research Award	"Spacial profiling of duodenum transcriptomic changes following administration of novel therapeutic agents in children with severe acute malnutrition"	**-**	5,000	-	-	**5,000**
Joseph Delo	Guts UK - BSG Trainee Research Award	"The role of the TIGIT immune checkpoint axis in susceptibility to infection in decompensated cirrhosis"	**-**	5,000	-	-	**5,000**
Adeel Harmad	Guts UK - BSG Trainee Research Award	"Exploring the role of the brainstem in human swallowing and post radiotherapy induced dysphagia using functional MRI"	**-**	5,000	-	-	**5,000**
Marcus Auth	BSPGHAN/GUTS UK/Falk	"Faecal volatile organic compounds in children with eosinophilic oesophagitis potential as non-invasive biomarkers"	**-**	39,995	-	-	**39,995**
Francis Robertson Newcastle	ASGBI	"Micro RNAs in acute pancreatitis"	**-**	9,954	-	(2,500)	**7,454**
Hwei Jene Ng	ASGBI	"Micro RNAs in acute pancreatitis"	**-**	4,000	-	(2,500)	**1,500**
Pancreatitis Priority Setting Partnership (PSP)			**-**	20,000	-	-	**20,000**
Dr Maria Alcolea	Worldwide Cancer Research	"Mechanomodulation of mutant clonal competition in oesophageal epithelium : relevance for early tumour formation "	**-**	124,143	-	-	**124,143**
Total New Commitments			**-**	**754,179**	**-**	**(19,000)**	**735,179**

APPENDIX 1 - Guts UK Research grants payable in the Financial year 1st January to 31st December 2022

18. Research grants payable (continued)

			At 1 January 2022 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2022 £**
Research completed during the year							
Dr Varinder Athwal	Guts UK Development Award	Investigating fibrosis pathobiology in cystic fibrosis related liver disease to improve clinical detection and management	**4,290**	-	(238)	(4,052)	**-**
Dr Jorge Gutierrez-Merino	For Crohn's Development Grant	Understanding how gut bacteria induce beneficial type 1 interferon responses	**10,393**	-	-	(10,393)	**-**
Dr Roosey Sheth	Guts UK-BSG Trainee Research Network Award	A UK wide Audit of the Management of Primary Biliary Cholangitis (PBC)	**5,000**	-	(500)	(4,500)	-
Falk Pharma 2021 awards - various	Guts UK - Dr Falk awards 2021		**2,500**	-	-	(2,500)	-
Dr Katja Christodoulou	Guts UK – BSG trainee grant	Consent for contact in endoscopy	**1,275**	-	(1,275)	-	**-**
Total research completed during the year			**23,458**	**-**	**(2,013)**	**(21,445)**	**-**
Total grants for the year			**1,251,335**	**1,004,179**	**(2,371)**	**(386,609)**	**1,866,534**

This page has been deliberately left blank

We’re getting to grips with guts

Guts UK Annual Report and Financial Accounts - 2022_FINAL

Final Audit Report 2023-09-25

Created:	2023-09-25
By:	Guts UK (info@gutscharity.org.uk)
Status:	Signed
Transaction ID:	CBJCHBCAABAACrVkUitvh8Y7CVOgmWR5BFGH4i-vx_1M

"Guts UK Annual Report and Financial Accounts - 2022_FINAL" History

Document created by Guts UK (info@gutscharity.org.uk)
2023-09-25 - 1:28:39 PM GMT- IP address: 109.159.79.211

Document emailed to ld@hlas.co.uk for signature
2023-09-25 - 1:30:25 PM GMT

Email viewed by ld@hlas.co.uk
2023-09-25 - 1:31:29 PM GMT- IP address: 104.47.85.126

Signer ld@hlas.co.uk entered name at signing as Laura Drew
2023-09-25 - 1:33:50 PM GMT- IP address: 213.249.136.98

Document e-signed by Laura Drew (ld@hlas.co.uk)
Signature Date: 2023-09-25 - 1:33:52 PM GMT - Time Source: server- IP address: 213.249.136.98

Agreement completed.
2023-09-25 - 1:33:52 PM GMT

Adobe Acrobat Sign

GUTS UK CHARITY

England & Wales - Charity number 1137029

Accounts

GUTS UK CHARITY ANNUAL REPORT AND FINANCIAL STATEMENTS 2021

“We’re getting to grips with guts so that no-one suffers alone.”

CONTENTS

Welcome	1
Who we are	3
Our 2021 highlights	4
Trustees' report	5
Financial statements	33
Governance, policies and standards	40
Independent auditor's report	47
Statement of financial activities	51
Balance sheet	52
Statement of cash flows	53
Principal accounting policies	54
Notes to the financial statements	60
Reference and administrative information	84

WELCOME

The past 50 years have seen great progress in the diagnosis and management of gastro-intestinal or GI conditions – diagnosis is much more accurate and easier thanks to endoscopy, computerised tomography (CT) and magnetic resonance imaging (MRI) scanning – substantially British inventions. The recognition of a bacterium – Helicobacter pylori (H pylori) – as the cause of peptic ulceration has transformed its management from surgical to medical. Viral hepatitis can usually be prevented by vaccines or treated by anti-virals and the management of Crohn's disease and ulcerative colitis has been greatly improved by biologic agents and key-hole surgery.

Our charity was formed in June 1971 in recognition of the relative lack of research support for GI disorders given their major impact on health – a problem that is still with us today. Now renamed as Guts UK Charity we are better serving those people who are struggling with digestive conditions, often in silence and alone.

When the pandemic struck, our superb team of staff worked harder than ever in the restricted circumstances to respond to a 400% increase in enquiries for information from the public. A huge unmet demand for our services has been demonstrated. As we serve more people with evidence-based information, this empowers our community to be in control of their conditions and their care. The more we serve, the more supporters Guts UK has gained. In 2020 we raised £550,019 and we are delighted to say in 2021 we have doubled the overall income to £1,078,130.

Our research programme has also continued through the pandemic. To date since our inception we have invested more than £16.5 million in 300 research grants. But with less than 2% of all medical research funding in the UK going into gastroenterology other than cancer, our specialty has been woefully underfunded for decades and lags behind other areas of health research. That's why in our 50th year, our campaign was that it was finally time for the UK to get to grips with guts. And our marching army of supporters will helped us lift that campaign high. A superb high for our 50th year was to feature on a BBC Radio 4 Appeal in June that raised a wonderful £27,600, raised awareness and boosted the profile of Guts UK.

Fifty years ago, our founders at the British Society of Gastroenterology (BSG) wanted to do something to end the pain and suffering of digestive diseases. A lot has changed since then. But the truth is, we haven't yet achieved our founders' goals. People are still in pain. People are still suffering. People are dying too early. They are dying unnecessarily. And they are dying without answers. We *have* to go faster in the next 50 years.

Huge changes are brought about by the generosity of our amazing community of Guts UK supporters who are so generous with their time and donations. Together, with their powerful and growing support, we cannot fail to achieve our ambition to finally help the UK get to grips with guts.

We are so grateful to you all.

Professor Jonathan Rhodes, Chair
(Resigned 10 June 2022)

Julie Harrington, CEO

WHO WE ARE

Guts UK is the charity for the digestive system. Though there are some 150 plus patient groups and charities in the field of digestive health in the UK, many of them are disease specific. Guts UK remains *the only charity* that covers all of the digestive system, from 'top to tail'. Guts UK works actively and collaboratively with other charities. However, with our own limited resources, we choose to focus particularly on the conditions that have no other specific charity, or voice - those illnesses that really are 'Cinderella' conditions such as pancreatitis, diverticular disease, irritable bowel syndrome (IBS), and childhood gut and liver disease plus the less common gastrointestinal cancers. These conditions affect millions of people every day and digestive diseases account for one in nine hospital deaths in the UK each year.

"People are suffering. People are dying. All because of a lack of knowledge about our guts. Guts UK exists to change that. Our guts have been underfunded, understaffed and undervalued for decades. Together we will join forces and bring about important change in this misunderstood area for health. With new knowledge, we will end the pain and suffering of the millions affected by digestive diseases."

Our Mission



OUR 2021 HIGHLIGHTS

Information Services and Support

1,162 emails

871 phone calls

152,752 leaflets

With the help of our Experts by Experience Panel we have awarded over £300K to research projects

Kranky Panky 2021 reached 216,779 people

#GUTSelfie
Organic impressions rose by 546% from April to June
550% increase in web clicks from April to June
Instagram followers grew by 250%

BBC Radio 4 Appeal to celebrate our 50th year raising £27.6K

TRUSTEES' REPORT

The trustees present their report together with the financial statements of Guts UK Charity ("Guts UK") for the year ended 31 December 2021. The report has been prepared in accordance with Part 8 of the Charities Act 2011 and constitutes a directors' report for the purposes of company legislation.

The financial statements have been prepared in accordance with the accounting policies set out on pages 54 to 58 and comply with the charitable company's memorandum and articles of association, applicable laws and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102).

Objectives and activities

Guts UK's charitable objectives are:

- The advancement of the science and practice of medicine and surgery for the benefit of the public with particular reference to the field of gastroenterology, which includes the study of the physiology and pathology of the digestive system;

- To promote the study of and research into medicine and surgery with particular reference to the physiology and pathology of the digestive system and to ensure dissemination where appropriate of the results of such study and research;

- To provide educational material, information and advice to the general public on gastrointestinal diseases.

To achieve these objectives, Guts UK works across six areas:

- Providing evidence-based information to patients and carers that enables people to take proactive decisions and control of their lives;

- Supporting medical research that increases our understanding of digestive diseases, leading to better diagnosis and treatment and improved outcomes for patients;

- Funding research training fellowships for clinicians and scientists to allow them to pursue academic gastroenterology and to enable the development of future researchers;

- Hosting scientific research symposia as part of the BSG Annual Meeting;

- Giving general advice and signposting to other organisations;

- Raising awareness of digestive health and the science surrounding it to increase public understanding.

When setting the objectives and planning the work of Guts UK for the year, the trustees give careful consideration to the Charity Commission's general guidance on public benefit.

The trustees always ensure that the activities undertaken are in line with the charitable objectives and aims of Guts UK. As highlighted in this report, we are continuing to develop our information provision and public education programme thereby helping the general population to better understand digestive diseases. Digestive diseases include diseases and disorders of the oesophagus, stomach and intestines, colon and rectum, liver, gall bladder, bile ducts, and pancreas; including inflammatory, neoplastic and functional disorders.

Achievements and performance

Research grant funding

Guts UK had research commitments at the start of the year totalling £1,454,984 (2020: £1,721,855). In 2021 the charity further awarded grants totalling £301,231 (2020: £61,950) with payments totalling £491,717 (2020: £325,308) and net commitments no longer required of £13,163 (2020: £3,513). Research commitments still to be paid at the end of the year were £1,251,335 (2020: £1,454,984).

In 2021 we renewed our commitment to focus on areas we believe are less well-resourced than other GI disease areas and where our funding can make a meaningful difference for patients.

Priority areas

- Upper gastrointestinal disease such as gastro-oesophageal reflux disease (GORD) and Barrett's oesophagus
- Diverticular disease
- Pancreatitis
- IBS
- Childhood gut, liver and pancreatic diseases.
- Gut microbiome and nutrition
- Less survivable digestive cancers: stomach, oesophageal, pancreatic and liver.

Funding trainee doctors in gastroenterology research

To promote research amongst gastroenterology trainees and in particular support the development of trainee research networks Guts UK has partnered with the BSG to award six grants to trainee doctors totalling £18,040. We had hoped to be able to award more trainee research grants but due to the ongoing Coronavirus pandemic, many gastroenterology trainees were diverted to the front line which disrupted their training and made it even more difficult than usual for them to engage in research. The six grants awarded were:

- Dr Katja Christodoulou, West Hertfordshire NHS Trust - Consent for contact in endoscopy.

- Dr Peter Rimmer, University of Birmingham - The Microbiome in inflammatory bowel disease (IBD) Inception: An exploratory two-year longitudinal analysis of the gastrointestinal microbiome through IBD onset, treatment, and relapse, to guide future microbiome-based interventions.

- West Midlands Research in Gastroenterology Group led by Dr Julian Yeh, New Cross Hospital, Wolverhampton - Microscopic Colitis: A regional multi-centre audit.

- The Severn and Peninsula Research in Gastroenterology (SPRinG) Trainee Network led by Emma Saunsbury, Royal Devon and Exeter Hospital - End of life care provision in patients with advanced liver disease in the Southwest: a regional perspective.

- Dr Oliver Tavabie, King's College Hospital - Does the implementation of the BASL*/BSG bundle improve the survival of patients with decompensated chronic liver disease acutely admitted into hospital.

*BASL – British Association for the Study of the Liver

- West Midlands Network led by Dr Ayman Bannaga, University Hospital Coventry & Warwickshire - The Fatty Liver and Liver Cancer Study (Tendency).

Guts UK/Dr Falk awards

Guts UK continues to work with Dr Falk Pharma UK to award prizes and grants to medical students, SpR trainees, F1/F2 clinicians, nurses and dietitians. These awards aim to acknowledge those who bring new insight into gastroenterology and hepatology through research or the improvement of patient care. They also provide the opportunity for foundation stage doctors to engage in research.

The Guts UK/Dr Falk 2021 award winners were:

- Medical student prizes
  Four £1,500 prizes for medical students taking full-time science degrees in the UK (BSc/MRes/MSc/MPH/MBPhD) focusing on gastroenterology (including hepatology and pancreatology) in the current academic year (2020/21)

- Aala Mohammed Ali, University of Manchester
  Characterising chronotype, sleep, and circadian disruption in IBD.

- Petra Paizs, Imperial College London
  Developing a direct mass spectrometric assay for the identification of early disease biomarkers for colorectal cancer.

- Reuben Veysey-Smith, University of Liverpool
  Investigating the Relative Impacts of Proton Pump Inhibitor (PPI) Therapy, H. pylori-induced Gastritis and Gastric Mucosal Atrophy on Fasting Serum Gastrin Concentrations.

- Kader Torbator, Imperial College London
  The Association between Psoriasis and Non-Alcoholic Fatty Liver Disease using Transient Elastography to Assess Fibrosis and Steatosis: A Retrospective Study.

- Medical essay prize

A £1,000 prize for the best essay on gastroenterology (including hepatology and pancreatology) research personally undertaken by medical students studying in the UK who were on an intercalated BSc/MRes/MSc/MPH/MBPhD course during the previous academic year (2019/20).

- Niraj Doshi, University College London
  A Genome-Wide Association Study of Non-Alcoholic Fatty Liver Disease in Trivandrum, India.

- Dietitian prize

A £1,000 award for dietitians working in GI/liver in recognition of an innovation that has led to an improvement in patient care.

- Helen Dumpleton, Cambridgeshire and Peterborough Foundation Trust
  Audit of the Effectiveness of IBS Dietary Advice in Cambridgeshire Community Setting.

- Nurse prize

A £1,000 prize for UK-based primary and secondary care nurses working in gastroenterology (including hepatology and pancreatology) for initiatives that have improved patient care.

- Laura Kent, Great Western Hospital Swindon
  The Long-Term indwelling Abdominal Drains (LTADs) pilot project.

- F1/F2 Research awards

  Two £2,500 awards for UK-based F1/F2 doctors to facilitate prospective research in an area relevant to gastroenterology (including hepatology and pancreatology).

    - Dr Rebecca Jeyaraj, King's College Hospital

      Variation in genes involved in bile acid homeostasis and their contribution to paediatric non-alcoholic fatty liver disease.

    - Dr Umair Akbani, Wythenshawe Hospital, Manchester Foundation Trust

      Evaluating the performance of a novel classification system for IBS in predicting outcomes to gut-focused hypnotherapy.

- SpR Audit/Quality Improvement award

  A total of £10,325 was awarded to UK-based gastroenterology SpR trainees conducting quality improvement projects in gastroenterology and hepatology.

    - Dr Flora Korkwaro, London North West University Healthcare NHS trust

      My Tube Passport – " Mind My Tube ". A hospital e-passport for the patient with an enterostomy device.

    - Dr Tessa Cacciottolo, Addenbrooke's Hospital, Cambridge

      Using age-appropriate information to support adolescents and young adults with liver disease as they transition from paediatric to adult services.

Early career researcher development grants

The grants are for developmental or translational research that will allow the collection of pilot or proof-of-concept data to enable high-quality competitive applications to be made subsequently to larger funders. This year the development grants were open to early career researchers to support the development of future leaders in academic gastroenterology. The BSG has contributed to these grants. This year, to support our priorities grants were awarded for gut microbiome and nutrition, IBS and oesophageal cancer projects.

- Dr Dimitrios Koutoukidis based at the University of Oxford has been awarded £14,996 for a proof-of-concept trial to explore if the gut bacteria and the barrier of the intestine are part of the mechanism through which weight loss improves the liver in non-alcoholic steatohepatitis with fibrosis. The study will aid understanding of the mechanism of the disease and how the treatment works.

- Dr Nicholas Edward Ilott based at the University of Oxford has been awarded £12,642 for his project that aims to find the bacterial products involved in gut inflammation in patients with primary sclerosing cholangitis (PSC) associated ulcerative colitis (UC). This is the first study to look at measurements in the blood and stool over time. The researchers believe that the information gathered in this study will enable them to identify new therapy avenues for PSC-UC such as restoring harmful changes in gut metabolite levels using dietary or metabolite-based interventions.

- Dr Benjamin Sharpe based at the University of Southampton has been awarded £14,649 to investigate cell communication in lymph nodes in metastatic oesophageal cancer with the objective of learning more about the biology that causes some patients' lymph nodes metastases to respond well to treatment where most do not and identifying new treatments to target these. This will enable future efforts to improve chemotherapy treatments in oesophageal cancer patients and allow more effective treatment of lymph node metastasis thus improving patient survival.

- Dr Rachael Slater based at the University of Liverpool has been awarded £11,075 to investigate the mechanisms of IBS to help patients get the right treatment faster. People with IBS produce different gases in their faeces to people without IBS. These different gases may help with finding the people who will respond to a low-FODMAP* diet. The team aim to find out if and how the gut bacteria produce these gases by studying the genetic make-up of the bacteria. Understanding where these gases are coming from will enable better diagnosis and treatment of IBS.

*FODMAP = fermentable oligosaccharides, disaccharides, monosaccharides and polyols, which are short-chain carbohydrates (sugars) that the small intestine absorbs poorly. Some people experience digestive distress after eating them.

- Dr Nikhil Vergis based at Imperial College London has been awarded £15,000 to investigate which socioeconomic and healthcare factors determine survival for patients with alcohol-related liver disease. Patients with liver disease live nine years longer in the least deprived compared to the most deprived areas of the UK. The team hope to gain a clearer picture of where additional support might be provided in the care pathway for these vulnerable patients, for example, support and help with early intervention by the primary care provider. The study results will inform efficient use of NHS resources to control this ongoing health disaster.

- Dr Naaventhan Palaniyappan based at the University of Nottingham has been awarded £13,350 for his pilot feasibility study to test if it will be possible to enrol patients with cirrhosis to measure the pressure within the liver before their planned surgery for bowel cancer treatment. The team will assess if the pressure measurement using magnetic resonance imaging (MRI) is related to the outcome of patients following their bowel surgery. The results from this initial study will be used to plan a bigger multi-site study to establish the risk of surgery in patients with cirrhosis and whether any of the MRI measurements correspond to that risk. This will help patients and surgeons to balance risk and benefits of surgery before deciding on the best treatment.

- Dr Paloma Ordóñez Morán based at the University of Southampton has been awarded £14,977 for her MINIGUTS project to develop novel in vitro models of paediatric IBD. Most of the clinical trials are first carried out in animals and the compounds validated in adult volunteers. These experiments do not exactly replicate children's disease and half the children diagnosed do not respond to current treatments. Paediatric patients would benefit if there were better models to test new and existing compounds for assessing epithelium damage and regeneration. The outcome of this project would be potentially translated into more effective treatments and would help to improve paediatric IBD patients' health.

forCrohn's research grants

We have continued our successful collaboration with forCrohn's to fund research specifically focusing on Crohn's Disease. In 2021 we focussed on projects investigating Crohn's and COVID, and quality of life for people with Crohn's disease.

- Dr Tariq Ahmad based at the Royal Devon and Exeter Hospitals has been awarded £25,220 to investigate whether specific IBD medications impact how long people carry the COVID-19

virus and whether they increase the risk of re-infection. Data generated from this study will aid understanding of whether biologic and immunomodulator drugs increase the risk of recurrent COVID-19 infection or cause people to carry the virus for longer. If this is observed, antibody and PCR testing may be implemented in routine care to identify these individuals who may be offered alternative treatments.

- Dr Zoe Saynor based at the University of Bournemouth has been awarded £21,807 for her qualitative study to understand the barriers and facilitators to physical activity and exercise in children and adolescents with Crohn's disease through conversations with young people, parents and clinicians. Physical activity and exercise are good for both mental and physical health particularly in people with a long-term condition. Alongside the team's other current research study "The ACTIVE-IBD Study" the information gathered will help with designing appropriate physical activity and exercise resources and training to benefit young people living with Crohn's. The long-term aim being to improve the quality of life for people with Crohn's through exercise as medicine.

Childhood gut and liver diseases

Guts UK has once again partnered with the British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) to fund paediatric research.

- Professor Anil Dhawan based at Kings College London has been awarded £38,902 to investigate the use of mesenchymal stromal cells (MSCs) as a potential cell therapy for the treatment of biliary atresia (BA). BA is a rare medical condition, occurring in small infants, in which the bile ducts outside and inside the liver become scarred and blocked. This results in a build-up of bile in the liver which causes damage leading to scarring, tissue loss and cirrhosis. This project may provide fundamental insights which can lead to MSCs being used as a cell therapy to treat children with BA by altering their immune reaction before lasting damage occurs in their livers.

- Dr Tassos Grammatikopoulos also based at Kings College London has been awarded £4,248 to explore quality of life, fatigue and mental health in children and young people with acute recurrent or chronic pancreatitis. The data resulting from this study will be used to better understand the needs of these children and young people and shape the development of services to better meet their needs.

Bringing the patient voice into research

Priority setting partnerships (PSPs)

The IBS and Pancreatitis PSPs are finally underway. The PSPs are facilitated by the James Lind Alliance (JLA) and bring together clinicians and other health care professionals, scientists, patients and carers to find the top ten research priorities in order to lead transformational change in research in these chronically underfunded areas with the ultimate aim of positively impacting diagnosis and treatment. High quality PSP's conducted in this way have a major impact on prioritisation of research funding by national bodies including the research councils and the National Institute for Health Research (NIHR). The Pancreatitis PSP is jointly funded by our Big Give campaign and other restricted pancreatitis income, the Pancreatic Society of Great Britain and Ireland (PSGBI) and the BSG. The IBS PSP is jointly funded with the BSG.

Experts by experience (EBEs) – our patient panel

The biggest boost in recent years is to actively have the patient voice at the heart of all we do at Guts UK. In 2021 we formed a new panel of Experts by Experience, affectionately known as our EBEs, who are people affected by, caring for and/or living with digestive conditions. They have taken part as equals alongside the professors and clinicians within our Research Awards Committee when deciding on the Guts UK research grants in 2021. They advise us on the way to ensure our information is accessible for all and promoted in various formats to particularly hard-to-reach groups. The EBEs hold the development of our equality and diversity programme at their heart, to ensure we will be tackling health inequalities we have all become so very aware of as a nation through this recent pandemic.



Completed research projects: sharing outcomes

As a result of the Coronavirus pandemic, many of Guts UK's research projects were put on hold as some of our funded researchers were called back to clinical duties. No-cost extensions were granted to several projects that were due to finish in 2021. These projects have now resumed and should complete in 2022.

Oesophageal cancer: Professor Laurence Lovat's team explored whether a single spit of saliva together with an easy to administer questionnaire regarding symptoms and risk factors could be used as a simple way to indicate whether a patient is at low or high risk of having oesophageal cancer. This would allow many patients who do not have the disease to avoid having a normal endoscopy which would free up resources to use on those who need them most. Saliva samples were collected from more than 300 patients at 20 hospitals around the UK. The team interrogated 850,000 individual epigenetic locations within the DNA of 192 patients and used complex bioinformatics approaches to identify a particular signature which distinguished patients with invasive oesophageal cancer with an accuracy of more than 95%. The test will need further validation in more patients and will need to be transferred to a cheaper system that is suitable for routine clinical use. But it appears that the team may have developed a clinically useful test for oesophageal cancer which simply relies on a little bit of spit. Alongside the saliva, the team also collected questionnaire data from 398 patients. Analysis showed that by asking only 8 questions, the team were able to predict which patients have Barrett's oesophagus with an accuracy of over 80%. These findings were compared to data collected in a previous study and were shown to be robust. This may help doctors identify which patients should have an endoscopy test to look for

precancerous changes. The questionnaire findings now need to be confirmed in a group of patients in general practice but might in future be a cheap and reliable way of screening patients who might need an endoscopy. The saliva assessment might lead to a completely non-invasive test for detecting patients with oesophageal cancer. Further validation is needed but the findings of this research are completely novel and are very exciting.

Achalasia and gastroparesis: The aim of Dr Conor McCann's research project was to test if gut nerve stem cells can fix achalasia and diabetic gastroparesis. A surgical technique was used to transplant gut nerve stem cells into the gullet (oesophagus) and stomach of mouse models to test if transplantation can rescue function in these regions. The team confirmed that the mouse models showed the same features as human diseases and were able to show that after transplantation of gut nerve stem cells, donor cells formed networks after four weeks in the stomach and gullet. These donor cells also showed key characteristics of the lost nerve cells. Promisingly, the team have also shown that after transplantation, function can be restored within small pieces of diseased tissue taken from these regions. This suggests that transplantation of gut nerve stem cells can be successful in the upper gut and may be able to partially reduce some disease symptoms. Over the course of the COVID-19 pandemic and national lockdown, the team developed new models which will allow the testing of new treatments or optimisation of stem cell treatments for gut diseases including achalasia and gastroparesis. The next steps for this work will be to confirm that the initial promising findings are carried over into functional rescue in terms of gut transit in these animal models. Following presentation of data from this project at international meetings, groups at the University of Melbourne and Harvard University have started to investigate cell-based treatments in both the gullet and stomach. Through future collaboration and sharing experiences across these groups, there is the potential to drive overall research into new treatments for these conditions. The team has been awarded further funding from two research councils to continue their work into gut nervous system stem cell treatments.

Crohn's disease: Dr Nick Powell's study aimed to identify biomarkers to predict response to medicines targeting the key cytokine called TNFα (the very molecule that is targeted by one of the key medications used in Crohn's disease). The study focused on the main target of Crohn's damage: the cells that line the bowel wall (called epithelial cells). These are the 'building blocks' of the gut

barrier that stops damaging substances or microbes from invading the human body. The analysis suggests that genetic changes of key chemicals driving the damage seen on the lining of the bowel wall can be tracked in the gut of patients with active IBD and that they may predict response to the drugs targeting the cytokines TNFα and IL23. This discovery will aid understanding of the reasons why some people respond to these medications and others don't and may allow identification of these people before they start their treatment. The next step is to test the value of these findings in clinical practice. The team aim to perform a prospective, validation study in the context of NHS based IBD care to see if this new knowledge can be used to predict in real life people's responses to their IBD medication. An application for a clinical trial of testing new therapeutic strategies to overcome the mechanisms of drug resistance described in this study is currently in preparation and targeted to major funders.

Childhood IBD: Dr Matthias Zilbauer's laboratory has established a novel experimental system, allowing the growth of 'mini-guts' (called organoids) from small, patient-derived tissue samples. The team has generated over 100 of such 'mini-guts' from children diagnosed with IBD and matching controls (i.e., children without the disease). They analysed these 'mini-guts' to find out how patients with IBD differ from children without the disease. The team also tested for differences between children with IBD in order to identify children with severe abnormalities. The team were able to show that the cells forming the inner lining of the gut harbour some changes that may lead them to be malfunctioning in children diagnosed with IBD and therefore could explain why these children suffer from chronic gut inflammation. The team confirmed that these cellular changes persist in 'mini-guts' generated from patient samples. This is hugely exciting as not only does this suggest that changes are permanent and very likely to have a key impact on the disease, but also that these 'mini-guts' can be used as models to test and develop novel drugs. These findings will pave the way for patient derived 'mini-guts' to be used to personalise the treatment of children suffering from IBD. As a next step the team have started to collect biopsies from more children diagnosed with IBD, obtained from centres across Europe. The pump priming funding we provided has contributed towards the team obtaining further funding including a networking grant from European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). A next crucial step is to work out ways to translate the findings into clinical practice. This includes validating findings in bigger cohorts but also reducing the number of methylation changes to a number that can be tested more easily.

Public education and awareness

Patient information

We provide evidence-based information written by medical experts in human digestive diseases to empower people to ask the right questions of the health professionals, to help get a timely diagnosis and the right treatment. Knowing more about what triggers a condition, learning about lifestyle factors or diet and nutrition can help people to better manage their condition and feel in control. This information is produced and co-branded with the BSG.

The demand for our information has increased dramatically over the last two years despite the fact that we do not run a helpline, nor do we advertise or promote such a service. Yet people email and phone when they find our website. The service we have been able to offer people suffering from digestive diseases, their families and friends has dramatically improved since the recruitment of the Information Manager in 2020. Telephone requests for information have increased 57% from last year and the Information Manager sent over 1,162 personal information support emails.



The demand for information continues to rise in 2022. People are suffering in silence and we would really like to be able to reach more people who need our help.

Our information is reviewed and updated by experts in the field and checked by people with digestive conditions to ensure it is easy to read and understand.

During 2021 the following information was updated:

- Barrett's oesophagus
- Coeliac disease
- Heartburn and reflux
- Ulcerative colitis
- Microscopic colitis
- Crohn's disease
- Diarrhoea
- IBS

New information has been added to the website:

- Oesophageal cancer
- Stomach cancer
- Gilbert's syndrome
- Mediterranean diet
- Opioid induced bowel dysfunction
- Rumination syndrome
- Food intolerance testing
- Perianal disease – this information has had a massive 51,000 views.

As clinics and endoscopy services began to reopen in 2021, we distributed 152,752 (2020: 112,240) patient information leaflets covering 18 digestive conditions to 92 (2020: 89) hospitals around the UK and Ireland.

We are continuing to develop the information on our website in video, audio and easy-read formats to ensure our patient facing information is accessible for all. Preparation began for the installation of the accessibility tool on our website to create a more inclusive experience online so people can customise our information in a format or language that works for them.

> "Thank you so much for all the attached information and for allowing me time to talk re my condition. I will look through the websites and talk to the consultant. We are very lucky to have people like you and your colleague."

Public awareness

Our printed magazines go out twice a year to our supporters and are packed with a wide variety of interesting and informative articles from diverticulosis around the world to a recipe for gut healthy digestive biscuits to information about the gallbladder and gallstones.

We send e-newsletters out every six weeks. In 2021 the number of people who signed up for our e-newsletter more than doubled.

We have given talks about the digestive system to home-schooled students at St Johns Church in Bradford and the Islam Bradford Centre and held a Science of Digestion event at the Bradford Muslim Centre encouraging people to go to their doctor if they have symptoms. Our research has shown that 51% of people wait six months or longer suffering from digestive symptoms before they seek professional advice.

Our Information Manager has been in growing demand and hosted several virtual talks: A Healthy Digestive System All You Need to Know for the Metropolitan Police Counter Terrorism Policing Headquarters and the Department of Work and Pensions and All you need to know about IBS for the Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust secure inpatient mental health unit. We hosted our first online webinar in conjunction with The Gut Stuff and received fantastic feedback.

We continue to take opportunities to provide information and articles for the media.

- Guardian Weekend – belching
- Mail On Sunday – IBS
- The Sun – gut symptoms and Christmas
- Telegraph – children with chronic health conditions
- Cycling Weekly – GI general
- Good Housekeeping – flatulence
- Pharmacy Magazine Training Matters – general GI and GI health at Christmas
- Pharmacy P3 Magazine – digestive health
- British Dietetic Association Magazine – commercial microbiome testing
- IBS Blog – sleep and the gut
- Science Focus blog – farting
- Patient UK – dumping syndrome, indigestion/GORD, and microbiome and gut health
- British Dietetic Association (BDA) Blog – diverticular disease

HIGHLIGHT

Guts UK's article on commercial microbiome testing had feedback that it was the best article in the BDA magazine and was also published on the BDA blog.

Warrington Disability Awareness Day (DAD)

We had attended DAD virtually in 2020 but this was the first time we had attended the event in person and Colin the Inflatable Colon proved a big hit, as ever, with adults and children alike.

Kranky Panky pancreatitis awareness campaign

Kranky Panky goes from strength to strength. In 2020 we reached 79,538 people, in 2021 we almost tripled this to 216,779. We shared a story a day for the month of November putting the patient voice at the heart of our awareness rising. The campaign helps connect families affected by this devastating condition who have expressed relief in finding, via Guts UK, a community that truly understands them.

> Thank you for being a real person at the end of a phone in difficult times."

The Kranky Panky campaign gives people so much more than a platform and a community, people also find it therapeutic.

> Thank you so much for your help and encouragement, this has been a big step forward for me in my mental health and it means a lot to me. It is comforting and also shocking to read the others' stories so far but I'm very happy to have taken part.

From the upsetting call in June 2019 that lasted almost two hours, to two years later Katie sharing her Dad, Danny's pancreatitis story.

https://gutscharity.org.uk/advice-and-information/kranky-panky/personal-stories/2021-stories/dannys-story/

Less Survivable Cancers Taskforce (LSCT)

Guts UK is a proud founding charity member of the LSCT. The LSCT was set up by a group of charities all aiming to double survival rates of the six less survivable cancers by 2029. These are stomach, oesophageal, pancreatic, liver, brain and lung cancer. **Guts UK funds research into the most underfunded, misunderstood and deadliest digestive cancers.**

Stomach cancer

Guts UK is currently funding Dr Marnix Jansen's research into stomach cancer. Dr Jansen's work is exploring an alternative, more targeted way of taking biopsies (small samples of tissue) from the stomach. The team will then use cutting-edge technology to begin understanding more about the changes in DNA that occur. **"The more we can understand about these DNA changes, the closer we come to finding a cure."**

"My husband was 64, a fit, healthy, daily dog walker. Tony suddenly began to get terrible indigestion that just wouldn't shift. After many visits and dismissals from the GP, Tony was eventually diagnosed with stomach cancer. Before he passed away, we made the decision to marry and we went on a beautiful honeymoon."

Oesophageal cancer

Guts UK is funding Dr Sara Jamel's research looking at the possibility of a 'breath-test' to diagnose oesophageal cancer. Currently people with Barrett's oesophagus have a routine endoscopy test where a small camera on a thin flexible tube looks at the lining of the oesophagus. The main research question is whether the cell changes in Barrett's oesophagus can be detected by testing the breath of people with the condition. This will provide an easy and cost-effective way to identify people at high risk of having oesophageal cancer. **If successful, this test could save lives by diagnosing oesophageal cancer earlier, when it is easier to treat.**

"I was 57 years old when I started with indigestion, which I'd never had before. After being prescribed with tablets to reduce stomach acid production, I was still struggling with symptoms so I asked my GP to send me for a gastroscopy. Even though I had suspected that I had oesophageal cancer, it was still a shock to be told. Thankfully, I am still here almost a decade on from having oesophageal cancer. I know this sadly isn't the case for many families, but I hope this helps to give others some hope."

Liver cancer

Guts UK is proud to fund Dr Salvatore Papa's research into liver cancer. It is thought that our livers when damaged, can change the way it gains energy in order to cheat cell death. But these damaged cells can eventually generate tumours, becoming cancerous. Dr Papa's team are looking to understand if it's possible to stop the liver changing the way it gains energy, in attempt to prevent cancerous cells from developing.

"Mum had just had a hip replacement, so she was trying to exercise more and build strength. One day she did tell me her wee was dark, but we thought little of it, as she was still recovering from her operation. A few weeks later mum was admitted to hospital with deep vein thrombosis. They ended up testing her liver as she started looking yellow (jaundice) and they found liver cancer. We had all expected upsetting news, but we didn't expect to be told mum's cancer was terminal and she had a month to live. Mum died just five days later at 64 years old, surrounded by the whole family. She was chatting away and making us all laugh, right until the end."

Only three in 20 people diagnosed with liver cancer in England survive their disease for five years or more. Guts UK wants to change this. Guts UK's research has the potential to save lives and give people a fighting chance.

Growing our Guts UK reach online



Instagram was new for 2021 for Guts UK!

Our first ever #GUTSelfie day took place in June 2021 and was a great success. We sent temporary tattoos and Guts UK merchandise out to supporters and asked them to take a #GUTSelfie and post it on Instagram. Comparing April to June **our reach increased by 446.1%.** There was a 550% increase in people clicking onto our website from Instagram in June.

"Your #GUTSelfie campaign is amazing! Seeing everyone posting their stories about living with a digestive disorder was so amazing and it makes everyone living with one feel less alone."

"I'm still very private with my gut issues but seeing what you're doing and reading people's stories has helped with the mind side today."

Microscopic colitis awareness week

We reached 20,000 people in this week. One in three people with microscopic colitis were initially diagnosed with IBS so it is vital to raise awareness of this condition to help people get the right diagnosis and treatment.



In September Clear Channel provided pro bono digital advertising in shopping centres across the country to boost awareness in our 50th year. We also tested washroom adverts with QR codes. The aim being to raise awareness of the need for the UK to get to grips with guts!

Income generation

Our goal in 2021 was to increase our long-term sustainable fundraising by growing our supporter base in order to make a transformational change to the levels of research into the gut, liver and pancreas and increase the number of people we are able to support with evidence-based information.

A programme of new donor acquisition was initiated to recruit individual financial support from the interested public, symptomatic public, patients and their families and friends.



2021 Increase in total voluntary income = 84%

London Marathon 2021

We had eight incredible runners (seven in person and one virtually). Between them they raised £14k for Guts UK!

BBC Radio 4 appeal

We are very grateful to Mr John Authers whose powerful first-hand account of pancreatitis helped us raise £27,600 and resulted in over 150 new donors as well as a legacy notification. The appeal continues to reap new contacts with people who had never heard of us before.

Plans for 2022

Diseases of the digestive system were the second most common primary diagnosis in 2020-21 and yet research in the area remains woefully underfunded. Guts UK exists to change that.

Research

Proposed grant funding

- The Guts UK Derek Butler Fellowship for £210,000, a 3-year fellowship for research in upper gastrointestinal tract diseases and conditions.
- The Guts UK Amelie Waring Fellowship for £180,00, a 3-year fellowship for research into any aspect of pancreatic inflammation or injury.
- Guts UK/Dr Falk awards £24,000 – investing in the gastroenterologists of the future

- Guts UK/forCrohns development grant – amount to be confirmed
- Guts UK/BSG trainee and early career researcher awards 10 x £5,000
- Guts UK development grants for early career researchers totalling £100,000
- Research Priority Setting Partnership – diverticular disease £20,000
- Guts UK/ASGBI awards – working in collaboration with surgeons £15,000

Fundraising, patient engagement and raising awareness

Sustainable growth in fundraising for Guts UK will remain focused on building up our supporter base which grows naturally as we serve more people via our information services. We will continue to build our presence via digital platforms such as Facebook and Instagram, and propose to venture into TikTok, all spaces that enable us to reach new audiences in a format they favour.

We will build more relationships with companies to increase corporate support and to find successful partnerships with the industry around digestive health, focusing on our shared objective of helping patients get the information they need, more, kinder treatments and ultimately a cure.

We will actively promote our patient information leaflets to gastroenterology clinics across all four nations of the UK in order that more patients are able to access evidence-based information about their symptoms and/or condition.

Staff, resources and capacity building

In 2021 the charity employed a new Fundraising Administrator to provide support to the Fundraising and Communications Officer to further enhance our income generation and awareness activities. We also recruited a Patient and Public Involvement and Engagement Officer whose key role is to deliver the Priority Setting Partnerships.

The Research Manager role was made redundant and a part time Research Administration Officer has been recruited in 2022.

We have also recruited two support hub administrators, one in the London office and one in the Huddersfield office and one Income Processing Administrator to assist with answering information queries and provide essential administrative support to existing staff to allow the charity to build and grow.

Office space

Guts UK currently occupies the third floor of 3 St Andrews Place as a direct tenant of the Royal College of Physicians. This is a new 5-year tenancy agreement with a break clause at 3 years. Whilst this does mean an increase in costs, it gives us security in the medium term, is good value for an office in a prime location, allows us to retain our registered office address and continue to work alongside the BSG.

In 2021 we moved into a larger space in the Media Centre in Huddersfield to house all the branded fundraising and awareness materials we have. The new space includes a separate, small office that staff can use to respond by telephone to the increasing number of in depth, personal information queries we receive.

Demand on our resources continues to increase as we serve the community of people affected by digestive disorders by providing relevant information, giving patients a voice and funding vital research. Income generation may be affected by the economic situation as the rise in the cost of living reduces people's disposable income. However, we will continue to support people with digestive conditions by getting to grips with guts.

FINANCIAL STATEMENTS

Financial review

The charity recorded income for the year of £1,078,130 (2020: £550,019) and expenditure of £920,771 (2020: £583,135). This resulted in net income, before investment gains, of £157,359 (2020: net expenditure before investment loss of £33,116). This is an exceptional performance in the second year of a pandemic and was much better than forecast due to legacy and investment income being higher than budgeted and the unexpected receipt of government funding via an MRC grant for research.

Income



During another year of tough fundraising conditions, total voluntary income increased by nearly 84%. Total voluntary income was £567,059 (2020 £308,435). We had an exceptional year for legacies including a one tenth share of a residuary estate as one of the ten Radio 4 appeals broadcast in the ten weeks prior to the legator's death. One legator told the executor of his will to leave a percentage of his residuary estate to a charity dealing with stomach problems, the executor found us on google and thought we were the most appropriate charity for the legacy. Another legator wanted to leave a donation to the Barrett's Oesophagus Foundation, their executor found that the Foundation no longer exists and thought we were the best fit as we are funding research in that area. This shows how our enhanced website presence benefits us. We are so grateful to these and others who so generously include us in their wills enabling us to continue to support people with digestive disorders and fund essential research.

Our increased profile has meant that people are more easily able to find us which is particularly important for those who have recently lost a loved one. In memoriam donations have doubled again over the last year; families and friends often find consolation in the thought that their fundraising may go some way to alleviating the suffering of others in the future.

Our digital advertising campaigns resulted in increased website donations, additional new donors and more than double last year's general donations figure. Community fundraising increased by 126% as our supporters continued to find new and inventive ways to fundraise. One of our supporters celebrated her 60th birthday by doing a Sky Dive to raise money and awareness in honour of our 50th birthday.

Research partner funding came from Dr Falk Pharma (UK) Ltd, the BSG, the PSGBI and BSPGHAN. We have utilised £47,027 of the forCrohn's funding received in 2020. The Parabola funding for Professor Rees colorectal cancer research was put on hold for the year but will resume in 2022. We will continue our current partnerships alongside building new partnerships to fund more research in the future.

For the first time in our history, we have received some funding from the government. We made a successful application to the UK Government COVID Medical Research Charity Support Fund to provide a valuable boost for our ongoing support for Early Career Researchers and gastroenterology trainees undergoing research projects during the financial year 2021-22. The total grant received was £151,099 for the following projects.

Researcher	Institution	Type of Grant	Amount Received
James O'Kelly	University of Edinburgh	Guts UK Amelie Waring Fellowship	£59,757
Sara Jamel	Imperial College London	Guts UK Olympus Fellowship	£45,844
Alessandra Frau (PI Chris Probert)	University of Liverpool	Guts UK Development Grant	£32,875
Varinder Athwal	University of Manchester	Guts UK Development Grant	£4,290
Robin Dart	Francis Crick Institute London	Guts UK/BSG Trainee Grant	£5,000
James Ashton	University of Southampton	Guts UK/BSG Trainee Grant	£3,333

Leaflet sales increased by 33% from 2020. We expect sales to increase further in 2022, as many hospitals and clinics reopen for face-to-face consultations and, with additional staff resources, we will be able to actively promote our leaflets.


Total Income 2021
£264,150
£302,909
£38,532
£169,250
£303,289
Legacies and in memoriam
Voluntary donations
Public education
Investment income
Partner research funding


Total Income 2020
£148,430
£160,005
£38,890
£163,694
£39,000
Legacies and in memoriam
Voluntary donations
Public education
Investment income
Partner research funding

Expenditure

We have worked hard to keep costs within budget whilst continuing to improve service provision for people with digestive disorders. Our salary costs increased to £328,886 due to the recruitment of a new Fundraising Administrator and a Patient and Public Involvement and Engagement Officer to assist with the delivery of our strategic objectives of raising awareness and transforming the research landscape. Overheads were 46% up on 2020 mainly due to the move to a larger office in Huddersfield and increased activity resulting in higher subscription fees for various services as well as higher bank charges, and printing, postage and stationery costs. During the year, we spent £641,333 on charitable activities (2020: £325,732), which represents 70% of total expenditure in the year. This is significantly higher than 2020 as we renewed our research funding programme. Whilst we have committed £301,231 to new research grants in 2021, we continued to focus on investment into income generation and raising awareness, reaching and recruiting new supporters to build a sustainable future for the charity hence the increase in fundraising expenditure.





Balance Sheet

The markets recovered somewhat in 2021, the investment portfolios contributed unrealised gains of £213,775 and realised gains of £373,228 (2020: unrealised losses of £76,009 and realised losses of £210,087). Of this amount, total realised and unrealised losses of £267,134 (2020: £117,933 total realised and unrealised losses) related to the endowment fund.

As at 31 December 2021, Guts UK had net assets of £6,389,416 (2020: £5,645,054) an increase of £744,362 with £6,435,629 held in listed investments. These include the Derek Butler endowment fund for research into upper gastrointestinal conditions of £3,266,446. The income from this fund will finance the new three-year fellowship to be awarded in 2022.

Unrestricted funds which can be spent at the discretion of the trustees were £3,090,435 of which £1,622,028 has been designated to contribute to the Amelie Waring pancreatitis fellowship and general gastrointestinal research grants awarded by the charity.

General funds amounted to £1,468,407 More details of the disposition of Guts UK net assets can be found in the financial statements on pages 51 and 52.

The principal liability of Guts UK Charity is to complete the research programme it has committed to of £1,251,335 at 31 December 2021 as set out in detail in note 18. Of these commitments, £90,000 is due from funding partners and £1,161,335 is to be funded from Guts UK's general unrestricted funds.

Reserves policy

Guts UK has reviewed the amount of reserves it regards as a minimum prudent requirement and has concluded that provision for twelve months administration, public education and fundraising costs is sufficient. This would allow time to manage cost reductions or fund appeals as required whilst minimising the impact on service provision. Based on the forecast for 2022, the desired minimum reserve is approximately £1,000,000. Currently free reserves total £1,468,407 less amounts held as fixed assets of £3,363 i.e. £1,465,044. Additional funds are to be utilised for research expenditure, building capacity and expanding the public information programme going forward.

Investment policy and performance

The charity's listed investments are managed by Cazenove. The investment strategy is set by the trustees and takes into account income requirements, the risk profile and the investment manager's advice on the market prospects in the medium term. The performance of the portfolio is monitored by the trustees.

In March 2021 the trustees reviewed the current investment strategy and agreed with the advice from Cazenove that investments should be moved to a Responsible Multi-Asset Fund. This fund adopts a total return approach and has the advantage of providing an even distribution payment as well as an ethically responsible investment policy. The Trustees are satisfied with the investment performance.

The Responsible Multi-Asset fund aims to meet the financial objectives of the charity whilst having a positive impact on people and the planet by:

1. Avoiding harm by adopting an investment screening policy that avoids areas of significant social or environmental harm, integrating environmental, social and governance factors in the investment process across all asset classes and supporting the Paris Agreement on Climate Change by reducing total portfolio carbon emissions and funding carbon offsets.
2. Benefiting society through sustainable business.
3. Contributing to solutions to environmental and social need by investing in impact investments.
4. Influencing companies and managers, through engagement and voting, to encourage progress towards the UN sustainable development goals.
5. Collaborate with other asset owners and managers to drive industry change.

Going concern

There is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. The trustees believe that there are no material uncertainties that call into doubt the charity's ability to continue operating as a going concern. Consequently, the financial statements have therefore been prepared on the basis that the charity remains a going concern.

GOVERNANCE, POLICIES AND STANDARDS

Guts UK is a charitable company limited by guarantee. Its governing document is its Memorandum and Articles of Association.

The trustees have overall responsibility for setting the strategic direction of the charitable company. The trustees delegate specific responsibility to several committees as follows:

a) Audit, Risk and Compliance Committee ("ARC") whose purpose is to oversee the operational activities of the charity covering finance, investment, audit, legal compliance, HR and risk management;

b) Research Awards Committee ("RAC") whose purpose is to ensure the integrity of Guts UK's research awards and that they align with the charity's stated objectives. The RAC is responsible for assessing, approving and monitoring applications for research funding. The RAC's processes are governed by the Terms of Reference and committee members (including those co-opted for specific awards) are required to sign a declaration of conflicts of interests form;
c) Funding, Communications and Industry Committee ("FUNCI") whose purpose is to deliver on Guts UK's fund-raising programmes, ensuring engagement with patients, public, the medical profession and industry alike;
d) Information Committee whose purpose is to recommend the strategic direction for information service provision; and to facilitate peer review and quality control of written and web-based information, plus any other public sources of information such as webinars provided by Guts UK.
e) Research Strategy Committee (RSC) whose purpose is to recommend areas of focus for Guts UK's research priorities.

The policies of the charity are determined by its board of trustees whose membership is listed on page 84. The research policy of the charity is decided by the trustees in consultation with the Research Committee of the BSG. Guts UK is a member of the Association of Medical Research Charities.

Guts UK advertises for new trustees as required. Prospective trustees are interviewed by the Chairman or other fellow trustees and are asked to submit a CV for review by the trustees. Candidates must be approved by a majority of trustees and the usual term of office is three years, renewable on approval by the board up to a maximum of 9 years total.

New trustees are provided with information concerning the finances, fundraising activities, grant-making and research policies of the charity. Those who are not familiar with the legal obligations and responsibilities of a trustee are provided with information published by organisations such as the Charity Commission. Training opportunities are offered to trustees on an ongoing basis.

Guts UK continues to work closely with the BSG to provide strong links with the main professional community and to improve its ability to disseminate research and patient information. The Chairman

of the BSG's Research Committee is a member of the board. The day-to-day operation of Guts UK is delegated to the Chief Executive who is supported by a team of staff.

Key management personnel

The key management personnel are those involved in managing the organisation, fundraising, communications, research and finance. These comprise the trustees, the Chief Executive and the Finance Manager.

The pay of all staff members, including members of key management, is reviewed annually by the trustees. Remuneration details in relation to key management personnel are provided in Note 10 to the financial statements.

Risk management

Guts UK maintain a risk register covering the major risks to which the charity is exposed. This covers governance and compliance, operational and administration, financial and investment and reputational risks.

Guts UK rates potential risks by likelihood and impact. The risk register is reviewed regularly by the trustees and the key risks together with the policies to mitigate them have been identified as:

Failure to comply with GDPR regulations

Policies and procedures have been developed and communicated to all staff. Ongoing training is provided. Data protection is a standing item on the ARC Committee and trustee meeting agendas to ensure trustees are kept up to date with actions taken to ensure compliance with the regulations. There will be ongoing monitoring of compliance with regulations.

Failure to meet strategy to increase donations

Management accounts are prepared and regularly reviewed by the ARC Committee to monitor fundraising performance. The fundraising strategy has been reviewed by the Chief Executive and trustees with a view to increasing the number of individual supporters and donors alongside developing different income sources to include approaching former funded researchers and gastroenterologists and industry/pharma for support. The trustees review income generation, reserves and strategy at each Board meeting to ensure the strategy is still the right one and that the charity has sufficient funds to meet it.

Impact of COVID-19

The COVID-19 Pandemic continues to pose some increased risks. The trustees will continue to monitor income and expenditure and adjust expenditure as required. Most staff are now working most days in the office, but all staff have the resources to work from home if required. Whilst it may be possible to hold Science of Digestion and other public awareness events in person in 2022, the possibility of digital public awareness events will be investigated as well. The public awareness programme is important to enable the charity to fulfil its charitable objectives of educating the public about digestive diseases but also impacts on the recruitment of new supporters and fundraisers.

Fundraising Standards at Guts UK

- Our donors are important to us and we seek to deliver the highest standards of donor care and support
- Open and accountable fundraising – we regularly tell our supporters how they can easily change their preferences.
- Communicating with our supporters – we update our supporters through our twice-yearly newsletter for those who prefer a print option, and regular e-newsletters.
- Complying with laws, regulation and standards – we are a member of the Chartered Institute of Fundraising and are committed to working to a best practice framework actively complying with the Fundraising Code of Practice. We are registered with the Fundraising Regulator and signed up to The Fundraising Promise.
- Protecting vulnerable people – we do everything possible to meet the needs of potential supporters and protect vulnerable people. In particular, the charity confirms that it complies with all relevant data protection laws. No instances of non-compliance have been identified during the year and no suppression requests were received in 2021 in relation to the fundraising activities.
- Complaints and negative feedback – we treat all complaints seriously and aim to respond in a timely and fair manner. All complaints inform and influence the charity's approach to fundraising. We use the feedback that we get from our supporters to improve the way we do things.
- Working with partner agencies – we may engage professional third parties to act on our behalf, for example, to produce and distribute direct mailings. To ensure that fundraising activities of third parties are compliant with regulation and the charity's own internal standards, the charity approves all third-party communication prior to distribution and sets out clear guidelines in the agreements made with such parties. We also work with commercial participators, such as Amazon Smile, Everyclick, Give as you Live and Easy Fundraising to raise funds. Agreements with commercial participators are checked and activity monitored to ensure compliance with the Fundraising Code of Practice.
- We never swap, sell or share any data.
- We work hard to ensure we deliver value for money in all of our charitable activities.

Statement of trustees' responsibilities

The trustees (who are also directors of Guts UK for the purposes of company law) are responsible for preparing the trustees' report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of Guts UK and the income and expenditure of Guts UK for that period.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Report Standard applicable to the United Kingdom and Republic of Ireland (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable United Kingdom Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on a going concern basis unless it is inappropriate to presume that Guts UK will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of Guts UK and enable them to ensure that the Financial Statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of Guts UK and for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Each of the trustees confirms that:

- so far as the trustee is aware, there is no relevant audit information of which Guts UK's auditor is unaware; and
- the trustee has taken all the steps that he/she ought to have taken as a trustee in order to make himself/herself aware of any relevant audit information and to establish that the charitable company's auditor is aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of s418 of the Companies Act 2006.

The trustees are responsible for the maintenance and integrity of corporate and financial information included on Guts UK's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the trustees and signed on their behalf by:

Mr S Williams BA ACA
Trustee



Prof JM Rhodes MD FRCP FMedSci
Chair of Trustees

Approved by the trustees on: 10th June 2022

Independent auditor's report to the trustees of Guts UK Charity

Opinion
We have audited the financial statements of Guts UK Charity (the 'charitable company') for the year ended 31 December 2021 which comprise the statement of financial activities, the balance sheet, the statement of cash flows, and the related notes to the financial statements, including a summary of accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2021 and of its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information
The trustees are responsible for the other information. The other information comprises the information included in the annual report and performance review 2020, and financial statements, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- the information given in the trustees' annual report is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees
As explained more fully in the trustees' responsibilities statement, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements (continued)
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations; and

- we obtained an understanding of the legal and regulatory frameworks that are applicable to the charitable company and determined that the most significant frameworks which are directly relevant to specific assertions in the financial statements are those that relate to the reporting framework (Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Companies Act 2006).

We assessed the susceptibility of the charitable company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to their knowledge of actual, suspected and alleged fraud; and

- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;

Auditor's responsibilities for the audit of the financial statements (continued)
In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- reading the minutes of meetings of those charged with governance; and
- enquiring of management as to actual and potential litigation and claims.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the trustees and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report
This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Shachi Blakemore (Senior Statutory Auditor)
For and on behalf of Buzzacott LLP
Statutory Auditor
130 Wood Street
London
EC2V 6DL

Statement of financial activities Year ended 31 December 2021
(including the income and expenditure account)

		Unrestricted funds £	Restricted funds £	Endowment funds £	**2021 Total funds £**	2020 Total funds £
Income and expenditure						
Income						
Donations and legacies	1	**508,081**	**58,978**	**—**	**567,059**	308,435
Other trading activities	2	**38,532**		**—**	**38,532**	38,890
Investment income	3	**88,174**	**81,076**	**—**	**169,250**	163,694
Charitable activities						
. Grants for research	4	**—**	**303,289**	**—**	**303,289**	39,000
Total income		**634,787**	**443,343**	**—**	**1,078,130**	550,019
Expenditure						
Cost of raising funds	5	**265,962**	**—**	**13,476**	**279,438**	257,403
Expenditure on charitable activities						
. Grants for research	6	**183,106**	**295,420**	**—**	**478,526**	170,930
. Public education and Science of Digestion		**162,807**	**—**	**—**	**162,807**	154,802
Total expenditure	8	**611,875**	**295,420**	**13,476**	**920,771**	583,135
Net income/(expenditure) before transfers	9	**22,912**	**147,923**	**(13,476)**	**157,359**	(33,116)
Transfers between funds	19	**41,297**	**(41,297)**	**—**	**—**	—
Net income/(expenditure) after transfers		**64,209**	**106,626**	**(13,476)**	**157,359**	(33,116)
Net gains/ (losses) on investments						
. Realised	14	**165,032**	**—**	**208,196**	**373,228**	(210,087)
. Unrealised		**154,837**	**—**	**58,938**	**213,775**	(76,009)
Net income/ (expenditure) and net movement in funds for the year		**384,078**	**106,626**	**253,658**	**744,362**	(319,212)
Reconciliation of funds:						
Funds balances brought forward		**2,706,357**	**255,282**	**2,683,415**	**5,645,054**	5,964,266
Fund balances carried forward		**3,090,435**	**361,908**	**2,937,073**	**6,389,416**	5,645,054

All of the charity's activities derived from continuing operations during the above two financial periods.

All recognised gains or losses are included in the above statement of financial activities.

A full comparative Statement of Financial Activities for the year ended 31 December 2020 is shown in note 28 to the financial statements.

Balance sheet 31 December 2021

	Notes	2021 £	2021 £	2020 £	2020 £
Fixed assets					
Tangible fixed assets	13		**3,363**		3,520
Investments	14		**6,435,629**		5,992,360
			6,438,992		5,995,880
Current assets					
Debtors: due within one year	15	**343,764**		358,480	
Short term cash deposits		**685,537**		526,860	
Cash at bank and in hand		**260,268**		332,599	
		1,289,569		1,217,939	
Liabilities:					
Creditors: amounts falling due within one year	16	**(1,119,105)**		(1,136,452)	
Net current assets			**170,464**		81,487
Total assets less current liabilities			**6,609,456**		6,077,367
Liabilities:					
Creditors: amounts falling due after one year	17		**(220,040)**		(432,313)
Total net assets			**6,389,416**		5,645,054
The funds of the charity					
Unrestricted income funds					
. General			**1,468,407**		1,096,988
. Designated funds	20		**1,622,028**		1,609,369
Restricted funds	19		**361,908**		255,282
Endowment fund	21		**2,937,073**		2,683,415
			6,389,416		5,645,054

Approved by the trustees and signed on their behalf by:

Mr S Williams BA ACA

Trustee

Approved on:

Guts UK Charity
Registered Company Number: 07274105 (England and Wales)

Statement of cash flows 31 December 2021

	Notes	2021 £	2020 £
Cash inflow used in operating activities:			
Net cash used in operating activities	A	**(225,219)**	(211,571)
Cash inflow from investing activities:			
Dividends and interest from investments		**169,250**	163,694
Purchase of tangible fixed assets		**(1,417)**	(2,921)
Proceeds from the disposal of investments		**6,504,709**	1,390,982
Purchase of investments		**(6,473,053)**	(1,454,396)
Net cash provided by investing activities		**199,489**	97,358
Change in cash and cash equivalents in the year		**(25,730)**	(114,213)
Cash and cash equivalents at 1 January	B	**1,321,977**	1,436,190
Cash and cash equivalents at 31 December	B	**1,296,247**	1,321,977

Notes to the statement of cash flows for the year to 31 December

A Reconciliation of net movement in funds to net cash (used in) provided by operating activities

	2021 £	2020 £
Net movement in funds (as per the statement of financial activities)	**744,362**	(319,212)
Adjustments for:		
Depreciation charge	**1,574**	1,386
(Gains) / losses on investments	**(587,003)**	286,096
Dividends and interest from investments	**(169,250)**	(163,694)
Decrease in debtors	**14,718**	173,795
(Decrease) in creditors	**(229,620)**	(189,942)
Net cash used in operating activities	**(225,219)**	(211,571)

B Analysis of changes in cashflow and net debt

	1 Jan 2021 £	Movement in year £	31 Dec 2021 £
Cash at bank and in hand	332,599	**(72,331)**	**260,268**
Short term cash deposits	526,860	**158,677**	**685,537**
Cash held by investment managers	462,518	**(112,076)**	**350,442**
Total cash and cash equivalents	1,321,977	**(25,730)**	**1,296,247**

No separate reconciliation of net debt has been prepared as there is no difference between the net cash (debt) of the Charity and the cash and cash equivalents.

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are laid out below.

Basis of preparation
These financial statements have been prepared for the year to 31 December 2021 and are presented in sterling and are rounded to the nearest pound.

The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant accounting policies below or the notes to these financial statements.

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (Charities SORP FRS 102) issued on 16 July 2014, the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The charity constitutes a public benefit entity as defined by FRS 102.

Critical accounting estimates and areas of judgement
Preparation of the financial statements requires the trustees and management to make significant judgements and estimates.

The items in the financial statements where these judgements and estimates have been made include:

- estimating the useful economic lives of tangible fixed assets for the purpose of determining the annual depreciation charge;
- assessing the probability of the receipt of legacy income;
- allocation of support costs between activities on the basis of staff time and
- estimating future cash flows for the purpose of determining going concern.

Assessment of going concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements and have made this assessment in respect to a period of one year from the date of approval of these financial statements.

The trustees have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the charity to continue as a going concern. The trustees are confident that the charity has sufficient funds to cover its existing liabilities.

With regard to the next accounting period, the year ending 31 December 2022, the most significant areas that affect the carrying value of the assets held by the charity are the level of investment return and the performance of the investment markets (see the investment policy and the risk management sections of the trustees' report for more information).

Income recognition

Income is recognised in the period in which the charity has entitlement to the income, the amount of income can be measured reliably and it is probable that the income will be received.

Donations are recognised when the charity has confirmation of both the amount and settlement date. In the event of donations pledged but not received, the amount is accrued for where the receipt is probable.

Legacies are included in the statement of financial activities when the charity is entitled to the legacy, the executors have established that there are sufficient surplus assets in the estate to pay the legacy, and any conditions attached to the legacy are within the control of the charity. Entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor to the charity that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity or the charity is aware of the granting of probate, but the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material. In the event that the gift is in the form of an asset other than cash or a financial asset traded on a recognised stock exchange, recognition is subject to the value of the gift being reliably measurable with a degree of reasonable accuracy and the title of the asset having being transferred to the charity.

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due.

Income recognition (continued)
Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

Research funding income is recognised in the period in which the charity receives a written commitment from the funder. Research funding is deferred only when the charity has to fulfil conditions before becoming entitled to it or the donor has specified that the income has to be spent in a future period.

Expenditure recognition
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to make a payment to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis and is stated inclusive of irrecoverable VAT. Expenditure comprises direct costs and support costs. All expenses, including support costs, are allocated or apportioned to the applicable expenditure headings. The classification between activities is as follows:

a) Cost of raising funds which includes direct fundraising costs and investment manager's fees.

b) Expenditure on charitable activities comprises expenditure on the charity's primary charitable purposes as described in the trustees' report. Such costs include grants payable, other direct costs and support costs, which are apportioned based on the level of activity in each area.

Research grants payable are included in the statement of financial activities when approved and when the intended recipient has either received the funds or been informed of the decision to make the grant, and has satisfied all relevant conditions. Grants approved but not paid at the end of the financial year are accrued for. Grants where the beneficiary has not been informed or has to meet certain conditions before the grant is payable are not accrued for but are noted as financial commitments in the notes to the financial statements.

The provision of a multi-year grant is recognised at its present value where settlement is due over more than one year from the date of the award, there are no unfulfilled performance conditions under the control of the charity that would permit the charity to avoid making the future payments, settlement is probable and the effect of the discounting is material. The discount rate used is the average rate of investment yield in the year in which the grant is made. This discount rate is regarded by the trustees as providing the most current available estimate of the opportunity cost of money reflecting the time value of money to the charity.

Allocation of support costs and governance costs
Support costs represent indirect charitable expenditure. In order to carry out the primary purposes of the charity it is necessary to provide support in the form of financial procedures, provision of office services and equipment and a suitable working environment.

Governance costs comprise the costs directly attributable to the governance of the charity, including audit costs and the necessary legal procedures for compliance with statutory requirements. Support costs and governance costs are allocated between activities with the allocation based on staff time.

Fixed asset investments
Listed investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price.

The charity does not acquire put options, derivatives or other complex financial instruments.

Realised gains (or losses) on investment assets are calculated as the difference between disposal proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value at that date. Realised and unrealised investment gains (or losses) are combined in the statement of financial activities and are credited (or debited) in the year in which they arise.

Debtors
Debtors are recognised at their settlement amount, less any provision for non-recoverability. Prepayments are valued at the amount prepaid. They have been discounted to the present value of the future cash receipt where such discounting is material.

Cash at bank and in hand and short term deposits
Cash at bank and in hand represents such accounts and instruments that are available on demand or have a maturity of less than three months from the date of acquisition. Deposits for more than three months but less than one year have been disclosed as short term deposits.

Creditors and provisions
Creditors and provisions are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Creditors and provisions are recognised at the amount the charity anticipates it will pay to settle the debt. They have been discounted to the present value of the future cash payment where such discounting is material.

Tangible fixed assets
Depreciation of fixed assets is calculated on cost at rates estimated to write off the assets, by equal instalments, over their expected working lives.

- Office furniture, fittings and equipment - 5 years
- IT equipment - 3 years

Items used in the day to day running of the charity and with a cost in excess of £500 are capitalised, and are stated at cost less accumulated depreciation.

Financial instruments
The charity only holds basic financial instruments as defined in FRS 102. The financial assets and financial liabilities of the charity and their measurement basis are as follows:

Financial assets – other debtors are basic financial instruments and are debt instruments measured at amortised cost. Listed investments are a basic financial instrument as detailed above. Prepayments are not financial instruments.

Cash at bank – classified as a basic financial instrument and is measured at face value.

Financial liabilities – accruals and other creditors are financial instruments, and are measured at amortised cost.

Fund structure
The charity has various types of funds for which it is responsible, and which require separate disclosure. These are as follows:

General funds
Funds which are expendable at the discretion of the trustees in furtherance of the objects of the charity.

Designated funds
Funds which are set aside as part of the charity's unrestricted funds for particular purposes in the future as determined by the trustees from time to time.

Restricted funds
Funds raised for, and their use restricted to, a specific purpose, or donations subject to donor imposed conditions.

Endowment funds
Funds which must be held indefinitely as capital. Income therefore is credited to general funds and applied for general purposes unless under the terms of the endowments such income must be used for specific purposes in which cases it is credited to restricted funds.

Pension costs

The charity operates a defined contribution scheme on behalf of its employees. The assets are held in separately administered funds. Costs are charged to the statement of financial activities in the period to which they relate.

1. Donations and legacies

	Unrestricted funds £	Restricted funds £	**2021 Total funds £**
Donations	276,420	26,489	**302,909**
Legacies & In Memoriam donations	231,661	32,489	**264,150**
2021 Total funds	508,081	58,978	**567,059**

	Unrestricted funds £	*Restricted funds £*	*2020 Total funds £*
Donations	*143,636*	*16,369*	*160,005*
Legacies & In Memoriam donations	*146,823*	*1,607*	*148,430*
2020 Total funds	*290,459*	*17,976*	*308,435*

2. Other trading activities

	Unrestricted funds £	Restricted funds £	**2021 Total funds £**
Public education	38,532	—	**38,532**
2021 Total funds	38,532	—	**38,532**

	Unrestricted funds £	*Restricted funds £*	*2020 Total funds £*
Public education	*28,890*	*—*	*28,890*
Public Education – leaflet sponsorship	*10,000*	*—*	*10,000*
2020 Total funds	*38,890*	*—*	*38,890*

3. Investment income

	Unrestricted funds £	Restricted funds £	**2021 Total funds £**
Interest – fixed interest securities	7	18	**25**
Dividends - UK and international equities	22,206	40,470	**62,476**
Bonds - UK and international	5,643	6,200	**11,843**
Multi asset funds	52,389	26,048	**78,437**
Charities property fund	5,086	4,886	**9,972**
Other funds	2,979	3,454	**6,433**
Interest on cash deposits	64	—	**64**
2021 Total funds	88,174	81,076	**169,250**

3. Investment income (continued)

	Unrestricted funds £	*Restricted funds £*	*2020 Total funds £*
Interest – fixed interest securities	*187*	*486*	*673*
Dividends - UK and international equities	*38,743*	*36,558*	*75,301*
Bonds - UK and international	*20,898*	*18,683*	*39,581*
Multi asset funds	*14,937*	*12,936*	*27,873*
Charities property fund	*6,103*	*4,775*	*10,878*
Other funds	*3,303*	*3,763*	*7,066*
Interest on cash deposits	*2,322*	*—*	*2,322*
2020 Total funds	*86,493*	*77,201*	*163,694*

4. Income from charitable activities

	Unrestricted funds £	Restricted funds £	**2021 Total funds £**
New grants for research	—	303,289	**303,289**
2021 Total funds	—	303,289	**303,289**

	Unrestricted funds £	*Restricted funds £*	*2020 Total funds £*
New grants for research	*—*	*39,000*	*39,000*
2020 Total funds	*—*	*39,000*	*39,000*

5. Cost of raising funds

	Unrestricted funds £	Endowment funds £	**2021 Total funds £**
Fundraising costs	81,417	—	**81,417**
Investment manager's fees	9,679	13,476	**23,155**
Support costs (note 8)	174,866	—	**174,866**
2021 Total funds	265,962	13,476	**279,438**

	Unrestricted funds £	*Restricted funds £*	*2020 Total funds £*
Fundraising costs	*48,040*	*—*	*48,040*
Investment manager's fees	*13,844*	*12,520*	*26,364*
Support costs (note 8)	*182,999*	*—*	*182,999*
2020 Total funds	*244,883*	*12,520*	*257,403*

6. Expenditure on charitable activities

	Direct costs £	Research grants awarded (note 7) £	Support costs (note 8) £	**2021 Total funds £**
Gastroenterology research	1,059	288,068	189,399	**478,526**
Public Education	58,263	—	104,544	**162,807**
2021 Total funds	59,322	288,068	293,943	**641,333**

	Direct costs £	*Research grants awarded (note 7) £*	*Support costs (note 8) £*	*2020 Total funds £*
Gastroenterology research	*1,893*	*58,437*	*110,600*	*170,930*
Public Education	*48,204*	*—*	*106,598*	*154,802*
2020 Total funds	*50,097*	*58,437*	*217,198*	*325,732*

7. Research grants awarded

	2021 Total funds £	2020 Total funds £
New research grants	**301,231**	61,950
Less grants no longer required – research commitments	**(13,163)**	(3,513)
Research grants awarded (note 6)	**288,068**	58,437

Research grants awarded represent commitments made for research, and are set out in detail in note 18.

8. Total expenditure

		Charitable activities		
	Cost of raising funds £	Gastro-enterology research £	Public education and Science of Digestion £	**2021 Total funds £**
Directly incurred				
Grants payable (see note 7)	—	288,068	—	**288,068**
Research administration	—	1,059	—	**1,059**
Fundraising costs	81,417	—	—	**81,417**
Public education	—	—	58,263	**58,263**
Investment management fees	23,155	—	—	**23,155**
	104,572	289,127	58,263	**451,962**
Support costs				
Staff costs (see note 10)	122,674	132,870	73,342	**328,886**
Premises and donated facilities	8,685	9,407	5,193	**23,285**
Postage	495	536	296	**1,327**
Telephone	1,727	1,871	1,033	**4,631**
Stationery, printing, design and marketing	2,566	2,780	1,534	**6,880**
Insurance	1,603	1,735	958	**4,296**
Bank charges	2,968	3,215	1,775	**7,958**
Meeting costs	1,732	1,874	1,033	**4,639**
Subscriptions/publications	3,685	3,992	2,203	**9,880**
Equipment/maintenance and website development	16,635	18,018	9,945	**44,598**
Depreciation	587	636	351	**1,574**
Training and recruitment	(464)	(504)	(278)	**(1,246)**
Governance costs:				
. Audit & Accountancy	3,702	4,010	2,213	**9,925**
. Professional fees	2,863	3,101	1,712	**7,676**
. Bookkeeping costs	1,697	1,838	1,015	**4,550**
Brand development	3,711	4,020	2,219	**9,950**
	174,866	189,399	104,544	**468,809**
2021 Total funds	279,438	478,526	162,807	**920,771**

8. Total expenditure (continued)

		Charitable activities		
	Cost of raising funds £	*Gastro-enterology research £*	*Public education and Science of Digestion £*	*2020 Total funds £*
Directly incurred				
Grants payable (see note 7)	*—*	*58,437*	*—*	*58,437*
Research administration	*—*	*1,893*	*—*	*1,893*
Fundraising costs	*48,040*	*—*	*—*	*48,040*
Public education	*—*	*—*	*48,204*	*48,204*
Investment management fees	*26,364*	*—*	*—*	*26,364*
	74,404	*60,330*	*48,204*	*182,938*
Support costs				
Staff costs (see note 10)	*135,957*	*82,169*	*79,195*	*297,321*
Premises and donated facilities	*5,101*	*3,083*	*2,971*	*11,155*
Postage	*183*	*111*	*107*	*401*
Telephone	*1,694*	*1,024*	*987*	*3,705*
Stationery, printing, design and marketing	*1,632*	*986*	*951*	*3,569*
Insurance	*529*	*320*	*308*	*1,157*
Bank charges	*1,597*	*965*	*930*	*3,492*
Meeting costs	*2,210*	*1,336*	*1,288*	*4,834*
Subscriptions/publications	*3,073*	*1,857*	*1,790*	*6,720*
Equipment/maintenance and website development	*8,760*	*5,294*	*5,103*	*19,157*
Depreciation	*634*	*383*	*369*	*1,386*
Training and recruitment	*7,084*	*4,282*	*4,127*	*15,493*
Governance costs:				
. Audit & Accountancy	*3,833*	*2,316*	*2,233*	*8,382*
. Professional fees	*956*	*578*	*557*	*2,091*
. Bookkeeping costs	*2,281*	*1,378*	*1,328*	*4,987*
Brand development	*7,475*	*4,518*	*4,354*	*16,347*
	182,999	*110,600*	*106,598*	*400,197*
2020 Total funds	*257,403*	*170,930*	*154,802*	*583,135*

9. Net income/(expenditure) before transfers

This is stated after charging:

	2021 Total funds £	2020 Total funds £
Staff costs (note 10)	**328,886**	297,321
Depreciation	**1,574**	1,386
Auditor's remuneration (including VAT)		
. Statutory audit services – current year	**9,000**	8,460

10. Staff costs and remuneration of key management personnel

	2021 Total funds £	2020 Total funds £
Salaries and wages	**294,066**	266,856
Social security	**26,352**	22,508
Pension costs	**8,468**	7,957
	328,886	297,321

The average number of employees during the period was 8 (2020: 8). One employee earned between £60,001 and £70,000 during the year (2020: one employee earned between £60,001 and £70,000).

The key management personnel of the charity in charge of directing and controlling, running and operating the charity on a day to day basis comprise the trustees, the CEO, the Finance and Research Managers. The total remuneration (including taxable benefits and employer's pension contributions) of the key management personnel for the year was £164,730 (2020: £159,857).

11. Trustees' remuneration and expenses

£nil remuneration (2020: £nil) was paid or payable, directly or indirectly, out of the funds of the charity for the period to any trustee, or to any person or persons known to be connected with any of them.

Five trustees were reimbursed for travel expenses of £308 during the period (2020: two trustees: £258).

12. Taxation

Guts UK is a registered charity and is potentially exempt from taxation in respect of income and capital gains received within the categories covered by Section 505 of the Taxes Act 1988 or Section 256 of the Taxation of Chargeable Gains Act 1992 to the extent that such income or gains are applied to exclusively charitable purposes.

13. Tangible fixed assets

	Computer equipment £
Cost	
At 1 January 2021	**9,564**
Additions in the year	**1,417**
At 31 December 2021	**10,981**
Depreciation	
At 1 January 2021	**6,044**
Charge for the year	**1,574**
At 31 December 2021	**7,618**
Net book value	
At 31 December 2021	**3,363**
At 31 December 2020	3,520

14. Investments

	Endowment portfolio £	Unrestricted portfolio £	**2021 £**	2020 £
At valuation				
Balance brought forward at 1 January	2,663,217	2,866,625	**5,529,842**	5,752,524
Additions	3,157,315	3,315,737	**6,473,052**	1,454,396
Disposal proceeds	(3,144,124)	(3,360,586)	**(6,504,710)**	(1,390,982)
Investment gains				
. Realised gains/(losses)	208,196	165,032	**373,228**	(210,087)
. Unrealised gains/(losses)	58,938	154,837	**213,775**	(76,009)
Total investment gains/(losses)	267,134	319,869	**587,003**	(286,096)
Balance carried forward at 31 December	2,943,542	3,141,645	**6,085,187**	5,529,842
Cash held by investment managers	322,904	27,538	**350,442**	462,518
Total investments	3,266,446	3,169,183	**6,435,629**	5,992,360
Analysis by Type				
Listed investments at market value				
. UK Equities	—	—	—	2,150,378
. Overseas Equities	—	—	—	1,666,706
. UK Bonds	—	—	—	472,081
. Overseas bonds	—	—	—	224,861
. Multi-asset funds	2,845,427	3,141,645	5,987,072	370,826
. Property funds	98,115	—	98,115	284,198
. Other	—	—	—	360,792
Total investments	2,943,542	3,141,645	**6,085,187**	5,529,842

14. Investments (continued)

Historic cost of listed investments (all are listed in the UK) - excluding cash held by investment managers	2,867,205	2,999,548	**5,866,753**	5,209,146

At 31 December the charity had the following material investment holdings:

	Endowment £	Unrestricted £	**Market value £**	Percentage of portfolio %
Listed investments within the portfolio are:				
SUTL Cazenove Charity Responsible	2,845,427	3,141,645	**5,987,072**	98%

The total unrealised gains as at 31 December constitute movements on revaluation and are as follows:

	2021 £	2020 £
Unrealised gains included above:		
On investments	**218,440**	320,696
Total unrealised gains at 31 December	**218,440**	320,696
Reconciliation of movements in unrealised gains:		
Unrealised gains at 1 January	**320,696**	709,656
(Losses) in respect to disposals in the year	**(316,031)**	(312,951)
	4,665	396,705
Add: net gains arising on revaluation in the year	**213,775**	(76,009)
Total unrealised gains at 31 December	**218,440**	320,696

15. Debtors

	2021 **£**	2020 £
Prepayments, accrued income and sundry debtors	**52,664**	78,414
Commitments due from funding partners	**291,100**	280,066
	343,764	358,480

Included within debtors under commitments due from funding partners is £291,100 (2020: £70,000) which is due within one year

16. Creditors: amounts falling due within one year

	2021 **£**	2020 £
Other creditors	**9,799**	8,722
Accruals and deferred income	**78,011**	105,059
Research grants payable (see note 18)	**1,031,295**	1,022,671
	1,119,105	1,136,452

17. Creditors: amounts falling due after more than one year

	2021 **£**	2020 £
Research grants payable (see note 18)	**220,040**	432,313

18. Research grants payable

	2021 **Total funds** **£**	2020 Total funds £
At 1 January	**1,454,984**	1,721,855
Research grants awarded in the year	**301,231**	61,950
Research grants no longer required	**(13,163)**	(3,513)
Paid during the year	**(491,717)**	(325,308)
At 31 December	**1,251,335**	1,454,984
Research grants at 31 December are payable as follows:		
Within one year (see note 16)	**1,031,295**	1,022,671
After more than one year (see note 17)	**220,040**	432,313
	1,251,335	1,454,984

Details of research grants payable are provided overleaf.

18. Research grants payable (continued)

			At 1 January 2021 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2021 £**
Ongoing research							
Dr Wadiamu Gashau	Core-BSG Trainee Research Network Award	RISE NoW (Regional IBD Surveillance Endoscopy North West) study: A real world experience of dysplasia and colorectal cancer surveillance in Inflammatory Bowel Disease (IBD)	**2,500**	-	-	-	**2,500**
Mr James O'Kelly	Guts UK/Amelie Waring Research Fellowship	Single cell definition of the mechanistic role of kynurenine monooxygenase at the innate immune interface in acute pancreatitis	**147,301**	-	-	-	**147,301**
Dr Sara Jamel	Olympus Guts UK Endoscopy Fellowship	Profiling of Dysplastic Changes in Barrett's Oesophagus and Early Oesophageal Cancer Using Non-Invasive Volatile Organic Compound Analysis of Exhaled Breath	**120,122**	-	-	(69,043)	**51,079**
Professor Colin Rees	Parabola-Guts UK Colorectal Cancer Research Grant	COLO-COHORT Colorectal Cancer Cohort Study	**404,045**	-	-	(132,540)	**271,505**
Dr Marc-Emmanuel Dumas	Guts UK Development Award	Precision medicine through integrative metagenomics and phenomics in a human NAFLD cohort	**49,797**	-	-	-	**49,797**
Dr Varinder Athwal	Guts UK Development Award	Investigating fibrosis pathobiology in cystic fibrosis related liver disease to improve clinical detection and management	**4,290**	-	-	-	**4,290**
Dr Dipesh Vasant	Guts UK-Dr Falk SpR Trainee Audit/Quality Improvement Award	Anorectal dysfunction in ulcerative colitis: a cross sectional survey	**1,300**	-	-	-	**1,300**
Dr Gwo-tzer Ho	Guts UK Development Award	Resolving Inflammation in IBD: Developing a new therapeutic approach by targeting pro-inflammatory mitochondrial formylated peptides on neutrophil FPR1-pathway	**13,830**	-	-	(2,171)	**11,659**
Balance carried forward			**743,185**	**-**	**-**	**(203,754)**	**539,431**

18. Research grants payable (continued)

			At 1 January 2021 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2021 £**
Ongoing research cont'd							
Balance brought forward			**743,185**	**-**	**-**	**(203,754)**	**539,431**
Dr Nick Powell	For Crohns	TNFα responsive transcriptional networks in the human intestinal epithelium - the key to predicting therapeutic response to antic-TNFα in Crohn's disease	48,737	-	-	(45,206)	**3,531**
Dr Louise China	Guts UK-BSG Trainee Research Award	Exploring Periodontitis in Cirrhosis (EPIC): a single arm feasibility study to explore the relationship between periodontitis and infection in patients with liver cirrhosis.	4,980	-	-	-	**4,980**
Dr Srivathsan Ravindran	Guts UK-BSG Trainee Research Award	Developing a patient-reported safety incident tool in endoscopy	1,887	-	-	-	**1,887**
Dr Mike Davies	Guts UK-BSG Trainee Research Network Award	Getting to the bottom of acute Lower Gastrointestinal Bleeding: Improving quality of care for patients with acute lower gastrointestinal bleeding and assessing resource implications of adherence to national guidelines	3,000	-	-	(1,500)	**1,500**
Dr Samuel Smith	Guts UK-BSG Trainee Research Network Award	Improving key performance measures in inflammatory bowel disease surveillance	5,000	-	-	-	**5,000**
Professor Jonathan Fallowfield	Development Grant	A molecular phenomic approach to define the high risk NAFLD population	49,623	-	-	(30,317)	**19,306**
Dr Salvatore Papa	Development Grant	Starving livers of glucose for HCC prevention and treatment	50,000	-	-	(1,428)	**48,572**
Professor Chris Probert	Development Grant	Evaluation of the gut metabolome, micro and myco biome in ulcerative colitis patients undergoing anti-fungal therapy: can we predict response to therapy?	48,099	-	-	-	**48,099**
Dr James Pritchett	Development Grant	Decoding Yes Associated Protein 1 driven hepatic stellate cell activation	29,138	-	-	(6,691)	**22,447**
Balance carried forward			**983,649**	**-**	**-**	**(288,896)**	**694,753**

18. Research grants payable (continued)

			At 1 January 2021 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2021 £**
Ongoing research cont'd							
Balance brought forward			**983,649**	**-**	**-**	**(288,896)**	**694,753**
Dr Marnix Jenson	Development Grant	The TARGET study (TArgeted biopsies to Risk Stratify Gastric cancer precursors for tailored Endoscopic surveillance and Treatment)	49,560	-	-	-	**49,560**
Dr Catherine Williamson	Nutrition Development Grant	Impact of cold exposure in conjunction with dietary modification on metabolic regulation in children with non-alcoholic fatty liver disease	48,283	-	-	-	**48,283**
Professor Christer Hogstrand	Nutrition Development Grant	Targeting "Leaky Gut" with combined dietary zinc and plant derived Aryl Hydrocarbon Receptor agonists	50,000	-	-	-	**50,000**
Dr Paul Henderson	Guts UK - BSPGHAN Development Grant	The PINPOINT study – The Prospective Incidence of Paediatric – Onset Inflammatory bowel disease in the United Kingdom	39,936	-	-	(2,396)	**37,540**
Professor Graham Lord	For Crohn's Development Grant	Modulation of the effector/regulatory T-cell balance by targeting a causal genetic variant as a novel therapeutic paradigm in Crohn's disease	43,336	-	-	-	**43,336**
Dr Jorge Gutierrez-Merino	For Crohn's Development Grant	Understanding how gut bacteria induce beneficial type 1 interferon responses	49,055	-	-	(38,662)	**10,393**
Dr Robin Dart	Guts UK-BSG Trainee Research Award	The cellular architecture of the human colonic mucosa : a pilot and feasibility study to facilitate longitudinal multi-centre studies	10,000	-	-	-	**10,000**
Dr James Ashton	Guts UK-BSG Trainee Research Award	To establish a UK wide Paediatric IBD Research network (PAIR network) to answer clinical research questions and enable rapid decision making	8,000	-	-	(4,000)	**4,000**
Balance carried forward			**1,281,819**	**-**	**-**	**(333,954)**	**947,865**

18. Research grants payable (continued)

			At 1 January 2021 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2021 £**
Ongoing research cont'd							
Balance brought forward			**1,281,819**	**-**	**-**	**(333,954)**	**947,865**
Dr John Thomas	Guts UK-BSG Trainee Research Award	Transcriptomic profiling of patient derived colonic epithelial organoids exposed to Ulcerative Colitis-relevant cytokines – a novel approach to uncover IBD pathogenesis and inform precision medicine strategies.	9,950	-	-	(4,975)	**4,975**
Dr Rebecca Harris	Guts UK-BSG Trainee Research Award	Non-invasive risk stratification of patients with compensated advanced chronic liver disease : Results from a real world cohort from the Nottingham Scarred Liver pathway	10,000	-	-	(5,000)	**5,000**
Dr Roosey Sheth	Guts UK-BSG Trainee Research Network Award	A UK wide Audit of the Management of Primary Biliary Cholangitis (PBC)	10,000	-	-	(5,000)	**5,000**
			1,311,769	**-**	**-**	**(348,929)**	**962,840**

18. Research grants payable (continued)

			At 1 January 2021 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2021 £**
New commitments							
Falk Pharma 2021 awards - various	Guts UK - Dr Falk awards 2021		-	14,000	-	(11,500)	**2,500**
Dr Flora Korkwaro	Guts UK - Dr Falk SpR Trainee Audit/Quality Improvement Award	My Tube Passport - "Mind My Tube" - a hospital e-passport for the patient with an enterostomy device	-	8,000	-	-	**8,000**
Dr Tessa Cacciottolo	Guts UK - Dr Falk SpR Trainee Audit/Quality Improvement Award	Using age-appropriate information to support adolescents and young adults with liver disease as they transition from paediatric to adult services	-	2,325	-	-	**2,325**
Dr Dimitrios Koutoukidis	Guts UK - BSG Early Career Researcher Grant	A proof-of-concept trial exploring the mechanism of diet-induced weight loss in non-alcoholic steatohepatitis with fibrosis through the gut microbiome and intestinal permeability	-	14,996	-	-	**14,996**
Dr Nicholas Edward Ilott	Guts UK - BSG Early Career Researcher Grant	DYNAMHIX in PSC : Longitudinal Dynamics of the Hepatic-Intestinal axis in PSC-UC	-	12,642	-	-	**12,642**
Dr Benjamin P Sharpe	Guts UK - BSG Early Career Researcher Grant	Investigating the cellular microenvironment of lymph node metastasis in oesophageal adenocarcinoma	-	14,649	-	-	**14,649**
Dr Rachael Slater	Guts UK - BSG Early Career Researcher Grant	Investigating the mechanisms of irritable bowel syndrome using shotgun metagenomics sequencing and volatile metabolomics in integrated omics analysis	-	11,075	-	-	**11,075**
Dr Nikhil Vergis	Guts UK - BSG Early Career Researcher Grant	Which socioeconomic and healthcare factors determine survival for patients with alcohol related liver disease? A secondary analysis of patient data from the Steroids or Pentoxyfilline for Alcoholic Hepatitis (STOPAH) trial 2011-2015	-	15,000	-	-	**15,000**
Balance carried forward			**-**	**92,687**	**-**	**(11,500)**	**81,187**

			At 1 January 2021 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2021 £**
Balance brought forward			**-**	**92,687**	**-**	**(11,500)**	**81,187**
Dr Naaventhan Palaniyappan	Guts UK - BSG Early Career Researcher Grant	Risk stratification of patients with cirrhosis undergoing colorectal surgery: pilot feasibility study."	-	13,350	-	-	**13,350**
Dr Paloma Ordonez Moran	Guts UK - BSG Early Career Researcher Grant	MINIGUTS: Development of novel in vitro models of paediatric IBD	-	14,977	-	-	**14,977**
Dr Zoe Saynor	For Crohn's Grant	EnablExercise in Crohn's: A qualitative study to understand the barriers and facilitators to physical activity and exercise in children and adolescents with Crohn's disease - perceptions of patients, caregivers and clinicians	-	21,807	-	-	**21,807**
Dr Tariq Ahmad	For Crohn's Grant	Impact of biologic and immunomodulatory therapy on SARS-CoV-2 re-infection, chronic carriage and evolution of viral variants	-	25,220	-	-	**25,220**
Pancreatitis Priority Setting Partnership (PSP)	Guts UK / BSG / PSGBI	Identification and prioritisation of gaps in evidence in the diagnosis, treatment, management and support of patients with pancreatitis	-	36,000	-	(618)	**35,382**
Irritable Bowel Syndrome (IBS) Priority Setting Partnership	Guts UK / BSG	Identification and prioritisation of the unanswered questions about the diagnosis, treatment and care of people (16 years +) with IBS	-	36,000	-	(618)	**35,382**
Professor Anil Dhawan	Guts UK - BSPGHAN Joint Development Grant	Umbilical Cord-Mesenchymal Stromal/stem cell immunotherapy for Biliary Atresia	-	38,902	-	-	**38,902**
Dr Tassos Grammatikopoulos	Guts UK - BSPGHAN Joint Small Grant	Mental health and quality of life in children and young people with acute recurrent and chronic pancreatitis	-	4,248	-	-	**4,248**
Dr Peter Rimmer	Guts UK – BSG trainee grant	The Microbiome in IBD Inception: An exploratory two year longitudinal analysis of the gastrointestinal microbiome through IBD onset, treatment, and relapse, to guide future microbiome based interventions	-	5,000	-	-	**5,000**
Balance carried forward			**-**	**288,191**	**-**	**(12,736)**	**275,455**

			At 1 January 2021 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2021 £**
Balance brought forward			**-**	**288,191**	**-**	**(12,736)**	**275,455**
Dr Katja Christodoulou	Guts UK – BSG trainee grant	Consent for contact in endoscopy	-	1,275	-	-	**1,275**
Dr Julian Yeh	Guts UK – BSG trainee grant	Microscopic Colitis: a regional multi-centre audit."	-	4,000	-	-	**4,000**
Dr Simeng Lin	Guts UK – BSG trainee grant	End of life care provision in patients with advanced liver disease in the south-west: a regional perspective	-	765	-	-	**765**
Dr Oliver Tavabie	Guts UK – BSG trainee grant	Does the implementation of the BASL/BSG bundle improve the survival of patients with decompensated chronic liver disease acutely admitted into hospital	-	2,000	-	-	**2,000**
Dr Ayman Bannaga	Guts UK – BSG trainee grant	The Fatty Liver and Liver Cancer Study (Tendency)	-	5,000	-	-	**5,000**
New commitments total			**-**	**301,231**	**-**	**(12,736)**	**288,495**

18. Research grants payable (continued)

			At 1 January 2021 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2021 £**
Research completed in during the year							
Professor Laurence Lovat	Development award	Salivary EpigeNetics to Stratify Oesophageal Cancer Risk (SENSOR)	**35,041**	-	-	(35,041)	**-**
Dr Conor McCann	Core-Derek Butler Fellowship	Enteric neural stem cell therapy for Oesophageal Achalasia and Diabetic Gastroparesis	**74,904**	-	(5,811)	(69,093)	**-**
Dr Michael Fitzpatrick	Guts UK-BSG Trainee Research Network Award	Effect of diet, nutritional status, and body composition on biologic therapy in IBD: The Oxford and Thames Valley Young Gastroenterologists Network (OxYGEN)	**2,000**	-	(3,605)	1,605	**-**
Dr Polychronis Pavlidis	Guts UK-BSG Trainee Research Network Award	Quality of care transition in adult IBD patients transferring between healthcare providers: a multicentre audit	**2,499**	-	(3,747)	1,248	**-**
Dr Matthias Zilbauer	Guts UK - BSPGHAN Development Grant	Stratification of inflammatory bowel disease treatment in children using human intestinal organoid derived epigenetic signatures	**14,771**	-	-	(14,771)	**-**
Falk Pharma 2020 awards - various	Guts UK-Dr Falk awards 2020		**14,000**	-	-	(14,000)	**-**
			143,215	**-**	**(13,163)**	**(130,052)**	**-**
		Total grants for the year	**1,454,984**	**301,231**	**(13,163)**	**(491,717)**	**1,251,335**

19. Restricted Funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust to be applied for specific purposes:

	At 1 January 2021 £	Income £	Expenditure £	Transfers £	**At 31 December 2021 £**
Guts UK / Dr Falk Awards	—	19,163	(24,325)	5,162	**—**
Restricted research grants	—	133,028	(242,000)	108,972	**—**
UK Government COVID Medical Research Charity support fund	—	151,100	—	(151,100)	**—**
Pancreatitis	8,114	12,100	(18,000)	—	**2,214**
Stomach Cancer	—	6,031	—	—	**6,031**
Research into adhesions	—	548	—	—	**548**
Diverticular	—	500	—	—	**500**
Oesophageal	—	1,312	(1,312)		**—**
Liver	—	831	—	(831)	**—**
Microbiome	—	625	—	—	**625**
Barrett's Oesophagus	—	18,633	—	—	**18,633**
Trust funding	2,500	—	(2,500)		**—**
Trust funding for Amelie Waring Fellow	—	3,500	—	(3,500)	**—**
Company donations - restricted	—	14,896	—	—	**14,896**
Derek Butler Endowment Income fund	244,668	81,076	(7,283)	—	**318,461**
	255,282	443,343	(295,420)	(41,297)	**361,908**

	At 1 January 2020 £	*Income £*	*Expenditure £*	*Transfers £*	*At 31 December 2020 £*
Research grants	*—*	*14,000*	*(14,000)*	*—*	*—*
Restricted research grants	*—*	*28,000*	*(47,950)*	*19,950*	*—*
Pancreatitis	*—*	*8,114*	*—*	*—*	*8,114*
Stomach Cancer	*—*	*1,362*	*(2,000)*	*638*	*—*
Trust Application Donations	*—*	*5,500*	*(3,000)*	*—*	*2,500*
Derek Butler Endowment Income fund	*126,037*	*77,201*	*—*	*41,430*	*244,668*
	126,037	*134,177*	*(66,950)*	*62,018*	*255,282*

The transfer represents the contribution from general funds towards the research grants or from restricted funds to general or designated funds for previously committed research as specified by the donor.

19. Restricted Funds (continued)

The purposes of Guts UK's restricted funds are as follows:

- Restricted research grants: grants for specific research schemes.
- Pancreatitis: contribution to the Pancreatitis PSP
- Oesophageal: contribution to Dr Benjamin Sharpe's research project into oesophageal cancer (Early Career Researcher Grant 2021)
- Liver: contribution to Dr Salvatore Papa's liver research (Development Grant 2019)
- Trust funding: contribution to the Early Career Researcher Grants 2021
- Trust funding for Amelie Waring fellow: contribution to James O'Kelly
- UK Government COVID Medical Research Charity Support Fund: contribution to the Amelie Waring Fellow, the Olympus Fellow, Development Grants and Trainee Awards.
- Derek Butler Endowment Income Fund: this represents the income received from the endowment fund and expenditure on research into the diseases of the upper gastrointestinal tract.

20. Designated Funds – Amelie Waring

	At 1 January 2021 £	Income £	Expenditure £	Transfers £	Investment gains £	**At 31 December 2021 £**
Investments	889,217	25,967	(8,604)	(120,000)	88,364	**874,944**
Research Commitments	(147,300)	—	—	46,775	—	**(100,525)**
Total Amelie Waring Fund	741,917	25,967	(8,604)	(73,225)	88,364	**774,419**

20. Designated Funds (continued)

Designated Funds – GI Research

	At 1 January 2021 £	Income £	Expenditure £	Transfers £	Investment gains £	**At 31 December 2021 £**
Investments	887,402	28,486	(26,959)		97,526	**986,455**
Research Commitments	(19,950)	—	—	(118,896)	—	**(138,846)**
Total GI Research Fund	867,452	28,486	(26,959)	(118,896)	97,526	**847,609**

Total Designated Funds

Total Designated Funds	**1,609,369**	**54,453**	**(35,563)**	**(192,121)**	**185,890**	**1,622,028**

	At 1 January 2020 £	Income £	Expenditure £	Transfers £	Investment (losses) £	At 31 December 2020 £
Investments	1,875,489	46,448	(74,219)	(810,601)	(147,900)	889,217
Research Commitments	(179,423)	—	32,123	—	—	(147,300)
Total Amelie Waring Fund	1,696,066	46,448	(42,096)	(810,601)	(147,900)	741,917

The Amelie Waring fund was initially established in memory of Amelie Waring to fund pancreatitis research, although the original bequest has been fully expended the trustees continue to designate funds to pancreatitis research in recognition of their ongoing commitment to funding research in this area.

The GI Research Fund is designated to general gastrointestinal research.

21. Endowment fund

	At 1 January 2021 £	Income £	Expenditure/ transfers £	Investment gains £	**At 31 December 2021 £**
Derek Butler Endowment	2,683,415		(13,476)	267,134	**2,937,073**

	At 1 January 2020 £	*Income £*	*Expenditure £*	*Investment losses £*	*At 31 December 2020 £*
Derek Butler Endowment	*2,855,298*	*—*	*(53,950)*	*(117,933)*	*2,683,415*

Income from the Derek Butler Endowment fund is credited to restricted funds and is to be spent on research into diseases of the upper gastrointestinal tract.

22. Analysis of net assets between funds

	Fixed assets £	Investments £	Net current (liabilities) / assets £	Long-term Liabilities £	**2021 Total £**
Unrestricted funds					
. General	3,363	1,307,784	298,362	(141,102)	**1,468,407**
. Designated funds – AW	—	874,944	(100,525)	—	**774,419**
. Designated funds – GI	—	986,454	(59,907)	(78,938)	**847,609**
Restricted funds	—	329,374	32,534	-	**361,908**
Endowment funds	—	2,937,073	-	-	**2,937,073**
	3,363	6,435,629	170,464	(220,040)	**6,389,416**

	Fixed assets £	*Investments £*	*Net current (liabilities) / assets £*	*Long-term Liabilities £*	*2020 Total £*
Unrestricted funds					
. General	*3,520*	*1,287,659*	*37,273*	*(231,464)*	*1,096,988*
. Designated funds – AW	—	*889,217*	*(102,480)*	*(44,820)*	*741,917*
. Designated funds – GI	—	*887,402*	—	*(19,950)*	*867,452*
Restricted funds	—	*244,667*	*146,694*	*(136,079)*	*255,282*
Endowment funds	—	*2,683,415*	—	—	*2,683,415*
	3,520	*5,992,360*	*81,487*	*(432,313)*	*5,645,054*

23. British Society of Gastroenterology

Guts UK works closely with the British Society of Gastroenterology (BSG) (Charity Registration No. 1149074 and Company Registration No. 08124892 (England and Wales)) to provide strong links with the main professional community and to improve its ability to disseminate research and patient information. The Chair of the Research Committee of BSG is a member of Guts UK's Board of Trustees. The Chair of Guts UK is an *ex-officio* member of BSG's Council.

Transactions between the two charities during the period were as follows:

The BSG provided a grant of £52,000 (2020: £25,000) to support trainee research grants, development grants for early career researchers and the IBS and Pancreatitis PSPs.

24. Contingent asset and liability

In 2018 the charity secured provisional funding amounting to £1,250,000 for the colorectal cancer research grant of which £410,000 has been received to date.

Up to £250,000 is receivable on an annual basis contingent on a satisfactory annual report being approved by the funding partner. Guts UK was therefore not entitled to these funds in the year ended 31 December 2021. Should the next stages of funding be received, Guts UK has agreed to distribute and monitor use of this funding as a sub-grant. As at 31 December 2021, £840,000 remains receivable, of which up to £240,000 is receivable and payable within one year.

25. Related party transactions

During the year the charity received donations of £3,200 from trustees (2020: £1,680). Transactions with the British Society of Gastroenterology are detailed in note 23.

There were no further related party transactions during the period requiring disclosure (2020: none).

26. Liability of members

The charity is constituted as a company limited by guarantee. In the event of the charity being wound up, members are required to contribute an amount not exceeding £1.

27. Commitments Under Operating Leases

At 31 December the charity had future minimum commitments under non-cancellable operating leases as set out below:

Payments which fall due:	**2021** **£**	2020 £
Within one year	**772**	772
Within 2 to 5 years	**1,160**	1,932
	1,932	2,704

28. Comparative Statement of Financial Activities for the year ended 31 December 2020

		Unrestricted funds £	Restricted funds £	Endowment funds £	**2020 Total funds £**
Income and expenditure					
Income					
Donations and legacies	1	**290,459**	**17,976**	**—**	**308,435**
Other trading activities	2	**38,890**	**—**	**—**	**38,890**
Investment income	3	**86,493**	**77,201**	**—**	**163,694**
Charitable activities	4				
. Grants for research		**—**	**39,000**	**—**	**39,000**
Total income		**415,842**	**134,177**	**—**	**550,019**
Expenditure					
Cost of raising funds	5	**244,883**	**—**	**12,520**	**257,403**
Expenditure on charitable activities	6				
. Grants for research		**103,980**	**66,950**	**—**	**170,930**
. Public education and Science of Digestion		**154,802**	**—**	**—**	**154,802**
Total expenditure	8	**503,665**	**66,950**	**12,520**	**583,135**
Net expenditure before transfers	9	**(87,823)**	**67,227**	**(12,520)**	**(33,116)**
Transfers between funds	19	**(20,588)**	**62,018**	**(41,430)**	**—**
Net (expenditure) / income after transfers		**(108,411)**	**129,245**	**(53,950)**	**(33,116)**
Net (losses) on investments	14				
. Realised		**(162,987)**	**—**	**(47,100)**	**(210,087)**
. Unrealised		**(5,176)**	**—**	**(70,833)**	**(76,009)**
Net (expenditure) / income and net movement in funds for the year		**(276,574)**	**129,245**	**(171,883)**	**(319,212)**
Reconciliation of funds:					
Funds balances brought forward		**2,982,931**	**126,037**	**2,855,298**	**,964,266**
Fund balances carried forward		**2,706,357**	**255,282**	**2,683,415**	**5,645,054**

Reference and administrative information

Royal Patron	HRH Princess Alexandra
Trustees	Professor D Adams MD FRCP FMedSci Professor R Arasaradnam* MB BcH, C Clin Ed, PhD, FRCP, FEBGH (EU) (Resigned 1st August 2021) Mrs K Au BSc (Resigned 4th March 2021) Miss M Boland (Appointed 9th December 2021) Dr L Dugdale-Bradley Miss N Bridge (Appointed 6th September 2021) Mr G Christian-Lim BSc (Resigned 14th March 2022) Professor A Ford MBChB, MD, FRCP (Resigned 15th March 2022) Professor C Hawkey DM FRCP FMedsci – President Dr M Lomer MBE PhD Professor J McLaughlin MBChB PhD FRCP – Deputy Chair (Until 10th June, appointed as Chair from 10th June 2022) Ms S Murray Professor C Norton (Appointed 14th March 2022) Professor C Probert MD FRCP (Appointed 10th June 2022 Professor J Rhodes MD FRCP FMedSci – Chair (Resigned as Chair 10th June 2022, resigned as Trustee 23rd June 2022) Professor S Sebastian* MD FRCP (Appointed 6th September 2021) Dr P Smith BMedSci BMBS MRCP MSc – Medical Director (Resigned 9th December 2021) Mr S Williams BA ACA – Honorary Treasurer * nominee of the British Society of Gastroenterology (BSG)
Chief Executive	Ms J Harrington
Principal office	3 St Andrews Place Regent's Park London NW1 4LB
Telephone	0207 486 0341

Reference and administrative information

Website	www.gutscharity.org.uk
E-mail	info@gutscharity.org.uk

Company registration number	07274105 (England and Wales)
Charity registration number	1137029
Auditor	Buzzacott LLP 130 Wood Street London EC2V 6DL
Bankers	National Westminster Bank plc 1 Cavendish Square London W1A 4NU
Investment managers	Cazenove Capital Management 12 Moorgate London EC2R 6DA
Solicitors	Hempsons 40 Villiers Street London WC2N 6NJ

GUTS UK CHARITY

England & Wales - Charity number 1137029

Accounts

Guts UK Charity

Annual Report and Financial Statements

31 December 2020

Charity Registration Number
1137029

Company Limited by Guarantee
Registration Number
07274105 (England and Wales)

Contents

Reports

Reference and administrative information 1

Trustees' report 3

Independent auditor's report 32

Financial statements

Statement of financial activities 38

Balance sheet 39

Statement of cash flows 40

Principal accounting policies 41

Notes to the financial statements 46

Reference and administrative information

Royal Patron	HRH Princess Alexandra
Trustees	Professor D Adams MD FRCP FMedSci Professor R Arasaradnam* MB BcH, C Clin Ed, PhD, FRCP, FEBGH (EU) Mrs K Au BSc (Resigned 4th March 2021) Dr L Bradley (Appointed 29th April 2020) Mr G Christian-Lim BSc Professor A Ford MBChB, MD, FRCP Professor C Hawkey DM FRCP FMedsci – President Dr M Lomer MBE PhD Professor J McLaughlin MBChB PhD FRCP – Deputy Chair Ms S Murray (Renewed 2nd December 2020) Professor J Rhodes MD FRCP FMedSci - Chair Dr P Smith BMedSci BMBS MRCP MSc – Medical Director (Renewed 2nd December 2020) Mr H Tran BSc FCA – Honorary Treasurer (Resigned 30th April 2020) Mr S Williams BA ACA (Appointed 13th March 2020, Honorary Treasurer from 1st May 2020) * nominee of the British Society of Gastroenterology (BSG)
Chief Executive	Ms J Harrington
Principal office	3 St Andrews Place Regent's Park London NW1 4LB
Telephone	0207 486 0341
Website	www.gutscharity.org.uk
E-mail	info@gutscharity.org.uk
Company registration number	07274105 (England and Wales)
Charity registration number	1137029

Reference and administrative information

Auditor	Buzzacott LLP 130 Wood Street London EC2V 6DL
Bankers	National Westminster Bank plc 1 Cavendish Square London W1A 4NU
Investment managers	Cazenove Capital Management 12 Moorgate London EC2R 6DA
Solicitors	Hempsons 40 Villiers Street London WC2N 6NJ

The trustees present their report together with the financial statements of Guts UK Charity ("Guts UK") for the year ended 31 December 2020. The report has been prepared in accordance with Part 8 of the Charities Act 2011 and constitutes a directors' report for the purposes of company legislation.

The financial statements have been prepared in accordance with the accounting policies set out on pages 41 to 45 and comply with the charitable company's memorandum and articles of association, applicable laws and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102).

Structure, governance and management

Guts UK is a charitable company limited by guarantee. Its governing document is its Memorandum and Articles of Association.

The trustees have overall responsibility for setting the strategic direction of the charitable company. The trustees delegate specific responsibility to several committees as follows:

a) Audit, Risk and Compliance Committee ("ARC") whose purpose is to oversee the operational activities of the charity covering finance, investment, audit, legal compliance, HR and risk management;

b) Research Awards Committee ("RAC") whose purpose is to ensure the integrity of Guts UK's research awards and that they align with the charity's stated objectives. The RAC is responsible for assessing, approving and monitoring applications for research funding. The RAC's processes are governed by the Terms of Reference and committee members (including those co-opted for specific awards) are required to sign a declaration of conflicts of interests form;

c) Funding, Communication and Industry Committee whose purpose is to deliver on Guts UK's fund-raising programmes, ensuring engagement with patients, public, the medical profession and industry alike; and

d) Research Strategy Committee whose purpose is to recommend areas of focus for Guts UK's research priorities.

The policies of the charity are determined by its board of trustees whose membership is listed on page 1. The research policy of the charity is decided by the trustees in consultation with the Research Committee of the British Society of Gastroenterology (BSG). Guts UK is a member of the Association of Medical Research Charities.

Guts UK advertises for new trustees as required. Prospective trustees are interviewed by the Chairman or other fellow trustees and are asked to submit a CV for review by the trustees. Candidates must be approved by a majority of trustees and the usual term of office is three years, renewable on approval by the board up to a maximum of 9 years total.

Structure, governance and management (continued)

New trustees are provided with information concerning the finances, fundraising activities, grant-making and research policies of the charity. Those who are not familiar with the legal obligations and responsibilities of a trustee are provided with information published by organisations such as the Charity Commission. Training opportunities are offered to trustees on an ongoing basis.

Guts UK continues to work closely with the BSG to provide strong links with the main professional community and to improve its ability to disseminate research and patient information. The Chairman of the BSG's Research Committee is a member of the board.

The day-to-day operation of Guts UK is delegated to the Chief Executive who is supported by a team of staff.

Key management personnel

The key management personnel are those involved in managing the organisation, fundraising, communications, research and finance. These comprise the trustees, the Chief Executive and the Finance and Research Managers.

The pay of all staff members, including members of key management, is reviewed annually by the trustees. Remuneration details in relation to key management personnel are provided in Note 10 to the financial statements.

Risk management

Guts UK maintain a risk register covering the major risks to which the charity is exposed. This covers governance and compliance, operational and administration, financial and investment and reputational risks.

Guts UK rates potential risks by likelihood and impact. The risk register is reviewed regularly by the trustees and the key risks together with the policies to mitigate them have been identified as:

Failure to comply with GDPR regulations

Policies and procedures have been developed and communicated to all staff. Ongoing training is provided. Data protection is a standing item on the ARC Committee and trustee meeting agendas to ensure trustees are kept up to date with actions taken to ensure compliance with the regulations. There will be ongoing monitoring of compliance with regulations.

Failure to meet strategy to increase donations

Management accounts are prepared and regularly reviewed by the ARC Committee to monitor fundraising performance. The fundraising strategy has been reviewed by the Chief Executive and trustees with a view to increasing the number of individual supporters and donors alongside developing different income sources to include approaching former funded researchers and gastroenterologists and industry/pharma for support. The trustees review income generation, reserves and strategy at each Board meeting to ensure the strategy is still the right one and that the charity has sufficient funds to meet it.

Risk management (continued)

Impact of COVID-19

The COVID-19 Pandemic has led to some increased risks. Financial risks have increased as a result of the decline in the value of the charity's assets and income from investments and fundraising which will affect future spending plans. The trustees will continue to monitor income and expenditure and adjust as required. Changes in operational practices which have been required, such as the move for staff to work from home, has created risks. Guts UK has taken measures to support staff working from home, including weekly virtual staff meetings held via MS Teams. No staff have been furloughed to-date. There is also the risk that the charity will not be able to hold any Science of Digestion or other public awareness events. This will affect the charity's ability to fulfill its charitable objectives of raising awareness as well as impact on the recruitment of new supporters and fundraisers. As far as possible the public awareness programme will be converted to a digital format.

WHO WE ARE

Guts UK is the charity for the digestive system.

"People are suffering. People are dying. All because of a lack of knowledge about our guts. Guts UK exists to change that. Our guts have been underfunded, understaffed and undervalued for decades. Together, we will join forces and bring about important change in this misunderstood area of health."

Guts UK is the only UK charity funding research into the digestive system from top to tail: the gut, liver and pancreas. Since 1971 we have funded almost 300 projects and invested nearly £16 million pounds into medical research that leads to better diagnoses and treatments for the millions of people who do not have the luxury of taking their guts for granted.

"With new knowledge, we will end the pain and suffering for the millions affected by digestive diseases."

OUR VISION

A world where digestive disorders are better understood, better treated and everyone who lives with one gets the support they need.

OUR MISSION

- **Provide expert information**
- **Raise awareness of digestive diseases**
- **Fund life-changing and life-saving research**

"WE'RE GETTING TO GRIPS WITH GUTS!"

Objectives and activities

Guts UK's charitable objectives are:

- The advancement of the science and practice of medicine and surgery for the benefit of the public with particular reference to the field of gastroenterology, which includes the study of the physiology and pathology of the digestive system;
- To promote the study of and research into medicine and surgery with particular reference to the physiology and pathology of the digestive system and to ensure dissemination where appropriate of the results of such study and research;
- To provide educational material, information and advice to the general public on gastrointestinal diseases.

To achieve these objectives, Guts UK works across six areas:

- Providing evidence-based information to patients and carers that enables people to take proactive decisions and control of their lives;
- Supporting medical research that increases our understanding of digestive diseases, leading to better diagnosis and treatment and improved outcomes for patients;
- Funding research training fellowships for clinicians and scientists to allow them to pursue academic gastroenterology and to enable the development of future researchers;
- Hosting scientific research symposia as part of the BSG Annual Meeting;
- Giving general advice and signposting to other organisations;
- Raising awareness of digestive health and the science surrounding it to increase public understanding.

When setting the objectives and planning the work of Guts UK for the year, the trustees give careful consideration to the Charity Commission's general guidance on public benefit.

The trustees always ensure that the activities undertaken are in line with the charitable objectives and aims of Guts UK. As highlighted in this report, we are continuing to develop our information provision and public education programme thereby helping the general population to better understand digestive diseases.

Digestive diseases include diseases and disorders of the oesophagus, stomach and intestines, colon and rectum, liver, gall bladder, bile ducts, and pancreas; including inflammatory, neoplastic and functional disorders.

Achievements and performance

A) Research strategy

In 2020 we updated our research strategy with the main aim being to support research that can make a difference to patients affected by digestive disorders.

We renewed our commitment to focus on areas we believe are less well-resourced than other gastrointestinal (GI) disease areas and where our funding can make a meaningful difference for patients.

Priority areas

- Upper gastrointestinal disease such as Gastro-Oesophageal Reflux Disease (GORD) and Barrett's oesophagus
- Diverticular disease
- Pancreatitis
- Irritable Bowel Syndrome (IBS)
- Childhood gut, liver and pancreatic diseases
- Gut microbiome and nutrition
- Less survivable digestive cancers: stomach, oesophageal, pancreatic and liver.

We will continue to support the development of future leaders in academic gastroenterology and research training for the next generation of clinical and non-clinical science professionals.

WHY IS RESEARCH IMPORTANT?

Investment in medical research keeps doctors, nurses, surgeons, dietitians and health care professionals at the top of their game enabling them to deliver the best healthcare they can and every patient benefits from this.

Research is everyone's business. We need a dramatic shift in perception and levels of research in this hugely important area. We want to start a national conversation about our guts and engage all ages with the fascinating facts, ignite interest, raise awareness and help the UK get to grips with guts by giving digestive disorders their time in the spotlight.

We will prioritise funding of junior doctors at the start of their career by working in partnership with the British Society of Gastroenterology (BSG) to support more research in the specialty of gastroenterology, including hepatology and pancreatic disease.

We will encourage research that draws on innovation and achievements of other fields to speed up progress in gastroenterology and hepatology, and develop joint collaborations with other organisations that can help us meet our aims sooner.

Achievements and performance (continued)

A) Research strategy (continued)

We will continue to campaign for better survival rates for digestive cancers as an active founder member of the Less Survivable Cancers Taskforce http://lesssurvivablecancers.org.uk/.

B) Research grant funding

Guts UK had research commitments at the start of the year totalling £1,721,855 (2019: £1,147,961). In 2020 the charity further awarded grants totalling £61,950 (2019: £790,566) with payments totalling £322,733 (2019: £211,498) and net commitments no longer required of £3,513 (2019: £5,174). Research commitments still to be paid at the end of the year were £1,454,984 (2019: £1,721,855).

As a result of the Coronavirus pandemic, many of Guts UK's research projects were put on hold during 2020 as some of our funded researchers were called back to clinical duties and their projects were postponed. Some researchers have already requested no-cost extensions. Several projects that were due to start in 2020 will now be starting in 2021. This was a common experience across the sector and many charities cancelled their grant rounds in 2020. We did postpone some of the awards we had initially included in the budget for 2020 but were still able to award some grants to specialty trainee and foundation stage doctors as well as prizes to medical students, nurses and dietitians.

Guts UK Charity has awarded several new grants in 2020:

Funding trainee doctors in gastroenterology research

To promote research amongst gastroenterology trainees and in particular support the development of trainee research networks Guts UK has partnered with the British Society of Gastroenterology (BSG) to award five grants of up to £10,000 each to trainee doctors:

- Dr Robin Dart, King's College London/Francis Crick Institute/Guy's and St Thomas Foundation Trust - The cellular architecture of the human colonic mucosa: a pilot and feasibility study to facilitate longitudinal multi-centre studies. £10,000.

- Dr James Ashton, University of Southampton - Establish a UK-wide Paediatric IBD Research network (PAIR-network) to answer clinical research questions and enable rapid decision making. £8,000.

- Dr John Thomas, Earlham Institute, Norwich - Transcriptomic profiling of patient-derived colonic epithelial organoids exposed to Ulcerative Colitis-relevant cytokines - a novel approach to uncover IBD pathogenesis and inform precision medicine strategies. £9,950.

- Dr Rebecca Harris, University of Nottingham - Non-invasive risk stratification of patients with compensated advanced chronic liver disease: Results from a real-world cohort from the Nottingham Scarred Liver pathway. £10,000.

- Dr Roosey Sheth, West Middlesex University Hospital, London - A UK-wide Audit of the Management of Primary Biliary Cholangitis (PBC). £10,000.

Achievements and performance (continued)

B) Research grant funding (continued)

Guts UK/Dr Falk Awards

Guts UK continues to work with Dr Falk Pharma UK to award prizes and grants to medical students, SpR trainees, F1/F2 clinicians, nurses and dietitians. These awards aim to acknowledge those who bring new insight into gastroenterology and hepatology through research or the improvement of patient care. They also provide the opportunity for foundation stage doctors to engage in research.

The Guts UK/Dr Falk 2020 award winners were:

- *Medical Student Essay Prize £1,000*
  William Cambridge, University of Edinburgh
  Meta-analysis and Meta-regression of Survival After Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma

- *Medical Student Prizes; 4 at £1,500 each*
  Sarah Coleman, Royal Hallamshire Hospital, Sheffield
  Assessment of Gluten-Free Diet adherence in adults with Coeliac Disease: The largest prospective study from the NHS England National Centre

  Aaminah Mohammed, University College London Medical School
  Sex related differences in alcohol-related liver disease

  Moksh Sharma, University College London
  A Genome-wide Association Study of Severe Alcoholic Hepatitis

  Dylan McClurg, University of Cambridge
  Characterising the heterogeneity of Barrett's oesophagus and oesophageal adenocarcinoma using a panel of patient-derived organoid models for translational research and precision medicine

- *Dietitian Prize £1,000*
  Cristian Costas Batlle, Bradford Teaching Hospitals
  Impact of a New Secondary Care Dietetic-Led Coeliac Service in Bradford

- *Nurse Prize £1,000*
  Louise Downey, University Hospital of Southampton
  A Data Driven Service Evaluation of an IBD Help Line

- *F1/F2 Research Grants; 2 at £2,500 each*
  Dr Maja Kopczynska, Salford Royal NHS Foundation Trust
  Psychosexual function and quality of life in Chronic Intestinal Failure

  Dr Nicole Cianci, Nottingham Digestive Diseases, Biomedical Research Centre
  Biomarkers for all-cause mortality in Non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis

Achievements and performance (continued)

C) Completed research projects: sharing some final reports

IBD: Professor David Wilson and his team at the University of Edinburgh have investigated a population of more than two million children born in Scotland between 1981 and 2017. This included almost 1,800 Paediatric Inflammatory bowel disease (PIBD) patients, diagnosed under 16 years of age. They have found a reassuring lack of relationship between perinatal factors, such as mode of delivery, gestational age or type of infant feeding and the risk for an infant to develop inflammatory bowel disease in the future. This means that whether children are born vaginally or via caesarean section, whether they are born prematurely or at term and whether they are breast fed or bottle fed does not appear to impact on their chance of being diagnosed with PIBD in the future. This is an important negative result given the suspected role of environmental factors in causing PIBD.

The team also investigated this population for further health risks. The risk of additional health problems (ischaemic heart disease, stroke, and cancer in early adult life) and mortality related to active IBD and its treatment is a major concern to both patients and families as well as clinicians, especially when IBD is diagnosed in childhood. The research team are currently analysing this data and will provide a further update when this is completed.

IBD: Dr Konstantinos Gerasimidis, based at the University of Glasgow, undertook a pilot study to assess the clinical efficacy of the novel CD-TREAT diet in patients with active Crohn's disease (CD). The investigators have tested CD-TREAT in more than 20 children and adults with Crohn's disease (CD) who needed treatment to help with their CD symptoms. They provided them with the CD-TREAT diet, as their only diet source, for a maximum period of 12 weeks. CD-TREAT meals were prepared and provided to the patients free, using a catering company for consistency. The preliminary results were very promising. Sixty-seven percent of the children who completed the CD-TREAT diet had reduced symptoms, while 60% had complete symptom resolution. In adults, 79% who took the CD-TREAT diet had reduced symptoms, while 71% had complete resolution.

The researchers plan to extend this study to explore the efficacy of the CD-TREAT diet in a larger cohort of patients in many centres looking after patients with CD and in comparison to other mainstream therapies. In the future, if CD-TREAT is proven to be effective, it may be possible to control disease symptoms and prevent flares with dietary-treatment-only for some patients. Moreover, the researchers hope that clinical teams will be able to decrease

Achievements and performance (continued)

C) Completed research projects: sharing some final reports (continued)

or even replace drugs with the diet and potentially avoid drug side-effects or even surgery in some CD patients.

IBD: Dr Dipesh Vasant, based at the University of Manchester, conducted a cross-sectional survey of anorectal dysfunction in ulcerative colitis. This project aimed to raise awareness amongst health professionals, and to find out how many people with IBD without active inflammation are unable to control their bowels. The research showed that regardless of how inflamed the bowel is, two thirds of ulcerative colitis patients suffer with leakage of stools, even when they are in remission.

No more poo taboo!

Controlling our bowels is something that we take for granted. People affected by inflammatory bowel disease (IBD) will have regular 'accidents' and are understandably worried about controlling the release of wind, liquid or solid stools from the bowel. These distressing symptoms lead to suffering, social embarrassment and reduced quality of life. Many will be too embarrassed to even tell their doctor. Some will not improve their bowel control even with the most effective anti-inflammatory medications. There is very little research in this area which is why we need to get to grips with guts and find better treatments for this group of often neglected patients.

IBD: Dr Polychronis Pavlidis, based at King's College London led a multi-centre audit into the quality-of-care transition in adult IBD patients transferring between health care providers. Dr Pavlidis and GLINT research network reported that the commonest reason to transfer IBD patient to a new health care provider is due to moving and change of address. IBD care is predominantly provided in hospital as outpatient (secondary or tertiary care). Researchers showed with this investigation that general practitioners (GPs - primary care) perform most of these referrals. However, more complete and informative medical history data for each patient, are kept in secondary care. Therefore, medical history can be partially or totally lost changing doctors and hospitals. One possible explanation for this, is the lack of resources and the many technical barriers that are present in accessing healthcare records between primary and secondary-tertiary care. This study highlights the importance of good communication between patient, primary and secondary/tertiary care providers to facilitate a smooth transfer of care. The investigators suggest that patients should be empowered to be 'in charge' of their IBD by keeping their own, hard copy or digital, clinical records. Dr Pavlidis and GLINT propose the use of digital health and smartphone technologies (such as the use of 'apps'). They also believe that

Achievements and performance (continued)

C) Completed research projects: sharing some final reports (continued)

gastroenterologists working in secondary care should take a proactive role in ensuring high-quality referral to the patient's receiving team.

Microscopic Colitis: Dr Suneil Raju, based at the University of Sheffield, reviewed current diagnostic procedure and management of patients with microscopic colitis. Microscopic colitis is a common cause of long-term diarrhoea, faecal incontinence, arthralgia and abdominal pain; symptoms which have a significant impact on a patient's quality of life. If microscopic colitis is diagnosed correctly, with effective management, symptoms can be controlled and the patients' quality of life improved. The study found that the incidence of microscopic colitis is increasing over time, therefore doctors need to be aware of this diagnosis to assure that patients aren't missed. Dr Raju also found that this condition can be more serious than initially thought as almost 8 in 100 patients with microscopic colitis were admitted to hospital because of the severity of their symptoms. They then stayed in hospital for on average 12 days which may have been preventable had they been diagnosed earlier and treatment initiated. This work has highlighted an important gap in the diagnostic work up for patients with diarrhoea and the first step to improving this is to increase the number of biopsies taken. Research into this condition needs to continue in order to find the best way to treat these patients to improve their symptoms.

D) Public education and awareness

- **Patient information**

  We provide evidence-based information written by medical experts in the area of human digestive diseases in order to empower people to ask the right questions of the health professionals, to help get a timely diagnosis and the right treatment. Knowing more about what triggers a condition, learning about lifestyle factors or diet and nutrition can help people to better manage their condition and feel in control. This information is produced and co-branded with the BSG.

  Our own research shows that 51% of people wait six months or longer with their digestive symptoms before seeking professional advice. People are suffering alone, due to embarrassment or stigma and don't know where to go for help. For some, that waiting can prove deadly.

  The recruitment of our first ever Information Manager in January 2020 has dramatically improved the service we are able to offer people suffering from digestive diseases, their families and friends. It is important to note we do not run a helpline, nor do we advertise or promote such a service. Yet people email and phone when they find our website. Requests for information in 2019 averaged 43 a month but this increased four-fold in 2020. The Information Manager sent over 1500 personal information support emails and responded to over 500 information phone calls. Our news posts online during the pandemic relating to COVID-19 and digestive conditions were particularly well received rising from an average of 300 readers to over 20,000 which reflects the concern felt by our community.

Achievements and performance (continued)

D) Public education and awareness (continued)

"Thank you so much for your supportive and helpful letter. It was such a relief to have someone actually take me seriously. … I feel empowered and positive (and a little overwhelmed, happy tear) Thank you again, keep up the good work (not thriving after GI surgery)."

As our profile and presence rises as a charity facing the public, the requests for information also rise. The demand for this service has continued to rise into 2021.

Imagine if we could resource and run a helpline? Imagine we could then afford to promote and advertise that helpline? How many more people suffering in silence could we reach?



During 2020, our new Information Manager undertook a thorough review of the charity's patient information which included an update by experts in the field as well as input and feedback from lay readers and people affected by these conditions. The printed leaflet range has been redesigned to improve readability and to put people affected by digestive disorders at the centre of our work.



Achievements and performance (continued)

D) Public education and awareness (continued)



Getting our leaflets into clinics in the UK: Despite many clinics and endoscopy services not operating during the lockdown periods or operating only telephone clinics we have still distributed 112,240 (2019: 195,810) patient information leaflets covering 16 digestive conditions to 89 (2019: 108) hospitals around the UK and Ireland. There are some 230 plus clinics in total and we will promote Guts UK leaflets to these in 2021 to improve our reach.

The breadth and depth of the information available on the website has been increased. Three new subject areas have been added: anal fistulas (Mid December, 64 views), gastroparesis (October, 1991 views), how to increase your fibre intake (February, 4,494 views), plus 11 recipes (throughout the year 5,471 views).

The range of subjects we cover includes:

- Achalasia
- Acute Pancreatitis
- Adhesions
- Anal Fistulas
- Ascites
- Barrett's Oesophagus
- Bile Acid Malabsorption
- Biliary Sphincter Disorders (Sphincter of Oddi Dysfunction)
- Bowel Cancer
- Chronic Intestinal Pseudo-Obstruction
- Chronic Pancreatitis
- Coeliac Disease
- Constipation
- Crohn's Disease
- Diarrhoea
- Diverticular Disease
- Dumping Syndrome
- Eosinophilic Diseases
- Faecal Incontinence
- Gallstones
- Gastroparesis
- Gut Microbiome (Poo Testing)
- Healthy Eating & The Digestive System
- Heartburn & Reflux
- Helicobacter Pylori
- Indigestion
- Irritable Bowel Syndrome (IBS)
- Liver Cancer
- Microscopic Colitis
- Non-Ulcer Dyspepsia
- Pancreatic Exocrine Insufficiency (Pancreatic Enzyme Replacement Therapy)
- Pelvic Radiation Disease
- Perianal Disease
- Polyps in the Bowel
- The Role of Gut Bacteria in Health & Disease
- Ulcerative Colitis
- Wind, Burping, Flatulence & Bloating

Achievements and performance (continued)

D) Public education and awareness (continued)

"So pleased to discover your website and updated advice about fibre and diverticulosis. In contrast to other older advice still there on the internet, I now know there is no need to avoid nuts, seed, skins etc. Hooray! Thanks also for directing us to NICE recommendations and other sources of research on this topic." - Kirsty

We are committed to continuing to develop a digital platform so our patient facing information is accessible for all. We have improved our digital profile and visibility through a concerted effort to reach and serve people affected by digestive disease, growing and engaging our community with relevant content that our supporters share and channel.

- **Public awareness**

It is worth remembering we have only been known as Guts UK Charity since June 2018; we are not yet three years old as a public facing charity.

We changed our name to Guts UK charity to say exactly who we are 'on the tin'. And crucially because people had to find us when searching the internet. But we also knew that people didn't search for digestive conditions – they don't know what they have. People search their symptoms. Our task, through a Search Engine Optimisation (SEO) strategy was to bring those people searching digestive symptoms to Guts UK.

We have grown our online presence organically, writing content and delivering articles and information on digestive health that people wanted to hear about. They find our website and sign up for more via our newsletter. This is how we have grown our presence and profile.

In the last year we were Core we had just 30,000 users of the website in a whole year.

Web analytics

- 1.1 million users to the website in 2020, 110,000 every month (2019: 518,000).
- Bounce rate 69% (2019: 84%) - we would like to reduce this further to 60% over the next two years. The reduction shows that more people are finding the information they want on our website.
- Average time on page 2min 36 sec (2019: 2min 07sec).

Achievements and performance (continued)

D) Public education and awareness (continued)

- E-news sign ups have nearly tripled over the last year to almost 500 a month.

"I came across Guts UK online after having my gallbladder removed. For a long time, I thought my symptoms were just life post-gallbladder removal, but I found Guts UK's information online, printed it out, highlighted and took to my doctor. I was finally referred to gastroenterology and have been diagnosed with Bile Acid Malabsorption." - Natalie

Social media activity

Reached 320,000 on Facebook in 2020 (320% increase from 2018, 42% from 2019)

Achievements and performance (continued)

D) Public education and awareness (continued)



Guts UK Charity @GutsCharityUK · Nov 28 "In each follow-up with my consultant, he reminds me that I had one of the worst cases of severe acute pancreatitis he had ever seen. But in the same breath, he tells me how remarkable my recovery has been" - Ian's **#KrankyPanky** story💜💚 gutscharity.org.uk/advice-and-inf… **#pancreatitis** pic.twitter.com/5vPlr5RvRd View Tweet activity	21,295	781	3.7% Promote
Guts UK Charity @GutsCharityUK · Dec 19 Researchers at **@imperialcollege** wish to involve oesophageal cancer surgery patients & carers to guide a study aiming to identify those who experience poor physical and mental health following their oesophageal cancer surgery. More info: Sheraz Markar, s.markar@imperial.ac.uk pic.twitter.com/fHw3DPjS3M View Tweet activity	11,014	101	0.9% Promote
Guts UK Charity @GutsCharityUK · Dec 16 Fewer than 1 in 5 with stomach cancer survive beyond 5 yrs after diagnosis. We want to change this. We're funding Dr Jansen, whose research has the capacity to save lives - diagnosing patients earlier & giving them a fighting chance 🔬💚 gutscharity.org.uk/research/meet-… **@LessSurvivable** pic.twitter.com/PXJhHzPC43 View Tweet activity	6,302	157	2.5% Promote
Guts UK Charity @GutsCharityUK · Dec 14 "Nutrition is fundamental to life & health. Without food, we die. The dietary choices we make and others make for us, from birth to grave, determine not only our lifespan but also our quality of life" - Dr McKinlay 💚**@BritSocGastro** president **@awmckinlay** gutscharity.org.uk/advice-and-inf… pic.twitter.com/3gbhQ1BUWQ	6,099	179	2.9% Promote

Reached 800,000 on Twitter in 2020 (190% increase from 2018, 44% from 2019)

"I was diagnosed with diverticular disease last May after presenting at A&E with a perforated bowel, resulting in life threatening peritonitis. It's something I'm learning to live with at just 43. I cannot thank Guts UK enough for your literature & online support at what has been a very scary time for myself and my family. Thank you for sharing uplifting stories like this (William's DD SkyDive on Facebook) and for all the important work your charity does" - Lucy.

Achievements and performance (continued)

D) Public education and awareness (continued)

We continue to take opportunities to provide information and articles for local media. A major success was coverage for less survivable cancers on World Cancer Day (4th February 2020) reaching a whopping 9,863,515 people.

Our hopes of delivering a public engagement programme were hampered by COVID-19 but we will be working on possible digital delivery of engaging presentations on digestive health until we are able to organise and attend public events again.

Achievements and performance (continued)

D) Public education and awareness (continued)

We continue to fund the only research fellowship focussed on pancreatitis in the UK. We first launched our Kranky Panky pancreatitis awareness campaign in November 2018. In 2019 we saw our Kranky Panky community grow even more and in 2020 we again shared a story a day, for the month of November, putting the patient voice at the heart of our awareness raising. Many families affected by this devastating condition have expressed relief in finding, via Guts UK, a community that truly understands them.

Achievements and performance (continued)

Fundraising Standards at Guts UK

- Our donors are important to us and we seek to deliver the highest standards of donor care and support.
- Open and accountable fundraising – we regularly tell our supporters how they can easily change their preferences.
- Communicating with our supporters – we update our supporters through our twice-yearly newsletter for those who prefer a print option, and regular e-newsletters.
- Complying with laws, regulation and standards – we are a member of the Chartered Institute of Fundraising and are committed to working to a best practice framework actively complying with the Fundraising Code of Practice. We are registered with the Fundraising Regulator and signed up to The Fundraising Promise.
- Protecting vulnerable people – we do everything possible to meet the needs of potential supporters and protect vulnerable people. In particular, the charity confirms that it complies with all relevant data protection laws. No instances of non-compliance have been identified during the year and no suppression requests were received in 2020 in relation to the fundraising activities.
- Complaints and negative feedback – we treat all complaints seriously and aim to respond in a timely and fair manner. All complaints inform and influence the charity's approach to fundraising. We use the feedback that we get from our supporters to improve the way we do things.
- Working with partner agencies – we may engage professional third parties to act on our behalf, for example, to produce and distribute direct mailings. To ensure that fundraising activities of third parties are compliant with regulation and the charity's own internal standards, the charity approves all third-party communication prior to distribution and sets out clear guidelines in the agreements made with such parties. We also work with commercial participators, such as Amazon Smile, Everyclick, Give as you Live and Easy Fundraising to raise funds. Agreements with commercial participators are checked and activity monitored to ensure compliance with the Fundraising Code of Practice.
- We never swap, sell or share any data.
- We work hard to ensure we deliver value for money in all of our charitable activities.

Achievements and performance (continued)

Income generation

Growing our income through fundraising is vital to enabling us to fund more much needed research and provide information to improve the lives of people affected by digestive disorders. Increasing the number of donors and exploring the potential of all income streams will diversify income sources and in the longer term reduce dependency on investment income. To this end, in 2020, we spent time preparing our 50th year case for support to put people affected by digestive diseases at the heart of our fundraising.

Medical research into gastroenterology has been woefully underfunded for decades. Guts UK is a small charity with a huge ambition, to make a transformational change to the levels of research into our gut, liver and pancreas. To do this we need to grow our supporter base and grow our income.

Achievements and performance (continued)

Income generation *(continued)*

Just as we were building our brand as Guts UK and recruiting new audiences, along came COVID-19. As a team of 8 we had thankfully moved to Cloud based technology in 2019 so we were all able to revert to working from home from the start of lockdown. Like all other charities struggling due to the cancellation of mass participation fundraising events, Guts UK was not untouched. We had planned our biggest ever events year with 66 places in Ride London and our events income dropped through the floor. We had neither the resources nor skills to pivot to a home grown virtual event as many other charities with larger numbers of staff could do. This was a huge blow to our fundraising targets. However, our supporters continued to inspire us by coming up with innovative ways to raise money with their own virtual events. Such as James who got sponsored to grow his hair and Yasmin who climbed the equivalent of Mount Everest on the stairs in her home!

As we adapted to a whole new fundraising context, the sources of income from individual supporters grew in 2020.

Achievements and performance (continued)

Income generation (continued)

Income from grant-making trusts dropped by 60% and totalled just £15,125 (2019: £40,443). Trusts and foundations have suffered investment losses, and many were not accepting applications or were only accepting applications for funding of COVID-19 related activities or local activities.

Despite the COVID-19 pandemic, voluntary income has increased by **£54K** in 2020

In December 2020 we tested paid-for digital advertising for the first time. This is part of the fundraising strategy to increase our profile and expand our supporter base. The adverts also help to raise awareness of the suffering experienced by people with digestive conditions. We reached 190,014 on Facebook and saw a **280%** increase in income via the website compared to 2019.



In addition, we had direct feedback from new supporters responding to the adverts;

"I suffer with pancreatitis myself and am aware of how much pain it causes. Unbearable for children" **– new regular giver**

"It's Christmas and this is a good reminder that not all of us are fortunate with our health" **- brand new supporter**

Achievements and performance (continued)

Income generation (continued)

Following on from the Kranky Panky awareness campaign we took part in the Big Give Christmas Appeal which raised a total of £11,767 including gift aid and matched funding from Candis.

Plans for 2021

Research

Priority Setting Partnerships (PSP) for pancreatitis and Irritable Bowel Syndrome (IBS) research are scheduled to begin in April with the arrival of a new member of staff, a Patient and Public Involvement and Engagement Officer. The BSG have agreed to co-fund the IBS PSP and will contribute funding to the pancreatitis PSP for which we are also seeking further funding. The PSPs will be facilitated by the James Lind Alliance (JLA) and the aim is to find the top ten research priorities to support calls for research funding in these desperately underfunded areas.

Proposed Grant Funding

- Guts UK/Dr Falk awards £24K
- Guts UK/forcrohns development grants 3x £25K
- Guts UK/British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) grant 1x £40K
- Guts UK/BSG trainee research awards 10x £5K
- Guts UK development grants 6x £15K

This year we will also advertise two fellowships:

- The Guts UK Derek Butler Fellowship for £210,000, a 3-year fellowship for research in upper gastrointestinal tract diseases and conditions.
- The Guts UK Amelie Waring Fellowship for £180,00 a 3-year fellowship for research into any aspect of pancreatic inflammation or injury.

Fundraising, patient engagement and raising awareness

We will continue to develop new patient information material and resources in different media for different audiences such as introducing patient focused videos and spoken versions of the patient information leaflets. We will also be getting our leaflets translated into Urdu and other languages.

We will continue to raise public awareness through an enhanced digital presence, building our communities through all social media channels.

Plans for 2021 (continued)

Fundraising, patient engagement and raising awareness (continued)

When circumstances allow, we will restart our public Science of Digestion events adapting content for different audiences. We will also get Colin the Colon back on the road to fascinate children and adults alike.

Colin the Colon at the Piece Hall in Halifax.

For 2021, our 50th year, we have ambitious targets in place to further strengthen our financial supporter base:

- **Recruit new regular givers**
  The launch of a new Guts UK Foundation is a key vehicle/fundraising product for major gifts and philanthropy. We hope BSG members and previously funded researchers, our Guts UK Alumni community will be instrumental in assisting us with establishing the Foundation.

- **Increase active cash donors**
  This will include optimising our BBC Radio 4 Appeal in June, continuing our test and trial digital acquisition programme, an enhanced Christmas Appeal and presenting a fundraising ask in existing communications.

- **Inspire more fundraisers to support us through paid events**
  With 50 places in the Vitality Big Half due to take place in August, 5 physical places in the London Marathon and 25 additional places in the Virtual London Marathon in October.

Staff, Resources and Capacity building

In 2020 the charity employed an Information Manager to focus on providing an enhanced programme in outreach, patient engagement and information. This appointment has been incredibly successful, greatly improving the service we offer to people affected by digestive disorders. The role has been made full time from February 2021. We have had considerable success with various graduate placements and have encouraged several young graduates to continue in the charity sector. We have employed an Individual Giving Manager who has already made a significant impact on income generation and raising our profile. In 2021 we will appoint a Public and Patient Involvement and Engagement Officer who will be responsible for delivering the Priority Setting Partnerships.

Plans for 2021 (continued)

Office space

Guts UK occupies a small office located within the premises occupied by the BSG, the current leaseholder of 3 St Andrews Place. The existing lease expires in December 2021 and earlier this year we negotiated, directly with the Royal College of Physicians, a new 5-year tenancy agreement with a break clause at 3 years. Whilst this will mean an increase in costs, it gives us security in the medium term, is good value for an office in a prime location, allows us to retain our registered office address and continue to work alongside the BSG.

To maintain our status as a national charity we continue to occupy office space in the Media Centre in Huddersfield which provides a northern base in addition to our base in the capital.

Impact of COVID-19

Like all charities, we have experienced a fall in the value of our investments and investment income. The ongoing impact of the pandemic along with the as-yet unknown long-term effects of BREXIT may mean investments continue to fall and dividend income is increasingly uncertain. The trustees are currently reviewing investment strategy to mitigate this risk. Our services are in demand more than ever as we serve the community of people affected by digestive disorders with relevant information. Income generation may continue to be affected by the cancellation and postponement of fundraising events. In addition, the economic situation may mean people have less disposable income to donate to charity or are worried about losing their jobs so do not want to commit to regular giving. However, we will continue to sail out our 50 year campaign to support people with digestive conditions by getting to grips with guts.

Financial review

The charity recorded income for the year of £550,019 (2019: £921,532) and expenditure of £583,135 (2019: £1,219,712). This resulted in net expenditure, before investment losses, of £33,116 (2019: £298,180). The deficit is due to the loss of fundraising event income and reduced investment income.

Income

During a year of tough fundraising conditions, total voluntary income increased by 21%. Total voluntary income was £308,435 (2019 £254,447). We receive no government funding so continue to depend on donations for everything we do.

We are grateful to those who so generously include us in their wills enabling us to continue to support people with digestive disorders and fund essential research. Our increased profile has meant that people are more easily able to find us which is particularly important for those who have recently lost a loved one. In memoriam donations have more than doubled over the last year; families and friends often find consolation in the thought that their fundraising may go some way to alleviating the suffering of others in the future.

The number of people regularly giving to our work has grown and continues to do so despite these turbulent economic times. We finished the year on a high with our Big Give Christmas campaign raising nearly £12,000 and digital advertising resulting in increased website donations. We were pleasantly surprised when one of our supporters donated a painting that raised an incredible £19,520 at auction. Community fundraising increased by 58% as our supporters went to incredible lengths with their virtual challenges.

Research partner funding came from Dr Falk Pharma (UK) Ltd and the BSG. We also received funding from forCrohn's for a research grant round in 2021. The Parabola funding for Professor Rees colorectal cancer research was put on hold for the year but will resume in 2021. We will continue our current partnerships alongside building new partnerships to fund more research in the future.

As many hospitals and clinics were closed or went virtual during the pandemic sales of leaflets to hospitals were reduced and income from this source was just over half that of last year.



Financial review (continued)



Expenditure

We have worked hard to keep costs under budget whilst continuing to improve service provision for people with digestive disorders. Our salary costs increased to £297,321 (2019: £226,204) due to building the capacity of the team to 8 FTE (2019: 6.5 FTE). Operational costs and overheads were slightly less than last year despite the expansion of activities. During the year, we spent £325,732 on charitable activities, which represents 56% of total expenditure in the year. This is significantly lower than 2019 when we invested heavily in research. This year, whilst medical research was on hold, it was decided to focus on investment into income generation and raising awareness, reaching and recruiting new supporters to build a sustainable future for the charity hence the increase in fundraising costs.



Financial review (continued)



Balance Sheet

In line with the performance of investments globally the investment portfolio contributed unrealised losses of £76,009 and realised losses of £210,087 (2019: unrealised gains of £548,718 and realised gains of £73,504). Of this amount, total realised and unrealised losses of £117,933 (2019: £297,132 total realised and unrealised losses) related to the endowment fund.

As at 31 December 2020, Guts UK had net assets of £5,645,054 (2019: £5,964,266) a decrease of £319,212 with £5,992,360 held in listed investments. These include the Derek Butler endowment fund for research into upper gastrointestinal conditions of £3,039,127. The income from this fund will continue to finance the three-year fellowship awarded in 2017 to be completed in 2021. A new fellowship will be advertised in 2021 to be awarded and begin in 2022.

Unrestricted funds which can be spent at the discretion of the trustees were £2,706,357 of which £1,609,369 has been designated to contribute to research grants awarded by the charity. In March 2020, the trustees agreed that half of the value of the designated investments should be designated specifically towards research in pancreatitis (the Amelie Waring fund) with the remaining half to be designated to more general gastrointestinal research.

General funds amounted to £1,096,988. More details of the disposition of Guts UK net assets can be found in the financial statements on page 39.

The principal liability of Guts UK Charity is to complete the research programme it has committed to of £1,454,984 at 31 December 2020 as set out in detail in note 18. Of these commitments, £222,205 is covered by endowed or designated funds, £280,066 is due from funding partners and £952,713 is to be funded from Guts UK's general unrestricted fund.

Financial review (continued)

Reserves policy

Guts UK has reviewed the amount of reserves it regards as a minimum prudent requirement and has concluded that provision for twelve months administration, public education and fundraising costs is sufficient. This would allow time to manage cost reductions or fund appeals as required whilst minimising the impact on service provision. Based on the forecast for 2021, the desired minimum reserve is £600,000. Currently general unrestricted funds total £1,096,988 less amounts held as fixed assets of £3,520 i.e. £1,093,468. Additional funds are to be utilised for research expenditure, building capacity and expanding the public information programme going forward.

Investment policy and performance

The charity's listed investments are managed by Cazenove. Investment in tobacco companies is not permitted. The investment strategy is set by the trustees and takes into account income requirements, the risk profile and the investment manager's advice on the market prospects in the medium term. Guts UK's investment objectives are to achieve a balance of capital growth and income.

The performance of the portfolio is regularly monitored by the trustees and an annual meeting is held where the performance against benchmarks and the overall investment policy is reviewed.

The performance of the portfolio has been satisfactory in the tough market conditions of 2020 and within the agreed risk profile. In March 2021 the trustees reviewed the current investment strategy and agreed with the advice from Cazenove that investments should be moved to a Responsible Multi-Asset Fund. This fund adopts a total return approach and has the advantage of providing an even distribution payment as well as an ethically responsible investment policy.

Going concern

There is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. The trustees believe that there are no material uncertainties that call into doubt the charity's ability to continue operating as a going concern. In making this decision, the trustees have taken into consideration the risks and uncertainties arising from the Coronavirus pandemic including the potential impact on fundraising and return on investments, and conclude that the charity can sustain its operations for a period of at least twelve months from the date of signing these accounts. Consequently, the financial statements have therefore been prepared on the basis that the charity remains a going concern.

Statement of trustees' responsibilities

The trustees (who are also directors of Guts UK for the purposes of company law) are responsible for preparing the trustees' report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of Guts UK and the income and expenditure of Guts UK for that period.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Report Standard applicable to the United Kingdom and Republic of Ireland (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable United Kingdom Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on a going concern basis unless it is inappropriate to presume that Guts UK will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of Guts UK and enable them to ensure that the Financial Statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of Guts UK and for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Each of the trustees confirms that:

- so far as the trustee is aware, there is no relevant audit information of which Guts UK's auditor is unaware; and
- the trustee has taken all the steps that he/she ought to have taken as a trustee in order to make himself/herself aware of any relevant audit information and to establish that the charitable company's auditor is aware of that information.

Statement of trustees' responsibilities (continued)

This confirmation is given and should be interpreted in accordance with the provisions of s418 of the Companies Act 2006.

The trustees are responsible for the maintenance and integrity of corporate and financial information included on Guts UK's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the trustees and signed on their behalf by:



Professor J Rhodes

Trustee

Approved by the trustees on: 10 June 2021

Independent auditor's report to the trustees of Guts UK Charity

Opinion

We have audited the financial statements of Guts UK Charity (the 'charitable company') for the year ended 31 December 2020 which comprise the statement of financial activities, the balance sheet, the statement of cash flows, and the related notes to the financial statements, including a summary of accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2020 and of its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report and performance review 2020, and financial statements, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- the information given in the trustees' annual report is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements (continued)

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations; and

- we obtained an understanding of the legal and regulatory frameworks that are applicable to the charitable company and determined that the most significant frameworks which are directly relevant to specific assertions in the financial statements are those that relate to the reporting framework (Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Companies Act 2006).

We assessed the susceptibility of the charitable company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to their knowledge of actual, suspected and alleged fraud; and

- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;

Auditor's responsibilities for the audit of the financial statements (continued)

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- reading the minutes of meetings of those charged with governance; and
- enquiring of management as to actual and potential litigation and claims.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the trustees and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Shachi Blakemore (Senior Statutory Auditor)
For and on behalf of Buzzacott LLP
Statutory Auditor
130 Wood Street
London
EC2V 6DL

Dated: 29 July 2021

Statement of financial activities Year ended 31 December 2020
(including the income and expenditure account)

		Unrestricted funds £	Restricted funds £	Endowment funds £	**2020 Total funds £**	2019 Total funds £
Income and expenditure						
Income						
Donations and legacies	1	**290,459**	**17,976**	**—**	**308,435**	254,447
Other trading activities	2	**38,890**	**—**	**—**	**38,890**	54,364
Investment income	3	**86,493**	**77,201**	**—**	**163,694**	203,755
Charitable activities	4					
. Grants for research		**—**	**39,000**	**—**	**39,000**	408,966
Total income		**415,842**	**134,177**	**—**	**550,019**	921,532
Expenditure						
Cost of raising funds	5	**244,883**	**—**	**12.520**	**257,403**	170,379
Expenditure on charitable activities	6					
. Grants for research		**103,980**	**66,950**	**—**	**170,930**	912,652
. Public education and Science of Digestion		**154,802**	**—**	**—**	**154,802**	136,681
Total expenditure	8	**503,665**	**66,950**	**12,520**	**583,135**	1,219,712
Net expenditure before transfers	9	**(87,823)**	**67,227**	**(12,520)**	**(33,116)**	(298,180)
Transfers between funds	19	**(20,588)**	**62,018**	**(41,430**)	**—**	—
Net (expenditure) / income after transfers		**(108,411)**	**129,245**	**(53,950)**	**(33,116)**	(298,180)
Net (losses) / gains on investments	14					
. Realised		**(162,987)**	**—**	**(47,100)**	**(210,087)**	73,504
. Unrealised		**(5,176)**	**—**	**(70,833)**	**(76,009)**	548,718
Net (expenditure) / income and net movement in funds for the year		**(276,574)**	**129,245**	**(171,883)**	**(319,212)**	324,042
Reconciliation of funds:						
Funds balances brought forward		**2,982,931**	**126,037**	**2,855,298**	**5,964,266**	5,640,224
Fund balances carried forward		**2,706,357**	**255,282**	**2,683,415**	**5,645,054**	5,964,266

All of the charity's activities derived from continuing operations during the above two financial periods.

All recognised gains or losses are included in the above statement of financial activities.

A full comparative Statement of Financial Activities for the year ended 31 December 2019 is shown in note 28 to the financial statements.

Balance sheet 31 December 2020

	Notes	2020 £	2020 £	2019 £	2019 £
Fixed assets					
Tangible fixed assets	13		**3,520**		1,984
Investments	14		**5,992,360**		6,318,604
			5,995,880		6,320,588
Current assets					
Debtors: due within one year	15	**358,480**		532,275	
Short term cash deposits		**526,860**		690,003	
Cash at bank and in hand		**332,599**		180,107	
		1,217,939		1,402,385	
Liabilities:					
Creditors: amounts falling due within one year	16	**(1,136,452)**		(1,145,034)	
Net current assets			**81,487**		257,351
Total assets less current liabilities			**6,077,367**		6,577,939
Liabilities:					
Creditors: amounts falling due after one year	17		**(432,313)**		(613,673)
Total net assets			**5,645,054**		5,964,266
The funds of the charity					
Unrestricted income funds					
. General			**1,096,988**		1,286,865
. Designated funds	20		**1,609,369**		1,696,066
Restricted funds	19		**255,282**		126,037
Endowment fund	21		**2,683,415**		2,855,298
			5,645,054		5,964,266

Approved by the trustees
and signed on their behalf by:



Professor J Rhodes

Trustee

Approved on: 10 June 2021

Guts UK Charity
Registered Company Number: 07274105 (England and Wales)

Statement of cash flows 31 December 2020

	Notes	2020 £	2019 £
Cash inflow used in operating activities:			
Net cash used in operating activities	A	**(211,571)**	(245,648)
Cash inflow from investing activities:			
Dividends and interest from investments		**163,694**	203,755
Purchase of tangible fixed assets		**(2,921)**	(2,301)
Proceeds from the disposal of investments		**1,390,982**	1,128,341
Purchase of investments		**(1,454,396)**	(987,808)
Net cash provided by investing activities		**97,358**	341,987
Change in cash and cash equivalents in the year		**(114,213)**	96,339
Cash and cash equivalents at 1 January	B	**1,436,190**	1,339,851
Cash and cash equivalents at 31 December	B	**1,321,977**	1,436,190

Notes to the statement of cash flows for the year to 31 December

A Reconciliation of net movement in funds to net cash (used in) provided by operating activities

	2020 £	2019 £
Net movement in funds (as per the statement of financial activities)	**(319,212)**	324,042
Adjustments for:		
Depreciation charge	**1,386**	488
Losses / (gains) on investments	**286,096**	(622,222)
Dividends and interest from investments	**(163,694)**	(203,755)
Decrease / (increase) in debtors	**173,795**	(327,354)
(Decrease) / increase in creditors	**(189,942)**	583,153
Net cash used in operating activities	**(211,571)**	(245,648)

B Analysis of cash and cash equivalents

	2020 £	2019 £
Cash at bank and in hand	**332,599**	180,107
Short term cash deposits	**526,860**	690,003
Cash held by investment managers	**462,518**	566,080
Total cash and cash equivalents	**1,321,977**	1,436,190

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are laid out below.

Basis of preparation

These financial statements have been prepared for the year to 31 December 2020 and are presented in sterling and are rounded to the nearest pound.

The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant accounting policies below or the notes to these financial statements.

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (Charities SORP FRS 102) issued on 16 July 2014, the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The charity constitutes a public benefit entity as defined by FRS 102.

Critical accounting estimates and areas of judgement

Preparation of the financial statements requires the trustees and management to make significant judgements and estimates.

The full impact following the recent emergence of the global coronavirus pandemic is still unknown. It is therefore not currently possible to evaluate all the potential implications for the charity's activities, beneficiaries, funders, suppliers and the wider economy. Estimates used in the accounts, particularly with respect to the value of listed investments (see note 14) are subject to a greater degree of uncertainty and volatility. As set out in these accounting policies under "going concern", the trustees have considered the impact of the pandemic on the charity and have concluded that although there may be some negative consequences, it is appropriate for the charity to continue to prepare its financial statements on the going concern basis.

The items in the financial statements where these judgements and estimates have been made include:

- estimating the useful economic lives of tangible fixed assets for the purpose of determining the annual depreciation charge;
- assessing the probability of the receipt of legacy income;
- allocation of support costs between activities on the basis of staff time;
- estimating future cash flows for the purpose of determining going concern.

Assessment of going concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements and have made this assessment in respect to a period of one year from the date of approval of these financial statements. They have taken into consideration the potential uncertainty in relation to COVID-19 on the charity's operations and finances. The trustees are of the opinion that the charity will have sufficient resources to meet its liabilities as they fall due.

The trustees have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the charity to continue as a going concern. The trustees are confident that the charity has sufficient funds to cover its existing liabilities.

With regard to the next accounting period, the year ending 31 December 2021, the most significant areas that affect the carrying value of the assets held by the charity are the level of investment return and the performance of the investment markets (see the investment policy and the risk management sections of the trustees' report for more information).

Income recognition

Income is recognised in the period in which the charity has entitlement to the income, the amount of income can be measured reliably and it is probable that the income will be received.

Donations are recognised when the charity has confirmation of both the amount and settlement date. In the event of donations pledged but not received, the amount is accrued for where the receipt is probable.

Legacies are included in the statement of financial activities when the charity is entitled to the legacy, the executors have established that there are sufficient surplus assets in the estate to pay the legacy, and any conditions attached to the legacy are within the control of the charity. Entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor to the charity that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity or the charity is aware of the granting of probate, but the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material. In the event that the gift is in the form of an asset other than cash or a financial asset traded on a recognised stock exchange, recognition is subject to the value of the gift being reliably measurable with a degree of reasonable accuracy and the title of the asset having being transferred to the charity.

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due.

Income recognition (continued)
Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

Research funding income is recognised in the period in which the charity receives a written commitment from the funder. Research funding is deferred only when the charity has to fulfil conditions before becoming entitled to it or the donor has specified that the income has to be spent in a future period.

Expenditure recognition
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to make a payment to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis and is stated inclusive of irrecoverable VAT. Expenditure comprises direct costs and support costs. All expenses, including support costs, are allocated or apportioned to the applicable expenditure headings. The classification between activities is as follows:

a) Cost of raising funds which includes direct fundraising costs and investment manager's fees.

b) Expenditure on charitable activities comprises expenditure on the charity's primary charitable purposes as described in the trustees' report. Such costs include grants payable, other direct costs and support costs, which are apportioned based on the level of activity in each area.

Research grants payable are included in the statement of financial activities when approved and when the intended recipient has either received the funds or been informed of the decision to make the grant, and has satisfied all relevant conditions. Grants approved but not paid at the end of the financial year are accrued for. Grants where the beneficiary has not been informed or has to meet certain conditions before the grant is payable are not accrued for but are noted as financial commitments in the notes to the financial statements.

The provision of a multi-year grant is recognised at its present value where settlement is due over more than one year from the date of the award, there are no unfulfilled performance conditions under the control of the charity that would permit the charity to avoid making the future payments, settlement is probable and the effect of the discounting is material. The discount rate used is the average rate of investment yield in the year in which the grant is made. This discount rate is regarded by the trustees as providing the most current available estimate of the opportunity cost of money reflecting the time value of money to the charity.

Allocation of support costs and governance costs

Support costs represent indirect charitable expenditure. In order to carry out the primary purposes of the charity it is necessary to provide support in the form of financial procedures, provision of office services and equipment and a suitable working environment.

Governance costs comprise the costs directly attributable to the governance of the charity, including audit costs and the necessary legal procedures for compliance with statutory requirements. Support costs and governance costs are allocated between activities with the allocation based on staff time.

Fixed asset investments

Listed investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price.

The charity does not acquire put options, derivatives or other complex financial instruments.

Realised gains (or losses) on investment assets are calculated as the difference between disposal proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value at that date. Realised and unrealised investment gains (or losses) are combined in the statement of financial activities and are credited (or debited) in the year in which they arise.

Debtors

Debtors are recognised at their settlement amount, less any provision for non-recoverability. Prepayments are valued at the amount prepaid. They have been discounted to the present value of the future cash receipt where such discounting is material.

Cash at bank and in hand and short term deposits

Cash at bank and in hand represents such accounts and instruments that are available on demand or have a maturity of less than three months from the date of acquisition. Deposits for more than three months but less than one year have been disclosed as short term deposits.

Creditors and provisions

Creditors and provisions are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Creditors and provisions are recognised at the amount the charity anticipates it will pay to settle the debt. They have been discounted to the present value of the future cash payment where such discounting is material.

Tangible fixed assets

Depreciation of fixed assets is calculated on cost at rates estimated to write off the assets, by equal instalments, over their expected working lives.

- Office furniture, fittings and equipment - 5 years
- IT equipment - 3 years

Items used in the day to day running of the charity and with a cost in excess of £500 are capitalised, and are stated at cost less accumulated depreciation.

Financial instruments

The charity only holds basic financial instruments as defined in FRS 102. The financial assets and financial liabilities of the charity and their measurement basis are as follows:

Financial assets – other debtors are basic financial instruments and are debt instruments measured at amortised cost. Listed investments are a basic financial instrument as detailed above. Prepayments are not financial instruments.

Cash at bank – classified as a basic financial instrument and is measured at face value.

Financial liabilities – accruals and other creditors are financial instruments, and are measured at amortised cost.

Fund structure

The charity has various types of funds for which it is responsible, and which require separate disclosure. These are as follows:

General funds

Funds which are expendable at the discretion of the trustees in furtherance of the objects of the charity.

Designated funds

Funds which are set aside as part of the charity's unrestricted funds for particular purposes in the future as determined by the trustees from time to time.

Restricted funds

Funds raised for, and their use restricted to, a specific purpose, or donations subject to donor imposed conditions.

Endowment funds

Funds which must be held indefinitely as capital. Income therefore is credited to general funds and applied for general purposes unless under the terms of the endowments such income must be used for specific purposes in which cases it is credited to restricted funds.

Pension costs

The charity operates a defined contribution scheme on behalf of its employees. The assets are held in separately administered funds. Costs are charged to the statement of financial activities in the period to which they relate.

1. Donations and legacies

	Unrestricted funds £	Restricted funds £	**2020 Total funds £**
Donations	143,636	16,369	**160,005**
Legacies & In Memoriam donations	146,823	1,607	**148,430**
2020 Total funds	290,459	17,976	**308,435**

	Unrestricted funds £	*Restricted funds £*	*2019 Total funds £*
Donations	*125,139*	*15,406*	*140,545*
Legacies & In Memoriam donations	*110,530*	*3,372*	*113,902*
2019 Total funds	*235,669*	*18,778*	*254,447*

2. Other trading activities

	Unrestricted funds £	Restricted funds £	**2020 Total funds £**
Public education	28,890	—	**28,890**
Science of Digestion	—	—	**—**
Public Education – one off donation	10,000	—	**10,000**
2020 Total funds	38,890	—	**38,890**

	Unrestricted funds £	*Restricted funds £*	*2019 Total funds £*
Public education	*50,364*	—	*50,364*
Science of Digestion	*2,500*	—	*2,500*
Public Education – leaflet sponsorship	*1,500*	—	*1,500*
2019 Total funds	*54,364*	—	*54,364*

3. Investment income

	Unrestricted funds £	Restricted funds £	**2020 Total funds £**
Interest – fixed interest securities	187	486	**673**
Dividends - UK and international equities	38,743	36,558	**75,301**
Bonds - UK and international	20,898	18,683	**39,581**
Multi asset funds	14,937	12,936	**27,873**
Charities property fund	6,103	4,775	**10,878**
Other funds	3,303	3,763	**7,066**
Interest on cash deposits	2,322	—	**2,322**
2020 Total funds	86,493	77,201	**163,694**

3. Investment income (continued)

	Unrestricted funds £	*Restricted funds £*	*2019 Total funds £*
Interest – fixed interest securities	*624*	*1,546*	*2,170*
Dividends - UK and international equities	*65,651*	*55,674*	*121,325*
Bonds - UK and international	*12,590*	*8,482*	*21,072*
Multi asset funds	*19,975*	*18,719*	*38,694*
Charities property fund	*6,862*	*5,369*	*12,231*
Other funds	*3,376*	*2,350*	*5,726*
Interest on cash deposits	*2,537*	*—*	*2,537*
2019 Total funds	*111,615*	*92,140*	*203,755*

4. Income from charitable activities

	Unrestricted funds £	Restricted funds £	**2020 Total funds £**
New grants for research	—	39,000	**39,000**
2020 Total funds	—	39,000	**39,000**

	Unrestricted funds £	*Restricted funds £*	*2019 Total funds £*
New grants for research	*—*	*408,966*	*408,966*
2019 Total funds	*—*	*408,966*	*408,966*

5. Cost of raising funds

	Unrestricted funds £	Restricted funds £	**2020 Total funds £**
Fundraising costs	48,040	—	**48,040**
Investment manager's fees	13,844	12,520	**26,364**
Support costs (note 8)	182,999	—	**182,999**
2020 Total funds	244,883	12,520	**257,403**

	Unrestricted funds £	*Restricted funds £*	*2019 Total funds £*
Fundraising costs	*16,744*	*—*	*16,744*
Investment manager's fees	*14,652*	*13,155*	*27,807*
Support costs (note 8)	*125,828*	*—*	*125,828*
2019 Total funds	*157,224*	*13,155*	*170,379*

6. Expenditure on charitable activities

	Direct costs £	Research grants awarded (note 7) £	Support costs (note 8) £	**2020 Total funds £**
Gastroenterology research	1,893	58,437	110,600	**170,930**
Public Education	48,204	—	106,598	**154,802**
2020 Total funds	50,097	58,437	217,198	**325,732**

	Direct costs £	*Research grants awarded (note 7) £*	*Support costs (note 8) £*	*2019 Total funds £*
Gastroenterology research	*3,564*	*785,392*	*123,696*	*912,652*
Public Education	*44,977*	*—*	*91,704*	*136,681*
2019 Total funds	*48,541*	*785,392*	*215,400*	*1,049,333*

7. Research grants awarded

	2020 Total funds £	2019 Total funds £
New research grants	**61,950**	790,566
Less grants no longer required – research commitments	**(3,513)**	(5,174)
Research grants awarded (note 6)	**58,437**	785,392

Research grants awarded represent commitments made for research, and are set out in detail in note 18.

8. Total expenditure

		Charitable activities		
	Cost of raising funds £	Gastro-enterology research £	Public education and Science of Digestion £	**2020 Total funds £**
Directly incurred				
Grants payable (see note 7)	—	58,437	—	**58,437**
Research administration	—	1,893	—	**1,893**
Fundraising costs	48,040	—	—	**48,040**
Public education	—	—	48,204	**48,204**
Investment management fees	26,364	—	—	**26,364**
	74,404	60,330	48,204	**182,938**
Support costs				
Staff costs (see note 10)	135,957	82,169	79,195	**297,321**
Premises and donated facilities	5,101	3,083	2,971	**11,155**
Postage	183	111	107	**401**
Telephone	1,694	1,024	987	**3,705**
Stationery, printing, design and marketing	1,632	986	951	**3,569**
Insurance	529	320	308	**1,157**
Bank charges	1,597	965	930	**3,492**
Meeting costs	2,210	1,336	1,288	**4,834**
Subscriptions/publications	3,073	1,857	1,790	**6,720**
Equipment/maintenance and website development	8,760	5,294	5,103	**19,157**
Depreciation	634	383	369	**1,386**
Training and recruitment	7,084	4,282	4,127	**15,493**
Governance costs:				
. Audit & Accountancy	3,833	2,316	2,233	**8,382**
. Professional fees	956	578	557	**2,091**
. Bookkeeping costs	2,281	1,378	1,328	**4,987**
Brand development	7,475	4,518	4,354	**16,347**
	182,999	110,600	106,598	**400,197**
2020 Total funds	257,403	170,930	154,802	**583,135**

8. Total expenditure (continued)

		Charitable activities		
	Cost of raising funds £	*Gastro-enterology research £*	*Public education and Science of Digestion £*	*2019 Total funds £*
Directly incurred				
Grants payable (see note 7)	*—*	*785,392*	*—*	*785,392*
Research administration	*—*	*3,564*	*—*	*3,564*
Fundraising costs	*16,744*	*—*	*—*	*16,744*
Public education	*—*	*—*	*44,977*	*44,977*
Investment management fees	*27,807*	*—*	*—*	*27,807*
	44,551	*788,956*	*44,977*	*878,484*
Support costs				
Staff costs (see note 10)	*83,413*	*81,999*	*60,792*	*226,204*
Premises and donated facilities	*7,528*	*7,401*	*5,487*	*20,416*
Postage	*250*	*246*	*182*	*678*
Telephone	*1,211*	*1,191*	*883*	*3,285*
Stationery, printing, design and marketing	*1,497*	*1,472*	*1,091*	*4,060*
Insurance	*429*	*421*	*312*	*1,162*
Bank charges	*939*	*922*	*684*	*2,545*
Meeting costs	*5,050*	*4,964*	*3,680*	*13,694*
Subscriptions/publications	*1,543*	*1,517*	*1,125*	*4,185*
Equipment/maintenance and website development	*7,973*	*7,838*	*5,811*	*21,622*
Depreciation	*180*	*177*	*131*	*488*
Training and recruitment	*5,557*	*5,463*	*4,050*	*15,070*
Governance costs:				
. Auditor's remuneration	*3,492*	*3,433*	*2,545*	*9,470*
. Professional fees	*1,844*	*1,813*	*1,344*	*5,001*
. Bookkeeping costs	*3,719*	*3,656*	*2,710*	*10,085*
Brand development	*1,203*	*1,183*	*877*	*3,263*
	125,828	*123,696*	*91,704*	*341,228*
2019 Total funds	*170,379*	*912,652*	*136,681*	*1,219,712*

9. Net income before transfers

This is stated after charging:

	2020 Total funds £	2019 Total funds £
Staff costs (note 10)	**297,321**	226,204
Depreciation	**1,386**	488
Auditor's remuneration (including VAT)		
. Statutory audit services – current year	**8,000**	7,464

10. Staff costs and remuneration of key management personnel

	2020 Total funds £	2019 Total funds £
Salaries and wages	**266,856**	203,129
Social security	**22,508**	16,584
Pension costs	**7,957**	6,491
	297,321	226,204

The average number of employees during the period was 8 (2019: 6.5). One employee earned between £60,001 and £70,000 during the year (2019: one employee earned between £60,001 and £70,000).

The key management personnel of the charity in charge of directing and controlling, running and operating the charity on a day to day basis comprise the trustees, the CEO, the Finance and Research Managers. The total remuneration (including taxable benefits and employer's pension contributions) of the key management personnel for the year was £159,857 (2019: £148,276).

11. Trustees' remuneration and expenses

£nil remuneration (2019: £nil) was paid or payable, directly or indirectly, out of the funds of the charity for the period to any trustee, or to any person or persons known to be connected with any of them.

Two trustees were reimbursed for travel expenses of £258 during the period (2019: six trustees: £1,687).

12. Taxation

Guts UK is a registered charity and is potentially exempt from taxation in respect of income and capital gains received within the categories covered by Section 505 of the Taxes Act 1988 or Section 256 of the Taxation of Chargeable Gains Act 1992 to the extent that such income or gains are applied to exclusively charitable purposes.

13. Tangible fixed assets

	Computer equipment £
Cost	
At 1 January 2020	**6,642**
Additions in the year	**2,922**
At 31 December 2020	**9,564**
Depreciation	
At 1 January 2020	**4,658**
Charge for the year	**1,386**
At 31 December 2020	**6,044**
Net book value	
At 31 December 2020	**3,520**
At 31 December 2019	1,984

14. Investments

	Endowment portfolio £	Unrestricted portfolio £	**2020 £**	2019 £
At valuation				
Balance brought forward at 1 January	2,734,531	3,017,993	**5,752,524**	5,270,835
Additions	667,910	786,486	**1,454,396**	987,808
Disposal proceeds	(621,291)	(769,691)	**(1,390,982)**	(1,128,341)
Investment gains				
. Realised (losses)/gains	(47,100)	(162,987)	**(210,087)**	73,504
. Unrealised (losses)/gains	(70,833)	(5,176)	**(76,009)**	548,718
Total investment (losses)/ gains	(117,933)	(168,163)	**(286,096)**	622,222
Balance carried forward at 31 December	2,663,217	2,866,625	**5,529,842**	5,752,524
Cash held by investment managers	375,910	86,608	**462,518**	566,080
Total investments	3,039,127	2,953,233	**5,992,360**	6,318,604
Analysis by Type				
Listed investments at market value				
. UK Equities	987,441	1,162,937	**2,150,378**	3,009,441
. Overseas Equities	882,080	784,626	**1,666,706**	1,071,659
. UK Bonds	207,163	264,918	**472,081**	594,058
. Overseas bonds	106,633	118,228	**224,861**	87,772
. Multi-asset funds	174,507	196,319	**370,826**	403,391
. Property funds	124,754	159,444	**284,198**	294,814
. Other	180,639	180,153	**360,792**	291,389
Total investments	2,663,217	2,866,625	**5,529,842**	5,752,524
Historic cost of listed investments (all are listed in the UK) - excluding cash held by investment managers	2,388,768	2,820,378	**5,209,146**	5,042,868

At 31 December the charity had the following material investment holdings:

	Endowment £	Unrestricted £	**Market value £**	Percentage of portfolio %
Listed investments within the portfolio are:				
M&G Equities Investment Fund for charities	259,416	274,514	**533,930**	10%
The Charity Equity Income Fund	250,372	228,295	**478,667**	9%
Trojan Income Fund Class S	233,844	269,820	**503,664**	9%
Fidelity Global Equity Income Fund Class D	216,876	220,558	**437,434**	8%
LF Majede UK Equity Fund	126,567	237,664	**364,231**	7%
Trojan Investment Funds – Trojan Fund	174,507	196,319	**370,826**	7%
The Charity Equity Value Fund	117,244	152,641	**269,885**	5%

14. **Investments** (continued)

The total unrealised gains as at 31 December 2020 constitute movements on revaluation and are as follows:

	2020 **£**	2019 £
Unrealised gains included above:		
On investments	**320,696**	709,656
Total unrealised gains at 31 December	**320,696**	709,656
Reconciliation of movements in unrealised gains:		
Unrealised gains at 1 January	**709,656**	320,028
(Losses) in respect to disposals in the year	**(312,951)**	(159,090)
	396,705	160,938
Add: net (losses)/gains arising on revaluation in the year	**(76,009)**	548,718
Total unrealised gains at 31 December	**320,696**	709,656

15. Debtors

	2020 **£**	2019 £
Prepayments, accrued income and sundry debtors	**78,414**	119,751
Commitments due from funding partners	**280,066**	412,524
	358,480	532,275

Included within debtors under commitments due from funding partners is £70,000 (2019: £30,067) which is due after one year

16. Creditors: amounts falling due within one year

	2020 **£**	2019 £
Other creditors	**8,722**	5,693
Accruals and deferred income	**105,059**	31,159
Research grants payable (see note 18)	**1,022,671**	1,108,182
	1,136,452	1,145,034

17. Creditors: amounts falling due after more than one year

	2020 **£**	2019 £
Research grants payable (see note 18)	**432,313**	613,673

18. Research grants payable

	2020 Total funds £	2019 Total funds £
At 1 January	**1,721,855**	1,147,961
Research grants awarded in the year	**61,950**	790,566
Research grants no longer required	**(3,513)**	(5,174)
Paid during the year	**(325,308)**	(211,498)
At 31 December	**1,454,984**	1,721,855
Research grants at 31 December are payable as follows:		
Within one year (see note 16)	**1,022,671**	1,108,182
After more than one year (see note 17)	**432,313**	613,673
	1,454,984	1,721,855

Details of research grants payable are provided overleaf.

18. Research grants payable (continued)

			At 1 January 2020 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2020 £**
Ongoing research							
Professor Laurence Lovat	Development award	Salivary EpigeNetics to Stratify Oesophageal Cancer Risk (SENSOR)	35,876	—	(835)	—	**35,041**
Dr Wadiamu Gashau	Core-BSG Trainee Research Network Award	RISE NoW (Regional IBD Surveillance Endoscopy North West) study: A real world experience of dysplasia and colorectal cancer surveillance in Inflammatory Bowel Disease (IBD)	2,500	—	—	—	**2,500**
Dr Conor McCann	Core-Derek Butler Fellowship	Enteric neural stem cell therapy for Oesophageal Achalasia and Diabetic Gastroparesis	94,618	—	—	(19,714)	**74,904**
Mr James O'Kelly	Guts UK/Amelie Waring Research Fellowship	Single cell definition of the mechanistic role of kynurenine monooxygenase at the innate immune interface in acute pancreatitis	179,423	—	—	(32,122)	**147,301**
Dr Sara Jamel	Olympus Guts UK Endoscopy Fellowship	Profiling of Dysplastic Changes in Barrett's Oesophagus and Early Oesophageal Cancer Using Non-Invasive Volatile Organic Compound Analysis of Exhaled Breath	180,244	—	—	(60,122)	**120,122**
Professor Colin Rees	Parabola-Guts UK Colorectal Cancer Research Grant	COLO-COHORT Colorectal Cancer Cohort Study	500,000	—	—	(95,955)	**404,045**
Dr Marc-Emmanuel Dumas	Guts UK Development Award	Precision medicine through integrative metagenomics and phenomics in a human NAFLD cohort	49,797	—	—	—	**49,797**
Dr Varinder Athwal	Guts UK Development Award	Investigating fibrosis pathobiology in cystic fibrosis related liver disease to improve clinical detection and management	25,351	—	—	(21,061)	**4,290**
Dr Dipesh Vasant	Guts UK-Dr Falk SpR Trainee Audit/Quality Improvement Award	Anorectal dysfunction in ulcerative colitis: a cross sectional survey	1,300	—	—	—	**1,300**
Balance carried forward			**1,069,109**	—	**(835)**	**(228,974)**	**839,300**

18. Research grants payable (continued)

			At 1 January 2020 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2020 £**
Ongoing research cont'd							
Balance brought forward			**1,069,109**	—	**(835)**	**(228,974)**	**839,300**
Dr Gwo-tzer Ho	Guts UK Development Award	Resolving Inflammation in IBD: Developing a new therapeutic approach by targeting pro-inflammatory mitochondrial formylated peptides on neutrophil FPR1-pathway	19,525	—	—	(5,695)	**13,830**
Dr Michael Fitzpatrick	Guts UK-BSG Trainee Research Network Award	Effect of diet, nutritional status, and body composition on biologic therapy in IBD: The Oxford and Thames Valley Young Gastroenterologists Network (OxYGEN)	2,000	—	—	—	**2,000**
Dr Polychronis Pavlidis	Guts UK-BSG Trainee Research Network Award	Quality of care transition in adult IBD patients transferring between healthcare providers: a multicentre audit	2,499	—	—	—	**2,499**
Dr Nick Powell	For Crohns	TNFα responsive transcriptional networks in the human intestinal epithelium - the key to predicting therapeutic response to antic-TNFα in Crohn's disease	48,737	—	—	—	**48,737**
Dr Louise China	Guts UK-BSG Trainee Research Award	Exploring Periodontitis in Cirrhosis (EPIC): a single arm feasibility study to explore the relationship between periodontitis and infection in patients with liver cirrhosis.	4,980	—	—	—	**4,980**
Dr Srivathsan Ravindran	Guts UK-BSG Trainee Research Award	Developing a patient-reported safety incident tool in endoscopy	3,775	—	—	(1,888)	**1,887**
Dr Mike Davies	Guts UK-BSG Trainee Research Network Award	Getting to the bottom of acute Lower Gastrointestinal Bleeding: Improving quality of care for patients with acute lower gastrointestinal bleeding and assessing resource implications of adherence to national guidelines	3,000	—	—	—	**3,000**
Dr Samuel Smith	Guts UK-BSG Trainee Research Network Award	Improving key performance measures in inflammatory bowel disease surveillance	5,000	—	—	—	**5,000**
Balance carried forward			**1,158,625**	—	**(835)**	**(236,557)**	**921,233**

18. Research grants payable (continued)

			At 1 January 2020 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2020 £**
Ongoing research cont'd							
Balance brought forward			**1,158,625**	—	**(835)**	**(236,557)**	**921,233**
Professor Jonathan Fallowfield	Development Grant	A molecular phenomic approach to define the high risk NAFLD population	49,623	—	—	—	**49,623**
Dr Salvatore Papa	Development Grant	Starving livers of glucose for HCC prevention and treatment	50,000	—	—	—	**50,000**
Professor Chris Probert	Development Grant	Evaluation of the gut metabolome, micro and myco biome in ulcerative colitis patients undergoing anti-fungal therapy: can we predict response to therapy?	48,099	—	—	—	**48,099**
Dr James Pritchett	Development Grant	Decoding Yes Associated Protein 1 driven hepatic stellate cell activation	29,138	—	—	—	**29,138**
Dr Marnix Jenson	Development Grant	The TARGET study (TArgeted biopsies to Risk Stratify Gastric cancer precursors for tailored Endoscopic surveillance and Treatment)	49,560	—	—	—	**49,560**
Dr Catherine Williamson	Nutrition Development Grant	Impact of cold exposure in conjunction with dietary modification on metabolic regulation in children with non-alcoholic fatty liver disease	48,283	—	—	—	**48,283**
Professor Christer Hogstrand	Nutrition Development Grant	Targeting "Leaky Gut" with combined dietary zinc and plant derived Aryl Hydrocarbon Receptor agonists	50,000	—	—	—	**50,000**
Dr Paul Henderson	Guts UK - BSPGHAN Development Grant	The PINPOINT study – The Prospective Incidence of Paediatric – Onset Inflammatory bowel disease in the United Kingdom	39,936	—	—	—	**39,936**
Dr Matthias Zilbauer	Guts UK - BSPGHAN Development Grant	Stratification of inflammatory bowel disease treatment in children using human intestinal organoid derived epigenetic signatures	40,000	—	—	(25,229)	**14,771**
Balance carried forward			**1,563,264**	—	**(835)**	**(261,786)**	**1,300,643**

18. Research grants payable (continued)

			At 1 January 2020 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2020 £**
Ongoing research cont'd							
Balance brought forward			1,563,264	—	(835)	(261,786)	**1,300,643**
Professor Graham Lord	For Crohn's Development Grant	Modulation of the effector/regulatory T-cell balance by targeting a causal genetic variant as a novel therapeutic paradigm in Crohn's disease	43,336	—	—	—	**43,336**
Dr Jorge Gutierrez-Merino	For Crohn's Development Grant	Understanding how gut bacteria induce beneficial type 1 interferon responses	49,055	—	—	—	**49,055**
			1,655,655	—	**(835)**	**(261,786)**	1,393,034

18. Research grants payable (continued)

			At 1 January 2020 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2020 £**
New commitments							
Dr Robin Dart	Guts UK-BSG Trainee Research Award	The cellular architecture of the human colonic mucosa : a pilot and feasibility study to facilitate longitudinal multi-centre studies	—	10,000	—	—	**10,000**
Dr James Ashton	Guts UK-BSG Trainee Research Award	To establish a UK wide Paediatric IBD Research network (PAIR network) to answer clinical research questions and enable rapid decision making	—	8,000	—	—	**8,000**
Dr John Thomas	Guts UK-BSG Trainee Research Award	Transcriptomic profiling of patient derived colonic epithelial organoids exposed to Ulcerative Colitis-relevant cytokines – a novel approach to uncover IBD pathogenesis and inform precision medicine strategies.	—	9,950	—	—	**9,950**
Dr Rebecca Harris	Guts UK-BSG Trainee Research Award	Non-invasive risk stratification of patients with compensated advanced chronic liver disease : Results from a real world cohort from the Nottingham Scarred Liver pathway	—	10,000	—	—	**10,000**
Dr Roosey Sheth	Guts UK-BSG Trainee Research Network Award	A UK wide Audit of the Management of Primary Biliary Cholangitis (PBC)	—	10,000	—	—	**10,000**
Falk Pharma 2020 awards - various	Guts UK-Dr Falk awards 2020		—	14,000	—	—	**14,000**
New commitments total			—	61,950	—	—	**61,950**

18. Research grants payable (continued)

			At 1 January 2020 £	Research grants awarded £	Grants no longer required £	Grants paid in the year £	**At 31 December 2020 £**
Research completed in during the year							
Professor David Wilson	BSPGHAN Award	Health informatics research in paediatric gastroenterology: nationwide data-linkage exploration of perinatal risk factors for and consequences of paediatric-onset Inflammatory Bowel Disease	**23,694**	—	—	(23,694)	—
Professor Chris Probert	Core-BSPGHAN Development Grant	Characterisation of the gut mycobiome in an inception cohort of paediatric inflammatory bowel disease patients	**993**	—	—	(993)	—
Professor Sarah Ennis	Core-BSPGHAN Development Grant	Metabolo-genomic interactions in paediatric Crohn's Disease (CD)	**12,898**	—	—	(12,898)	—
Dr Misha Kabir	Guts UK-Dr Falk SpR Trainee Audit/Quality Improvement Award	Developing a personalised patient decision aid to improve the quality of shared decision-making between Ulcerative Colitis patients diagnosed with dysplasia and their clinicians	**1,400**	—	—	(1,400)	—
Dr Suneil Raju	Guts UK-BSG Trainee Research Award	Review of current diagnostic procedure and management of patients with microscopic colitis: Are we getting it right?	**2,500**	—	—	(2,500)	—
Dr Konstantinos Gerasimidis	For Crohns	A pilot study to assess the clinical efficacy of the novel CD-TREAT diet in patients with active Crohn's disease	**19,566**	—	(104)	(19,462)	—
Dr Rishi Fofaria	Guts UK-Dr Falk SpR Trainee Audit/Quality Improvement Award	Prospective observational study to investigate the role of pre-procedure faecal calprotectin before scheduled IBD surveillance colonoscopy to improve quality of care	**5,149**	—	(2,574)	(2,575)	—
			66,200	—	**(2,679)**	**(63,522)**	—
		Total grants for the year	**1,721,855**	**61,950**	**(3,513)**	**(325,308)**	**1,454,984**

19. Restricted Funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust to be applied for specific purposes:

	At 1 January 2020 £	Income £	Expenditure £	Transfers £	**At 31 December 2020 £**
Research grants	—	14,000	(14,000)	**—**	**—**
Restricted research grants	—	28,000	(47,950)	19,950	**—**
Restricted – Pancreatitis	—	8,114	**—**	**—**	**8,114**
Restricted – Stomach Cancer	—	1,362	(2,000)	638	**—**
Trust Application Donations	—	5,500	(3,000)	**—**	**2,500**
Derek Butler Endowment Income fund	126,037	77,201	**—**	41,430	**244,668**
	126,037	134,177	(66,950)	62,018	**255,282**

	At 1 January 2019 £	*Income £*	*Expenditure £*	*Transfers £*	*At 31 December 2019 £*
Research grants	*—*	*16,575*	*(19,149)*	*2,574*	*—*
Restricted research grants	*—*	*407,466*	*(439,102)*	*31,636*	*—*
Restricted - Pancreatitis	*8,938*	*3,703*	*(12,641)*	*—*	*—*
Derek Butler Endowment Income fund	*57,699*	*92,140*	*(20,786)*	*(3,016)*	*126,037*
	66,637	*519,884*	*(491,678)*	*31,194*	*126,037*

The transfer represents the contribution from general funds towards the research grants.

The purposes of Guts UK's restricted funds are as follows:

- Research grants: grants for research into a range of digestive disorders.
- Restricted research grants: grants for specific research schemes.
- Derek Butler Endowment Income Fund: this represents the income received from the endowment fund and expenditure on research into the diseases of the upper gastrointestinal tract.

20. Designated Funds – Amelie Waring

	At 1 January 2020 £	Income £	Expenditure £	Transfers £	Investment (losses) £	**At 31 December 2020 £**
Investments	1,875,489	46,448	(74,219)	(810,601)	(147,900)	**889,217**
Research Commitments	(179,423)	**—**	32,123	**—**	**—**	**(147,300)**
Total Amelie Waring Fund	1,696,066	46,448	(42,096)	(810,601)	(147,900)	**741,917**

Designated Funds – GI Research

	At 1 January 2020 £	Income £	Expenditure £	Transfers £	Investment gains £	**At 31 December 2020 £**
Investments	**—**	4,715	20,462	810,601	51,624	**887,402**
Research Commitments	**—**	**—**	(19,950)	**—**	**—**	**(19,950)**
Total GI Research Fund	**—**	4,715	512	810,601	51,624	**867,452**

Total Designated Funds

Total Designated Funds	**1,696,066**	**51,163**	**(41,584)**	**—**	**(96,276)**	**1,609,369**

	At 1 January 2019 £	Income £	Expenditure £	Transfers £	Investment (losses) £	At 31 December 2019 £
Investments	*1,685,450*	*77,847*	*(83,555)*	—	*195,747*	*1,875,489*
Research Commitments	*(179,423)*	—	—	—	—	*(179,423)*
Total Amelie Waring Fund	*1,506,027*	*77,847*	*(83,555)*	—	*195,747*	*1,696,066*

The Amelie Waring fund was initially established in memory of Amelie Waring to fund pancreatitis research, although the original bequest has been fully expended the trustees continue to designate funds to pancreatitis research in recognition of their ongoing commitment to funding research in this area.

The GI Research Fund is designated to general gastrointestinal research. During the year, the trustees designated £810,601 to this fund.

21. Endowment fund

	At 1 January 2020 £	Income £	Expenditure/ transfers £	Investment losses £	**At 31 December 2020 £**
Derek Butler Endowment	2,855,298	**—**	(53,950)	(117,933)	**2,683,415**

	At 1 January 2019 £	*Income £*	*Expenditure £*	*Investment losses £*	*At 31 December 2019 £*
Derek Butler Endowment	*2,558,166*	*—*	*—*	*297,132*	*2,855,298*

Income from the Derek Butler Endowment fund is credited to restricted funds and is to be spent on research into diseases of the upper gastrointestinal tract.

22. Analysis of net assets between funds

	Fixed assets £	Investments £	Net current (liabilities) / assets £	Long-term Liabilities £	**2020 Total £**
Unrestricted funds					
. General	3,520	1,287,659	37,273	(231,464)	**1,096,988**
. Designated funds – AW	**—**	889,217	(102,480)	(44,820)	**741,917**
. Designated funds – GI		887,402	**—**	(19,950)	**867,452**
Restricted funds	**—**	244,667	146,694	(136,079)	**255,282**
Endowment funds	**—**	2,683,415	**—**	**—**	**2,683,415**
	3,520	5,992,360	81,487	(432,313)	**5,645,054**

	Fixed assets £	*Investments £*	*Net current (liabilities) / assets £*	*Long-term Liabilities £*	*2019 Total £*
Unrestricted funds					
. General	*1,984*	*1,461,786*	*(15,016)*	*(161,889)*	*1,286,865*
. Designated funds	*—*	*1,875,489*	*(70,950)*	*(108,473)*	*1,696,066*
Restricted funds	*—*	*126,037*	*343,311*	*(343,311)*	*126,037*
Endowment funds	*—*	*2,855,298*	*—*	*—*	*2,855,298*
	1,984	*6,318,604*	*257,351*	*(613,673)*	*5,964,266*

23. British Society of Gastroenterology

Guts UK works closely with the British Society of Gastroenterology (BSG) (Charity Registration No. 1149074 and Company Registration No. 08124892 (England and Wales)) to provide strong links with the main professional community and to improve its ability to disseminate research and patient information. The Chair of the Research Committee of BSG is a member of Guts UK's Board of Trustees. The Chair of Guts UK is an *ex-officio* member of BSG's Council.

Transactions between the two charities during the period were as follows:

The BSG provided a grant of £25,000 (2019: £10,000) to support trainee research grants.

24. Contingent asset and liability

In 2018 the charity secured provisional funding amounting to £1,250,000 for the colorectal cancer research grant of which £250,000 has been received to date.

Up to £250,000 is receivable on an annual basis contingent on a satisfactory annual report being approved by the funding partner. Guts UK was therefore not entitled to these funds in the year ended 31 December 2020. Should the next stages of funding be received, Guts UK has agreed to distribute and monitor use of this funding as a sub-grant. As at 31 December 2020, £1,000,000 remains receivable, of which up to £250,000 is receivable and payable within one year.

25. Related party transactions

During the year the charity received donations of £1,680 from trustees (2019: £665). Transactions with the British Society of Gastroenterology are detailed in note 23.

There were no further related party transactions during the period requiring disclosure (2019: none).

26. Liability of members

The charity is constituted as a company limited by guarantee. In the event of the charity being wound up, members are required to contribute an amount not exceeding £1.

27. Commitments Under Operating Leases

At 31 December the charity had future minimum commitments under non-cancellable operating leases as set out below:

Payments which fall due:	**2020** **£**	2019 £
Within one year	**772**	772
Within 2 to 5 years	**1,932**	2,704
	2,704	3,476

28. Comparative Statement of Financial Activities for the year ended 31 December 2019

		Unrestricted funds £	Restricted funds £	Endowment funds £	**2019 Total funds £**
Income and expenditure					
Income					
Donations and legacies	1	235,669	18,778	—	**254,447**
Other trading activities	2	54,364	—	—	**54,364**
Investment income	3	111,615	92,140	—	**203,755**
Charitable activities	4				
. Grants for research		—	408,966	—	**408,966**
Total income		401,648	519,884	—	**921,532**
Expenditure					
Cost of raising funds	5	157,224	13,155	—	**170,379**
Expenditure on charitable activities	6				
. Grants for research		434,129	478,523	—	**912,652**
. Public education and Science of Digestion		136,681	—	—	**136,681**
Total expenditure	8	728,034	491,678	—	**1,219,712**
Net expenditure before transfers	9	(326,386)	28,206	—	**(298,180)**
Transfers between funds	19	(31,194)	31,194	—	—
Net (expenditure) / income after transfers		(357,580)	59,400	—	**(298,180)**
Net gains on investments	14				
. Realised		42,071	—	31,433	**73,504**
. Unrealised		283,019	—	265,699	**548,718**
Net (expenditure) / income and net movement in funds for the year		(32,490)	59,400	297,132	**324,042**
Reconciliation of funds:					
Funds balances brought forward		3,015,421	66,637	2,558,166	**5,640,224**
Fund balances carried forward		**2,982,931**	**126,037**	**2,855,298**	**5,964,266**